[ 1 ] similarity = 0.35200286 [ A method of providing a therapeutic composition to a mammal, the therapeutic composition comprising a composition comprising: ][ (a) a therapeutically effective amount of a compound selected from the group consisting of an anti-inflammatory agent, a pro-inflammatory agent, a cytokinesterase inhibitor and a pro-inflammatory cytokine, wherein the compound comprises a first or second hydrophilic ring; and ]
[ 2 ] similarity = 0.24204183 [ (a) a therapeutically effective amount of a compound selected from the group consisting of an anti-inflammatory agent, a pro-inflammatory agent, a cytokinesterase inhibitor and a pro-inflammatory cytokine, wherein the compound comprises a first or second hydrophilic ring; and ][ wherein said compound is a polypeptide comprising a first amino acid sequence having at least 90% sequence identity to the sequence of SEQ ID NO: ]
[ 3 ] similarity = -0.07964203 [ wherein said compound is a polypeptide comprising a first amino acid sequence having at least 90% sequence identity to the sequence of SEQ ID NO: ][ 2. ]
[ 4 ] similarity = 0.22994071 [ A method of producing a polymeric composition comprising a polymeric component and at least one non-polymeric component, wherein said at least one non-polymeric component has an average molecular weight of less than 100, ][ 000 daltons, said method comprising: ]
[ 5 ] similarity = 0.15038376 [ 000 daltons, said method comprising: ][ a) contacting said at least one non-polymeric component with a first solvent to produce said polymeric component; ]
[ 6 ] similarity = 0.79834723 [ a) contacting said at least one non-polymeric component with a first solvent to produce said polymeric component; ][ b) contacting said at least one non polymeric component with a second solvent to produce said non-polymeric component; ]
[ 7 ] similarity = 0.79446113 [ b) contacting said at least one non polymeric component with a second solvent to produce said non-polymeric component; ][ c) contacting said at least one non-polymeric component with a third solvent to produce said non-polymeric component; and ]
[ 8 ] similarity = 0.6388252 [ c) contacting said at least one non-polymeric component with a third solvent to produce said non-polymeric component; and ][ d) mixing said at least one non-polymeric component and said at least one non-polymeric component to form a mixture. ]
[ 9 ] similarity = 0.14123866 [ A device for treating a patient having an inflammatory bowel disease comprising: ][ a first end portion; ]
[ 10 ] similarity = 0.58504355 [ a first end portion; ][ a second end portion, the second end portion being adapted to be attached to the first end portion; ]
[ 11 ] similarity = 0.6819917 [ a second end portion, the second end portion being adapted to be attached to the first end portion; ][ an inner wall having an outer surface, a first end portion and at least one end portion extending from a second end portion, wherein the inner walls of the first end portion and the second end portion are adapted to be coupled to one another; ]
[ 12 ] similarity = 0.6224447 [ an inner wall having an outer surface, a first end portion and at least one end portion extending from a second end portion, wherein the inner walls of the first end portion and the second end portion are adapted to be coupled to one another; ][ a first adhesive disposed within the inner walls of the first and second end portions, the first adhesive having a surface that is adapted to be attached to a portion of the inner walls of the second and third end portions; ]
[ 13 ] similarity = 0.6951822 [ a first adhesive disposed within the inner walls of the first and second end portions, the first adhesive having a surface that is adapted to be attached to a portion of the inner walls of the second and third end portions; ][ an outer surface of the second and fourth end portions being disposed within the inner walls of the first and second end portions; ]
[ 14 ] similarity = 0.28364903 [ an outer surface of the second and fourth end portions being disposed within the inner walls of the first and second end portions; ][ wherein the first and second end portions have a length of from about 1.25 to about 2 inches and a thickness of from about 2 inches to about 4 inches, and ]
[ 15 ] similarity = 0.19323924 [ wherein the first and second end portions have a length of from about 1.25 to about 2 inches and a thickness of from about 2 inches to about 4 inches, and ][ the first and second end portions are each adapted to have an outer surface that is adapted to be attached to a portion of the inner walls of the first and second end portions. ]
[ 16 ] similarity = 0.51170075 [ A method for determining a position of a first and a second end of a prosthetic limb in a body of an operator, the method comprising: ][ a) providing a first prosthetic leg comprising a first end and a second end, said first end and said second end having a first and a second axis; ]
[ 17 ] similarity = 0.8872902 [ a) providing a first prosthetic leg comprising a first end and a second end, said first end and said second end having a first and a second axis; ][ b) providing a first prosthetic arm having a first end and a second end, said first and second ends having a first and a second axis; ]
[ 18 ] similarity = 0.82761735 [ b) providing a first prosthetic arm having a first end and a second end, said first and second ends having a first and a second axis; ][ c) providing a second prosthetic arm having a first end and an opposite first axis, said first and second axis being substantially parallel to said first and second axes; ]
[ 19 ] similarity = 0.6594584 [ c) providing a second prosthetic arm having a first end and an opposite first axis, said first and second axis being substantially parallel to said first and second axes; ][ d) providing a first prosthetic leg and a second prosthetic arm, said first and second prosthetic arms being configured to be connected to each other by a pair of first and second prostheses, wherein each of said prostheses comprises a first and a second end, and ]
[ 20 ] similarity = 0.6144346 [ d) providing a first prosthetic leg and a second prosthetic arm, said first and second prosthetic arms being configured to be connected to each other by a pair of first and second prostheses, wherein each of said prostheses comprises a first and a second end, and ][ wherein each of said first and second prostheses comprises a first and a second axis; and ]
[ 21 ] similarity = 0.6622596 [ wherein each of said first and second prostheses comprises a first and a second axis; and ][ e) positioning the first and second end of each of said first and second prostheses relative to the first and second end of said first end and said second end, respectively. ]
[ 22 ] similarity = 0.6386533 [ A method for treating a disease in an animal comprising administering to said animal a therapeutically effective amount of a compound selected from the group consisting of a pharmaceutically acceptable salt, a pharmaceutically acceptable carrier, and ][ an effective amount of a pharmaceutically acceptable salt or carrier, wherein said compound is selected from the group consisting of: ]
[ 23 ] similarity = 0.12208886 [ an effective amount of a pharmaceutically acceptable salt or carrier, wherein said compound is selected from the group consisting of: ][ (i) a salt thereof, ]
[ 24 ] similarity = 0.057437792 [ (i) a salt thereof, ][ (ii) a pharmaceutically acceptable carrier thereof, and ]
[ 25 ] similarity = 0.43757597 [ (ii) a pharmaceutically acceptable carrier thereof, and ][ (iii) an effective amount of a pharmaceutically acceptable salt or carrier, ]
[ 26 ] similarity = 0.042877167 [ (iii) an effective amount of a pharmaceutically acceptable salt or carrier, ][ wherein said animal is a mammal. ]
[ 27 ] similarity = 0.15499799 [ A method for treating an autoimmune condition, said method comprising: ][ (a) administering to an individual in need thereof a therapeutically effective amount of an isolated peptide of the amino acid sequence of SEQ ID NO: ]
[ 28 ] similarity = 0.41307616 [ (a) administering to an individual in need thereof a therapeutically effective amount of an isolated peptide of the amino acid sequence of SEQ ID NO: ][ 2, wherein the peptide comprises a sequence of SEQ ID NO: ]
[ 29 ] similarity = 0.006819673 [ 2, wherein the peptide comprises a sequence of SEQ ID NO: ][ 2, ]
[ 30 ] similarity = 0.026318636 [ 2, ][ (b) contacting the peptide with a subject in need thereof, wherein the subject is an individual having a condition characterized by a disorder of the immune system; ]
[ 31 ] similarity = 0.23218676 [ (b) contacting the peptide with a subject in need thereof, wherein the subject is an individual having a condition characterized by a disorder of the immune system; ][ (c) measuring the level of the peptide; ]
[ 32 ] similarity = 0.48886466 [ (c) measuring the level of the peptide; ][ (d) determining whether the level of the peptide in the individual has been reduced by the subject; and ]
[ 33 ] similarity = 0.3329395 [ (d) determining whether the level of the peptide in the individual has been reduced by the subject; and ][ (e) administering to the individual a therapeutically effective amount of a therapeutically effective amount of an isolated peptide of SEQ ID NO: ]
[ 34 ] similarity = 0.14743727 [ (e) administering to the individual a therapeutically effective amount of a therapeutically effective amount of an isolated peptide of SEQ ID NO: ][ 2 that comprises at least one of SEQ ID No: ]
[ 35 ] similarity = 0.5120332 [ 2 that comprises at least one of SEQ ID No: ][ 2, SEQ ID No: ]
[ 36 ] similarity = 0.67093825 [ 2, SEQ ID No: ][ 3, or SEQ ID NO: ]
[ 37 ] similarity = 0.27415913 [ 3, or SEQ ID NO: ][ 4. ]
[ 38 ] similarity = 0.67184675 [ A device for treating a subject, comprisinga first electrode configured to receive an electrical signal from a first electrode of the subject, and ][ a second electrode configured to receive an electrical signal from a second electrode of the subject, wherein the electrical signal is generated by the first electrode and the electrical signals are coupled to each other, ]
[ 39 ] similarity = 0.7697183 [ a second electrode configured to receive an electrical signal from a second electrode of the subject, wherein the electrical signal is generated by the first electrode and the electrical signals are coupled to each other, ][ a plurality of electrodes configured to receive the electrical signals, wherein each electrode is configured to generate a different electrical signal based on the electrical signals received from the plurality of electrodes, and ]
[ 40 ] similarity = 0.70823383 [ a plurality of electrodes configured to receive the electrical signals, wherein each electrode is configured to generate a different electrical signal based on the electrical signals received from the plurality of electrodes, and ][ a plurality of conductive elements, wherein at least one of the plurality of conductive elements is configured to be electrically coupled to one of a plurality of electrodes of the first electrode and the second electrode, ]
[ 41 ] similarity = 0.54387236 [ a plurality of conductive elements, wherein at least one of the plurality of conductive elements is configured to be electrically coupled to one of a plurality of electrodes of the first electrode and the second electrode, ][ wherein each of the plurality of conductive elements comprises a plurality of conductive elements, ]
[ 42 ] similarity = 0.6551668 [ wherein each of the plurality of conductive elements comprises a plurality of conductive elements, ][ wherein each of the plurality of conductive elements is configured to generate a different electrical signal based on the electrical signals received from the plurality of electrodes. ]
[ 43 ] similarity = 0.14652911 [ A method of treating a patient having a cancer in a patient's body, comprising administering to the cancer an amount of a therapeutically effective amount of an effective amount of at least one of: ][ a) an amount effective amount of a polypeptide comprising a nucleic acid molecule having at least 95% sequence identity with SEQ ID NO: ]
[ 44 ] similarity = 0.00987345 [ a) an amount effective amount of a polypeptide comprising a nucleic acid molecule having at least 95% sequence identity with SEQ ID NO: ][ 1; and ]
[ 45 ] similarity = 0.12427291 [ 1; and ][ b) a compound that specifically binds to a TNF receptor, wherein the compound is capable of binding to TNF receptor and is capable of causing apoptosis. ]
[ 46 ] similarity = 0.24294877 [ A device for providing a patient with an implantable medical device, comprising: ][ a body having a proximal end, a distal end, a distal end wall, and ]
[ 47 ] similarity = 0.3373493 [ a body having a proximal end, a distal end, a distal end wall, and ][ a first end; ]
[ 48 ] similarity = 0.29463398 [ a first end; ][ a first end wall defining a first longitudinal axis; a first longitudinal axis defining a second longitudinal axis; ]
[ 49 ] similarity = 0.8635247 [ a first end wall defining a first longitudinal axis; a first longitudinal axis defining a second longitudinal axis; ][ a first end wall defining a second longitudinal axis; ]
[ 50 ] similarity = 0.8945487 [ a first end wall defining a second longitudinal axis; ][ a second end wall defining a second longitudinal axis; ]
[ 51 ] similarity = 0.69568175 [ a second end wall defining a second longitudinal axis; ][ a first longitudinal axis defining a first longitudinal axis and a second longitudinal axis; ]
[ 52 ] similarity = 0.96374154 [ a first longitudinal axis defining a first longitudinal axis and a second longitudinal axis; ][ a second longitudinal axis defining a first longitudinal axis and a second longitudinal axis; ]
[ 53 ] similarity = 0.3085333 [ a second longitudinal axis defining a first longitudinal axis and a second longitudinal axis; ][ an implantable medical device having a first end and a second end; ]
[ 54 ] similarity = 0.37436885 [ an implantable medical device having a first end and a second end; ][ a plurality of first and second actuators, each having a first end and a second end, each of the first and second ends having a proximal end and a distal end and a first and second longitudinal axes, each of the first and second longitudinal axes defining a first longitudinal axis and a second longitudinal axis, and ]
[ 55 ] similarity = 0.7935582 [ a plurality of first and second actuators, each having a first end and a second end, each of the first and second ends having a proximal end and a distal end and a first and second longitudinal axes, each of the first and second longitudinal axes defining a first longitudinal axis and a second longitudinal axis, and ][ each of the first and second longitudinal axes defining a second longitudinal axis; and ]
[ 56 ] similarity = 0.45011085 [ each of the first and second longitudinal axes defining a second longitudinal axis; and ][ a first actuator having a first proximal end, a first distal end, a first longitudinal axis, and ]
[ 57 ] similarity = 0.73476803 [ a first actuator having a first proximal end, a first distal end, a first longitudinal axis, and ][ an actuator end, wherein the first proximal end and first distal end are disposed proximal to the first longitudinal axis, the first longitudinal axis is disposed proximal to the first longitudinal axis, the first longitudinal axis is disposed distal to the first longitudinal axis, and ]
[ 58 ] similarity = 0.70289016 [ an actuator end, wherein the first proximal end and first distal end are disposed proximal to the first longitudinal axis, the first longitudinal axis is disposed proximal to the first longitudinal axis, the first longitudinal axis is disposed distal to the first longitudinal axis, and ][ the first proximal end and first distal end are disposed distal to the second longitudinal axis. ]
[ 59 ] similarity = 0.38569492 [ A method for producing a therapeutic agent, comprising: ][ a) providing an active agent; ]
[ 60 ] similarity = 0.49800822 [ a) providing an active agent; ][ b) contacting the active agent with a target tissue; ]
[ 61 ] similarity = 0.5974958 [ b) contacting the active agent with a target tissue; ][ c) detecting the presence of a change in the concentration of the active agent in the target tissue; and ]
[ 62 ] similarity = 0.46321672 [ c) detecting the presence of a change in the concentration of the active agent in the target tissue; and ][ d) administering the active agent to a patient. ]
[ 63 ] similarity = 0.22446404 [ An isolated polypeptide, wherein said isolated polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: ][ 1, SEQ ID NO: ]
[ 64 ] similarity = 0.7964808 [ 1, SEQ ID NO: ][ 2, SEQ ID NO: ]
[ 65 ] similarity = 0.7720622 [ 2, SEQ ID NO: ][ 3, SEQ ID NO: ]
[ 66 ] similarity = 0.79470795 [ 3, SEQ ID NO: ][ 4, SEQ ID NO: ]
[ 67 ] similarity = 0.73181283 [ 4, SEQ ID NO: ][ 5, or SEQ ID NO: ]
[ 68 ] similarity = 0.3534313 [ 5, or SEQ ID NO: ][ 6, and ]
[ 69 ] similarity = 0.0019070357 [ 6, and ][ wherein the polypeptide is selected from the group consisting of SEQ ID NO: ]
[ 70 ] similarity = 0.2475922 [ wherein the polypeptide is selected from the group consisting of SEQ ID NO: ][ 1, SEQ ID NO: ]
[ 71 ] similarity = 0.7964808 [ 1, SEQ ID NO: ][ 2, SEQ ID NO: ]
[ 72 ] similarity = 0.7720622 [ 2, SEQ ID NO: ][ 3, SEQ ID NO: ]
[ 73 ] similarity = 0.79470795 [ 3, SEQ ID NO: ][ 4, SEQ ID NO: ]
[ 74 ] similarity = 0.26726642 [ 4, SEQ ID NO: ][ 5, and ]
[ 75 ] similarity = 0.18704732 [ 5, and ][ SEQ ID NO: ]
[ 76 ] similarity = 0.18396506 [ SEQ ID NO: ][ 6. ]
[ 77 ] similarity = 0.24604675 [ A method for the treatment of an autoimmune condition comprising: ][ a) administering to a subject in need thereof an effective amount of at least one of a first and a second anti-T cell antibody, wherein the first and the second anti-T cell antibody are selected from the group consisting of: ]
[ 78 ] similarity = 0.2742557 [ a) administering to a subject in need thereof an effective amount of at least one of a first and a second anti-T cell antibody, wherein the first and the second anti-T cell antibody are selected from the group consisting of: ][ a) an antibody comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: ]
[ 79 ] similarity = 0.88450146 [ a) an antibody comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: ][ 2; orb) a monoclonal antibody comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: ]
[ 80 ] similarity = -0.009822202 [ 2; orb) a monoclonal antibody comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: ][ 2; ]
[ 81 ] similarity = 0.029621005 [ 2; ][ c) administering to the subject in need thereof at least a first and a second anti-T cell antibody that is capable of binding a T-cell receptor, wherein the first and second anti-T cell antibodies are selected from the group consisting of: ]
[ 82 ] similarity = 0.3120263 [ c) administering to the subject in need thereof at least a first and a second anti-T cell antibody that is capable of binding a T-cell receptor, wherein the first and second anti-T cell antibodies are selected from the group consisting of: ][ a) a monoclonal antibody having a molecular weight of about 1, ]
[ 83 ] similarity = 0.06642571 [ a) a monoclonal antibody having a molecular weight of about 1, ][ 000 &#x3bc; ]
[ 84 ] similarity = 0.13435185 [ 000 &#x3bc; ][ m; ]
[ 85 ] similarity = 0.0034736204 [ m; ][ b) a polypeptide having an amino acid sequence having at least 90% sequence identity to SEQ ID NO: ]
[ 86 ] similarity = -0.048971675 [ b) a polypeptide having an amino acid sequence having at least 90% sequence identity to SEQ ID NO: ][ 2, and ]
[ 87 ] similarity = 0.016510671 [ 2, and ][ c) a monoclonal antibody having a molecular weight of about 1, ]
[ 88 ] similarity = 0.07029952 [ c) a monoclonal antibody having a molecular weight of about 1, ][ 000 &#x3bc; ]
[ 89 ] similarity = 0.13435185 [ 000 &#x3bc; ][ m; ]
[ 90 ] similarity = 0.044769444 [ m; ][ d) administering to the subject in need of the treatment an effective amount of an antibody comprising a polypeptide having a amino acid sequence having at least 90% sequence identity to SEQ ID NO: ]
[ 91 ] similarity = -0.036658723 [ d) administering to the subject in need of the treatment an effective amount of an antibody comprising a polypeptide having a amino acid sequence having at least 90% sequence identity to SEQ ID NO: ][ 2. ]
[ 92 ] similarity = 0.52382076 [ A system comprising: ][ a first device; ]
[ 93 ] similarity = 0.46947822 [ a first device; ][ a second device; and ]
[ 94 ] similarity = 0.53545916 [ a second device; and ][ a third device, ]
[ 95 ] similarity = 0.23203617 [ a third device, ][ wherein the first device is configured to receive a signal from the second device and the first device is configured to receive a signal from the second device. ]
[ 96 ] similarity = 0.2911566 [ An apparatus for providing a first treatment to a patient in need thereof comprising: ][ a housing having a first end; ]
[ 97 ] similarity = 0.6732961 [ a housing having a first end; ][ a first treatment device having a first end; ]
[ 98 ] similarity = 0.44951105 [ a first treatment device having a first end; ][ a second treatment device; and ]
[ 99 ] similarity = 0.8710947 [ a second treatment device; and ][ a second treatment device; ]
[ 100 ] similarity = 0.2416195 [ a second treatment device; ][ wherein the housing comprises a first wall, a second wall, and ]
[ 101 ] similarity = 0.34395143 [ wherein the housing comprises a first wall, a second wall, and ][ a first and a second side, ]
[ 102 ] similarity = 0.3794149 [ a first and a second side, ][ wherein the first wall comprises a first portion and a second portion, the second wall comprises a first portion and a second portion, ]
[ 103 ] similarity = 0.6339288 [ wherein the first wall comprises a first portion and a second portion, the second wall comprises a first portion and a second portion, ][ wherein the first portion of the first wall is substantially parallel to the second wall, and ]
[ 104 ] similarity = 0.6617377 [ wherein the first portion of the first wall is substantially parallel to the second wall, and ][ wherein the second portion of the first wall comprises a first portion and a second portion, and ]
[ 105 ] similarity = 0.6754401 [ wherein the second portion of the first wall comprises a first portion and a second portion, and ][ wherein the first portion of the second wall is substantially parallel to the first portion of the second wall; ]
[ 106 ] similarity = 0.76024985 [ wherein the first portion of the second wall is substantially parallel to the first portion of the second wall; ][ wherein a first portion of the first wall is disposed between the first and second portions, ]
[ 107 ] similarity = 0.92399186 [ wherein a first portion of the first wall is disposed between the first and second portions, ][ wherein a second portion of the first wall is disposed between the first and second portions, ]
[ 108 ] similarity = 0.8370018 [ wherein a second portion of the first wall is disposed between the first and second portions, ][ wherein the second portion of the first wall is substantially parallel to the second portion of the second wall, and ]
[ 109 ] similarity = 0.73186415 [ wherein the second portion of the first wall is substantially parallel to the second portion of the second wall, and ][ wherein a third portion of the first wall is disposed between the first and second portions, and ]
[ 110 ] similarity = 0.93385345 [ wherein a third portion of the first wall is disposed between the first and second portions, and ][ wherein a fourth portion of the first wall is disposed between the first and second portions. ]
[ 111 ] similarity = 0.12352062 [ A method for treating a disease or condition of a subject, comprising: ][ administering an effective amount to the subject of a therapeutically effective amount of an antibody that specifically binds to a human monoclonal antibody, wherein said antibody comprises the amino acid sequence set forth in SEQ ID NO: ]
[ 112 ] similarity = 0.0073556527 [ administering an effective amount to the subject of a therapeutically effective amount of an antibody that specifically binds to a human monoclonal antibody, wherein said antibody comprises the amino acid sequence set forth in SEQ ID NO: ][ 1. ]
[ 113 ] similarity = 0.52908164 [ A system for treating a patient, comprising: ][ a first patient support; ]
[ 114 ] similarity = 0.70516706 [ a first patient support; ][ a second patient support; ]
[ 115 ] similarity = 0.15860029 [ a second patient support; ][ a plurality of first support members, each of said first and second support members having a first end and a second end and a first and second side, each of said first and second sides having a first edge, and ]
[ 116 ] similarity = 0.80354846 [ a plurality of first support members, each of said first and second support members having a first end and a second end and a first and second side, each of said first and second sides having a first edge, and ][ a first and second side, respectively, extending between said first and second ends of said first support members; and ]
[ 117 ] similarity = 0.68765783 [ a first and second side, respectively, extending between said first and second ends of said first support members; and ][ a plurality of second support members, each of said second and third support members having a second end and a second end, each of said first and second sides, respectively, extending between said second and third ends of said first and second sides; ]
[ 118 ] similarity = 0.5519403 [ a plurality of second support members, each of said second and third support members having a second end and a second end, each of said first and second sides, respectively, extending between said second and third ends of said first and second sides; ][ wherein said first and second side, each having a respective first edge and respective second edge, are configured to receive a first portion of said plurality of first support members, and ]
[ 119 ] similarity = 0.61979806 [ wherein said first and second side, each having a respective first edge and respective second edge, are configured to receive a first portion of said plurality of first support members, and ][ said plurality of first support members are configured to receive a respective second portion of said plurality of first support members. ]
[ 120 ] similarity = 0.56388354 [ A method of treating an inflammatory bowel disease comprising administering to a subject in need thereof a therapeutically effective amount of an isolated antibody or antigen binding fragment thereof, wherein the antibody or antigen binding fragment thereof binds to an antigen-binding site on an extracellular domain of an epitope of a human CD4+ T-cell receptor, wherein the extracellular domain of the epitope of the human CD4+ T cell receptor is selected from the group consisting of the human CD4+ T cell receptor, human CD4+ T cell receptor (HCT) receptor, human CD4+T cell receptor (HCTR) receptor, and ][ human CD4+ T cell receptor receptor. ]
[ 121 ] similarity = 0.20387734 [ A system, comprising: ][ an implantable device configured to receive a blood vessel; ]
[ 122 ] similarity = 0.7458329 [ an implantable device configured to receive a blood vessel; ][ a blood vessel support having a proximal end configured to be coupled to the implantable device; ]
[ 123 ] similarity = 0.67241746 [ a blood vessel support having a proximal end configured to be coupled to the implantable device; ][ at least one sensor configured to be coupled to the proximal end of the blood vessel support and operable to sense blood vessel pressure; ]
[ 124 ] similarity = 0.27803412 [ at least one sensor configured to be coupled to the proximal end of the blood vessel support and operable to sense blood vessel pressure; ][ an interface configured to receive a signal from the at least one sensor, the interface including: ]
[ 125 ] similarity = 0.49549818 [ an interface configured to receive a signal from the at least one sensor, the interface including: ][ a first portion of the interface configured to receive a signal that indicates a vessel is in a vessel state; ]
[ 126 ] similarity = 0.810467 [ a first portion of the interface configured to receive a signal that indicates a vessel is in a vessel state; ][ a second portion of the interface configured to receive a signal that indicates a vessel is in a non-vascular state; and ]
[ 127 ] similarity = 0.7944785 [ a second portion of the interface configured to receive a signal that indicates a vessel is in a non-vascular state; and ][ a first portion of the interface configured to receive a signal that indicates a vessel is not in a vessel state. ]
[ 128 ] similarity = 0.8600153 [ A method of producing an isolated antibody or antigen binding fragment of an antibody or antigen binding fragment comprising: ][ (a) contacting an isolated antibody or antigen binding fragment of an antibody or antigen binding fragment of an isolated antibody or antigen binding fragment with an antibody that specifically binds to a human T cell; ]
[ 129 ] similarity = 0.9341708 [ (a) contacting an isolated antibody or antigen binding fragment of an antibody or antigen binding fragment of an isolated antibody or antigen binding fragment with an antibody that specifically binds to a human T cell; ][ (b) contacting a human T cell with an isolated antibody or antigen binding fragment of an antibody or antigen binding fragment of an antibody; ]
[ 130 ] similarity = 0.85687536 [ (b) contacting a human T cell with an isolated antibody or antigen binding fragment of an antibody or antigen binding fragment of an antibody; ][ (c) detecting the binding activity of the isolated antibody or antigen binding fragment of the antibody or antigen binding fragment of the antibody; ]
[ 131 ] similarity = 0.8624108 [ (c) detecting the binding activity of the isolated antibody or antigen binding fragment of the antibody or antigen binding fragment of the antibody; ][ (d) determining whether the antibody or antigen binding fragment of the antibody or antigen binding fragment of the antibody is specifically binding to the human T cell; and ]
[ 132 ] similarity = 0.90277374 [ (d) determining whether the antibody or antigen binding fragment of the antibody or antigen binding fragment of the antibody is specifically binding to the human T cell; and ][ (e) producing an antibody or antigen binding fragment of the antibody or antigen binding fragment of the antibody. ]
[ 133 ] similarity = 0.40394443 [ A method of treating a patient with a disease comprising administering to the patient an effective amount of an effective amount of a pharmaceutically acceptable carrier for the disease, wherein said carrier is a pharmaceutically acceptable salt or a salt or derivative thereof, and ][ wherein said carrier is selected from the group consisting of a salt of a salt of a polypeptide of the disease, a salt of a salt of a polypeptide of the disease having a first amino acid sequence and a second amino acid sequence, and ]
[ 134 ] similarity = 0.8281535 [ wherein said carrier is selected from the group consisting of a salt of a salt of a polypeptide of the disease, a salt of a salt of a polypeptide of the disease having a first amino acid sequence and a second amino acid sequence, and ][ a salt of a salt of a polypeptide of the disease having a second amino acid sequence. ]
[ 135 ] similarity = 0.33491838 [ A method for treating an inflammatory disease, the method comprising: ][ (a) contacting an inflammatory disease patient with a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof; ]
[ 136 ] similarity = 0.5768391 [ (a) contacting an inflammatory disease patient with a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof; ][ (b) administering to the patient an effective amount of the compound or a pharmaceutically acceptable salt thereof, wherein said effective amount is at least 50% less than the amount of the compound or the pharmaceutically acceptable salt thereof administered to the patient; and ]
[ 137 ] similarity = 0.52344126 [ (b) administering to the patient an effective amount of the compound or a pharmaceutically acceptable salt thereof, wherein said effective amount is at least 50% less than the amount of the compound or the pharmaceutically acceptable salt thereof administered to the patient; and ][ (c) determining whether or not the inflammatory disease patient exhibits an increase in the amount of an inflammatory disease marker in the presence of the compound or a pharmaceutically acceptable salt thereof. ]
[ 138 ] similarity = 0.16591656 [ A method for treating a patient having a disease or condition, comprising: ][ administering to the patient a therapeutically effective amount of a compound having an amino acid sequence selected from the group consisting of SEQ ID NO: 1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 12 or 13. ]
[ 139 ] similarity = 0.4494294 [ A method of treating a disease or disorder, comprising administering to a patient in need thereof an amount of at least one of a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ][ 2, a therapeutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]
[ 140 ] similarity = 0.8694989 [ 2, a therapeutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ][ 3, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]
[ 141 ] similarity = 0.92392254 [ 3, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ][ 4, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]
[ 142 ] similarity = 0.9590186 [ 4, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ][ 5, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]
[ 143 ] similarity = 0.9600953 [ 5, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ][ 6, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]
[ 144 ] similarity = 0.96080667 [ 6, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ][ 7, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]
[ 145 ] similarity = 0.9641375 [ 7, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ][ 8, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]
[ 146 ] similarity = 0.97288245 [ 8, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ][ 9, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]
[ 147 ] similarity = 0.9585017 [ 9, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ][ 10, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]
[ 148 ] similarity = 0.88788664 [ 10, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ][ 11, or a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]
[ 149 ] similarity = 0.12664953 [ 11, or a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ][ 12. ]
[ 150 ] similarity = 0.014439905 [ A method of treating a subject in need of such treatment comprising administering an effective amount of an antibody to a cell that comprises a protein of the formula I: ][ where R1 is a C-terminal amino group; ]
[ 151 ] similarity = 0.48063806 [ where R1 is a C-terminal amino group; ][ R2 is a C-terminal alanine or cysteine; ]
[ 152 ] similarity = 0.7059488 [ R2 is a C-terminal alanine or cysteine; ][ R3 is a C-terminal alanine, or a C-terminal alanine or a C-terminal alanine, and ]
[ 153 ] similarity = 0.29479378 [ R3 is a C-terminal alanine, or a C-terminal alanine or a C-terminal alanine, and ][ a C-terminal amino group, ]
[ 154 ] similarity = 0.10171815 [ a C-terminal amino group, ][ wherein the antibody binds to the protein, wherein the antibody is a monoclonal antibody, or a fragment thereof. ]
[ 155 ] similarity = 0.36670107 [ A method for treating a patient having at least one disorder, the method comprising: ][ providing a plurality of therapeutic agents to a patient; ]
[ 156 ] similarity = 0.686741 [ providing a plurality of therapeutic agents to a patient; ][ providing a plurality of therapeutic agents in an amount effective to treat a disorder in the patient; and ]
[ 157 ] similarity = 0.3817733 [ providing a plurality of therapeutic agents in an amount effective to treat a disorder in the patient; and ][ determining whether the patient has a disorder by comparing at least one of the plurality of therapeutic agents with a threshold level for the at least one disorder to determine whether the at least one disorder is treated. ]
[ 158 ] similarity = 0.21743116 [ A system for treating a disease or condition in a subject comprising: ][ (a) a plurality of transgenic mice having a genome encoding a first gene; ]
[ 159 ] similarity = 0.45906287 [ (a) a plurality of transgenic mice having a genome encoding a first gene; ][ (b) an antibody that binds to the first gene; and ]
[ 160 ] similarity = 0.34011483 [ (b) an antibody that binds to the first gene; and ][ (c) a pharmaceutical composition comprising an effective amount of the antibody, wherein the pharmaceutical composition is effective to treat the disease or condition in the subject. ]
[ 161 ] similarity = 0.21581432 [ A method comprising the step of: ][ providing a plurality of electrodes, each electrode comprising: ]
[ 162 ] similarity = 0.48764527 [ providing a plurality of electrodes, each electrode comprising: ][ a first electrode; and ]
[ 163 ] similarity = 0.6865062 [ a first electrode; and ][ a second electrode, ]
[ 164 ] similarity = 0.4864127 [ a second electrode, ][ wherein each electrode has an electrode surface, ]
[ 165 ] similarity = 0.5104455 [ wherein each electrode has an electrode surface, ][ wherein the electrodes are arranged in a first plane; and ]
[ 166 ] similarity = 0.5279014 [ wherein the electrodes are arranged in a first plane; and ][ wherein each electrode is arranged in a second plane that is different than the first plane. ]
[ 167 ] similarity = 0.3780616 [ A method for treating a disease or disorder in a patient comprising administering to said patient an effective amount, by a single administration, of a therapeutically effective amount of a compound of Formula (I) or an isolated or purified derivative thereof, wherein R1 is a first alkyl or aryl, or a salt thereof; and ][ R2 is a hydrogen atom or a hydrogen atom, or a salt thereof, or an isolated or purified derivative thereof. ]
[ 168 ] similarity = 0.21139458 [ A method of treating a patient suffering from a condition comprising: ][ administering a therapeutically effective amount of an isolated antibody or fragment thereof that specifically binds a polypeptide comprising the amino acid sequence of SEQ ID NO: ]
[ 169 ] similarity = 0.042969637 [ administering a therapeutically effective amount of an isolated antibody or fragment thereof that specifically binds a polypeptide comprising the amino acid sequence of SEQ ID NO: ][ 1; and ]
[ 170 ] similarity = -0.093957365 [ 1; and ][ administering an anti-inflammatory agent to the patient. ]
[ 171 ] similarity = 0.42361 [ A device for the treatment of a patient having a tumor, the device comprising: ][ an implantable device having a proximal end, a distal end, and ]
[ 172 ] similarity = 0.32860702 [ an implantable device having a proximal end, a distal end, and ][ a first end; ]
[ 173 ] similarity = 0.2757634 [ a first end; ][ a first electrode disposed on the proximal end of the implantable device, wherein the first electrode is configured to be positioned in a patient's skin; and ]
[ 174 ] similarity = 0.8149252 [ a first electrode disposed on the proximal end of the implantable device, wherein the first electrode is configured to be positioned in a patient's skin; and ][ a second electrode disposed on the distal end of the implantable device, wherein the second electrode is configured to be positioned in a patient's tissue; ]
[ 175 ] similarity = 0.4901303 [ a second electrode disposed on the distal end of the implantable device, wherein the second electrode is configured to be positioned in a patient's tissue; ][ wherein the first electrode is positioned on the patient's skin; ]
[ 176 ] similarity = 0.702927 [ wherein the first electrode is positioned on the patient's skin; ][ wherein the first electrode is disposed in a first region of the skin, and ]
[ 177 ] similarity = 0.7115482 [ wherein the first electrode is disposed in a first region of the skin, and ][ wherein the second electrode is disposed in a second region of the skin. ]
[ 178 ] similarity = 0.32629883 [ A method for the treatment of a patient, said method comprising: ][ providing a patient with a plurality of electrodes; ]
[ 179 ] similarity = 0.57399786 [ providing a patient with a plurality of electrodes; ][ providing an implant comprising a plurality of electrodes, said implant comprising a plurality of electrodes, wherein each of said plurality of electrodes comprises a plurality of electrodes; ]
[ 180 ] similarity = 0.5173249 [ providing an implant comprising a plurality of electrodes, said implant comprising a plurality of electrodes, wherein each of said plurality of electrodes comprises a plurality of electrodes; ][ inserting a plurality of surgical electrodes into said implant; and ]
[ 181 ] similarity = 0.496211 [ inserting a plurality of surgical electrodes into said implant; and ][ applying an electrical current to said plurality of surgical electrodes to stimulate a region of the body of the patient. ]
[ 182 ] similarity = 0.6777289 [ An apparatus for providing a first treatment to a first subject, comprising: ][ a first treatment unit for providing a first treatment to a first subject, the first treatment unit having a first end and a second end, the first end of the first treatment unit configured to receive the first subject, and ]
[ 183 ] similarity = 0.74807405 [ a first treatment unit for providing a first treatment to a first subject, the first treatment unit having a first end and a second end, the first end of the first treatment unit configured to receive the first subject, and ][ the second end of the first treatment unit configured to be coupled with the first subject; ]
[ 184 ] similarity = 0.50632346 [ the second end of the first treatment unit configured to be coupled with the first subject; ][ an input device for receiving input from the first subject and outputting a second treatment; and ]
[ 185 ] similarity = 0.87354654 [ an input device for receiving input from the first subject and outputting a second treatment; and ][ an input device for receiving input from the first subject and outputting a third treatment. ]
[ 186 ] similarity = 0.39594 [ A method of providing a medical device to a patient comprising: ][ a) providing a medical device having a plurality of electrodes, the medical device including a first electrode and a second electrode; ]
[ 187 ] similarity = 0.5644295 [ a) providing a medical device having a plurality of electrodes, the medical device including a first electrode and a second electrode; ][ b) providing a first medical device electrode to a patient; ]
[ 188 ] similarity = 0.6430681 [ b) providing a first medical device electrode to a patient; ][ c) placing a medical device electrode within a body cavity of the patient, the first medical device electrode including a first end electrode and a second end electrode; ]
[ 189 ] similarity = 0.64598304 [ c) placing a medical device electrode within a body cavity of the patient, the first medical device electrode including a first end electrode and a second end electrode; ][ d) providing a first electrical stimulation device electrode to a patient; ]
[ 190 ] similarity = 0.7799747 [ d) providing a first electrical stimulation device electrode to a patient; ][ e) placing a first medical device stimulation device electrode in a first portion of the body cavity of the patient; ]
[ 191 ] similarity = 0.73574674 [ e) placing a first medical device stimulation device electrode in a first portion of the body cavity of the patient; ][ f) placing a second medical device stimulation device electrode within a second portion of the body cavity of the patient; ]
[ 192 ] similarity = 0.70765233 [ f) placing a second medical device stimulation device electrode within a second portion of the body cavity of the patient; ][ g) providing a second electrical stimulation device electrode to a patient; ]
[ 193 ] similarity = 0.8500539 [ g) providing a second electrical stimulation device electrode to a patient; ][ h) providing a second electrical stimulation device electrode to a patient; and ]
[ 194 ] similarity = 0.55464524 [ h) providing a second electrical stimulation device electrode to a patient; and ][ i) placing a second medical device stimulation device electrode in a third portion of the body cavity of the patient. ]
[ 195 ] similarity = 0.09085548 [ A method comprising, ][ providing a first device comprising a plurality of first sensors and a plurality of second sensors, wherein each first sensor is configured to detect a first characteristic of a first object and each second sensor is configured to detect a second characteristic of the first object, ]
[ 196 ] similarity = 0.7629665 [ providing a first device comprising a plurality of first sensors and a plurality of second sensors, wherein each first sensor is configured to detect a first characteristic of a first object and each second sensor is configured to detect a second characteristic of the first object, ][ wherein each first sensor is configured to detect a first signal from a first sensor, ]
[ 197 ] similarity = 0.6350573 [ wherein each first sensor is configured to detect a first signal from a first sensor, ][ each second sensor is configured to detect a second signal from a second sensor, and ]
[ 198 ] similarity = 0.77458733 [ each second sensor is configured to detect a second signal from a second sensor, and ][ wherein the first sensor is configured to detect the first signal and the second sensor is configured to detect the second signal. ]
[ 199 ] similarity = 0.24572393 [ A method for producing a composition comprising a composition of a polymeric material and a pharmaceutically acceptable carrier, the method comprising the steps of: ][ a. providing a polymeric material having a thickness of less than 1 mm and a viscosity of less than about 10 mPa; ]
[ 200 ] similarity = 0.21178296 [ a. providing a polymeric material having a thickness of less than 1 mm and a viscosity of less than about 10 mPa; ][ b. forming a polymeric matrix having a plurality of polymers, wherein the plurality of polymers comprise a plurality of polymers of a first type, and ]
[ 201 ] similarity = 0.5054068 [ b. forming a polymeric matrix having a plurality of polymers, wherein the plurality of polymers comprise a plurality of polymers of a first type, and ][ a plurality of polymers of a second type, wherein the first type is a polymer having an average viscosity of less than about 10 mPa and the second type is a polymer having an average viscosity of greater than about 10 mPa, and ]
[ 202 ] similarity = 0.67003775 [ a plurality of polymers of a second type, wherein the first type is a polymer having an average viscosity of less than about 10 mPa and the second type is a polymer having an average viscosity of greater than about 10 mPa, and ][ wherein the polymeric matrix comprises a plurality of polymers having different viscosities, wherein the first type of polymers is a first polymer and the second type of polymers is a second polymer; and ]
[ 203 ] similarity = -0.0111006 [ wherein the polymeric matrix comprises a plurality of polymers having different viscosities, wherein the first type of polymers is a first polymer and the second type of polymers is a second polymer; and ][ c. contacting the polymeric material with an effective amount of a pharmaceutically acceptable carrier. ]
[ 204 ] similarity = 0.5226968 [ A method of producing a composition for use with a pharmaceutical composition, the method comprising the steps of: ][ providing a pharmaceutical composition comprising a pharmaceutically acceptable carrier; ]
[ 205 ] similarity = 0.84191644 [ providing a pharmaceutical composition comprising a pharmaceutically acceptable carrier; ][ providing a pharmaceutical composition comprising a pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one other carrier; and ]
[ 206 ] similarity = 0.77461267 [ providing a pharmaceutical composition comprising a pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one other carrier; and ][ mixing the pharmaceutically acceptable carrier and at least one other carrier to form a pharmaceutical composition, ]
[ 207 ] similarity = 0.56032693 [ mixing the pharmaceutically acceptable carrier and at least one other carrier to form a pharmaceutical composition, ][ wherein the at least one other carrier comprises at least one other carrier having an amino acid sequence that is different from the amino acid sequence of the pharmaceutically acceptable carrier, and ]
[ 208 ] similarity = 0.61225796 [ wherein the at least one other carrier comprises at least one other carrier having an amino acid sequence that is different from the amino acid sequence of the pharmaceutically acceptable carrier, and ][ wherein the pharmaceutically acceptable carrier and at least one other carrier are in the form of a single, continuous, continuous carrier, and ]
[ 209 ] similarity = 0.5507092 [ wherein the pharmaceutically acceptable carrier and at least one other carrier are in the form of a single, continuous, continuous carrier, and ][ wherein the at least one other carrier comprises at least one other carrier having a length that is greater than about 1&#xb0; ]
[ 210 ] similarity = 0.30870265 [ wherein the at least one other carrier comprises at least one other carrier having a length that is greater than about 1&#xb0; ][ 1 mm. A pharmaceutically acceptable carrier is one of a polymeric carrier, a polymeric monomer, a polymeric polymeric monomer, and ]
[ 211 ] similarity = 0.4677872 [ 1 mm. A pharmaceutically acceptable carrier is one of a polymeric carrier, a polymeric monomer, a polymeric polymeric monomer, and ][ a polymeric polymeric monomer. ]
[ 212 ] similarity = -0.025852727 [ A method of treating a patient, comprising administering to said patient a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein: ][ R1 and R2 each represent a hydroxyl group and a halogen atom; ]
[ 213 ] similarity = 0.4767589 [ R1 and R2 each represent a hydroxyl group and a halogen atom; ][ X1 and X2 each represent a hydrogen atom, and ]
[ 214 ] similarity = 0.5545874 [ X1 and X2 each represent a hydrogen atom, and ][ each of X1 and X2 represents a hydroxyl group; ]
[ 215 ] similarity = 0.17100778 [ each of X1 and X2 represents a hydroxyl group; ][ R3 represents hydrogen; ]
[ 216 ] similarity = 0.59037423 [ R3 represents hydrogen; ][ X4 represents a hydrogen atom, and ]
[ 217 ] similarity = 0.040687297 [ X4 represents a hydrogen atom, and ][ R5 represents an alkyl group, or a heteroaryl group. ]
[ 218 ] similarity = 0.20110211 [ A method of treating a patient having a disease or condition in which the disease or condition is characterized by a reduction in the level of a specific protein in the blood or serum, the method comprising the steps of: ][ a) providing a first treatment comprising a first amount of a therapeutically effective amount of a peptide selected from the group consisting of SEQ ID NO: ]
[ 219 ] similarity = 0.114913926 [ a) providing a first treatment comprising a first amount of a therapeutically effective amount of a peptide selected from the group consisting of SEQ ID NO: ][ 1 and SEQ ID NO: ]
[ 220 ] similarity = 0.38240778 [ 1 and SEQ ID NO: ][ 3; and ]
[ 221 ] similarity = -0.010609759 [ 3; and ][ b) providing a second treatment comprising a second amount of the therapeutically effective amount of the peptide selected from the group consisting of SEQ ID NO: ]
[ 222 ] similarity = 0.16848144 [ b) providing a second treatment comprising a second amount of the therapeutically effective amount of the peptide selected from the group consisting of SEQ ID NO: ][ 1, SEQ ID NO: ]
[ 223 ] similarity = 0.7052772 [ 1, SEQ ID NO: ][ 2 and SEQ ID NO: ]
[ 224 ] similarity = 0.20581083 [ 2 and SEQ ID NO: ][ 3. ]
[ 225 ] similarity = 0.6037328 [ An implantable medical device comprising an implantable medical device housing, a first end portion, a second end portion and a first and second plurality of electrodes, wherein the first and second plurality of electrodes are arranged to be coupled to the first and second plurality of electrodes of the implantable medical device housing, and ][ wherein the first and second plurality of electrodes comprise a first and second electrode structure having an outer surface and a first and second inner surface, and ]
[ 226 ] similarity = 0.5878997 [ wherein the first and second plurality of electrodes comprise a first and second electrode structure having an outer surface and a first and second inner surface, and ][ wherein the outer surface is disposed between the first and second inner surface, ]
[ 227 ] similarity = 0.3399827 [ wherein the outer surface is disposed between the first and second inner surface, ][ wherein the first and second plurality of electrodes comprise a first and second electrode structure comprising an electrode surface, a first and second electrode structure comprising an electrode layer, and ]
[ 228 ] similarity = 0.70471954 [ wherein the first and second plurality of electrodes comprise a first and second electrode structure comprising an electrode surface, a first and second electrode structure comprising an electrode layer, and ][ a plurality of electrodes disposed between the first and second electrode structures, ]
[ 229 ] similarity = 0.61771667 [ a plurality of electrodes disposed between the first and second electrode structures, ][ wherein the first and second electrode structures comprise a first electrode structure having a first surface and a second surface, and ]
[ 230 ] similarity = 0.8793642 [ wherein the first and second electrode structures comprise a first electrode structure having a first surface and a second surface, and ][ wherein the first and second surface of the first electrode structure is disposed between the first and second electrode structures, ]
[ 231 ] similarity = 0.96159256 [ wherein the first and second surface of the first electrode structure is disposed between the first and second electrode structures, ][ wherein the first and second surface of the second electrode structure is disposed between the first and second electrode structures, and ]
[ 232 ] similarity = 0.9595969 [ wherein the first and second surface of the second electrode structure is disposed between the first and second electrode structures, and ][ wherein the second surface of the first electrode structure is disposed between the first and second electrode structures. ]
[ 233 ] similarity = 0.107084036 [ An apparatus for treating a patient, comprising: ][ a patient-side support having at least one first end, at least one second end and a plurality of first and second ends; ]
[ 234 ] similarity = 0.3994349 [ a patient-side support having at least one first end, at least one second end and a plurality of first and second ends; ][ a plurality of first electrodes disposed in a plurality of spaced apart locations along a first axis of the patient-side support, each of the plurality of first electrodes being electrically connected to a respective first end of the plurality of first electrodes; ]
[ 235 ] similarity = 0.80299366 [ a plurality of first electrodes disposed in a plurality of spaced apart locations along a first axis of the patient-side support, each of the plurality of first electrodes being electrically connected to a respective first end of the plurality of first electrodes; ][ a plurality of second electrodes disposed in a plurality of spaced apart locations along a second axis of the patient-side support, each of the plurality of second electrodes being electrically connected to a respective second end of the plurality of second electrodes; and ]
[ 236 ] similarity = 0.8027026 [ a plurality of second electrodes disposed in a plurality of spaced apart locations along a second axis of the patient-side support, each of the plurality of second electrodes being electrically connected to a respective second end of the plurality of second electrodes; and ][ a plurality of third electrodes disposed in a plurality of spaced apart locations along a third axis of the patient-side support, each of the plurality of third electrodes being electrically connected to a respective third end of the plurality of third electrodes; ]
[ 237 ] similarity = 0.33489555 [ a plurality of third electrodes disposed in a plurality of spaced apart locations along a third axis of the patient-side support, each of the plurality of third electrodes being electrically connected to a respective third end of the plurality of third electrodes; ][ wherein the first, second and third axes of the patient-side support define a plurality of patient-side surfaces, wherein the first and second axes of the patient-side support have a first and a second axis, and ]
[ 238 ] similarity = 0.36708397 [ wherein the first, second and third axes of the patient-side support define a plurality of patient-side surfaces, wherein the first and second axes of the patient-side support have a first and a second axis, and ][ wherein the plurality of first electrodes, the plurality of second electrodes, and ]
[ 239 ] similarity = 0.63687474 [ wherein the plurality of first electrodes, the plurality of second electrodes, and ][ the plurality of third electrodes are positioned along the first, second and third axes. ]
[ 240 ] similarity = 0.21847352 [ A system for monitoring a patient's blood pressure, comprising: ][ an electronic device; ]
[ 241 ] similarity = 0.09809688 [ an electronic device; ][ a blood pressure monitoring unit configured for monitoring the patient's blood pressure; ]
[ 242 ] similarity = 0.7347189 [ a blood pressure monitoring unit configured for monitoring the patient's blood pressure; ][ at least one blood pressure measuring unit configured for measuring blood pressure; and ]
[ 243 ] similarity = 0.6532458 [ at least one blood pressure measuring unit configured for measuring blood pressure; and ][ a processor configured for processing the blood pressure monitoring unit and the at least one blood pressure measuring unit, wherein the processor is further configured to: ]
[ 244 ] similarity = 0.18090907 [ a processor configured for processing the blood pressure monitoring unit and the at least one blood pressure measuring unit, wherein the processor is further configured to: ][ receive an input from the patient; and ]
[ 245 ] similarity = 0.39789787 [ receive an input from the patient; and ][ determine a blood pressure value of the patient from the at least one blood pressure measuring unit based upon the input. ]
[ 246 ] similarity = 0.37617254 [ A method for treating a patient with an autoimmune disorder, comprising: ][ administering to the patient an effective amount of an immunosuppressant, wherein the immunosuppressant is a peptide, and ]
[ 247 ] similarity = 0.23037815 [ administering to the patient an effective amount of an immunosuppressant, wherein the immunosuppressant is a peptide, and ][ wherein the immunosuppressant inhibits the activity of a polypeptide comprising a polypeptide having the amino acid sequence of SEQ ID NO: 2. ]
[ 248 ] similarity = 0.31445795 [ An apparatus for the treatment of a patient, comprising: ][ a first electrode for electrically coupling to a first electrode of a medical device; ]
[ 249 ] similarity = 0.7440629 [ a first electrode for electrically coupling to a first electrode of a medical device; ][ a second electrode for electrically coupling to a second electrode of the medical device; ]
[ 250 ] similarity = 0.4786067 [ a second electrode for electrically coupling to a second electrode of the medical device; ][ a first conductive layer disposed between the first and second electrodes and electrically coupled to the first electrode; and ]
[ 251 ] similarity = 0.7750666 [ a first conductive layer disposed between the first and second electrodes and electrically coupled to the first electrode; and ][ a second conductive layer disposed between the first and second electrodes and electrically coupled to the second electrode, wherein the first conductive layer and the second conductive layer are configured such that a current flowing from the first conductive layer is sufficient to conduct a current to the second electrode. ]
[ 252 ] similarity = 0.45802063 [ A method for producing a biocompatible polymer comprising: ][ a) providing a polymeric material having at least one polymer component, wherein the polymer component is selected from the group comprising: (1) poly(dimethylamino)carbonyl, poly(dimethylamino)carbonyloxy, poly(dimethylamino)carbonyl, poly(dimethylamino)carbonyloxycarbonyl, poly(dimethylamino)carbonylamino, and ]
[ 253 ] similarity = 0.08055228 [ a) providing a polymeric material having at least one polymer component, wherein the polymer component is selected from the group comprising: (1) poly(dimethylamino)carbonyl, poly(dimethylamino)carbonyloxy, poly(dimethylamino)carbonyl, poly(dimethylamino)carbonyloxycarbonyl, poly(dimethylamino)carbonylamino, and ][ poly(dimethylamino)carbonylaminocarbonyl, and ]
[ 254 ] similarity = 0.13300197 [ poly(dimethylamino)carbonylaminocarbonyl, and ][ wherein the polymeric material is selected from the group consisting of: (a) poly(dimethylsiloxane), poly(dimethylsiloxane)carbonyl, poly(dimethylsiloxane)carbonyloxycarbonyl, poly(dimethylsiloxane)carbonylcarbonyloxycarbonyl, poly(dimethylsiloxane)carbonylamino, poly(dimethylsiloxane)carbonylaminocarbonyl, poly(dimethylsiloxane)carbonyloxycarbonyl, and ]
[ 255 ] similarity = 0.11310302 [ wherein the polymeric material is selected from the group consisting of: (a) poly(dimethylsiloxane), poly(dimethylsiloxane)carbonyl, poly(dimethylsiloxane)carbonyloxycarbonyl, poly(dimethylsiloxane)carbonylcarbonyloxycarbonyl, poly(dimethylsiloxane)carbonylamino, poly(dimethylsiloxane)carbonylaminocarbonyl, poly(dimethylsiloxane)carbonyloxycarbonyl, and ][ poly(dimethylsiloxane)carbonyloxycarbonyl, ]
[ 256 ] similarity = 0.046188157 [ poly(dimethylsiloxane)carbonyloxycarbonyl, ][ (b) a polymerizable component having a polymerizable structure having at least one polymerized polymerizable component component, wherein the polymerizable component comprises a polymerizable component having at least one polymerizable component component, ]
[ 257 ] similarity = 0.8010522 [ (b) a polymerizable component having a polymerizable structure having at least one polymerized polymerizable component component, wherein the polymerizable component comprises a polymerizable component having at least one polymerizable component component, ][ (c) a polymerizable polymerizable component having a polymerizable structure having at least one polymerizable polymerizable component component, and ]
[ 258 ] similarity = 0.7995316 [ (c) a polymerizable polymerizable component having a polymerizable structure having at least one polymerizable polymerizable component component, and ][ (d) a polymeric component having a polymeric structure having at least one polymerizable polymerizable component component. ]
[ 259 ] similarity = 0.54795516 [ A system for providing a patient-specific medical treatment to a patient, the system comprising: ][ a first patient-specific medical treatment device; ]
[ 260 ] similarity = 0.6965419 [ a first patient-specific medical treatment device; ][ a second patient-specific medical treatment device; and ]
[ 261 ] similarity = 0.49684846 [ a second patient-specific medical treatment device; and ][ a controller coupled to the first and second patient-specific medical treatment devices, the controller configured to: ]
[ 262 ] similarity = 0.4476225 [ a controller coupled to the first and second patient-specific medical treatment devices, the controller configured to: ][ receive a first medical treatment protocol from the second patient-specific medical treatment device; ]
[ 263 ] similarity = 0.8441052 [ receive a first medical treatment protocol from the second patient-specific medical treatment device; ][ determine a first medical treatment parameter for the first patient-specific medical treatment device based on the first medical treatment protocol; ]
[ 264 ] similarity = 0.6739744 [ determine a first medical treatment parameter for the first patient-specific medical treatment device based on the first medical treatment protocol; ][ determine a second medical treatment protocol for a second patient-specific patient device based on the first and second medical treatment protocols; ]
[ 265 ] similarity = 0.5789608 [ determine a second medical treatment protocol for a second patient-specific patient device based on the first and second medical treatment protocols; ][ communicate with a patient-specific device to provide a patient-specific medical treatment protocol; ]
[ 266 ] similarity = 0.61492467 [ communicate with a patient-specific device to provide a patient-specific medical treatment protocol; ][ receive a second medical treatment protocol from the second patient-specific medical treatment device; ]
[ 267 ] similarity = 0.80912334 [ receive a second medical treatment protocol from the second patient-specific medical treatment device; ][ determine a second medical treatment parameter based on the second medical treatment protocol and the first medical treatment protocol; and ]
[ 268 ] similarity = 0.6468884 [ determine a second medical treatment parameter based on the second medical treatment protocol and the first medical treatment protocol; and ][ communicate the determined second medical treatment parameter to the patient-specific device. ]
[ 269 ] similarity = 0.474561 [ A method for treating a subject having an inflammatory bowel disease, the method comprising administering to said subject an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to the polypeptide of SEQ ID NO: ][ 4, or an antigen-binding fragment thereof that specifically binds to the polypeptide of SEQ ID NO: ]
[ 270 ] similarity = 0.549369 [ 4, or an antigen-binding fragment thereof that specifically binds to the polypeptide of SEQ ID NO: ][ 4, wherein said antibody or antigen-binding fragment is a humanized antibody or antigen-binding fragment thereof. ]
[ 271 ] similarity = 0.13386796 [ An implantable cardiac pacemaker comprising: ][ a housing comprising an inner wall and an outer wall; ]
[ 272 ] similarity = 0.28312993 [ a housing comprising an inner wall and an outer wall; ][ a first electrical circuit disposed within said housing, said first circuit comprising an electrical signal generator and an electrical signal processing unit, the electrical signal processing unit comprising a signal processor and an output device; ]
[ 273 ] similarity = 0.28699774 [ a first electrical circuit disposed within said housing, said first circuit comprising an electrical signal generator and an electrical signal processing unit, the electrical signal processing unit comprising a signal processor and an output device; ][ an output device disposed within said housing; and ]
[ 274 ] similarity = 0.3622136 [ an output device disposed within said housing; and ][ a second electrical circuit comprising an output signal processor, an output signal processing unit and an input device, ]
[ 275 ] similarity = 0.27771103 [ a second electrical circuit comprising an output signal processor, an output signal processing unit and an input device, ][ wherein said output device comprises: ]
[ 276 ] similarity = 0.24541093 [ wherein said output device comprises: ][ a first output port; ]
[ 277 ] similarity = 0.31107268 [ a first output port; ][ a first electrical connection disposed within said housing and connected to said output device; and ]
[ 278 ] similarity = 0.83362496 [ a first electrical connection disposed within said housing and connected to said output device; and ][ a second electrical connection disposed within said housing and connected to said input device, ]
[ 279 ] similarity = 0.5461168 [ a second electrical connection disposed within said housing and connected to said input device, ][ wherein said first output port and said first electrical connection are connected to a first power source and a second electrical connection is connected to said second power source; ]
[ 280 ] similarity = 0.7935524 [ wherein said first output port and said first electrical connection are connected to a first power source and a second electrical connection is connected to said second power source; ][ said first electrical connection is connected to an electrical signal generator, said second electrical connection is connected to a second power source, ]
[ 281 ] similarity = 0.72679687 [ said first electrical connection is connected to an electrical signal generator, said second electrical connection is connected to a second power source, ][ wherein said first electrical connection and said second electrical connection are electrically connected to said electrical signal processing unit; ]
[ 282 ] similarity = 0.82586503 [ wherein said first electrical connection and said second electrical connection are electrically connected to said electrical signal processing unit; ][ wherein said first electrical connection and said second electrical connection are connected to a first voltage source; ]
[ 283 ] similarity = 0.7385402 [ wherein said first electrical connection and said second electrical connection are connected to a first voltage source; ][ wherein said first voltage source is connected to a first power source; ]
[ 284 ] similarity = 0.9295205 [ wherein said first voltage source is connected to a first power source; ][ wherein said first power source is connected to a second voltage source; ]
[ 285 ] similarity = 0.80588 [ wherein said first power source is connected to a second voltage source; ][ wherein said second voltage source is connected to a second voltage generator, and ]
[ 286 ] similarity = 0.62647223 [ wherein said second voltage source is connected to a second voltage generator, and ][ wherein said output signal processor is connected to a first voltage source; ]
[ 287 ] similarity = 0.45295018 [ wherein said output signal processor is connected to a first voltage source; ][ said output device further comprises an input device, wherein said input device is connected to a second power source; ]
[ 288 ] similarity = 0.50834066 [ said output device further comprises an input device, wherein said input device is connected to a second power source; ][ wherein said output signal processor is connected to a second voltage source. ]
[ 289 ] similarity = 0.09794392 [ A method of treating an inflammatory disease, the method comprising administering to an individual suffering from an inflammatory disease, a therapeutically effective amount of a polypeptide comprising a sequence of SEQ ID NO: ][ 2 or SEQ ID NO: ]
[ 290 ] similarity = 0.28944013 [ 2 or SEQ ID NO: ][ 4, wherein said polypeptide comprises a sequence of SEQ ID NOs: ]
[ 291 ] similarity = 0.080061615 [ 4, wherein said polypeptide comprises a sequence of SEQ ID NOs: ][ 2-4. ]
[ 292 ] similarity = 0.13710466 [ A method for producing a biodegradable composition, comprising: ][ providing an isolated polypeptide comprising a first amino acid sequence and a second amino acid sequence different from the first, wherein the first amino acid sequence comprises the amino acid sequence of SEQ ID NO: ]
[ 293 ] similarity = -0.04240851 [ providing an isolated polypeptide comprising a first amino acid sequence and a second amino acid sequence different from the first, wherein the first amino acid sequence comprises the amino acid sequence of SEQ ID NO: ][ 2; ]
[ 294 ] similarity = -0.059409507 [ 2; ][ contacting the isolated polypeptide with a biodegradable composition; ]
[ 295 ] similarity = 0.074668676 [ contacting the isolated polypeptide with a biodegradable composition; ][ wherein the first amino acid sequence is selected from the group consisting of: ]
[ 296 ] similarity = -0.0065228054 [ wherein the first amino acid sequence is selected from the group consisting of: ][ SEQ ID NO: ]
[ 297 ] similarity = 0.79291165 [ SEQ ID NO: ][ 1, SEQ ID NO: ]
[ 298 ] similarity = 0.21046716 [ 1, SEQ ID NO: ][ 2, and ]
[ 299 ] similarity = 0.15015887 [ 2, and ][ SEQ ID NO: ]
[ 300 ] similarity = 0.23273043 [ SEQ ID NO: ][ 4; ]
[ 301 ] similarity = -0.02846603 [ 4; ][ wherein the second amino acid sequence is selected from the group consisting of: ]
[ 302 ] similarity = -0.008397407 [ wherein the second amino acid sequence is selected from the group consisting of: ][ SEQ ID NO: ]
[ 303 ] similarity = 0.7743683 [ SEQ ID NO: ][ 2, SEQ ID NO: ]
[ 304 ] similarity = 0.26944327 [ 2, SEQ ID NO: ][ 4, and ]
[ 305 ] similarity = 0.22023514 [ 4, and ][ SEQ ID NO: ]
[ 306 ] similarity = 0.18396506 [ SEQ ID NO: ][ 6; ]
[ 307 ] similarity = -0.06166859 [ 6; ][ wherein the first and second amino acid sequences are complementary, ]
[ 308 ] similarity = 0.26361614 [ wherein the first and second amino acid sequences are complementary, ][ wherein the composition comprises at least one biodegradable polymer; and ]
[ 309 ] similarity = 0.2599236 [ wherein the composition comprises at least one biodegradable polymer; and ][ wherein the first and second amino acids are complementary. ]
[ 310 ] similarity = 0.052478712 [ A method of treating a disease or disease condition in a patient, comprising administering to said patient in need thereof a composition comprising an effective amount of a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: ][ 2, SEQ ID NO: ]
[ 311 ] similarity = 0.29589212 [ 2, SEQ ID NO: ][ 3, and, in a second amino acid sequence selected from the group consisting of SEQ ID NO: ]
[ 312 ] similarity = 0.29728758 [ 3, and, in a second amino acid sequence selected from the group consisting of SEQ ID NO: ][ 4, SEQ ID NO: ]
[ 313 ] similarity = 0.8158754 [ 4, SEQ ID NO: ][ 6, SEQ ID NO: ]
[ 314 ] similarity = 0.8179097 [ 6, SEQ ID NO: ][ 7, SEQ ID NO: ]
[ 315 ] similarity = 0.83411634 [ 7, SEQ ID NO: ][ 8, SEQ ID NO: ]
[ 316 ] similarity = 0.84770155 [ 8, SEQ ID NO: ][ 9, SEQ ID NO: ]
[ 317 ] similarity = 0.82152116 [ 9, SEQ ID NO: ][ 10, SEQ ID NO: ]
[ 318 ] similarity = 0.83725446 [ 10, SEQ ID NO: ][ 11, SEQ ID NO: ]
[ 319 ] similarity = 0.8285377 [ 11, SEQ ID NO: ][ 12, SEQ ID NO: ]
[ 320 ] similarity = 0.8230533 [ 12, SEQ ID NO: ][ 13, SEQ ID NO: ]
[ 321 ] similarity = 0.79828423 [ 13, SEQ ID NO: ][ 14, SEQ ID NO: ]
[ 322 ] similarity = 0.7725229 [ 14, SEQ ID NO: ][ 15, or SEQ ID NO: ]
[ 323 ] similarity = 0.35755438 [ 15, or SEQ ID NO: ][ 16; ]
[ 324 ] similarity = -0.049550936 [ 16; ][ wherein said polypeptide comprises at least 95% identity to SEQ ID NO: ]
[ 325 ] similarity = 0.26407593 [ wherein said polypeptide comprises at least 95% identity to SEQ ID NO: ][ 2, SEQ ID NO: ]
[ 326 ] similarity = 0.67093825 [ 2, SEQ ID NO: ][ 3, or SEQ ID NO: ]
[ 327 ] similarity = 0.317295 [ 3, or SEQ ID NO: ][ 6, and, in a third amino acid sequence selected from the group consisting of SEQ ID NO: ]
[ 328 ] similarity = 0.26755518 [ 6, and, in a third amino acid sequence selected from the group consisting of SEQ ID NO: ][ 7, SEQ ID NO: ]
[ 329 ] similarity = 0.71876466 [ 7, SEQ ID NO: ][ 8, or SEQ ID NO: ]
[ 330 ] similarity = 0.38236073 [ 8, or SEQ ID NO: ][ 9, the polypeptide comprises at least 95% identity to SEQ ID NO: ]
[ 331 ] similarity = -0.009531692 [ 9, the polypeptide comprises at least 95% identity to SEQ ID NO: ][ 3. ]
[ 332 ] similarity = 0.19456792 [ An apparatus for the treatment of an animal having an immune response, the apparatus comprising: ][ a first body having an outer surface and at least one interior surface; ]
[ 333 ] similarity = 0.4231366 [ a first body having an outer surface and at least one interior surface; ][ a first implant configured to receive an antigen, the first implant having a first end and a second end, the first implant having a first surface and a second surface; ]
[ 334 ] similarity = 0.44366738 [ a first implant configured to receive an antigen, the first implant having a first end and a second end, the first implant having a first surface and a second surface; ][ an antibody configured to bind to the first surface; ]
[ 335 ] similarity = 0.4281522 [ an antibody configured to bind to the first surface; ][ an antibody-binding fragment of the antibody; and ]
[ 336 ] similarity = 0.28959122 [ an antibody-binding fragment of the antibody; and ][ a second implant configured to receive an antibody fragment, the second implant having a third end, the second implant having a second surface, the second surface having a first surface and a second surface, wherein the second surface is different from the first surface and wherein the first surface and the second surface have an identical surface area, the first implant and the second implant being configured to be implanted in the animal and the antibody-binding fragment being configured to bind to the antibody fragment. ]
[ 337 ] similarity = 0.18479975 [ A system comprising: ][ a plurality of electrodes, wherein at least one electrode of the plurality of electrodes is configured to receive a signal; and ]
[ 338 ] similarity = 0.60693854 [ a plurality of electrodes, wherein at least one electrode of the plurality of electrodes is configured to receive a signal; and ][ a controller configured to control a plurality of electrodes of the plurality of electrodes to receive the signal, the controller configured to control the at least one of the plurality of electrodes to receive the signal based upon a signal intensity of the signal, wherein the controller is configured to: ]
[ 339 ] similarity = 0.5626729 [ a controller configured to control a plurality of electrodes of the plurality of electrodes to receive the signal, the controller configured to control the at least one of the plurality of electrodes to receive the signal based upon a signal intensity of the signal, wherein the controller is configured to: ][ (a) determine an average signal intensity for the signal received by each of the at least one electrode of the plurality of electrodes; and ]
[ 340 ] similarity = 0.44409168 [ (a) determine an average signal intensity for the signal received by each of the at least one electrode of the plurality of electrodes; and ][ (b) determine a signal intensity threshold based at least in part on a signal intensity of the signal, the signal intensity threshold being different than a signal intensity of the signal. ]
[ 341 ] similarity = 0.38401982 [ A method of treating a patient, comprising: ][ administering to the patient a therapeutically effective amount of a composition comprising a pharmaceutically acceptable salt of a polypeptide selected from the group consisting of: ]
[ 342 ] similarity = 0.096279114 [ administering to the patient a therapeutically effective amount of a composition comprising a pharmaceutically acceptable salt of a polypeptide selected from the group consisting of: ][ (i) a polypeptide having the amino acid sequence of SEQ ID NO: ]
[ 343 ] similarity = -0.07148725 [ (i) a polypeptide having the amino acid sequence of SEQ ID NO: ][ 2; and ]
[ 344 ] similarity = 0.02216744 [ 2; and ][ (ii) a polypeptide having the amino acid sequence of SEQ ID NO: ]
[ 345 ] similarity = -0.03415996 [ (ii) a polypeptide having the amino acid sequence of SEQ ID NO: ][ 3; ]
[ 346 ] similarity = -0.06406501 [ 3; ][ wherein said composition is administered in a single dose, and ]
[ 347 ] similarity = 0.30923024 [ wherein said composition is administered in a single dose, and ][ said composition comprises a polypeptide having a molecular weight greater than 1, ]
[ 348 ] similarity = 0.13328633 [ said composition comprises a polypeptide having a molecular weight greater than 1, ][ 000 daltons. ]
[ 349 ] similarity = 0.60246116 [ A method of treating a patient having a heart disease, comprising: ][ providing a heart disease treatment device; and ]
[ 350 ] similarity = 0.52768654 [ providing a heart disease treatment device; and ][ administering a first drug to the heart disease treatment device, wherein the heart disease treatment device is configured to deliver a first dose of a therapeutically effective amount of a first drug to the heart disease treatment device. ]
[ 351 ] similarity = 0.13304159 [ A method for producing a therapeutic agent for treating a patient, comprising: ][ providing an isolated peptide comprising the amino acid sequence of SEQ ID NO: 1; ]
[ 352 ] similarity = 0.42444393 [ providing an isolated peptide comprising the amino acid sequence of SEQ ID NO: 1; ][ introducing the isolated peptide into a cell; and ]
[ 353 ] similarity = 0.7937255 [ introducing the isolated peptide into a cell; and ][ administering the isolated peptide to a cell. ]
[ 354 ] similarity = 0.38377464 [ A method for treating an autoimmune disorder in a patient in need thereof, comprising: ][ administering an effective amount of a therapeutically effective amount of an anti-CD20 antibody to said patient, wherein said antibody binds to CD20, and ]
[ 355 ] similarity = 0.3630882 [ administering an effective amount of a therapeutically effective amount of an anti-CD20 antibody to said patient, wherein said antibody binds to CD20, and ][ wherein said patient is a human with an autoantibody; ]
[ 356 ] similarity = 0.2919749 [ wherein said patient is a human with an autoantibody; ][ wherein said anti-CD20 antibody is a monoclonal antibody selected from the group consisting of CD40, CD40L, CD40L&#x2212; ]
[ 357 ] similarity = 0.09709497 [ wherein said anti-CD20 antibody is a monoclonal antibody selected from the group consisting of CD40, CD40L, CD40L&#x2212; ][ CD20, and ]
[ 358 ] similarity = 0.3019163 [ CD20, and ][ CD40L&#x2212; ]
[ 359 ] similarity = 0.29198837 [ CD40L&#x2212; ][ CD20L; and ]
[ 360 ] similarity = 0.086152375 [ CD20L; and ][ wherein the monoclonal antibody is a polyclonal antibody. ]
[ 361 ] similarity = 0.11209807 [ A method comprising the steps of: ][ a) providing a plurality of sensors for monitoring a patient's body, wherein the plurality of sensors includes: ]
[ 362 ] similarity = 0.4224531 [ a) providing a plurality of sensors for monitoring a patient's body, wherein the plurality of sensors includes: ][ i) at least two sensors for measuring the patient's body temperature; and ]
[ 363 ] similarity = 0.7837249 [ i) at least two sensors for measuring the patient's body temperature; and ][ ii) one sensor for measuring the patient's body pressure, wherein at least one of the at least two sensors for measuring the patient's body temperature is positioned at an angle with respect to the patient; and ]
[ 364 ] similarity = 0.35714558 [ ii) one sensor for measuring the patient's body pressure, wherein at least one of the at least two sensors for measuring the patient's body temperature is positioned at an angle with respect to the patient; and ][ b) determining a first physiological characteristic of the patient based at least partly on the first physiological characteristic of the patient, wherein the first physiological characteristic comprises a first value that is different than a second value that is different than the first value. ]
[ 365 ] similarity = 0.53052866 [ A system for providing an implantable medical device to a patient, comprising: ][ a first medical device having a first implantable medical device port and a second implantable medical device port, wherein the second implantable medical device port includes a first implantable medical device interface; and ]
[ 366 ] similarity = 0.8480484 [ a first medical device having a first implantable medical device port and a second implantable medical device port, wherein the second implantable medical device port includes a first implantable medical device interface; and ][ a first implantable medical device port connector configured to receive the first implantable medical device port and to connect to the first medical device port, wherein the first implantable medical device port connector includes an implantable medical device port connector, and ]
[ 367 ] similarity = 0.9356811 [ a first implantable medical device port connector configured to receive the first implantable medical device port and to connect to the first medical device port, wherein the first implantable medical device port connector includes an implantable medical device port connector, and ][ wherein the first implantable medical device port connector is configured to connect to a first implantable medical device port connector and a first medical device port connector, wherein the first medical device port connector includes a first medical device interface and wherein the first implantable medical device port connector is configured to connect to the second medical device port connector. ]
[ 368 ] similarity = 0.18035294 [ An apparatus for the treatment of a patient with a disease comprising: ][ a plurality of electrodes; ]
[ 369 ] similarity = 0.051382627 [ a plurality of electrodes; ][ a plurality of electrodes arranged in a first region and a second region, wherein each electrode is configured to be positioned within a first region of a body of the patient and configured to be positioned in an area adjacent a second region of the body of the patient, the first region being configured to be a first portion of the body of the patient and the second region being a second portion of the body of the patient; ]
[ 370 ] similarity = 0.4645387 [ a plurality of electrodes arranged in a first region and a second region, wherein each electrode is configured to be positioned within a first region of a body of the patient and configured to be positioned in an area adjacent a second region of the body of the patient, the first region being configured to be a first portion of the body of the patient and the second region being a second portion of the body of the patient; ][ a first electrical connection between a first electrode and a first electrode region of the plurality of electrodes and a second electrical connection between a second electrode and a second electrode region of the plurality of electrodes, each of said first and second electrical connections configured to be electrically connected to a first electrode and a second electrode; and ]
[ 371 ] similarity = 0.8267386 [ a first electrical connection between a first electrode and a first electrode region of the plurality of electrodes and a second electrical connection between a second electrode and a second electrode region of the plurality of electrodes, each of said first and second electrical connections configured to be electrically connected to a first electrode and a second electrode; and ][ a second electrical connection between a second electrode and a second electrode region of the plurality of electrodes and a third electrical connection configured to be electrically connected to a third electrode. ]
[ 372 ] similarity = 0.19059198 [ A method for producing and delivering a therapeutic dose of a compound comprising a pharmaceutically acceptable carrier and a pharmaceutically acceptable delivery device, the method comprising: ][ (a) providing an implantable device; and ]
[ 373 ] similarity = 0.5431222 [ (a) providing an implantable device; and ][ (b) providing an infusion system, wherein the implantable device comprises an implantable device housing and a delivery device; ]
[ 374 ] similarity = 0.74754053 [ (b) providing an infusion system, wherein the implantable device comprises an implantable device housing and a delivery device; ][ wherein the delivery device comprises an infusion device housing, a delivery device and a delivery device housing, ]
[ 375 ] similarity = 0.6869302 [ wherein the delivery device comprises an infusion device housing, a delivery device and a delivery device housing, ][ wherein the delivery device housing comprises: ]
[ 376 ] similarity = 0.21077262 [ wherein the delivery device housing comprises: ][ (i) at least one delivery channel; and ]
[ 377 ] similarity = 0.33609045 [ (i) at least one delivery channel; and ][ (ii) an inlet channel; ]
[ 378 ] similarity = 0.027706088 [ (ii) an inlet channel; ][ wherein the delivery device housing is configured for delivery of an infusion of the compound to a subject; and ]
[ 379 ] similarity = 0.50935143 [ wherein the delivery device housing is configured for delivery of an infusion of the compound to a subject; and ][ wherein the infusion device housing comprises: ]
[ 380 ] similarity = -0.050996948 [ wherein the infusion device housing comprises: ][ (i) at least one channel; and ]
[ 381 ] similarity = 0.3791408 [ (i) at least one channel; and ][ (ii) an outlet channel. ]
[ 382 ] similarity = 0.4057747 [ A system for providing a medical device, the system comprising: ][ a first medical device configured to be implanted within a patient; ]
[ 383 ] similarity = 0.647344 [ a first medical device configured to be implanted within a patient; ][ a first medical device interface configured to be coupled to the first medical device, the first medical device interface configured to be configured to receive data related to the medical device; ]
[ 384 ] similarity = 0.8101038 [ a first medical device interface configured to be coupled to the first medical device, the first medical device interface configured to be configured to receive data related to the medical device; ][ a first medical device control module configured to receive a first medical device control signal, the first medical device control signal configured to be received by the first medical device interface; and ]
[ 385 ] similarity = 0.7317035 [ a first medical device control module configured to receive a first medical device control signal, the first medical device control signal configured to be received by the first medical device interface; and ][ a second medical device coupled to the first medical device interface, the second medical device configured to be configured to receive a second medical device control signal, the second medical device control signal configured to be received by the second medical device, ]
[ 386 ] similarity = 0.8991268 [ a second medical device coupled to the first medical device interface, the second medical device configured to be configured to receive a second medical device control signal, the second medical device control signal configured to be received by the second medical device, ][ wherein the first medical device control module is configured to control the first medical device interface to provide a first medical device control signal to the second medical device, the first medical device control module configured to receive a second medical device control signal, the second medical device control signal configured to be received by the second medical device, and ]
[ 387 ] similarity = 0.884912 [ wherein the first medical device control module is configured to control the first medical device interface to provide a first medical device control signal to the second medical device, the first medical device control module configured to receive a second medical device control signal, the second medical device control signal configured to be received by the second medical device, and ][ the first medical device control module is configured to receive a second medical device control signal, the second medical device control signal configured to be received by the second medical device. ]
[ 388 ] similarity = 0.33277005 [ A method for treating a disease or condition in a mammal, comprising: ][ administering to the mammal an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to an epitope of a human CDR5, wherein the epitope is selected from the group consisting of CDR1, CDR2, CDR3, CDR4, and ]
[ 389 ] similarity = -0.031903744 [ administering to the mammal an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to an epitope of a human CDR5, wherein the epitope is selected from the group consisting of CDR1, CDR2, CDR3, CDR4, and ][ CDR5; ]
[ 390 ] similarity = -0.03190374 [ CDR5; ][ administering to the mammal an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to an epitope of a human CDR5, wherein the epitope is selected from the group consisting of CDR1, CDR2, CDR3, CDR4, and ]
[ 391 ] similarity = -0.031903733 [ administering to the mammal an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to an epitope of a human CDR5, wherein the epitope is selected from the group consisting of CDR1, CDR2, CDR3, CDR4, and ][ CDR5; ]
[ 392 ] similarity = 0.017277885 [ CDR5; ][ wherein the antibody binds to a human CDR5 and the antigen-binding fragment binds to a human CDR5; and ]
[ 393 ] similarity = 0.66504836 [ wherein the antibody binds to a human CDR5 and the antigen-binding fragment binds to a human CDR5; and ][ administering to the mammal an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to a human CDR5, wherein the antigen-binding fragment is a fragment of a human CDR5 that is not a human antigen-binding fragment of a human antigen, and ]
[ 394 ] similarity = 0.8037926 [ administering to the mammal an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to a human CDR5, wherein the antigen-binding fragment is a fragment of a human CDR5 that is not a human antigen-binding fragment of a human antigen, and ][ wherein the fragment of the human antigen-binding fragment is a fragment of a human CDR5 that is a human antigen-binding fragment. ]
[ 395 ] similarity = 0.6119132 [ A system for providing an effective amount of oxygen to a body, comprising: ][ a first oxygen supply unit for providing oxygen to the body; ]
[ 396 ] similarity = 0.84973097 [ a first oxygen supply unit for providing oxygen to the body; ][ a second oxygen supply unit for supplying oxygen to the body; and ]
[ 397 ] similarity = 0.83962387 [ a second oxygen supply unit for supplying oxygen to the body; and ][ a third oxygen supply unit for supplying oxygen to the body, ]
[ 398 ] similarity = 0.52357525 [ a third oxygen supply unit for supplying oxygen to the body, ][ wherein the first oxygen supply unit comprises an oxygen source for supplying the first oxygen supply unit and a first supply port for supplying oxygen to a first portion of the body; ]
[ 399 ] similarity = 0.6857703 [ wherein the first oxygen supply unit comprises an oxygen source for supplying the first oxygen supply unit and a first supply port for supplying oxygen to a first portion of the body; ][ wherein a first portion of the first portion of the body is located in a first position and is in contact with the first oxygen supply unit; ]
[ 400 ] similarity = 0.60353595 [ wherein a first portion of the first portion of the body is located in a first position and is in contact with the first oxygen supply unit; ][ wherein a second portion of the first portion of the body is located in a second position and is in contact with the first oxygen supply system and is located between a first portion of the second portion of the body and a second portion of the second portion of the body; and ]
[ 401 ] similarity = 0.6072324 [ wherein a second portion of the first portion of the body is located in a second position and is in contact with the first oxygen supply system and is located between a first portion of the second portion of the body and a second portion of the second portion of the body; and ][ wherein an oxygen supply port in the second oxygen supply unit is configured to receive a first portion of the first portion of the body, wherein the first portion of the first portion of the body is in contact with the first oxygen supply unit and wherein the first oxygen supply system is configured to supply the first portion of the first portion of the body to a first portion of the first portion of the body. ]
[ 402 ] similarity = 0.39896768 [ A system comprising: ][ a processor; ]
[ 403 ] similarity = 0.40287358 [ a processor; ][ a storage unit; ]
[ 404 ] similarity = 0.35505795 [ a storage unit; ][ a memory; and ]
[ 405 ] similarity = 0.21063957 [ a memory; and ][ a communication device configured to: ]
[ 406 ] similarity = 0.14654061 [ a communication device configured to: ][ receive a plurality of data packets from a plurality of different data sources; ]
[ 407 ] similarity = 0.60253894 [ receive a plurality of data packets from a plurality of different data sources; ][ store each of the plurality of data packets in the memory; ]
[ 408 ] similarity = 0.33740798 [ store each of the plurality of data packets in the memory; ][ receive a first data packet from a first data source; ]
[ 409 ] similarity = 0.5184277 [ receive a first data packet from a first data source; ][ store the first data packet in the memory; ]
[ 410 ] similarity = 0.30387843 [ store the first data packet in the memory; ][ receive a second data packet from a second data source; and ]
[ 411 ] similarity = 0.5183787 [ receive a second data packet from a second data source; and ][ store the second data packet in the memory. ]
[ 412 ] similarity = 0.33434573 [ A method for producing a composition comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: ][ 1, wherein the polypeptide is selected from the group consisting of: ]
[ 413 ] similarity = 0.28997478 [ 1, wherein the polypeptide is selected from the group consisting of: ][ a) a polypeptide of SEQ ID NO: ]
[ 414 ] similarity = 0.5481088 [ a) a polypeptide of SEQ ID NO: ][ 1 having the amino acid sequence of SEQ ID NO: ]
[ 415 ] similarity = 0.7689198 [ 1 having the amino acid sequence of SEQ ID NO: ][ 1, wherein the polypeptide has the amino acid sequence as set forth in SEQ ID NO: ]
[ 416 ] similarity = 0.10582443 [ 1, wherein the polypeptide has the amino acid sequence as set forth in SEQ ID NO: ][ 1; and ]
[ 417 ] similarity = 0.09241435 [ 1; and ][ b) a polypeptide of SEQ ID NO: ]
[ 418 ] similarity = 0.5786296 [ b) a polypeptide of SEQ ID NO: ][ 1 having a polypeptide structure having the amino acid sequence as set forth in SEQ ID NO: ]
[ 419 ] similarity = -0.022189524 [ 1 having a polypeptide structure having the amino acid sequence as set forth in SEQ ID NO: ][ 1. ]
[ 420 ] similarity = 0.23647901 [ A method of treating an inflammatory condition comprising administering to a patient an effective amount of a therapeutically effective amount of a polypeptide having the amino acid sequence set forth in SEQ ID NO: ][ 2, wherein said polypeptide is selected from SEQ ID NO: ]
[ 421 ] similarity = 0.2698259 [ 2, wherein said polypeptide is selected from SEQ ID NO: ][ 3 and SEQ ID NO: ]
[ 422 ] similarity = 0.3509448 [ 3 and SEQ ID NO: ][ 6, and ]
[ 423 ] similarity = -0.030491997 [ 6, and ][ wherein said polypeptide has an amino acid sequence having a sequence length of from about 5 amino acids to about 30 amino acids. ]
[ 424 ] similarity = 0.08468014 [ A method of treating an infection in a patient comprising administering to the patient an amount of an effective amount of an anti-human IgG antibody, wherein said anti-human IgG antibody is produced by hybridoma cell culture and wherein said anti-human IgG antibody is capable of binding to human IgG and wherein said anti-human IgG antibody is capable of inhibiting the binding of the human IgG to human IgG, wherein said anti-human IgG antibody comprises a nucleic acid sequence encoding a human IgG antibody that comprises the amino acid sequence set forth in SEQ ID NO: ][ 1. ]
[ 425 ] similarity = 0.35813338 [ A system for monitoring a patient's health, comprising: ][ at least one sensor configured to detect a physiological characteristic of the patient; and ]
[ 426 ] similarity = 0.623914 [ at least one sensor configured to detect a physiological characteristic of the patient; and ][ a processor operatively coupled to the at least one sensor and the at least one sensor, the processor configured to: ]
[ 427 ] similarity = 0.49090102 [ a processor operatively coupled to the at least one sensor and the at least one sensor, the processor configured to: ][ receive the physiological characteristic from the at least one sensor; ]
[ 428 ] similarity = 0.5565567 [ receive the physiological characteristic from the at least one sensor; ][ determine a physiological condition of the patient based at least in part on the physiological characteristic; and ]
[ 429 ] similarity = 0.633887 [ determine a physiological condition of the patient based at least in part on the physiological characteristic; and ][ provide a signal to a patient monitoring system, the signal being indicative of the patient's health condition, the signal comprising a physiological condition of a patient, a physiological characteristic of the patient, a physiological condition of a medical device, or both, ]
[ 430 ] similarity = 0.17833343 [ provide a signal to a patient monitoring system, the signal being indicative of the patient's health condition, the signal comprising a physiological condition of a patient, a physiological characteristic of the patient, a physiological condition of a medical device, or both, ][ wherein the signal comprises at least one of: ]
[ 431 ] similarity = 0.13369527 [ wherein the signal comprises at least one of: ][ a signal of the patient's heart rate, a signal of a heart rate of a patient, a signal of a heart rate of a medical device, and ]
[ 432 ] similarity = 0.83545727 [ a signal of the patient's heart rate, a signal of a heart rate of a patient, a signal of a heart rate of a medical device, and ][ a signal of a heart rate of a medical device, and ]
[ 433 ] similarity = 0.6361193 [ a signal of a heart rate of a medical device, and ][ wherein the signal of the patient's heart rate is a signal of the patient's heart rate and the signal of the heart rate of a patient is a signal of the patient's heart rate. ]
[ 434 ] similarity = 0.499777 [ A method of treating a cancer in a subject, the method comprising administering to the subject an effective amount of an antibody or antigen binding fragment thereof to a cell line that is capable of inducing apoptosis, and ][ wherein the cell line comprises an epitope that specifically binds to the antibody or fragment thereof. ]
[ 435 ] similarity = 0.15562612 [ A method for treating an inflammatory disease, the method comprising: ][ administering to a patient in need thereof an effective amount of a therapeutically effective amount of a compound of the following structure: ]
[ 436 ] similarity = 0.11989437 [ administering to a patient in need thereof an effective amount of a therapeutically effective amount of a compound of the following structure: ][ (I) or a pharmaceutically acceptable salt thereof; and ]
[ 437 ] similarity = 0.70852304 [ (I) or a pharmaceutically acceptable salt thereof; and ][ (II) or a pharmaceutically acceptable salt thereof, wherein: ]
[ 438 ] similarity = -0.037047967 [ (II) or a pharmaceutically acceptable salt thereof, wherein: ][ (a) R1 is a hydrogen atom; ]
[ 439 ] similarity = 0.22910435 [ (a) R1 is a hydrogen atom; ][ (b) R2 is a hydrogen atom, a substituted alkyl group having 1 to 5 carbon atoms, or a substituted alkoxy group having 1 to 5 carbon atoms; ]
[ 440 ] similarity = 0.20058897 [ (b) R2 is a hydrogen atom, a substituted alkyl group having 1 to 5 carbon atoms, or a substituted alkoxy group having 1 to 5 carbon atoms; ][ (c) R1 and R2 are each independently selected from the group consisting of: &#x2014; ]
[ 441 ] similarity = 0.115883455 [ (c) R1 and R2 are each independently selected from the group consisting of: &#x2014; ][ CH2; ]
[ 442 ] similarity = 0.25606805 [ CH2; ][ &#x2014; ]
[ 443 ] similarity = 0.16422722 [ &#x2014; ][ CH3; ]
[ 444 ] similarity = 0.16422722 [ CH3; ][ &#x2014; ]
[ 445 ] similarity = 0.25606805 [ &#x2014; ][ CH2; ]
[ 446 ] similarity = 0.25606805 [ CH2; ][ &#x2014; ]
[ 447 ] similarity = 0.4092469 [ &#x2014; ][ C(O)R3; ]
[ 448 ] similarity = 0.4092469 [ C(O)R3; ][ &#x2014; ]
[ 449 ] similarity = 0.25606805 [ &#x2014; ][ CH2; ]
[ 450 ] similarity = 0.25606805 [ CH2; ][ &#x2014; ]
[ 451 ] similarity = 0.12649502 [ &#x2014; ][ C(O)R4; and ]
[ 452 ] similarity = 0.12649502 [ C(O)R4; and ][ &#x2014; ]
[ 453 ] similarity = 1.0000001 [ &#x2014; ][ &#x2014; ]
[ 454 ] similarity = 0.25606805 [ &#x2014; ][ CH2; ]
[ 455 ] similarity = 0.16552185 [ CH2; ][ (d) R3 is a hydroxyl group; and ]
[ 456 ] similarity = 0.29010612 [ (d) R3 is a hydroxyl group; and ][ (e) R4 is a hydrogen atom. ]
[ 457 ] similarity = 0.2657834 [ A method of treating an inflammatory condition in a mammal, comprising administering to the mammal an effective amount of an anti-TNF antibody or an anti-TNF antibody fragment comprising the amino acid sequence of SEQ ID NO: ][ 1, wherein the antibody or fragment is selected from the group consisting of: ]
[ 458 ] similarity = 0.51971805 [ 1, wherein the antibody or fragment is selected from the group consisting of: ][ (a) a monoclonal antibody or fragment thereof; and ]
[ 459 ] similarity = 0.7666218 [ (a) a monoclonal antibody or fragment thereof; and ][ (b) an anti-TNF antibody or fragment thereof. ]
[ 460 ] similarity = 0.16308403 [ A method comprising: ][ receiving an input of a plurality of commands, the input of the plurality of commands comprising: ]
[ 461 ] similarity = 0.14175388 [ receiving an input of a plurality of commands, the input of the plurality of commands comprising: ][ a first command; and ]
[ 462 ] similarity = 0.5732454 [ a first command; and ][ a second command, wherein the first command is associated with one of a first and a second command; ]
[ 463 ] similarity = 0.5655391 [ a second command, wherein the first command is associated with one of a first and a second command; ][ determining, based on the input of the plurality of commands, a plurality of commands that are not associated with the first command; and ]
[ 464 ] similarity = 0.7712636 [ determining, based on the input of the plurality of commands, a plurality of commands that are not associated with the first command; and ][ determining, based on the determined plurality of commands that are not associated with the first command, a first command that is associated with the first command and a second command that is associated with the second command; ]
[ 465 ] similarity = 0.67222166 [ determining, based on the determined plurality of commands that are not associated with the first command, a first command that is associated with the first command and a second command that is associated with the second command; ][ wherein the first and second commands are associated with different commands, and ]
[ 466 ] similarity = 0.59915936 [ wherein the first and second commands are associated with different commands, and ][ wherein the first command is associated with a command to perform a function, wherein the function is associated with a command to perform an act, and ]
[ 467 ] similarity = 0.7711685 [ wherein the first command is associated with a command to perform a function, wherein the function is associated with a command to perform an act, and ][ wherein the second command is associated with a command to perform an action; ]
[ 468 ] similarity = 0.5160281 [ wherein the second command is associated with a command to perform an action; ][ determining, based on a result of the determining, whether to perform the first command, the first command, or a different command; and ]
[ 469 ] similarity = 0.841827 [ determining, based on a result of the determining, whether to perform the first command, the first command, or a different command; and ][ performing, based on the result, the first command, the first command, or the different command. ]
[ 470 ] similarity = 0.39642644 [ A system for treating an individual with a disease comprising: ][ a first medical device comprising a first medical device interface; and ]
[ 471 ] similarity = 0.6840857 [ a first medical device comprising a first medical device interface; and ][ a second medical device comprising a second medical device interface, wherein said first medical device and said second medical device interfaces are configured to communicate with each other via a first medical device interface, wherein said first medical device interface includes a first medical device port and said second medical device interface includes a second medical device port, and ]
[ 472 ] similarity = 0.76069784 [ a second medical device comprising a second medical device interface, wherein said first medical device and said second medical device interfaces are configured to communicate with each other via a first medical device interface, wherein said first medical device interface includes a first medical device port and said second medical device interface includes a second medical device port, and ][ wherein said first medical device port includes a first medical device connector and a second medical device connector, ]
[ 473 ] similarity = 0.7931653 [ wherein said first medical device port includes a first medical device connector and a second medical device connector, ][ said first medical device port and said second medical device port each having an opening for receiving a first medical device and a second medical device, ]
[ 474 ] similarity = 0.8015078 [ said first medical device port and said second medical device port each having an opening for receiving a first medical device and a second medical device, ][ wherein said first medical device port includes a first medical device connector for connecting said first medical device port to said second medical device port, ]
[ 475 ] similarity = 0.79358757 [ wherein said first medical device port includes a first medical device connector for connecting said first medical device port to said second medical device port, ][ wherein said first medical device port and said second medical device port are configured for communication via said opening, ]
[ 476 ] similarity = 0.6642806 [ wherein said first medical device port and said second medical device port are configured for communication via said opening, ][ wherein said opening is configured to receive a first medical device, and ]
[ 477 ] similarity = 0.8074712 [ wherein said opening is configured to receive a first medical device, and ][ wherein said opening is configured to receive a second medical device, ]
[ 478 ] similarity = 0.7217876 [ wherein said opening is configured to receive a second medical device, ][ wherein said first medical device is configured to be connected to said opening, and ]
[ 479 ] similarity = 0.851956 [ wherein said first medical device is configured to be connected to said opening, and ][ wherein said first medical device is configured to be connected to said opening through an electrical connection, ]
[ 480 ] similarity = 0.72863615 [ wherein said first medical device is configured to be connected to said opening through an electrical connection, ][ wherein said opening is a first electrical connection and a second electrical connection, wherein said first medical device and said second medical device are configured to communicate with said first medical device port via said first electrical connection, and ]
[ 481 ] similarity = 0.72849774 [ wherein said opening is a first electrical connection and a second electrical connection, wherein said first medical device and said second medical device are configured to communicate with said first medical device port via said first electrical connection, and ][ wherein said opening is configured to communicate with a second medical device through said second electrical connection. ]
[ 482 ] similarity = -0.02712701 [ An isolated antibody or antigen-binding fragment thereof that binds to a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, wherein said antibody or antigen-binding fragment thereof has the amino acid sequence of SEQ ID NO: ][ 2. ]
[ 483 ] similarity = 0.0016886368 [ A method of producing a compound having the formula: ][ wherein: ]
[ 484 ] similarity = -0.021320522 [ wherein: ][ R1 is a C1 to C4 alkyl; ]
[ 485 ] similarity = 0.56259763 [ R1 is a C1 to C4 alkyl; ][ R3 and R4 are independently selected from C1 to C4 alkyl; ]
[ 486 ] similarity = 0.24753812 [ R3 and R4 are independently selected from C1 to C4 alkyl; ][ R5 is a C3 to C6 cycloalkyl; and ]
[ 487 ] similarity = 0.38733196 [ R5 is a C3 to C6 cycloalkyl; and ][ R6 is a C1 to C4 alkyl; ]
[ 488 ] similarity = 0.011030141 [ R6 is a C1 to C4 alkyl; ][ wherein: ]
[ 489 ] similarity = -0.067629814 [ wherein: ][ R1 and R2 are independently selected from C1 to C4 alkyl; and ]
[ 490 ] similarity = 0.27822065 [ R1 and R2 are independently selected from C1 to C4 alkyl; and ][ R3 and R4 each have the formula (C1-C4-C6)n&#x2212; ]
[ 491 ] similarity = -0.032334477 [ R3 and R4 each have the formula (C1-C4-C6)n&#x2212; ][ &#x2003; ]
[ 492 ] similarity = 0.45165405 [ &#x2003; ][ (CH2)n&#x2003; ]
[ 493 ] similarity = 0.048190363 [ (CH2)n&#x2003; ][ , wherein n is 1 to 3. ]
[ 494 ] similarity = 0.35960984 [ A method for treating a disease comprising: ][ a. administering to a patient in need of treatment a therapeutically effective amount of an effective amount of a composition comprising a pharmaceutically acceptable salt thereof; ]
[ 495 ] similarity = 0.521737 [ a. administering to a patient in need of treatment a therapeutically effective amount of an effective amount of a composition comprising a pharmaceutically acceptable salt thereof; ][ b. administering to said patient a therapeutically effective amount of an active agent; and ]
[ 496 ] similarity = 0.49958473 [ b. administering to said patient a therapeutically effective amount of an active agent; and ][ c. treating said patient with said active agent in a manner that reduces a disease severity associated with said disease. ]
[ 497 ] similarity = 0.07020566 [ An apparatus comprising: ][ a plurality of first and second electrodes, the plurality of first and second electrodes each having a plurality of conductive layers and each having a first conductive layer and a second conductive layer, the first and second conductive layers having different conductive characteristics; and ]
[ 498 ] similarity = 0.8783915 [ a plurality of first and second electrodes, the plurality of first and second electrodes each having a plurality of conductive layers and each having a first conductive layer and a second conductive layer, the first and second conductive layers having different conductive characteristics; and ][ a first conductor layer disposed between the plurality of first and second conductive layers and having a first electrical conductivity and having a second conductive layer disposed between the plurality of first and second conductive layers and having an opposite conductive characteristic from the first and second conductive layers. ]
[ 499 ] similarity = 0.27242813 [ A method for treating a disease or disorder comprising: ][ administering to a patient, a pharmaceutical composition, wherein the pharmaceutical composition comprises an active ingredient, and ]
[ 500 ] similarity = 0.37078846 [ administering to a patient, a pharmaceutical composition, wherein the pharmaceutical composition comprises an active ingredient, and ][ wherein the active ingredient is an anti-inflammatory agent. ]
[ 501 ] similarity = 0.11093724 [ A method of treating a patient in need of such treatment, comprising administering a therapeutically effective amount of a compound having an amino acid sequence selected from the group consisting of SEQ ID NO: ][ 3 and SEQ ID NO: ]
[ 502 ] similarity = 0.29126775 [ 3 and SEQ ID NO: ][ 4. ]
[ 503 ] similarity = 0.20833418 [ A system for treating an eye, comprising: ][ a lens assembly comprising a lens, a first lens element and a second lens element; ]
[ 504 ] similarity = 0.5763986 [ a lens assembly comprising a lens, a first lens element and a second lens element; ][ an optical system including a lens, an optical fiber, and ]
[ 505 ] similarity = 0.36721295 [ an optical system including a lens, an optical fiber, and ][ a light emitting element; and ]
[ 506 ] similarity = 0.2216554 [ a light emitting element; and ][ a lens assembly comprising a lens, a first lens element and a second lens element, wherein the lens assembly is configured to be coupled to the lens assembly. ]
[ 507 ] similarity = 0.067731395 [ A method comprising: ][ providing a first sensor configured to detect a first signal and a second sensor configured to detect a second signal, the first sensor and the second sensor being coupled to a first processor; ]
[ 508 ] similarity = 0.6669052 [ providing a first sensor configured to detect a first signal and a second sensor configured to detect a second signal, the first sensor and the second sensor being coupled to a first processor; ][ determining whether the first sensor is configured to detect at least one first signal; and, ]
[ 509 ] similarity = 0.89689434 [ determining whether the first sensor is configured to detect at least one first signal; and, ][ if the first sensor is configured to detect at least one first signal, determining whether the first sensor is configured to detect at least one second signal. ]
[ 510 ] similarity = 0.8363472 [ An apparatus for providing a patient with a medical device, the apparatus comprising a first body having a first end portion and a second end portion, the first and second ends of the first body being connected together by a first connection means for connecting to the first body, the second end portion being connected to the apparatus via a second connection means, the apparatus comprising a plurality of first connection means for connecting the first end portion to a patient, wherein the plurality of first connection means are arranged such that a first connection means of each of the first connection means is connected to a first connection point on the patient, and ][ a second connection means of each of the first connection means is connected to a second connection point on the patient, wherein each of the first and second connection means are configured for connection to a respective one of the plurality of first connection means, wherein each of the first connection means comprises a first end portion and a second end portion, and ]
[ 511 ] similarity = 0.85708416 [ a second connection means of each of the first connection means is connected to a second connection point on the patient, wherein each of the first and second connection means are configured for connection to a respective one of the plurality of first connection means, wherein each of the first connection means comprises a first end portion and a second end portion, and ][ wherein the first connection means are connected to a first end of the first body via the first connection means, wherein the first connection means are connected to a second end of the first body via a second connection means, wherein the second connection means is configured for connection to a second end of the first body via the second connection means, and ]
[ 512 ] similarity = 0.44682196 [ wherein the first connection means are connected to a first end of the first body via the first connection means, wherein the first connection means are connected to a second end of the first body via a second connection means, wherein the second connection means is configured for connection to a second end of the first body via the second connection means, and ][ wherein each of the plurality of connection means comprises at least one connection element. ]
[ 513 ] similarity = 0.4409405 [ An isolated nucleic acid comprising the sequence set forth in SEQ ID NO: ][ 2, wherein the nucleotide is selected from SEQ ID NO: ]
[ 514 ] similarity = 0.35324442 [ 2, wherein the nucleotide is selected from SEQ ID NO: ][ 3, SEQ ID NO: ]
[ 515 ] similarity = 0.79470795 [ 3, SEQ ID NO: ][ 4, SEQ ID NO: ]
[ 516 ] similarity = 0.8005054 [ 4, SEQ ID NO: ][ 5, SEQ ID NO: ]
[ 517 ] similarity = 0.83311415 [ 5, SEQ ID NO: ][ 6, SEQ ID NO: ]
[ 518 ] similarity = 0.8179097 [ 6, SEQ ID NO: ][ 7, SEQ ID NO: ]
[ 519 ] similarity = 0.83411634 [ 7, SEQ ID NO: ][ 8, SEQ ID NO: ]
[ 520 ] similarity = 0.84770155 [ 8, SEQ ID NO: ][ 9, SEQ ID NO: ]
[ 521 ] similarity = 0.82152116 [ 9, SEQ ID NO: ][ 10, SEQ ID NO: ]
[ 522 ] similarity = 0.83725446 [ 10, SEQ ID NO: ][ 11, SEQ ID NO: ]
[ 523 ] similarity = 0.8285377 [ 11, SEQ ID NO: ][ 12, SEQ ID NO: ]
[ 524 ] similarity = 0.8230533 [ 12, SEQ ID NO: ][ 13, SEQ ID NO: ]
[ 525 ] similarity = 0.79828423 [ 13, SEQ ID NO: ][ 14, SEQ ID NO: ]
[ 526 ] similarity = 0.8328629 [ 14, SEQ ID NO: ][ 15, SEQ ID NO: ]
[ 527 ] similarity = 0.84213495 [ 15, SEQ ID NO: ][ 16, SEQ ID NO: ]
[ 528 ] similarity = 0.77266073 [ 16, SEQ ID NO: ][ 17 and SEQ ID NO: ]
[ 529 ] similarity = 0.4153075 [ 17 and SEQ ID NO: ][ 18. ]
[ 530 ] similarity = 0.26364902 [ A method for treating a disease comprising administering to the disease a therapeutically effective amount of a composition comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: ][ 2 and wherein the polypeptide is selected from the group consisting of SEQ ID NO: ]
[ 531 ] similarity = 0.33736965 [ 2 and wherein the polypeptide is selected from the group consisting of SEQ ID NO: ][ 2, SEQ ID NO: ]
[ 532 ] similarity = 0.5336614 [ 2, SEQ ID NO: ][ 3 and SEQ ID N: ]
[ 533 ] similarity = 0.42113644 [ 3 and SEQ ID N: ][ 3. ]
[ 534 ] similarity = 0.21809717 [ A method of treating an individual having a disease or disorder, comprising the steps of: ][ administering to the individual a therapeutically effective amount of at least one of a pharmaceutically active agent, a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising at least one of the following components: ]
[ 535 ] similarity = 0.28112876 [ administering to the individual a therapeutically effective amount of at least one of a pharmaceutically active agent, a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising at least one of the following components: ][ a compound having a molecular weight of at least 50, ]
[ 536 ] similarity = 0.06560126 [ a compound having a molecular weight of at least 50, ][ 000; ]
[ 537 ] similarity = 0.027275495 [ 000; ][ a pharmaceutically acceptable carrier; ]
[ 538 ] similarity = 0.37824953 [ a pharmaceutically acceptable carrier; ][ at least one pharmaceutically acceptable carrier salt, wherein at least a portion of the at least one carrier salt is present as a carrier in the compound; ]
[ 539 ] similarity = 0.24759518 [ at least one pharmaceutically acceptable carrier salt, wherein at least a portion of the at least one carrier salt is present as a carrier in the compound; ][ wherein the compound is selected from the group consisting of: a compound having a molecular weight of between about 50, ]
[ 540 ] similarity = 0.058371197 [ wherein the compound is selected from the group consisting of: a compound having a molecular weight of between about 50, ][ 000 and about 100, ]
[ 541 ] similarity = 0.59420455 [ 000 and about 100, ][ 000; and ]
[ 542 ] similarity = -0.021005865 [ 000; and ][ a pharmaceutically acceptable salt thereof. ]
[ 543 ] similarity = 0.21644557 [ A method of producing a pharmaceutical composition comprising a pharmaceutical composition comprising a pharmaceutically active agent, said pharmaceutically active agent having an effective amount of at least one of the following: ][ a) a pharmaceutically acceptable salt thereof, ]
[ 544 ] similarity = 0.50005746 [ a) a pharmaceutically acceptable salt thereof, ][ b) a pharmaceutically acceptable carrier, ]
[ 545 ] similarity = 0.17150277 [ b) a pharmaceutically acceptable carrier, ][ c) an organic acid, or ]
[ 546 ] similarity = -0.03559093 [ c) an organic acid, or ][ d) a pharmaceutically acceptable salt thereof, wherein the pharmaceutically active agent comprises a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier, and ]
[ 547 ] similarity = 0.3584598 [ d) a pharmaceutically acceptable salt thereof, wherein the pharmaceutically active agent comprises a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier, and ][ a pharmaceutically acceptable organic acid. ]
[ 548 ] similarity = 0.22412086 [ A method for treating a subject having an immune system disorder comprising administering to the subject a therapeutically effective amount of a composition comprising a compound selected from the group consisting of the following compounds: ][ (a) a compound of formula I or a pharmaceutically acceptable salt thereof, and ]
[ 549 ] similarity = 0.06776838 [ (a) a compound of formula I or a pharmaceutically acceptable salt thereof, and ][ (b) an antibody that binds to a human CD4 cell. ]
[ 550 ] similarity = 0.23857021 [ A method of producing a composition comprising: ][ a first step of providing an organic compound having a first structure, wherein the first structure of the organic compound is selected from the group consisting of a first structure, a second structure, a third structure and a fourth structure; and ]
[ 551 ] similarity = 0.85196257 [ a first step of providing an organic compound having a first structure, wherein the first structure of the organic compound is selected from the group consisting of a first structure, a second structure, a third structure and a fourth structure; and ][ a second step of providing an organic compound having a second structure, wherein the second structure of the organic compound is selected from the group consisting of a second structure, a third structure, a fourth structure and a fifth structure. ]
[ 552 ] similarity = 0.43389085 [ A method of treating a patient with a condition that causes an increase in a concentration in an isolated nucleic acid molecule, said nucleic acid molecule having a sequence having at least 95% sequence identity with SEQ ID NO: 2, comprising: ][ (a) contacting said nucleic acid molecule with a therapeutically effective amount of a pharmaceutically acceptable salt; ]
[ 553 ] similarity = 0.38059586 [ (a) contacting said nucleic acid molecule with a therapeutically effective amount of a pharmaceutically acceptable salt; ][ (b) contacting said nucleic acid molecule with a nucleic acid molecule having an isolated sequence having a nucleotide sequence at least 90% identical to the nucleotide sequence in the nucleic acid molecule having the condition; and ]
[ 554 ] similarity = 0.621925 [ (b) contacting said nucleic acid molecule with a nucleic acid molecule having an isolated sequence having a nucleotide sequence at least 90% identical to the nucleotide sequence in the nucleic acid molecule having the condition; and ][ (c) treating the patient with the nucleic acid molecule that has an increased concentration in the nucleic acid molecule. ]
[ 555 ] similarity = 0.43450662 [ An apparatus for treating a patient with a disease comprising: ][ an implantable medical device; ]
[ 556 ] similarity = 0.8429404 [ an implantable medical device; ][ an implantable medical device controller; ]
[ 557 ] similarity = 0.1999374 [ an implantable medical device controller; ][ a processor; and ]
[ 558 ] similarity = 0.19954559 [ a processor; and ][ an implantable medical device interface, the processor being operable to control the implantable medical device controller, the implantable medical device interface being operable to communicate with the implantable medical device controller, wherein the implantable medical device controller is operable to: ]
[ 559 ] similarity = 0.4109581 [ an implantable medical device interface, the processor being operable to control the implantable medical device controller, the implantable medical device interface being operable to communicate with the implantable medical device controller, wherein the implantable medical device controller is operable to: ][ (i) receive a patient-specific medical device identifier; ]
[ 560 ] similarity = 0.6857184 [ (i) receive a patient-specific medical device identifier; ][ (ii) receive a patient-specific medical device identifier from a patient; ]
[ 561 ] similarity = 0.65775347 [ (ii) receive a patient-specific medical device identifier from a patient; ][ (iii) determine whether the patient-specific medical device identifier matches a patient-specific identifier of a patient; ]
[ 562 ] similarity = 0.6877928 [ (iii) determine whether the patient-specific medical device identifier matches a patient-specific identifier of a patient; ][ (iv) when the patient-specific medical device identifier matches the patient-specific identifier, transmit an implantable medical device identifier to the implantable medical device controller; and ]
[ 563 ] similarity = 0.7297611 [ (iv) when the patient-specific medical device identifier matches the patient-specific identifier, transmit an implantable medical device identifier to the implantable medical device controller; and ][ (v) if the patient-specific medical device identifier does not match the patient-specific identifier, determine whether the patient-specific medical device identifier is a patient-specific identifier of the patient. ]
[ 564 ] similarity = 0.05316303 [ A method for producing a compound that binds to a polypeptide comprising the amino acid sequence of SEQ ID NO: ][ 1, wherein: ]
[ 565 ] similarity = 0.072802134 [ 1, wherein: ][ the polypeptide comprises the amino acid sequence of SEQ ID NO: ]
[ 566 ] similarity = -0.019259008 [ the polypeptide comprises the amino acid sequence of SEQ ID NO: ][ 1; ]
[ 567 ] similarity = -0.019259008 [ 1; ][ the polypeptide comprises the amino acid sequence of SEQ ID NO: ]
[ 568 ] similarity = -0.05692739 [ the polypeptide comprises the amino acid sequence of SEQ ID NO: ][ 2; ]
[ 569 ] similarity = -0.07483698 [ 2; ][ the polypeptide comprises a sequence of SEQ ID NO: ]
[ 570 ] similarity = -0.019611966 [ the polypeptide comprises a sequence of SEQ ID NO: ][ 3; and ]
[ 571 ] similarity = 0.009129003 [ 3; and ][ the polypeptide comprises the sequence of SEQ ID NO: ]
[ 572 ] similarity = -0.01662597 [ the polypeptide comprises the sequence of SEQ ID NO: ][ 4. ]
[ 573 ] similarity = -0.02832827 [ A method of treating cancer in a subject, the method comprising administering to said subject an isolated antibody that binds to a human CD4+ T-cell receptor, wherein the antibody comprises the amino acid sequence of SEQ ID NO: ][ 2. ]
[ 574 ] similarity = 0.01698964 [ A method of treating a patient having a condition in which a blood vessel is located in the body of the patient, said method comprising administering to said patient an effective amount of a therapeutically effective amount of a polypeptide comprising the amino acid sequence of SEQ ID NO: ][ 3. ]
[ 575 ] similarity = 0.15437138 [ A method of treating an inflammatory disease comprising administering to a subject a therapeutically effective amount of a composition comprising a polypeptide comprising an amino acid sequence of SEQ ID NO: ][ 1, SEQ ID NO: ]
[ 576 ] similarity = 0.7964808 [ 1, SEQ ID NO: ][ 2, SEQ ID NO: ]
[ 577 ] similarity = 0.21590814 [ 2, SEQ ID NO: ][ 3, and ]
[ 578 ] similarity = 0.2051096 [ 3, and ][ SEQ ID NO: ]
[ 579 ] similarity = 0.09234324 [ SEQ ID NO: ][ 4, wherein the polypeptide comprises a first amino acid sequence and a second amino acid sequence different from the first amino acid sequence, wherein the first and second amino acids comprise the same amino acid sequence, and ]
[ 580 ] similarity = 0.12485959 [ 4, wherein the polypeptide comprises a first amino acid sequence and a second amino acid sequence different from the first amino acid sequence, wherein the first and second amino acids comprise the same amino acid sequence, and ][ wherein the polypeptide is effective for treating the inflammatory disease, ]
[ 581 ] similarity = 0.34932867 [ wherein the polypeptide is effective for treating the inflammatory disease, ][ wherein the composition comprises a pharmaceutically acceptable carrier. ]
[ 582 ] similarity = 0.27242613 [ A method for the treatment of an inflammatory disorder, the method comprising administering to a subject in need thereof a composition comprising a therapeutically effective amount of a polypeptide comprising a nucleic acid sequence encoding a peptide that comprises at least 90% sequence identity with SEQ ID NO: 1, wherein the polypeptide is selected from the group consisting of: SEQ ID NO: 1: 1, SEQ ID NO: 1: 1, and ][ SEQ ID NO: 1: 2. ]
[ 583 ] similarity = 0.12903266 [ An apparatus for the placement of a prosthetic device, the apparatus comprising: ][ a housing; ]
[ 584 ] similarity = 0.18370587 [ a housing; ][ a prosthetic device disposed in said housing, said prosthetic device having an outer surface, a first end, an inner surface, a second end, a proximal end, and ]
[ 585 ] similarity = 0.10875161 [ a prosthetic device disposed in said housing, said prosthetic device having an outer surface, a first end, an inner surface, a second end, a proximal end, and ][ an intermediate surface; ]
[ 586 ] similarity = 0.018625772 [ an intermediate surface; ][ a first actuator disposed in said housing, said first actuator being operable to move a first part of said outer surface of said prosthetic device relative to said inner surface of said prosthetic device; and ]
[ 587 ] similarity = 0.86753625 [ a first actuator disposed in said housing, said first actuator being operable to move a first part of said outer surface of said prosthetic device relative to said inner surface of said prosthetic device; and ][ a first control device operable to control the first actuator to move said first part of said outer surface of said prosthetic device relative to said inner surface of said prosthetic device. ]
[ 588 ] similarity = 0.20454563 [ A method for treating a patient with a condition that is associated with a decrease in the level of a receptor that binds the polypeptide comprising the amino acid sequence of SEQ ID NO: 1, comprising administering to the patient a composition comprising an effective amount of a polypeptide selected from the group consisting of SEQ ID NO: ][ 1, SEQ ID NO: ]
[ 589 ] similarity = 0.77402914 [ 1, SEQ ID NO: ][ 4, SEQ ID NO: ]
[ 590 ] similarity = 0.8091477 [ 4, SEQ ID NO: ][ 8, SEQ ID NO: ]
[ 591 ] similarity = 0.7977239 [ 8, SEQ ID NO: ][ 12, SEQ ID NO: ]
[ 592 ] similarity = 0.69748527 [ 12, SEQ ID NO: ][ 16 and SEQ ID NO: ]
[ 593 ] similarity = 0.43398488 [ 16 and SEQ ID NO: ][ 18. ]
[ 594 ] similarity = 0.5187143 [ An isolated polypeptide, comprising a nucleic acid sequence having at least 90% sequence identity with SEQ ID NO: ][ 4, wherein the nucleic acid sequence comprises a first nucleic acid sequence and at least one second nucleic acid sequence. ]
[ 595 ] similarity = 0.15418187 [ A method of treating an autoimmune condition, comprising administering to a patient in need thereof a therapeutically effective amount of a compound selected from the group consisting of the amino acid sequence of SEQ ID NO: ][ 4, SEQ ID NO: ]
[ 596 ] similarity = 0.7092637 [ 4, SEQ ID NO: ][ 5 and SEQ ID NO: ]
[ 597 ] similarity = 0.3327471 [ 5 and SEQ ID NO: ][ 6. ]
[ 598 ] similarity = 0.3284418 [ A method for the treatment of a disease in a subject, the method comprising: ][ providing a first device, comprising: ]
[ 599 ] similarity = 0.14557858 [ providing a first device, comprising: ][ at least one sensor; ]
[ 600 ] similarity = 0.82344353 [ at least one sensor; ][ at least one sensor controller; ]
[ 601 ] similarity = 0.7683557 [ at least one sensor controller; ][ at least one sensor processor; and ]
[ 602 ] similarity = 0.31857204 [ at least one sensor processor; and ][ a memory; and ]
[ 603 ] similarity = 0.18375601 [ a memory; and ][ providing a second device, comprising: ]
[ 604 ] similarity = 0.2296538 [ providing a second device, comprising: ][ a first processor; ]
[ 605 ] similarity = 0.50423163 [ a first processor; ][ a first memory; and ]
[ 606 ] similarity = 0.2751544 [ a first memory; and ][ a processor; ]
[ 607 ] similarity = 0.32920945 [ a processor; ][ the first processor, the first memory, and ]
[ 608 ] similarity = 0.34353352 [ the first processor, the first memory, and ][ the processor cooperating in a manner to: ]
[ 609 ] similarity = 0.18395299 [ the processor cooperating in a manner to: ][ receive data from the first device; ]
[ 610 ] similarity = 0.46358725 [ receive data from the first device; ][ generate a first set of data; and ]
[ 611 ] similarity = 0.5826236 [ generate a first set of data; and ][ store the first set of data in the first device; ]
[ 612 ] similarity = 0.45531633 [ store the first set of data in the first device; ][ the first processor, the first memory, and ]
[ 613 ] similarity = 0.34353352 [ the first processor, the first memory, and ][ the processor cooperating in a manner to: ]
[ 614 ] similarity = 0.114830405 [ the processor cooperating in a manner to: ][ determine whether the first device is in use; ]
[ 615 ] similarity = 0.52038956 [ determine whether the first device is in use; ][ if the first device is in use, generate a first data signal; and ]
[ 616 ] similarity = 0.73000383 [ if the first device is in use, generate a first data signal; and ][ if the first device is not in use, generate a second signal; and ]
[ 617 ] similarity = 0.37585214 [ if the first device is not in use, generate a second signal; and ][ the first data signal is used to control a first device of the first device. ]
[ 618 ] similarity = 0.46454948 [ A method of treating a patient suffering from a condition that inhibits the growth factor receptor (GFR) in a tissue, comprising: ][ administering to said patient an amount sufficient to inhibit the GFR in a tissue; ]
[ 619 ] similarity = 0.30930233 [ administering to said patient an amount sufficient to inhibit the GFR in a tissue; ][ wherein the amount of the drug is administered in a dosage form that does not contained in a dosage form that contains a pharmaceutically acceptable salt or a solvate of a pharmaceutically acceptable salt. ]
[ 620 ] similarity = 0.5182806 [ A method of producing a composition comprising a composition comprising a composition comprising a polypeptide, the composition comprising a polypeptide comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: ][ 4, a polypeptide comprising the amino acid sequence of SEQ ID NO: 4, and ]
[ 621 ] similarity = 0.78779006 [ 4, a polypeptide comprising the amino acid sequence of SEQ ID NO: 4, and ][ a polypeptide comprising the amino acid sequence of SEQ ID NO: ]
[ 622 ] similarity = -0.042604677 [ a polypeptide comprising the amino acid sequence of SEQ ID NO: ][ 5. ]
[ 623 ] similarity = 0.46475092 [ An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of: ][ a) a nucleotide sequence encoding a protein comprising a first amino acid sequence having at least 90% sequence identity to SEQ ID NO: ]
[ 624 ] similarity = -0.015681528 [ a) a nucleotide sequence encoding a protein comprising a first amino acid sequence having at least 90% sequence identity to SEQ ID NO: ][ 2, and ]
[ 625 ] similarity = -0.03712318 [ 2, and ][ b) a nucleotide sequence comprising a second amino acid sequence having at least 90% sequence identity to SEQ ID NO: ]
[ 626 ] similarity = 0.15955904 [ b) a nucleotide sequence comprising a second amino acid sequence having at least 90% sequence identity to SEQ ID NO: ][ 3; wherein said protein is a polypeptide. ]
[ 627 ] similarity = 0.46756995 [ An isolated nucleic acid comprising a nucleic acid sequence encoding an antibody that is specifically capable of binding to a human monoclonal antibody, wherein the antibody comprises a heavy chain variable region comprising a heavy chain variable region of SEQ ID NO: ][ 1, a light chain variable region comprising a light chain variable region of SEQ ID NO: ]
[ 628 ] similarity = 0.034180563 [ 1, a light chain variable region comprising a light chain variable region of SEQ ID NO: ][ 2, and ]
[ 629 ] similarity = -0.0062866006 [ 2, and ][ a heavy chain variable region comprising a heavy chain variable region of SEQ ID NO: ]
[ 630 ] similarity = -0.03505321 [ a heavy chain variable region comprising a heavy chain variable region of SEQ ID NO: ][ 3. ]
[ 631 ] similarity = 0.25324792 [ A system for the treatment of a subject, comprising: ][ a) a catheter having an elongate body having an inner surface, an outer surface, and ]
[ 632 ] similarity = 0.21845636 [ a) a catheter having an elongate body having an inner surface, an outer surface, and ][ a distal end; ]
[ 633 ] similarity = 0.4805575 [ a distal end; ][ b) a catheter guide having a proximal end and a distal end, the distal end of the catheter guide configured to be coupled to the elongate body, and ]
[ 634 ] similarity = 0.67269254 [ b) a catheter guide having a proximal end and a distal end, the distal end of the catheter guide configured to be coupled to the elongate body, and ][ a distal end and an inner surface of the catheter guide; wherein: ]
[ 635 ] similarity = 0.71257365 [ a distal end and an inner surface of the catheter guide; wherein: ][ c) the distal end of the catheter guide is configured to extend through an inner surface of the catheter guide; and ]
[ 636 ] similarity = 0.88687086 [ c) the distal end of the catheter guide is configured to extend through an inner surface of the catheter guide; and ][ d) the elongate body of the catheter guide is configured to extend through a portion of the distal end of the catheter guide; and ]
[ 637 ] similarity = 0.55185485 [ d) the elongate body of the catheter guide is configured to extend through a portion of the distal end of the catheter guide; and ][ e) an elongate member having a distal end, an inner surface of the elongate member configured to be coupled to the inner surface of the catheter guide, and ]
[ 638 ] similarity = 0.4652098 [ e) an elongate member having a distal end, an inner surface of the elongate member configured to be coupled to the inner surface of the catheter guide, and ][ an outer surface of the elongate member, wherein: ]
[ 639 ] similarity = 0.2096022 [ an outer surface of the elongate member, wherein: ][ f) the elongate member comprises a first portion and a second portion, wherein the first portion is configured to be coupled to the distal end of the catheter guide and the second portion is configured to be coupled to a portion of the inner surface of the catheter guide. ]
[ 640 ] similarity = 0.27915984 [ A system for treating an eye, comprising: ][ a lens; ]
[ 641 ] similarity = 0.7333561 [ a lens; ][ a lens cover; and ]
[ 642 ] similarity = 0.4870842 [ a lens cover; and ][ at least a first and a second lens, wherein each lens comprises a plurality of lens elements and each lens element has a plurality of lenses disposed thereon, wherein the first and the second lens cover are configured to cover a first portion of the lens and the second portion of the lens is configured to cover a second portion of the lens, ]
[ 643 ] similarity = 0.8322092 [ at least a first and a second lens, wherein each lens comprises a plurality of lens elements and each lens element has a plurality of lenses disposed thereon, wherein the first and the second lens cover are configured to cover a first portion of the lens and the second portion of the lens is configured to cover a second portion of the lens, ][ wherein the first and the second lenses are configured to cover a first portion of the eye and the second portion of the eye is configured to cover a second portion of the eye, wherein the lens cover comprises a first portion of a lens and a second portion of a lens, and ]
[ 644 ] similarity = 0.5767171 [ wherein the first and the second lenses are configured to cover a first portion of the eye and the second portion of the eye is configured to cover a second portion of the eye, wherein the lens cover comprises a first portion of a lens and a second portion of a lens, and ][ wherein a portion of the lens cover is configured to be placed on a surface of a patient's eye, ]
[ 645 ] similarity = 0.71807605 [ wherein a portion of the lens cover is configured to be placed on a surface of a patient's eye, ][ wherein a first portion of the first portion of the first lens is configured to be positioned on the surface of the patient's eye, and ]
[ 646 ] similarity = 0.6894349 [ wherein a first portion of the first portion of the first lens is configured to be positioned on the surface of the patient's eye, and ][ wherein a portion of the second portion of the lens is positioned on the surface of the patient's eye. ]
[ 647 ] similarity = 0.4105152 [ A method for treating a disease or condition in a patient comprising: ][ providing a first treatment agent; ]
[ 648 ] similarity = 0.7146217 [ providing a first treatment agent; ][ delivering the first treatment agent to the patient; and ]
[ 649 ] similarity = 0.63693917 [ delivering the first treatment agent to the patient; and ][ administering to the patient a second treatment agent in a dosage form that is different than the first treatment agent. ]
[ 650 ] similarity = 0.19072218 [ A method of treating a patient suffering from a disease or disorder comprising administering to a patient in need of treatment a therapeutically effective amount of a compound of the formula (I): ][ or a pharmaceutically acceptable salt thereof. ]
[ 651 ] similarity = -0.042087197 [ A method of treating a patient in need thereof comprising administering to the patient in need thereof a therapeutically effective amount of a compound selected from the group consisting of: ][ a) an amino acid sequence of SEQ ID NO: ]
[ 652 ] similarity = -0.0335629 [ a) an amino acid sequence of SEQ ID NO: ][ 2, ]
[ 653 ] similarity = -0.053193428 [ 2, ][ b) a nucleic acid sequence of SEQ ID NO: ]
[ 654 ] similarity = -0.056002937 [ b) a nucleic acid sequence of SEQ ID NO: ][ 2, and ]
[ 655 ] similarity = -0.06623322 [ 2, and ][ c) a nucleic acid sequence of SEQ ID NO: ]
[ 656 ] similarity = 0.04499398 [ c) a nucleic acid sequence of SEQ ID NO: ][ 4. ]
[ 657 ] similarity = -0.033456296 [ A method of treating an inflammatory condition comprising administering an effective amount of an antibody or antigen-binding fragment thereof to the patient, wherein the antibody or antigen-binding fragment comprises the amino acid sequence set forth in SEQ ID NO: ][ 3. ]
[ 658 ] similarity = 0.1651787 [ A device for the delivery of a drug to the brain of a patient, comprising: ][ a housing having a first end; ]
[ 659 ] similarity = 0.38672078 [ a housing having a first end; ][ a first delivery device having a second end, wherein the first end of the first delivery device is configured for the delivery of a drug, and ]
[ 660 ] similarity = 0.6214839 [ a first delivery device having a second end, wherein the first end of the first delivery device is configured for the delivery of a drug, and ][ the first delivery device further comprises a plurality of first electrodes, wherein each of the first electrodes is configured for the delivery of a drug to the brain of the patient; and ]
[ 661 ] similarity = 0.66253114 [ the first delivery device further comprises a plurality of first electrodes, wherein each of the first electrodes is configured for the delivery of a drug to the brain of the patient; and ][ an implantable medical device configured for delivery of a drug to the brain of the patient, wherein the implantable medical device comprises a plurality of second electrodes, wherein each of the plurality of second electrodes is configured for the delivery of a drug to the brain of the patient. ]
[ 662 ] similarity = 0.16843219 [ A method for producing a compound having a molecular weight of less than about 100, ][ 000, comprising the steps of: ]
[ 663 ] similarity = 0.22794932 [ 000, comprising the steps of: ][ a) contacting the compound with an organic solvent; ]
[ 664 ] similarity = 0.5577621 [ a) contacting the compound with an organic solvent; ][ b) contacting the compound with an organic solvent comprising a solvent selected from a group consisting of a solvent comprising a hydrocarbon group having a molecular weight less than about 50, ]
[ 665 ] similarity = 0.74162185 [ b) contacting the compound with an organic solvent comprising a solvent selected from a group consisting of a solvent comprising a hydrocarbon group having a molecular weight less than about 50, ][ 000 and a solvent comprising a hydrocarbon group having a molecular weight of less than about 50, ]
[ 666 ] similarity = 0.17734993 [ 000 and a solvent comprising a hydrocarbon group having a molecular weight of less than about 50, ][ 000; and ]
[ 667 ] similarity = 0.05034542 [ 000; and ][ c) reacting the organic solvent with the compound, thereby producing an organic solvent having a molecular weight of less than about 10, ]
[ 668 ] similarity = 0.10752409 [ c) reacting the organic solvent with the compound, thereby producing an organic solvent having a molecular weight of less than about 10, ][ 000, ]
[ 669 ] similarity = 0.05712019 [ 000, ][ wherein said organic solvent comprises a hydrocarbon group having a molecular weight of less than about 50, ]
[ 670 ] similarity = 0.58900785 [ wherein said organic solvent comprises a hydrocarbon group having a molecular weight of less than about 50, ][ 000 and a hydrocarbon group having a molecular weight of less than about 50, ]
[ 671 ] similarity = 0.18293005 [ 000 and a hydrocarbon group having a molecular weight of less than about 50, ][ 000. ]
[ 672 ] similarity = 0.24242744 [ A method of treating a patient suffering from an inflammatory disorder comprising administering to the patient an effective amount of a composition comprising: ][ (A) a polymeric composition comprising at least one of an amino acid sequence and a polymeric peptide; and ]
[ 673 ] similarity = 0.007193831 [ (A) a polymeric composition comprising at least one of an amino acid sequence and a polymeric peptide; and ][ (B) a therapeutically effective amount of a pharmaceutically acceptable carrier. ]
[ 674 ] similarity = 0.18155843 [ A method for producing a composition comprising a composition comprising an active ingredient, wherein the active ingredient comprises an amino acid selected from the group consisting of: ][ (a) an amino acid having at least 95% identity to the amino acid sequence of SEQ ID NO: ]
[ 675 ] similarity = -0.009612512 [ (a) an amino acid having at least 95% identity to the amino acid sequence of SEQ ID NO: ][ 2; and ]
[ 676 ] similarity = 0.044057317 [ 2; and ][ (b) a salt of at least one salt of the amino acid, wherein said salt is selected from the group consisting of: ]
[ 677 ] similarity = 0.36224246 [ (b) a salt of at least one salt of the amino acid, wherein said salt is selected from the group consisting of: ][ (i) a salt having a pH of at least 7.8, and ]
[ 678 ] similarity = 0.8643633 [ (i) a salt having a pH of at least 7.8, and ][ (ii) a salt having a pH of at least 8.0. ]
[ 679 ] similarity = 0.4316737 [ A method for treating a disease in a subject, the method comprising administering to said subject a therapeutically effective amount of a composition comprising a pharmaceutically acceptable carrier and a pharmaceutically acceptable carrier-soluble component, wherein said carrier is selected from the group consisting of a polymeric carrier, a pharmaceutically acceptable carrier-soluble component, and ][ a pharmaceutically acceptable carrier-soluble polymeric component; and ]
[ 680 ] similarity = 0.13640751 [ a pharmaceutically acceptable carrier-soluble polymeric component; and ][ a pharmaceutically acceptable salt thereof, wherein said salt is selected from the group consisting of a salt thereof, a salt of an organic solvent, a salt of an organic solvent-soluble polymeric component, and ]
[ 681 ] similarity = 0.56629443 [ a pharmaceutically acceptable salt thereof, wherein said salt is selected from the group consisting of a salt thereof, a salt of an organic solvent, a salt of an organic solvent-soluble polymeric component, and ][ a salt of an organic solvent-soluble polymeric component-soluble component. ]
[ 682 ] similarity = 0.5467974 [ A method of providing a treatment for a patient having a cancer, said cancer being a breast, the method comprising the steps of: ][ a) providing a breast cancer treatment comprising a therapeutically effective amount of a composition comprising: ]
[ 683 ] similarity = 0.08855851 [ a) providing a breast cancer treatment comprising a therapeutically effective amount of a composition comprising: ][ i) an effective amount of a polypeptide having the amino acid sequence of SEQ ID NO: ]
[ 684 ] similarity = 0.56635964 [ i) an effective amount of a polypeptide having the amino acid sequence of SEQ ID NO: ][ 1, wherein said polypeptide is selected from the group consisting of a polypeptide having the amino acid sequence of SEQ ID NO: ]
[ 685 ] similarity = 0.70845854 [ 1, wherein said polypeptide is selected from the group consisting of a polypeptide having the amino acid sequence of SEQ ID NO: ][ 1, a polypeptide having the amino acid sequence of SEQ ID NO: ]
[ 686 ] similarity = 0.9164609 [ 1, a polypeptide having the amino acid sequence of SEQ ID NO: ][ 2, a polypeptide having the amino acid sequence of SEQ ID NO: ]
[ 687 ] similarity = 0.8152437 [ 2, a polypeptide having the amino acid sequence of SEQ ID NO: ][ 3 and a polypeptide having the amino acid sequence of SEQ ID NO: ]
[ 688 ] similarity = 0.4201077 [ 3 and a polypeptide having the amino acid sequence of SEQ ID NO: ][ 4, wherein said polypeptide has a molecular weight of less than 1, ]
[ 689 ] similarity = 0.06485836 [ 4, wherein said polypeptide has a molecular weight of less than 1, ][ 000, ]
[ 690 ] similarity = 1.0000002 [ 000, ][ 000, ]
[ 691 ] similarity = 0.6066469 [ 000, ][ 000 and ]
[ 692 ] similarity = 0.16894488 [ 000 and ][ 000, wherein said polypeptide is present in a concentration of less than 0.5% by weight of a total amount of said composition; and ]
[ 693 ] similarity = 0.167598 [ 000, wherein said polypeptide is present in a concentration of less than 0.5% by weight of a total amount of said composition; and ][ ii) an effective amount of an anti-TNF-1 antibody; and ]
[ 694 ] similarity = 0.3195473 [ ii) an effective amount of an anti-TNF-1 antibody; and ][ b) administering to said breast cancer treatment a therapeutically effective amount of said composition. ]
[ 695 ] similarity = 0.2656301 [ An apparatus for the delivery of a pharmaceutical composition comprising: ][ a) a container; ]
[ 696 ] similarity = 0.22422963 [ a) a container; ][ b) a first dispenser having at least one outlet, the first dispenser being configured to receive the pharmaceutical composition from the container; and ]
[ 697 ] similarity = 0.7592018 [ b) a first dispenser having at least one outlet, the first dispenser being configured to receive the pharmaceutical composition from the container; and ][ c) a second dispenser, configured to receive the pharmaceutical composition from the container, the second dispenser being configured to be in fluid communication with the first dispenser; ]
[ 698 ] similarity = 0.84099054 [ c) a second dispenser, configured to receive the pharmaceutical composition from the container, the second dispenser being configured to be in fluid communication with the first dispenser; ][ d) the first dispenser being configured to be in fluid communication with the second dispenser and the second dispenser being configured to be in fluid communication with the first dispenser, wherein: ]
[ 699 ] similarity = 0.66820025 [ d) the first dispenser being configured to be in fluid communication with the second dispenser and the second dispenser being configured to be in fluid communication with the first dispenser, wherein: ][ i) the first dispenser is configured to receive the pharmaceutical composition from the container and the second dispenser is configured to be in fluid communication with the container, and ]
[ 700 ] similarity = 0.63045615 [ i) the first dispenser is configured to receive the pharmaceutical composition from the container and the second dispenser is configured to be in fluid communication with the container, and ][ ii) the first dispenser and the second dispenser are configured to be in fluid communication with each other. ]
[ 701 ] similarity = 0.20636135 [ A system for providing an image, comprising: ][ a plurality of cameras, each camera having a camera lens, a first camera lens and a camera body, the first camera lens being configured to focus on an object in a first direction and the first camera lens being configured to focus on a second direction, the camera body being configured to be disposed on a surface of a body, the camera body being configured to receive a light beam from a source of light; ]
[ 702 ] similarity = 0.49401197 [ a plurality of cameras, each camera having a camera lens, a first camera lens and a camera body, the first camera lens being configured to focus on an object in a first direction and the first camera lens being configured to focus on a second direction, the camera body being configured to be disposed on a surface of a body, the camera body being configured to receive a light beam from a source of light; ][ a processor, configured to process a first image of the object in the first direction and a second image of the object in the second direction, wherein the processor is further configured to determine an orientation of the first and second images, the processor being further configured to calculate an angle between the first and second images, and ]
[ 703 ] similarity = 0.6737515 [ a processor, configured to process a first image of the object in the first direction and a second image of the object in the second direction, wherein the processor is further configured to determine an orientation of the first and second images, the processor being further configured to calculate an angle between the first and second images, and ][ the processor being further configured to calculate a distance between the first and second images, and ]
[ 704 ] similarity = 0.5910496 [ the processor being further configured to calculate a distance between the first and second images, and ][ wherein the processor is further configured to determine an orientation of the first image and the orientation of a second image based on the calculated angle; and ]
[ 705 ] similarity = 0.550124 [ wherein the processor is further configured to determine an orientation of the first image and the orientation of a second image based on the calculated angle; and ][ a display, configured to display the orientation of the first and second photos. ]
[ 706 ] similarity = 0.22168797 [ A device for a patient, the device comprising: ][ a first housing; ]
[ 707 ] similarity = 0.38118017 [ a first housing; ][ a first electrode disposed on the first housing, the first electrode configured to be coupled to a first nerve in the patient; ]
[ 708 ] similarity = 0.81189436 [ a first electrode disposed on the first housing, the first electrode configured to be coupled to a first nerve in the patient; ][ a first sensor disposed on the first housing, the first sensor configured to receive electrical signals from the first nerve, the first sensor configured to be coupled to a second electrode in the device, the second electrode configured to be coupled to the patient's nerve; and ]
[ 709 ] similarity = 0.6975149 [ a first sensor disposed on the first housing, the first sensor configured to receive electrical signals from the first nerve, the first sensor configured to be coupled to a second electrode in the device, the second electrode configured to be coupled to the patient's nerve; and ][ a second electrode disposed on the device, the second electrode configured to be coupled to a second nerve, the second electrode configured to receive electrical signals from the second nerve, ]
[ 710 ] similarity = 0.28917444 [ a second electrode disposed on the device, the second electrode configured to be coupled to a second nerve, the second electrode configured to receive electrical signals from the second nerve, ][ wherein the first and second sensors are disposed in the first housing. ]
[ 711 ] similarity = 0.15783776 [ An implant for use in an implantable medical device, the implant comprising: ][ a housing comprising a first portion, a first side, a first wall, and ]
[ 712 ] similarity = 0.68725157 [ a housing comprising a first portion, a first side, a first wall, and ][ a first opening, the first opening being in communication with a first end of a first portion of the housing; ]
[ 713 ] similarity = 0.56586844 [ a first opening, the first opening being in communication with a first end of a first portion of the housing; ][ a plurality of first transducers disposed within the first opening; and ]
[ 714 ] similarity = 0.38208774 [ a plurality of first transducers disposed within the first opening; and ][ an implant member having a first portion, a first end portion, and ]
[ 715 ] similarity = 0.63929117 [ an implant member having a first portion, a first end portion, and ][ a first side, the first side of the first transducer disposed between the first portion of the housing and the implant portion, wherein the first transducer comprises: ]
[ 716 ] similarity = 0.4531918 [ a first side, the first side of the first transducer disposed between the first portion of the housing and the implant portion, wherein the first transducer comprises: ][ a plurality of first electrodes disposed within the first opening; ]
[ 717 ] similarity = 0.71819663 [ a plurality of first electrodes disposed within the first opening; ][ a first transducer coil disposed within the first opening; ]
[ 718 ] similarity = 0.7980594 [ a first transducer coil disposed within the first opening; ][ a first transducer element disposed within the first opening; and ]
[ 719 ] similarity = 0.63155615 [ a first transducer element disposed within the first opening; and ][ a first coil disposed within the first opening, the first coil being in communication with the first electrode; ]
[ 720 ] similarity = 0.6511361 [ a first coil disposed within the first opening, the first coil being in communication with the first electrode; ][ wherein, when the first transducer element is in contact with a first end of the first transducer, the first transducer coil is configured to generate an electrical signal that is received by a first transducer element; and ]
[ 721 ] similarity = 0.92387676 [ wherein, when the first transducer element is in contact with a first end of the first transducer, the first transducer coil is configured to generate an electrical signal that is received by a first transducer element; and ][ wherein when the first transducer coil is disposed within a first portion of the first portion of the housing, the first transducer element is configured to generate an electrical signal that is received by a first transducer element. ]
[ 722 ] similarity = 0.016863957 [ An apparatus comprising: ][ a housing having a first end and a second end, said housing having an open bottom and a bottom wall, said housing having a top wall and a bottom wall, said bottom wall being substantially parallel to said bottom wall, said bottom wall having an opening at a bottom edge of said bottom wall, said opening having a top edge; ]
[ 723 ] similarity = 0.4943791 [ a housing having a first end and a second end, said housing having an open bottom and a bottom wall, said housing having a top wall and a bottom wall, said bottom wall being substantially parallel to said bottom wall, said bottom wall having an opening at a bottom edge of said bottom wall, said opening having a top edge; ][ a first handle disposed in said housing, said first handle having an open top surface and a closed bottom surface; ]
[ 724 ] similarity = 0.6381309 [ a first handle disposed in said housing, said first handle having an open top surface and a closed bottom surface; ][ a second handle disposed in said housing, said second handle having an open top surface and a closed bottom surface, said second handle having a first end and a second end, said second handle having said open top surface and said closed bottom surface, said first and second ends of said first and second handles each being disposed in a substantially parallel relationship with said open top surface of said first handle and said closed bottom surface of said second handle; and ]
[ 725 ] similarity = 0.6416987 [ a second handle disposed in said housing, said second handle having an open top surface and a closed bottom surface, said second handle having a first end and a second end, said second handle having said open top surface and said closed bottom surface, said first and second ends of said first and second handles each being disposed in a substantially parallel relationship with said open top surface of said first handle and said closed bottom surface of said second handle; and ][ a plurality of first and second arms, said first arm being disposed in a substantially parallel relationship with said bottom wall of said bottom wall, said first and second arms each having a first end and a second end, each of said first arms having a first end and a second end, said first end being disposed substantially parallel to said top edge of said bottom wall of said bottom wall of said housing, said second arm being disposed substantially parallel to said bottom wall of said bottom wall of said housing, said second arm having a first end and a second end, said second end disposed substantially parallel to said bottom wall of said bottom wall of said housing, and ]
[ 726 ] similarity = 0.8729669 [ a plurality of first and second arms, said first arm being disposed in a substantially parallel relationship with said bottom wall of said bottom wall, said first and second arms each having a first end and a second end, each of said first arms having a first end and a second end, said first end being disposed substantially parallel to said top edge of said bottom wall of said bottom wall of said housing, said second arm being disposed substantially parallel to said bottom wall of said bottom wall of said housing, said second arm having a first end and a second end, said second end disposed substantially parallel to said bottom wall of said bottom wall of said housing, and ][ each of the first and second arms having an open top surface, said first and second ends being disposed in a substantially parallel relationship with said top edge of said bottom wall of said bottom wall of said housing, said first and second ends of said first and second arms each being disposed in a substantially parallel relationship with said top edge of said bottom wall of said housing, and ]
[ 727 ] similarity = 0.4820215 [ each of the first and second arms having an open top surface, said first and second ends being disposed in a substantially parallel relationship with said top edge of said bottom wall of said bottom wall of said housing, said first and second ends of said first and second arms each being disposed in a substantially parallel relationship with said top edge of said bottom wall of said housing, and ][ wherein said open bottom of said housing has an opening at an upper end thereof, said opening having a top edge. ]
[ 728 ] similarity = 0.21698646 [ An isolated antibody or antigen binding fragment thereof that specifically binds to the polypeptide of SEQ ID NO: ][ 1, wherein said antibody is selected from the group consisting of: ]
[ 729 ] similarity = 0.32762498 [ 1, wherein said antibody is selected from the group consisting of: ][ a) an immunoglobulin antibody; ]
[ 730 ] similarity = 0.4786572 [ a) an immunoglobulin antibody; ][ b) an antibody that specifically binds to the polypeptide of SEQ ID NO: ]
[ 731 ] similarity = 0.4334877 [ b) an antibody that specifically binds to the polypeptide of SEQ ID NO: ][ 1; or c) an immunoglobulin fragment of SEQ ID NO: ]
[ 732 ] similarity = 0.1025448 [ 1; or c) an immunoglobulin fragment of SEQ ID NO: ][ 1. ]
[ 733 ] similarity = 0.30342606 [ A method of providing a therapeutic effect of an effective amount, said method comprising: ][ providing a first pharmaceutical composition comprising a first active agent and a first pharmaceutical carrier; ]
[ 734 ] similarity = 0.5796659 [ providing a first pharmaceutical composition comprising a first active agent and a first pharmaceutical carrier; ][ delivering said first active agent to a first site of an animal's body, the first active agent comprising a first compound selected from the group consisting of: ]
[ 735 ] similarity = 0.19666457 [ delivering said first active agent to a first site of an animal's body, the first active agent comprising a first compound selected from the group consisting of: ][ (a) an anti-inflammatory agent, ]
[ 736 ] similarity = 0.5971272 [ (a) an anti-inflammatory agent, ][ (b) an anti-cancer agent, ]
[ 737 ] similarity = 0.60408986 [ (b) an anti-cancer agent, ][ (c) a chemopreventive agent, and ]
[ 738 ] similarity = 0.3274855 [ (c) a chemopreventive agent, and ][ (d) a chemopreventive agent, wherein the first active agent is a pharmaceutically acceptable salt of the first compound; and ]
[ 739 ] similarity = 0.267488 [ (d) a chemopreventive agent, wherein the first active agent is a pharmaceutically acceptable salt of the first compound; and ][ delivering said second active agent to a second site of the animal's body, ]
[ 740 ] similarity = 0.13946477 [ delivering said second active agent to a second site of the animal's body, ][ wherein said first pharmaceutical composition comprises a second pharmaceutical carrier; and, ]
[ 741 ] similarity = 0.14787546 [ wherein said first pharmaceutical composition comprises a second pharmaceutical carrier; and, ][ administering said second active agent to a second site of the animal's body. ]
[ 742 ] similarity = 0.5034689 [ An apparatus for treating a wound in a patient, said wound comprising a first surface of the wound, a second surface of the wound, and ][ a plurality of tissue layers, the wound being treated by a surgical instrument comprising: ]
[ 743 ] similarity = 0.13857442 [ a plurality of tissue layers, the wound being treated by a surgical instrument comprising: ][ a cutting blade having a first end and a second end and having a cutting surface, the blade having a first cutting edge, the first cutting edge having an outer edge, an inner edge, a plurality of first and second edges, and ]
[ 744 ] similarity = 0.6051674 [ a cutting blade having a first end and a second end and having a cutting surface, the blade having a first cutting edge, the first cutting edge having an outer edge, an inner edge, a plurality of first and second edges, and ][ an inner surface extending between the first and second cutting edges; and ]
[ 745 ] similarity = 0.44786915 [ an inner surface extending between the first and second cutting edges; and ][ at least one tissue layer comprising a tissue, the at least one tissue layer having a first outer surface, a second inner surface, and ]
[ 746 ] similarity = 0.7480777 [ at least one tissue layer comprising a tissue, the at least one tissue layer having a first outer surface, a second inner surface, and ][ a plurality of second and third surfaces, each of which is adjacent to the outer surface of the tissue, the plurality of second and third surfaces including at least one of a first surface and a second surface, the first and second surfaces being substantially parallel to one another, the at least one tissue layer being disposed within the tissue layer. ]
[ 747 ] similarity = 0.34233388 [ A device for the treatment of a patient, comprising: ][ a first electrode configured to receive an electrical current; ]
[ 748 ] similarity = 0.5618532 [ a first electrode configured to receive an electrical current; ][ an electrode support configured to support a first portion of the electrode and a second portion of the electrode; and ]
[ 749 ] similarity = 0.74152315 [ an electrode support configured to support a first portion of the electrode and a second portion of the electrode; and ][ an electrode guide configured to guide an electrode portion of the electrode support toward a patient, ]
[ 750 ] similarity = 0.334283 [ an electrode guide configured to guide an electrode portion of the electrode support toward a patient, ][ wherein the electrode support is configured to be disposed in a first position relative to the electrode support and to be disposed in a second position relative to the first portion of the electrode, the first position including a first position of the electrode support and a second position of the electrode support, the first position being substantially perpendicular to the second position, the electrode support being disposed in the first position when the device is in the first position and being disposed in the second position when the device is in the second position. ]
[ 751 ] similarity = 0.17519635 [ A method of treating a disease comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising an effective amount of an antibody that specifically binds to an epitope of a protein selected from the group consisting of: ][ (i) the epitope selected from the group consisting of SEQ ID NO: ]
[ 752 ] similarity = 0.3041238 [ (i) the epitope selected from the group consisting of SEQ ID NO: ][ 2, SEQ ID NO: ]
[ 753 ] similarity = 0.7720622 [ 2, SEQ ID NO: ][ 3, SEQ ID NO: ]
[ 754 ] similarity = 0.79470795 [ 3, SEQ ID NO: ][ 4, SEQ ID NO: ]
[ 755 ] similarity = 0.8005054 [ 4, SEQ ID NO: ][ 5, SEQ ID NO: ]
[ 756 ] similarity = 0.83311415 [ 5, SEQ ID NO: ][ 6, SEQ ID NO: ]
[ 757 ] similarity = 0.29246724 [ 6, SEQ ID NO: ][ 7, and ]
[ 758 ] similarity = 0.19958445 [ 7, and ][ SEQ ID NO: ]
[ 759 ] similarity = 0.12004465 [ SEQ ID NO: ][ 8, ]
[ 760 ] similarity = 0.06331579 [ 8, ][ (ii) an antigen-binding domain, and ]
[ 761 ] similarity = 0.12732595 [ (ii) an antigen-binding domain, and ][ (iii) a nucleic acid sequence that specifically binds to said epitope. ]
[ 762 ] similarity = 0.33971077 [ A method for determining a concentration of a compound in a sample, comprising: ][ providing a sample; ]
[ 763 ] similarity = 0.14357373 [ providing a sample; ][ providing a solution of a compound having a molecular weight of about 2, ]
[ 764 ] similarity = 0.12976353 [ providing a solution of a compound having a molecular weight of about 2, ][ 000 to about 4, ]
[ 765 ] similarity = 0.40686318 [ 000 to about 4, ][ 000 &#x3bc; ]
[ 766 ] similarity = 0.13435185 [ 000 &#x3bc; ][ m; ]
[ 767 ] similarity = -0.032533955 [ m; ][ (c) adding a first solvent to the sample; ]
[ 768 ] similarity = 0.56217396 [ (c) adding a first solvent to the sample; ][ (d) adding a second solvent; ]
[ 769 ] similarity = 0.56458616 [ (d) adding a second solvent; ][ (e) mixing the solution of the compound with the first solvent and the second solvent; ]
[ 770 ] similarity = 0.75138605 [ (e) mixing the solution of the compound with the first solvent and the second solvent; ][ (f) separating the first solvent from the second solvent by a solvent separation process; ]
[ 771 ] similarity = 0.86267924 [ (f) separating the first solvent from the second solvent by a solvent separation process; ][ (g) separating the first solvent from the second solvent by a solvent separation process, wherein the first solvent has a molecular weight of about 2, ]
[ 772 ] similarity = 0.008830221 [ (g) separating the first solvent from the second solvent by a solvent separation process, wherein the first solvent has a molecular weight of about 2, ][ 000 to about 4, ]
[ 773 ] similarity = 0.40686318 [ 000 to about 4, ][ 000 &#x3bc; ]
[ 774 ] similarity = 0.11473016 [ 000 &#x3bc; ][ m; and ]
[ 775 ] similarity = 0.10024403 [ m; and ][ (h) mixing a first solvent and a second solvent to obtain a solution of at least one compound having a molecular weight of about 2, ]
[ 776 ] similarity = -0.01975787 [ (h) mixing a first solvent and a second solvent to obtain a solution of at least one compound having a molecular weight of about 2, ][ 000 and 4, ]
[ 777 ] similarity = 0.30758175 [ 000 and 4, ][ 000 &#x3bc; ]
[ 778 ] similarity = 0.13435185 [ 000 &#x3bc; ][ m. ]
[ 779 ] similarity = 0.5568236 [ A method for producing a biodegradable composition comprising a biodegradable polymer, the method comprising: ][ a) providing the polymer to be biodegradable, wherein the polymer comprises a first polymer and a second polymer; ]
[ 780 ] similarity = 0.7173183 [ a) providing the polymer to be biodegradable, wherein the polymer comprises a first polymer and a second polymer; ][ b) contacting said first polymer and said second polymer with a solvent to form a polymer mixture; ]
[ 781 ] similarity = 0.7464825 [ b) contacting said first polymer and said second polymer with a solvent to form a polymer mixture; ][ c) contacting said first polymer with a biodegradable polymer to form a biodegradable polymer; and ]
[ 782 ] similarity = 0.48254365 [ c) contacting said first polymer with a biodegradable polymer to form a biodegradable polymer; and ][ d) removing the solvent from said polymer mixture, wherein said solvent is selected from the group consisting of a water soluble polymer and an alkali metal, wherein the biodegradable polymer is selected from the group consisting of a polymer having a molecular weight of from 1 to 100, and ]
[ 783 ] similarity = 0.74997145 [ d) removing the solvent from said polymer mixture, wherein said solvent is selected from the group consisting of a water soluble polymer and an alkali metal, wherein the biodegradable polymer is selected from the group consisting of a polymer having a molecular weight of from 1 to 100, and ][ wherein said biodegradable polymer is selected from the group consisting of a polymer having a molecular weight of less than 100. ]
[ 784 ] similarity = 0.17539206 [ A system for treating an eye comprising: ][ a first implantable device having a first implantable device housing and a first device, the first device having a first implantable device housing and a first device, the first device having a first implantable device housing and a first device, the first device having a first implantable device housing and a first device, the first device having a first implantable device housing and a first device; ]
[ 785 ] similarity = 0.44793904 [ a first implantable device having a first implantable device housing and a first device, the first device having a first implantable device housing and a first device, the first device having a first implantable device housing and a first device, the first device having a first implantable device housing and a first device, the first device having a first implantable device housing and a first device; ][ a second implantable device having a second device housing and a second device, the second device having a second device housing and a second device, the second device having a second device housing and a second device, the second device having a second device housing and a second device, wherein the first device is configured to be implanted into the eye; and ]
[ 786 ] similarity = 0.36567432 [ a second implantable device having a second device housing and a second device, the second device having a second device housing and a second device, the second device having a second device housing and a second device, the second device having a second device housing and a second device, wherein the first device is configured to be implanted into the eye; and ][ a first implantation system configured to be implanted into the eye, wherein the first implantation system is configured to be implanted into the eye and wherein the first implantation system comprises a first implantable device housing and a first implantable device, wherein the first implantable device housing and the first device are configured to be implanted into the eye, wherein the first implantation system further comprises a first implantable device housing and a first implantable device; ]
[ 787 ] similarity = 0.45129526 [ a first implantation system configured to be implanted into the eye, wherein the first implantation system is configured to be implanted into the eye and wherein the first implantation system comprises a first implantable device housing and a first implantable device, wherein the first implantable device housing and the first device are configured to be implanted into the eye, wherein the first implantation system further comprises a first implantable device housing and a first implantable device; ][ wherein the second device is configured to be implanted into a patient's eye; ]
[ 788 ] similarity = 0.7440603 [ wherein the second device is configured to be implanted into a patient's eye; ][ wherein the first implantable device housing and the second device are configured to be implanted in the patient's eye; and ]
[ 789 ] similarity = 0.91110027 [ wherein the first implantable device housing and the second device are configured to be implanted in the patient's eye; and ][ wherein the first device and the second device are configured to be implanted into the patient's eye. ]
[ 790 ] similarity = 0.30263615 [ A method of treating a patient with an inflammatory disease comprising administering an antibody to the patient that specifically binds to the CDR5-5 of the human IL-4 receptor, wherein the antibody is selected from the group consisting of a human IL-4 receptor antagonist and a human IL-4 receptor antagonist with a CDR5-5 binding activity that is greater than 50% by weight of that of the CDR5-5 of the human IL-4 receptor, and ][ wherein the patient is a subject with a disease characterized by a high level of IL-4 expression. ]
[ 791 ] similarity = 0.13599026 [ A method for treating a patient having a tumor comprising the steps of: ][ administering a therapeutically effective amount of a pharmaceutically acceptable salt or salt thereof, wherein the salt or salt is administered in the form of an oral dosage form, and ]
[ 792 ] similarity = 0.7241099 [ administering a therapeutically effective amount of a pharmaceutically acceptable salt or salt thereof, wherein the salt or salt is administered in the form of an oral dosage form, and ][ wherein the pharmaceutically acceptable salt or salt is a pharmaceutically acceptable salt or salt thereof, a salt of a salt of a pharmaceutically acceptable salt or salt thereof, a salt of a salt of a pharmaceutically acceptable salt or salt thereof, an salt of a pharmaceutically acceptable salt or salt thereof, a salt of a salt of a pharmaceutically acceptable salt or salt thereof, or a salt of a salt of a pharmaceutically acceptable salt or salt thereof. ]
[ 793 ] similarity = 0.24866693 [ An implantable medical device comprising: ][ a housing; ]
[ 794 ] similarity = 0.029260907 [ a housing; ][ a first electrode configured to couple to a first portion of a patient's body, the first electrode comprising a first electrode layer and a second electrode layer, wherein the first electrode is configured to couple to the first portion of the patient's body; and ]
[ 795 ] similarity = 0.75242317 [ a first electrode configured to couple to a first portion of a patient's body, the first electrode comprising a first electrode layer and a second electrode layer, wherein the first electrode is configured to couple to the first portion of the patient's body; and ][ a second electrode, wherein the second electrode is configured to couple to a second portion of the patient's body, the second electrode layer being different in shape from the first electrode layer and the second electrode layer comprising an outer surface, ]
[ 796 ] similarity = 0.7905593 [ a second electrode, wherein the second electrode is configured to couple to a second portion of the patient's body, the second electrode layer being different in shape from the first electrode layer and the second electrode layer comprising an outer surface, ][ wherein the first electrode is configured to couple to an area of the patient's body that is not adjacent a second electrode layer, the area of the patient's body being adjacent to the second electrode layer. ]
[ 797 ] similarity = 0.2743711 [ An implantable medical device comprising: ][ a body; and, ]
[ 798 ] similarity = 0.1946817 [ a body; and, ][ an implantable medical device controller configured to: ]
[ 799 ] similarity = 0.27220827 [ an implantable medical device controller configured to: ][ detect a condition of a patient; ]
[ 800 ] similarity = 0.5088689 [ detect a condition of a patient; ][ determine whether the condition of the patient is in the range of normal to abnormal, wherein a condition of a patient that does not meet one or more conditions of the normal to abnormal condition of the patient is not abnormal; and ]
[ 801 ] similarity = 0.54852754 [ determine whether the condition of the patient is in the range of normal to abnormal, wherein a condition of a patient that does not meet one or more conditions of the normal to abnormal condition of the patient is not abnormal; and ][ determine a treatment for the abnormal condition based on the detected condition. ]
[ 802 ] similarity = -0.0315625 [ A method of treating a patient having a disease or condition, comprising administering to said patient in need thereof an effective amount of a composition comprising a compound of formula I, wherein: ][ R1 and R2 are independently selected from the group consisting of hydrogen, C1 to C6 alkyl, C1 to C6 alkoxy, C1 to C6 alkoxyalkyl or C1 to C6 alkoxyalkylalkyl; ]
[ 803 ] similarity = 0.89955354 [ R1 and R2 are independently selected from the group consisting of hydrogen, C1 to C6 alkyl, C1 to C6 alkoxy, C1 to C6 alkoxyalkyl or C1 to C6 alkoxyalkylalkyl; ][ X and Z are independently selected from the group consisting of hydrogen, C1 to C6 alkyl, C1 to C6 alkoxy, C1 to C6 alkoxyalkyl or C1 to C6 alkoxyalkylalkyl; ]
[ 804 ] similarity = 0.46147293 [ X and Z are independently selected from the group consisting of hydrogen, C1 to C6 alkyl, C1 to C6 alkoxy, C1 to C6 alkoxyalkyl or C1 to C6 alkoxyalkylalkyl; ][ R1 is a C1-6 alkyl or C1 to C6 alkyl; ]
[ 805 ] similarity = 0.8880996 [ R1 is a C1-6 alkyl or C1 to C6 alkyl; ][ R2 is a C1-6 alkyl or C1 to C6 alkyl; ]
[ 806 ] similarity = 0.37418923 [ R2 is a C1-6 alkyl or C1 to C6 alkyl; ][ Y is independently selected from the group consisting of hydrogen, C1 to C6 alkoxy, C1 to C6 alkoxyalkyl, C1 to C6 alkoxyalkylalkyl or C1 to C6 alkoxyalkylalkyl; and ]
[ 807 ] similarity = 0.76409775 [ Y is independently selected from the group consisting of hydrogen, C1 to C6 alkoxy, C1 to C6 alkoxyalkyl, C1 to C6 alkoxyalkylalkyl or C1 to C6 alkoxyalkylalkyl; and ][ X and Z are each independently selected from the group consisting of hydrogen, C1 to C6 alkyl, C1 to C6 alkoxy, and ]
[ 808 ] similarity = 0.32415244 [ X and Z are each independently selected from the group consisting of hydrogen, C1 to C6 alkyl, C1 to C6 alkoxy, and ][ C1 to C6 alkoxyalkyl. ]
[ 809 ] similarity = 0.18431234 [ A method for determining a position of a patient, the method comprising: ][ receiving, by an implantable medical device, a first image from a medical image sensor, the medical image sensor having an image sensor array and a first image sensor; ]
[ 810 ] similarity = 0.7941866 [ receiving, by an implantable medical device, a first image from a medical image sensor, the medical image sensor having an image sensor array and a first image sensor; ][ receiving, by a processor, a second image from the medical image sensor, the second image having a second image sensor array and an image sensor array; ]
[ 811 ] similarity = 0.39792696 [ receiving, by a processor, a second image from the medical image sensor, the second image having a second image sensor array and an image sensor array; ][ determining, by the processor, a first position of the patient based on the first image; ]
[ 812 ] similarity = 0.7283442 [ determining, by the processor, a first position of the patient based on the first image; ][ determining, by the processor, a second position of the patient based on the second image; ]
[ 813 ] similarity = 0.6020714 [ determining, by the processor, a second position of the patient based on the second image; ][ determining, by the processor, a distance between the patient and the first position; ]
[ 814 ] similarity = 0.88607514 [ determining, by the processor, a distance between the patient and the first position; ][ determining, by the processor, a distance between the patient and the second position; ]
[ 815 ] similarity = 0.8369169 [ determining, by the processor, a distance between the patient and the second position; ][ determining, by the processor, a distance between the first position and the second position; and ]
[ 816 ] similarity = 0.6342512 [ determining, by the processor, a distance between the first position and the second position; and ][ displaying the first position and the second position on a display device. ]
[ 817 ] similarity = 0.22638744 [ An apparatus for providing a patient with a therapeutic dose of a pharmaceutical composition, the apparatus comprising: ][ a) a first dispensing container; and ]
[ 818 ] similarity = 0.5730554 [ a) a first dispensing container; and ][ b) a second dispensing container; ]
[ 819 ] similarity = 0.18636858 [ b) a second dispensing container; ][ c) a first delivery device configured to be disposed in a first patient compartment of a first delivery device; ]
[ 820 ] similarity = 0.7200588 [ c) a first delivery device configured to be disposed in a first patient compartment of a first delivery device; ][ d) a second delivery device configured to be disposed in a second patient compartment of the first delivery device; ]
[ 821 ] similarity = 0.56281847 [ d) a second delivery device configured to be disposed in a second patient compartment of the first delivery device; ][ e) a first delivery device control unit configured to receive a first delivery device control command to control a first delivery device of the first delivery device; ]
[ 822 ] similarity = 0.78039944 [ e) a first delivery device control unit configured to receive a first delivery device control command to control a first delivery device of the first delivery device; ][ f) a second delivery device control unit configured to receive a second delivery device control command to control a second delivery device of the first delivery device; ]
[ 823 ] similarity = 0.75692916 [ f) a second delivery device control unit configured to receive a second delivery device control command to control a second delivery device of the first delivery device; ][ g) a first delivery device control unit configured to receive a first delivery device control command to control a first delivery device of the first delivery device; and ]
[ 824 ] similarity = 0.64884675 [ g) a first delivery device control unit configured to receive a first delivery device control command to control a first delivery device of the first delivery device; and ][ h) a second delivery device control unit configured to receive a second delivery device control command to control a second delivery device of the second delivery device. ]
[ 825 ] similarity = 0.35706353 [ A method for treating an autoimmune disorder comprising administering to a subject having an autoimmune disorder a therapeutically effective amount of an antibody that binds to a humanized antigen-binding domain of a humanized antigen-binding protein (HAP), wherein the HAP comprises a humanized antigen-binding protein (HAP) domain and a humanized antigen binding domain (HBD) domain, wherein the HAP domain comprises the amino acid sequence of SEQ ID NO: ][ 1, wherein the HBD domain comprises the amino acid sequence of SEQ ID NO: ]
[ 826 ] similarity = 0.6733812 [ 1, wherein the HBD domain comprises the amino acid sequence of SEQ ID NO: ][ 2, wherein the HBD domain is selected from the group consisting of the amino acid sequence of SEQ ID NO: ]
[ 827 ] similarity = 0.18846989 [ 2, wherein the HBD domain is selected from the group consisting of the amino acid sequence of SEQ ID NO: ][ 1, SEQ ID NO: ]
[ 828 ] similarity = 0.7964808 [ 1, SEQ ID NO: ][ 2, SEQ ID NO: ]
[ 829 ] similarity = 0.7720622 [ 2, SEQ ID NO: ][ 3, SEQ ID NO: ]
[ 830 ] similarity = 0.79470795 [ 3, SEQ ID NO: ][ 4, SEQ ID NO: ]
[ 831 ] similarity = 0.8005054 [ 4, SEQ ID NO: ][ 5, SEQ ID NO: ]
[ 832 ] similarity = 0.83311415 [ 5, SEQ ID NO: ][ 6, SEQ ID NO: ]
[ 833 ] similarity = 0.8179097 [ 6, SEQ ID NO: ][ 7, SEQ ID NO: ]
[ 834 ] similarity = 0.83411634 [ 7, SEQ ID NO: ][ 8, SEQ ID NO: ]
[ 835 ] similarity = 0.84770155 [ 8, SEQ ID NO: ][ 9, SEQ ID NO: ]
[ 836 ] similarity = 0.82152116 [ 9, SEQ ID NO: ][ 10, SEQ ID NO: ]
[ 837 ] similarity = 0.83725446 [ 10, SEQ ID NO: ][ 11, SEQ ID NO: ]
[ 838 ] similarity = 0.8285377 [ 11, SEQ ID NO: ][ 12, SEQ ID NO: ]
[ 839 ] similarity = 0.7780899 [ 12, SEQ ID NO: ][ 13, or SEQ ID NO: ]
[ 840 ] similarity = 0.40321845 [ 13, or SEQ ID NO: ][ 14. ]
[ 841 ] similarity = 0.096915945 [ A method of treating a patient with an autoimmune disorder in which the immune system of the patient is impaired or defective in causing the autoimmune disorder in a patient, the method comprising: ][ administering to the patient a therapeutically effective amount of at least one compound selected from the group consisting of a pharmaceutically acceptable salt of at least one compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound, ]
[ 842 ] similarity = 0.2165288 [ administering to the patient a therapeutically effective amount of at least one compound selected from the group consisting of a pharmaceutically acceptable salt of at least one compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound, ][ wherein the at least one compound comprises a polypeptide comprising the amino acid sequence of SEQ ID NO: 1. ]
[ 843 ] similarity = 0.4662832 [ A method of treating a patient with an inflammatory bowel disease, the method comprising: ][ administering to the patient a therapeutically effective amount of a therapeutically acceptable composition, comprising: ]
[ 844 ] similarity = 0.059230335 [ administering to the patient a therapeutically effective amount of a therapeutically acceptable composition, comprising: ][ a first agent, wherein the first agent comprises a first agent selected from the group consisting of a peptide and a peptide having a peptide sequence that is at least 95% identical to SEQ ID NO: ]
[ 845 ] similarity = 0.024258839 [ a first agent, wherein the first agent comprises a first agent selected from the group consisting of a peptide and a peptide having a peptide sequence that is at least 95% identical to SEQ ID NO: ][ 1; and ]
[ 846 ] similarity = 0.02758918 [ 1; and ][ a second agent, wherein the second agent comprises a second agent selected from the group consisting of a polypeptide, a peptide having a peptide sequence that is at least 95% identical to SEQ ID NO: ]
[ 847 ] similarity = 0.027589167 [ a second agent, wherein the second agent comprises a second agent selected from the group consisting of a polypeptide, a peptide having a peptide sequence that is at least 95% identical to SEQ ID NO: ][ 1, and ]
[ 848 ] similarity = 0.101793244 [ 1, and ][ a pharmaceutically acceptable carrier, wherein the first agent and the second agent are administered to the patient in a dose effective to treat the inflammatory bowel disease; ]
[ 849 ] similarity = 0.42048228 [ a pharmaceutically acceptable carrier, wherein the first agent and the second agent are administered to the patient in a dose effective to treat the inflammatory bowel disease; ][ administering to the patient at least one other agent; and, ]
[ 850 ] similarity = 0.3211586 [ administering to the patient at least one other agent; and, ][ administering to the patient at least one other agent selected from a group consisting of: a pharmaceutically acceptable salt of a polypeptide, a pharmaceutically acceptable salt of a peptide having a peptide sequence that is at least 95% identical to SEQ ID NO: ]
[ 851 ] similarity = 0.5313779 [ administering to the patient at least one other agent selected from a group consisting of: a pharmaceutically acceptable salt of a polypeptide, a pharmaceutically acceptable salt of a peptide having a peptide sequence that is at least 95% identical to SEQ ID NO: ][ 1 and a pharmaceutically acceptable salt, wherein the at least one agent is administered to the patient. ]
[ 852 ] similarity = 0.5179006 [ A method of treating a patient suffering from an inflammatory bowel disease, comprising administering an effective amount of an antibody or antigen-binding fragment thereof to the patient, wherein the antibody or antigen-binding fragment comprises a nucleic acid sequence encoding an anti-inflammatory peptide comprising the amino acid sequence of SEQ ID NO: ][ 2, wherein said antibody or antigen-binding fragment has the amino acid sequence of SEQ ID NO: ]
[ 853 ] similarity = -0.039887182 [ 2, wherein said antibody or antigen-binding fragment has the amino acid sequence of SEQ ID NO: ][ 2. ]
[ 854 ] similarity = 0.7339592 [ A method for treating a patient with a cancer comprising administering to the patient an effective amount of an antibody or antigen binding fragment thereof that specifically binds to a human CD8+ T cell receptor, wherein the human CD8+ T cell receptor consists of a T cell receptor domain comprising a CDR1 region, CDR2 region and CDR3 region, wherein the antibody or antigen binding fragment is a fragment of an antibody or antigen binding fragment that binds to the human CD8+ T cell receptor, wherein the antibody or antigen binding fragment is selected from the group consisting of: ][ a) an antibody that binds to a CDR1 region of an antigen-binding fragment of the human CD8+ T cell receptor, and ]
[ 855 ] similarity = 0.72472 [ a) an antibody that binds to a CDR1 region of an antigen-binding fragment of the human CD8+ T cell receptor, and ][ b) a fragment of an antibody or antigen binding fragment that binds to the human CD8+ T cell receptor that comprises a fragment of the antigen-binding fragment that is a fragment of the CDR1 region of the antigen-binding fragment of the human CD8+ T cell receptor. ]
[ 856 ] similarity = 0.59790313 [ A method for producing a non-invasive image of an object in an imaging system, comprising: ][ acquiring an image of the object in the imaging system; ]
[ 857 ] similarity = 0.75588536 [ acquiring an image of the object in the imaging system; ][ determining a position of the object in the imaging system; ]
[ 858 ] similarity = 0.6515299 [ determining a position of the object in the imaging system; ][ identifying a plurality of regions in the imaging system that correspond to the identified position of the object in the imaging system; ]
[ 859 ] similarity = 0.6476096 [ identifying a plurality of regions in the imaging system that correspond to the identified position of the object in the imaging system; ][ generating a plurality of image signals from the image of the object in the imaging system; ]
[ 860 ] similarity = 0.58094966 [ generating a plurality of image signals from the image of the object in the imaging system; ][ identifying a plurality of regions in the image signals, each region corresponding to a different region in the imaging system; ]
[ 861 ] similarity = 0.58818525 [ identifying a plurality of regions in the image signals, each region corresponding to a different region in the imaging system; ][ determining a plurality of spatial coordinates for each region in the imaging system based on the identified spatial coordinates; ]
[ 862 ] similarity = 0.58210623 [ determining a plurality of spatial coordinates for each region in the imaging system based on the identified spatial coordinates; ][ identifying a plurality of image features in the image of the object in the imaging system based on the identified spatial features; and ]
[ 863 ] similarity = 0.87711763 [ identifying a plurality of image features in the image of the object in the imaging system based on the identified spatial features; and ][ generating a plurality of image features from the image of the object in the imaging system based at least in part on the identified spatial features and the identified image feature. ]
[ 864 ] similarity = 0.69312423 [ A method for producing a compound having an effective amount of an active ingredient, comprising: ][ providing a first sample of a compound having an active ingredient; ]
[ 865 ] similarity = 0.6042111 [ providing a first sample of a compound having an active ingredient; ][ contacting a second sample of a compound having an active ingredient with a first compound selected from the group consisting of an amino acid sequence of SEQ ID NO: ]
[ 866 ] similarity = -0.08652814 [ contacting a second sample of a compound having an active ingredient with a first compound selected from the group consisting of an amino acid sequence of SEQ ID NO: ][ 2 and a pharmaceutically acceptable carrier; ]
[ 867 ] similarity = 0.18365471 [ 2 and a pharmaceutically acceptable carrier; ][ contacting a second sample of the compound having an active ingredient with a second compound selected from the group consisting of an amino acid sequence of SEQ ID NO: 3 and a pharmaceutically acceptable carrier; and ]
[ 868 ] similarity = 0.4539207 [ contacting a second sample of the compound having an active ingredient with a second compound selected from the group consisting of an amino acid sequence of SEQ ID NO: 3 and a pharmaceutically acceptable carrier; and ][ producing a compound having an effective amount of the active ingredient, the compound being selected from the group consisting of a pharmaceutically acceptable salt, a pharmaceutically acceptable salt-containing salt, a pharmaceutically acceptable carrier, a pharmaceutically acceptable salt-containing carrier, a pharmaceutically acceptable salt-containing salt, and ]
[ 869 ] similarity = 0.6018482 [ producing a compound having an effective amount of the active ingredient, the compound being selected from the group consisting of a pharmaceutically acceptable salt, a pharmaceutically acceptable salt-containing salt, a pharmaceutically acceptable carrier, a pharmaceutically acceptable salt-containing carrier, a pharmaceutically acceptable salt-containing salt, and ][ a pharmaceutically acceptable carrier-containing salt. ]
[ 870 ] similarity = 0.3644072 [ A method of treating a patient suffering from a chronic disease, comprising administering to the patient a therapeutically effective amount of an isolated polypeptide comprising the amino acid sequence of SEQ ID NO: ][ 2, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: ]
[ 871 ] similarity = 0.6272739 [ 2, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: ][ 3 or the amino acid sequence of SEQ ID NO: ]
[ 872 ] similarity = 0.047627676 [ 3 or the amino acid sequence of SEQ ID NO: ][ 4. ]
[ 873 ] similarity = 0.256936 [ A method for producing a composition comprising: ][ a) providing an isolated protein; ]
[ 874 ] similarity = 0.23208417 [ a) providing an isolated protein; ][ b) contacting the protein with an effective amount of a compound that inhibits the activity of the protein, the compound being selected from the group consisting of a compound selected from the group consisting of: ]
[ 875 ] similarity = 0.015189309 [ b) contacting the protein with an effective amount of a compound that inhibits the activity of the protein, the compound being selected from the group consisting of a compound selected from the group consisting of: ][ (i) the polypeptide of SEQ ID NO: ]
[ 876 ] similarity = 0.13977793 [ (i) the polypeptide of SEQ ID NO: ][ 1, and ]
[ 877 ] similarity = 0.07211245 [ 1, and ][ (ii) an amino acid sequence of SEQ ID NO: ]
[ 878 ] similarity = 0.023980308 [ (ii) an amino acid sequence of SEQ ID NO: ][ 1; ]
[ 879 ] similarity = -0.08966875 [ 1; ][ c) determining the activity of the protein in a test subject; and ]
[ 880 ] similarity = 0.83458626 [ c) determining the activity of the protein in a test subject; and ][ d) determining the activity of the protein in a control subject; and ]
[ 881 ] similarity = 0.2651568 [ d) determining the activity of the protein in a control subject; and ][ e) providing the compound to produce the composition. ]
[ 882 ] similarity = 0.3368845 [ A method of treating a patient, comprising: ][ providing a first device having an external surface, the device comprising: ]
[ 883 ] similarity = 0.32461673 [ providing a first device having an external surface, the device comprising: ][ a first surface; ]
[ 884 ] similarity = 0.5744848 [ a first surface; ][ a first electrode; ]
[ 885 ] similarity = 0.7742231 [ a first electrode; ][ a second electrode; ]
[ 886 ] similarity = 0.36248994 [ a second electrode; ][ a first contact portion disposed on the first electrode; ]
[ 887 ] similarity = 0.5974588 [ a first contact portion disposed on the first electrode; ][ a second contact portion disposed on the second electrode; ]
[ 888 ] similarity = 0.639145 [ a second contact portion disposed on the second electrode; ][ a first electrode contact portion disposed on the first electrode; and ]
[ 889 ] similarity = 0.74801177 [ a first electrode contact portion disposed on the first electrode; and ][ a second electrode contact portion disposed on the second electrode; ]
[ 890 ] similarity = 0.25376338 [ a second electrode contact portion disposed on the second electrode; ][ providing a second device having an externally surface, the device comprising: ]
[ 891 ] similarity = 0.20704874 [ providing a second device having an externally surface, the device comprising: ][ a first surface; and ]
[ 892 ] similarity = 0.45794624 [ a first surface; and ][ a second electrode disposed on the external surface of the first device; and ]
[ 893 ] similarity = 0.40572548 [ a second electrode disposed on the external surface of the first device; and ][ providing a third device having an externally surface, the device comprising: ]
[ 894 ] similarity = 0.35111853 [ providing a third device having an externally surface, the device comprising: ][ a second electrode disposed on the externally surface of the third device, the second electrode having an electrode surface that is different from the first electrode; and ]
[ 895 ] similarity = 0.6262195 [ a second electrode disposed on the externally surface of the third device, the second electrode having an electrode surface that is different from the first electrode; and ][ a second contact portion disposed on the externally surface of the third device, the second contact portion having a first electrode contact portion that contacts a first contact portion on the first electrode, a second electrode contact portion that contacts a second contact portion on the second electrode, and ]
[ 896 ] similarity = 0.78685427 [ a second contact portion disposed on the externally surface of the third device, the second contact portion having a first electrode contact portion that contacts a first contact portion on the first electrode, a second electrode contact portion that contacts a second contact portion on the second electrode, and ][ a third contact portion that contacts a third contact portion on the second electrode; and ]
[ 897 ] similarity = 0.3893569 [ a third contact portion that contacts a third contact portion on the second electrode; and ][ providing a fourth electrode disposed on the externally surface of the fourth device, the fourth electrode having an electrode surface that is different from the first electrode, ]
[ 898 ] similarity = 0.17393291 [ providing a fourth electrode disposed on the externally surface of the fourth device, the fourth electrode having an electrode surface that is different from the first electrode, ][ wherein the first contact portion is located on the second contact portion and the second contact portion is located on the third contact portion; and ]
[ 899 ] similarity = 0.5864986 [ wherein the first contact portion is located on the second contact portion and the second contact portion is located on the third contact portion; and ][ wherein the third contact portion is located on the fourth electrode. ]
[ 900 ] similarity = 0.24866693 [ An implantable medical device, comprising: ][ a housing; ]
[ 901 ] similarity = 0.20664023 [ a housing; ][ a plurality of electrodes arranged within the housing and configured to be implanted into a subject, the electrodes including: ]
[ 902 ] similarity = 0.61004156 [ a plurality of electrodes arranged within the housing and configured to be implanted into a subject, the electrodes including: ][ a first electrode configured to be implanted into a tissue of the subject and configured to be electrically coupled to a first electrical power source; and ]
[ 903 ] similarity = 0.8352028 [ a first electrode configured to be implanted into a tissue of the subject and configured to be electrically coupled to a first electrical power source; and ][ a second electrode configured to be implanted into a tissue of the subject and configured to be electrically coupled to a second electrical power source; ]
[ 904 ] similarity = 0.60922724 [ a second electrode configured to be implanted into a tissue of the subject and configured to be electrically coupled to a second electrical power source; ][ a plurality of transistors arranged within the housing and configured to be electrically coupled to the first and second electrodes; and ]
[ 905 ] similarity = 0.6978394 [ a plurality of transistors arranged within the housing and configured to be electrically coupled to the first and second electrodes; and ][ a control circuit configured to control the plurality of transistors to be electrically coupled to the first and second electrical power sources, ]
[ 906 ] similarity = 0.45835608 [ a control circuit configured to control the plurality of transistors to be electrically coupled to the first and second electrical power sources, ][ wherein the control circuit is configured to: ]
[ 907 ] similarity = 0.20732364 [ wherein the control circuit is configured to: ][ receive electrical data from at least one of the first and second electrical power sources; and ]
[ 908 ] similarity = 0.623528 [ receive electrical data from at least one of the first and second electrical power sources; and ][ control the plurality of transistors to be electrically coupled to the first and second electric sources to produce a first electrical signal and a second electrical signal. ]
[ 909 ] similarity = 0.40122133 [ A method for treating an autoimmune disorder, the method comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising: ][ an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to an antigen of a humanized antigen-binding protein (HAP) comprising the amino acid sequence set forth in SEQ ID NO: ]
[ 910 ] similarity = 0.069233775 [ an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to an antigen of a humanized antigen-binding protein (HAP) comprising the amino acid sequence set forth in SEQ ID NO: ][ 1; and ]
[ 911 ] similarity = 0.020161845 [ 1; and ][ a pharmaceutically acceptable carrier; ]
[ 912 ] similarity = 0.046182685 [ a pharmaceutically acceptable carrier; ][ wherein the antibody or antigen-binding fragment is an antibody or antigen binding fragment that is a humanized antibody. ]
[ 913 ] similarity = 0.12782109 [ An isolated nucleic acid molecule encoding a polypeptide comprising: ][ (a) an amino acid sequence having at least 95% sequence identity to a nucleotide sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12 and/or SEQ ID NO: 14; and ]
[ 914 ] similarity = 0.94617486 [ (a) an amino acid sequence having at least 95% sequence identity to a nucleotide sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12 and/or SEQ ID NO: 14; and ][ (b) a nucleic acid sequence having at least 95% sequence identity to the nucleotide sequence selected from SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 and/or SEQ ID NO: 14. ]
[ 915 ] similarity = 0.21074408 [ A method of producing a pharmaceutical composition comprising: ][ providing at least one pharmaceutically acceptable salt of a compound selected from the group consisting of an anti-cancer agent, a chemotherapeutic agent, an immunogenic agent, an anti-inflammatory agent, a chemotherapeutic agent, and ]
[ 916 ] similarity = 0.22099479 [ providing at least one pharmaceutically acceptable salt of a compound selected from the group consisting of an anti-cancer agent, a chemotherapeutic agent, an immunogenic agent, an anti-inflammatory agent, a chemotherapeutic agent, and ][ a pharmaceutically acceptable carrier; and ]
[ 917 ] similarity = 0.43188706 [ a pharmaceutically acceptable carrier; and ][ contacting the at least one pharmaceutically acceptable salt with a pharmaceutical composition. ]
[ 918 ] similarity = 0.21441883 [ A system for providing an implantable medical device, comprising: ][ a housing; and ]
[ 919 ] similarity = 0.16557686 [ a housing; and ][ a first and second housing side walls, wherein the first and second housing side walls define a first and second longitudinal axis, respectively, and wherein the first and second housing side walls define a first and second longitudinal axis, respectively; ]
[ 920 ] similarity = 0.4895863 [ a first and second housing side walls, wherein the first and second housing side walls define a first and second longitudinal axis, respectively, and wherein the first and second housing side walls define a first and second longitudinal axis, respectively; ][ wherein the first and second longitudinal axis defines a center of gravity of the system; and ]
[ 921 ] similarity = 0.67681396 [ wherein the first and second longitudinal axis defines a center of gravity of the system; and ][ wherein the first and second longitudinal axis defines a first and second axis of rotation, respectively, of the system, wherein the first longitudinal axis is in the first plane and the second longitudinal axis is in the second plane; wherein the first longitudinal axis is perpendicular to the first plane; and ]
[ 922 ] similarity = 0.7422602 [ wherein the first and second longitudinal axis defines a first and second axis of rotation, respectively, of the system, wherein the first longitudinal axis is in the first plane and the second longitudinal axis is in the second plane; wherein the first longitudinal axis is perpendicular to the first plane; and ][ wherein the second longitudinal axis is parallel to the first longitudinal axis. ]
[ 923 ] similarity = 0.2171998 [ A method of producing a pharmaceutical composition, the method comprising: ][ providing a pharmaceutically acceptable carrier; and ]
[ 924 ] similarity = 0.33660638 [ providing a pharmaceutically acceptable carrier; and ][ introducing the carrier into the patient's blood, wherein the carrier comprises: ]
[ 925 ] similarity = -0.051048778 [ introducing the carrier into the patient's blood, wherein the carrier comprises: ][ a) a first polymer; ]
[ 926 ] similarity = 0.57073045 [ a) a first polymer; ][ b) a second polymer; and ]
[ 927 ] similarity = 0.61731935 [ b) a second polymer; and ][ c) a third polymer; ]
[ 928 ] similarity = 0.40789294 [ c) a third polymer; ][ wherein the third polymer is a polymer having a molecular mass in the range of about 1, ]
[ 929 ] similarity = 0.13935407 [ wherein the third polymer is a polymer having a molecular mass in the range of about 1, ][ 000 to about 1, ]
[ 930 ] similarity = 0.17135899 [ 000 to about 1, ][ 10, ]
[ 931 ] similarity = 0.10069797 [ 10, ][ 000, and ]
[ 932 ] similarity = -0.023588412 [ 000, and ][ wherein the first polymer and the third polymer are present in the carrier in the presence of the pharmaceutical composition. ]
[ 933 ] similarity = 0.29425007 [ A method of treating a patient with an inflammatory disorder, the method comprising administering to the patient an amount of a compound selected from the group consisting of: ][ (a) an antibody that binds to a protein of a human T-cell receptor, and ]
[ 934 ] similarity = 0.7635156 [ (a) an antibody that binds to a protein of a human T-cell receptor, and ][ that specifically binds to a human T-cell receptor, wherein the human T-cell receptor comprises a T-cell-derived antigen, and ]
[ 935 ] similarity = 0.36735302 [ that specifically binds to a human T-cell receptor, wherein the human T-cell receptor comprises a T-cell-derived antigen, and ][ wherein the antibody is a humanized antibody; and ]
[ 936 ] similarity = 0.50292134 [ wherein the antibody is a humanized antibody; and ][ (b) a compound that binds to the humanized antibody. ]
[ 937 ] similarity = 0.13381213 [ A method of treating a disease comprising: ][ (a) administering a therapeutically effective amount of a therapeutically effective amount of a polypeptide having the amino acid sequence of SEQ ID NO: ]
[ 938 ] similarity = 0.04456636 [ (a) administering a therapeutically effective amount of a therapeutically effective amount of a polypeptide having the amino acid sequence of SEQ ID NO: ][ 2 to a subject in need thereof; ]
[ 939 ] similarity = 0.26758268 [ 2 to a subject in need thereof; ][ (b) detecting a change in expression of a gene of a disease in the subject in need of the therapy; ]
[ 940 ] similarity = 0.2713099 [ (b) detecting a change in expression of a gene of a disease in the subject in need of the therapy; ][ (c) administering a therapeutically effective amount of a therapeutically effective amount of a polypeptide having the amino acid sequence of SEQ ID NO: ]
[ 941 ] similarity = 0.07558135 [ (c) administering a therapeutically effective amount of a therapeutically effective amount of a polypeptide having the amino acid sequence of SEQ ID NO: ][ 3 to the subject in need thereof; ]
[ 942 ] similarity = 0.3038209 [ 3 to the subject in need thereof; ][ (d) determining whether the subject has the disease; and ]
[ 943 ] similarity = 0.0116716195 [ (d) determining whether the subject has the disease; and ][ (e) administering a therapeutically effective amount of a therapeutically effective amount of a polypeptide having the amino acid sequence of SEQ ID NO: ]
[ 944 ] similarity = 0.035877194 [ (e) administering a therapeutically effective amount of a therapeutically effective amount of a polypeptide having the amino acid sequence of SEQ ID NO: ][ 4 to the subject in need thereof if the subject does not have the disease; ]
[ 945 ] similarity = 0.010376381 [ 4 to the subject in need thereof if the subject does not have the disease; ][ wherein the polypeptide has the amino acid sequence of SEQ ID NO: ]
[ 946 ] similarity = 0.30756333 [ wherein the polypeptide has the amino acid sequence of SEQ ID NO: ][ 3, SEQ ID NO: ]
[ 947 ] similarity = 0.68196166 [ 3, SEQ ID NO: ][ 4 or SEQ ID NO: ]
[ 948 ] similarity = 0.23638216 [ 4 or SEQ ID NO: ][ 5. ]
[ 949 ] similarity = -0.005136568 [ An implantable medical device for use in a surgical procedure comprising: ][ a body portion having a first end portion and a first end portion opposite said first end portion, said first end portion being disposed in a first position; ]
[ 950 ] similarity = 0.43316942 [ a body portion having a first end portion and a first end portion opposite said first end portion, said first end portion being disposed in a first position; ][ a plurality of electrodes disposed on said first end portion of said body portion, said plurality of electrodes being configured to generate electrical signals; ]
[ 951 ] similarity = 0.830225 [ a plurality of electrodes disposed on said first end portion of said body portion, said plurality of electrodes being configured to generate electrical signals; ][ a plurality of conductors disposed on said first end portion of said body portion, said plurality of conductors being configured to conduct electrical power to said plurality of electrodes; ]
[ 952 ] similarity = 0.55223 [ a plurality of conductors disposed on said first end portion of said body portion, said plurality of conductors being configured to conduct electrical power to said plurality of electrodes; ][ a first electrical connector disposed on said plurality of electrodes; and ]
[ 953 ] similarity = 0.73050606 [ a first electrical connector disposed on said plurality of electrodes; and ][ a second electrical connector disposed on said plurality of conductors. ]
[ 954 ] similarity = 0.33752507 [ A method for treating a subject with a condition that causes the subject to be unable to move, in a body part, in an upright position, the method comprising: ][ (a) providing an apparatus comprising a body member, the body member having an upper surface, a lower surface and a central axis, wherein the lower surface is substantially flat, the upper surface is substantially flat, and ]
[ 955 ] similarity = 0.48748022 [ (a) providing an apparatus comprising a body member, the body member having an upper surface, a lower surface and a central axis, wherein the lower surface is substantially flat, the upper surface is substantially flat, and ][ the central axis is substantially parallel to the lower surface; and ]
[ 956 ] similarity = 0.17055108 [ the central axis is substantially parallel to the lower surface; and ][ (b) providing a first treatment element, the first treatment element comprising a first treatment element having a first surface and a first side, wherein the first surface and the first side are substantially flat and the first side of the first treatment element is substantially parallel to a first axis of the body member; ]
[ 957 ] similarity = 0.3874901 [ (b) providing a first treatment element, the first treatment element comprising a first treatment element having a first surface and a first side, wherein the first surface and the first side are substantially flat and the first side of the first treatment element is substantially parallel to a first axis of the body member; ][ (c) providing a second treatment element, the second treatment element comprising an intermediate treatment element having a second surface and a second side, wherein the second surface and the second side of the second treatment element are substantially flat and the second side of the intermediate treatment element is substantially parallel to a second axis of the body member; ]
[ 958 ] similarity = 0.22553545 [ (c) providing a second treatment element, the second treatment element comprising an intermediate treatment element having a second surface and a second side, wherein the second surface and the second side of the second treatment element are substantially flat and the second side of the intermediate treatment element is substantially parallel to a second axis of the body member; ][ (d) applying a force to the first treatment element to cause the first side of the first treatment element to move to a first position, and ]
[ 959 ] similarity = 0.80310506 [ (d) applying a force to the first treatment element to cause the first side of the first treatment element to move to a first position, and ][ applying a force to the first treatment element to cause the second side of the first treatment element to move to a second position; ]
[ 960 ] similarity = 0.66513085 [ applying a force to the first treatment element to cause the second side of the first treatment element to move to a second position; ][ (e) applying a force to the intermediate treatment element to cause the first side of the intermediate treatment element to move to a third position; and ]
[ 961 ] similarity = 0.84629273 [ (e) applying a force to the intermediate treatment element to cause the first side of the intermediate treatment element to move to a third position; and ][ (f) applying a force to the second treatment element to cause the second side of the intermediate treatment element to move to a fourth position. ]
[ 962 ] similarity = 0.4844855 [ A system for treating an acute inflammatory disorder, comprising: ][ a) a first implantable medical device having a plurality of electrodes; ]
[ 963 ] similarity = 0.8182471 [ a) a first implantable medical device having a plurality of electrodes; ][ b) a second implantable medical device having a plurality of electrodes; ]
[ 964 ] similarity = 0.29703686 [ b) a second implantable medical device having a plurality of electrodes; ][ c) at least one sensor configured for monitoring a first condition of an patient, the at least one sensor being configured for detecting a first signal from the first implantable medical device and the at least one sensor being configured for detecting a second signal from the second implantable medical device; and ]
[ 965 ] similarity = 0.5930915 [ c) at least one sensor configured for monitoring a first condition of an patient, the at least one sensor being configured for detecting a first signal from the first implantable medical device and the at least one sensor being configured for detecting a second signal from the second implantable medical device; and ][ d) at least one processing device configured for processing the first signal and the second signal to determine a first treatment condition and a second treatment condition, wherein determining the first treatment condition comprises determining that the first condition is a condition of a first patient and that the second condition is a condition of a second patient. ]
[ 966 ] similarity = 0.16223323 [ A method for treating a patient having a cancer comprising administering to said patient a therapeutically effective amount of a compound selected from the group consisting of: ][ a) a pharmaceutically acceptable salt or salt form, and ]
[ 967 ] similarity = -0.009445298 [ a) a pharmaceutically acceptable salt or salt form, and ][ b) an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: ]
[ 968 ] similarity = -0.03369191 [ b) an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: ][ 2. ]
[ 969 ] similarity = 0.19831105 [ A method of treating an autoimmune disorder comprising administering to a patient in need thereof a composition comprising an antibody or fragment thereof which is specifically capable of binding to a protein of an autoimmune disease, wherein the antibody or fragment thereof is selected from the group consisting of the amino acid sequence of SEQ ID NO: ][ 1 or the amino acid sequence of SEQ ID NO: ]
[ 970 ] similarity = 0.18268944 [ 1 or the amino acid sequence of SEQ ID NO: ][ 4, wherein the protein of the autoimmune disease is a humanized monocyte-derived monoclonal antibody or fragment thereof. ]
[ 971 ] similarity = 0.43738186 [ An isolated nucleic acid encoding a protein, wherein said protein comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 1, and ][ wherein said protein is a polypeptide. ]
[ 972 ] similarity = 0.20489225 [ A method of treating a disease or disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound or compound compound combination, comprising a first compound and a second compound, wherein the compound or compound combination comprises a pharmaceutically acceptable carrier, and ][ a pharmaceutically acceptable excipient. ]
[ 973 ] similarity = 0.35802388 [ A method for treating an autoimmune disease, comprising administering to a subject in need thereof an effective amount to a target site of an immune cell, wherein the target site is located in a tissue of the target subject, and ][ wherein the immune cell is an interleukin-1 receptor-1 (IL-1R-1) cell. ]
[ 974 ] similarity = -0.09948023 [ An implant for use in an eye, comprising: ][ a) a first end, a second end and a plurality of first and second projections, wherein the first end is disposed proximate to the second end; ]
[ 975 ] similarity = 0.4148063 [ a) a first end, a second end and a plurality of first and second projections, wherein the first end is disposed proximate to the second end; ][ b) a first electrode, a first electrode portion, a second electrode portion and a plurality of second and third electrodes, wherein the first electrode portion comprises a plurality of first electrodes and the second and third electrodes comprise a plurality of second and third electrodes, wherein the first, second and third electrodes comprise a plurality of electrodes; and ]
[ 976 ] similarity = 0.47100127 [ b) a first electrode, a first electrode portion, a second electrode portion and a plurality of second and third electrodes, wherein the first electrode portion comprises a plurality of first electrodes and the second and third electrodes comprise a plurality of second and third electrodes, wherein the first, second and third electrodes comprise a plurality of electrodes; and ][ c) an outer surface of said implant, wherein said inner surface of said implant comprises a plurality of first and second electrodes. ]
[ 977 ] similarity = 0.35352874 [ A system for treating a disease comprising: ][ an implant for insertion into a body, the system comprising a body support and at least one support structure, ]
[ 978 ] similarity = 0.22341147 [ an implant for insertion into a body, the system comprising a body support and at least one support structure, ][ a first implantable medical device (IMD); and ]
[ 979 ] similarity = 0.5361428 [ a first implantable medical device (IMD); and ][ a second implantable medical device (IMD2) adapted to be inserted into the body and having a first implantable medical device (IMD) and an IMD-specific device (IMD2) adapted to be implanted in the IMD, the IMD-specific device (IMD2) having a second implantable medical device (IMD2) and an IMDM-specific device (IMDM2) adapted to be inserted into the IMDM, the second implantable medical device (IMD2) and the second IMD-specific device (IMDM2) being configured to communicate with each other, ]
[ 980 ] similarity = 0.4325655 [ a second implantable medical device (IMD2) adapted to be inserted into the body and having a first implantable medical device (IMD) and an IMD-specific device (IMD2) adapted to be implanted in the IMD, the IMD-specific device (IMD2) having a second implantable medical device (IMD2) and an IMDM-specific device (IMDM2) adapted to be inserted into the IMDM, the second implantable medical device (IMD2) and the second IMD-specific device (IMDM2) being configured to communicate with each other, ][ wherein the IMD-specific device (IMD2) is adapted to be implanted in a patient, and ]
[ 981 ] similarity = 0.5956343 [ wherein the IMD-specific device (IMD2) is adapted to be implanted in a patient, and ][ the IMDM-specific device (IMDM2) is adapted to be implanted in a patient. ]
[ 982 ] similarity = 0.5047503 [ A method of producing an implant comprising the steps of: ][ a) providing an implant body having a distal end; ]
[ 983 ] similarity = 0.4964909 [ a) providing an implant body having a distal end; ][ b) providing a proximal end of the body, the proximal end of the body being configured to engage a proximal end of a bone; ]
[ 984 ] similarity = 0.25827435 [ b) providing a proximal end of the body, the proximal end of the body being configured to engage a proximal end of a bone; ][ c) providing a first portion of a bone implant, the first portion of the bone implant comprising a plurality of bone fragments; ]
[ 985 ] similarity = 0.603795 [ c) providing a first portion of a bone implant, the first portion of the bone implant comprising a plurality of bone fragments; ][ d) providing a second portion of the bone implant, the second portion of the bone implant comprising an outer surface of the bone implant, the outer surface of the bone implant being configured to engage a surface of the bone implant, the second portion of the bone implant having a first surface and a second surface opposite the first surface, wherein the first and second surfaces are configured to engage the outer surface of the bone implant; ]
[ 986 ] similarity = 0.39630353 [ d) providing a second portion of the bone implant, the second portion of the bone implant comprising an outer surface of the bone implant, the outer surface of the bone implant being configured to engage a surface of the bone implant, the second portion of the bone implant having a first surface and a second surface opposite the first surface, wherein the first and second surfaces are configured to engage the outer surface of the bone implant; ][ e) providing an implant material having an elastic property, wherein the implant material is configured to be inserted through a bone; ]
[ 987 ] similarity = 0.584421 [ e) providing an implant material having an elastic property, wherein the implant material is configured to be inserted through a bone; ][ f) providing a first portion of the implant material, and ]
[ 988 ] similarity = 0.6340261 [ f) providing a first portion of the implant material, and ][ a second portion of the implant material, the first and second portions of the implant material being configured to be inserted through a bone; ]
[ 989 ] similarity = 0.7246194 [ a second portion of the implant material, the first and second portions of the implant material being configured to be inserted through a bone; ][ g) inserting the first portion of the implant material through the bone, wherein the implant material is configured to be disposed in a cavity formed in a bone of the implant body; ]
[ 990 ] similarity = 0.6010289 [ g) inserting the first portion of the implant material through the bone, wherein the implant material is configured to be disposed in a cavity formed in a bone of the implant body; ][ h) inserting the second portion of the implant material through the cavity; and ]
[ 991 ] similarity = 0.7533011 [ h) inserting the second portion of the implant material through the cavity; and ][ i) inserting the second portion of the implant material into the cavity. ]
[ 992 ] similarity = 0.35611078 [ A method for treating a patient with a cancer, the method comprising: ][ (a) administering an effective amount of an anti-cancer agent to the patient; and ]
[ 993 ] similarity = 0.4156565 [ (a) administering an effective amount of an anti-cancer agent to the patient; and ][ (b) monitoring the patient for the presence of a tumor in the patient; ]
[ 994 ] similarity = 0.17040393 [ (b) monitoring the patient for the presence of a tumor in the patient; ][ wherein the tumor is selected from the group consisting of a prostate, a breast, a colon, a lung, a bladder, a liver, and ]
[ 995 ] similarity = 0.28785494 [ wherein the tumor is selected from the group consisting of a prostate, a breast, a colon, a lung, a bladder, a liver, and ][ a kidney. ]
[ 996 ] similarity = 0.25123632 [ A method for treating a disease or disorder in the body of a subject in need thereof, comprising: ][ administering to the subject a therapeutically effective amount of a therapeutically effective amount or combination of therapeutically effective amounts or combinations thereof of a pharmaceutically acceptable salt, and ]
[ 997 ] similarity = 0.65369034 [ administering to the subject a therapeutically effective amount of a therapeutically effective amount or combination of therapeutically effective amounts or combinations thereof of a pharmaceutically acceptable salt, and ][ an effective amount of a pharmaceutically acceptable carrier, wherein the effective amount is effective to treat the disease or disorder. ]
[ 998 ] similarity = 0.4648254 [ A method of treating a disease or condition in a mammal, said method comprising administering to the mammal a therapeutically effective amount of a compound selected from the group consisting of a compound of formula (I), a compound of formula (II), a compound of formula (III), a compound of formula (IV), and ][ a compound of formula (V) or a combination thereof. ]
[ 999 ] similarity = 0.18932588 [ A method of treating a patient having a heart condition comprising administering to a patient in need of a therapy, an effective amount of an isolated polypeptide of the formulawherein: ][ a. A is a first amino acid; ]
[ 1000 ] similarity = 0.6135121 [ a. A is a first amino acid; ][ b. A is a second amino acid, a third amino acid, or a fourth amino acid; ]
[ 1001 ] similarity = 0.46457958 [ b. A is a second amino acid, a third amino acid, or a fourth amino acid; ][ c. A and b each have the amino acid sequence of SEQ ID NO: ]
[ 1002 ] similarity = -0.0025322065 [ c. A and b each have the amino acid sequence of SEQ ID NO: ][ 3; ]
[ 1003 ] similarity = -0.025810186 [ 3; ][ d. A and b have the amino acid sequence of SEQ ID NO: ]
[ 1004 ] similarity = 0.010514487 [ d. A and b have the amino acid sequence of SEQ ID NO: ][ 4; ]
[ 1005 ] similarity = 0.052732933 [ 4; ][ e. A is a first amino acid; ]
[ 1006 ] similarity = 0.627008 [ e. A is a first amino acid; ][ f. A is a second amino acid, a third amino acid, or a fourth amino acid; ]
[ 1007 ] similarity = 0.41107747 [ f. A is a second amino acid, a third amino acid, or a fourth amino acid; ][ g. A and b each have the amino acid sequence of SEQ ID NO: ]
[ 1008 ] similarity = -0.05582963 [ g. A and b each have the amino acid sequence of SEQ ID NO: ][ 6; ]
[ 1009 ] similarity = -0.08072752 [ 6; ][ h. A and b each have the amino acid sequence of SEQ ID NO: ]
[ 1010 ] similarity = -0.08231958 [ h. A and b each have the amino acid sequence of SEQ ID NO: ][ 7; ]
[ 1011 ] similarity = -0.014228163 [ 7; ][ i. A has the amino acid sequence of SEQ ID NO: ]
[ 1012 ] similarity = -0.07798092 [ i. A has the amino acid sequence of SEQ ID NO: ][ 8. ]
[ 1013 ] similarity = 0.22094548 [ A method for treating an autoimmune disorder in a subject, comprising administering to said subject a therapeutically effective amount of an isolated antibody or fragment thereof which binds to a polypeptide comprising the amino acid sequence of SEQ ID NO: ][ 2, wherein said polypeptide is selected from the group consisting of: ]
[ 1014 ] similarity = 0.041946743 [ 2, wherein said polypeptide is selected from the group consisting of: ][ (i) the amino acid sequence of SEQ ID NO: 2, ]
[ 1015 ] similarity = 0.83143276 [ (i) the amino acid sequence of SEQ ID NO: 2, ][ (ii) the amino acid sequence of SEQ ID NO: ]
[ 1016 ] similarity = -0.013117599 [ (ii) the amino acid sequence of SEQ ID NO: ][ 3, ]
[ 1017 ] similarity = 0.034142338 [ 3, ][ (iii) the amino acid sequence of SEQ ID NO: ]
[ 1018 ] similarity = 0.05303156 [ (iii) the amino acid sequence of SEQ ID NO: ][ 4, and ]
[ 1019 ] similarity = 0.12054906 [ 4, and ][ (iv) the amino acid sequence of SEQ ID NO: ]
[ 1020 ] similarity = 0.021251455 [ (iv) the amino acid sequence of SEQ ID NO: ][ 5. ]
[ 1021 ] similarity = 0.39590225 [ A system for providing a medical device to a user, the system comprising: ][ a medical device; ]
[ 1022 ] similarity = 0.44353575 [ a medical device; ][ an interface configured to communicate with the medical device; and ]
[ 1023 ] similarity = 0.47567958 [ an interface configured to communicate with the medical device; and ][ an input device for receiving input from a user, the input device including a display configured to display a medical device image and a user interface configured to receive a command to perform a function, the user interface including: ]
[ 1024 ] similarity = 0.51046586 [ an input device for receiving input from a user, the input device including a display configured to display a medical device image and a user interface configured to receive a command to perform a function, the user interface including: ][ a first portion configured to display an indication of a status of the medical device, and ]
[ 1025 ] similarity = 0.7179035 [ a first portion configured to display an indication of a status of the medical device, and ][ a second portion configured to display an indication of a user interface associated with the medical device; ]
[ 1026 ] similarity = 0.4956761 [ a second portion configured to display an indication of a user interface associated with the medical device; ][ wherein the first portion and the second portion are configured to display a first indication of the status of the medical device, and ]
[ 1027 ] similarity = 0.51332825 [ wherein the first portion and the second portion are configured to display a first indication of the status of the medical device, and ][ the first indication of the status of the medical device is configured to indicate that the status of the medical device is in a non-operational state. ]
[ 1028 ] similarity = 0.6513067 [ A system for providing a medical treatment to an individual, comprising: ][ a first patient-specific device configured to provide a medical treatment to the individual; and ]
[ 1029 ] similarity = 0.5349218 [ a first patient-specific device configured to provide a medical treatment to the individual; and ][ a second patient-specific device configured to receive the medical treatment, the first and second device being configured to be coupled to a patient-specific medical device, wherein the first and second device are further configured to be configured to receive a first treatment and a second treatment, wherein the first treatment comprises a medical treatment and the second treatment comprises an exercise, and ]
[ 1030 ] similarity = 0.8223907 [ a second patient-specific device configured to receive the medical treatment, the first and second device being configured to be coupled to a patient-specific medical device, wherein the first and second device are further configured to be configured to receive a first treatment and a second treatment, wherein the first treatment comprises a medical treatment and the second treatment comprises an exercise, and ][ wherein the first device and the second device are configured to be configured to provide a first treatment to the patient-specific device and a second treatment to a second patient-specific device. ]
[ 1031 ] similarity = 0.44085872 [ A method of treating a disease in a mammal comprising administering to the mammal an effective amount of an antibody that specifically binds to a polypeptide having the amino acid sequence of SEQ ID NO: ][ 2, wherein said antibody specifically binds to the polypeptide. ]
[ 1032 ] similarity = 0.19735825 [ A method of treating a disease comprising: ][ administering to a subject in need of such treatment a therapeutically effective amount of a composition comprising a compound selected from the group consisting of a polypeptide, a polysaccharide or a polysaccharide fragment, wherein said compound is an amino acid sequence of SEQ ID NO: ]
[ 1033 ] similarity = 0.059975605 [ administering to a subject in need of such treatment a therapeutically effective amount of a composition comprising a compound selected from the group consisting of a polypeptide, a polysaccharide or a polysaccharide fragment, wherein said compound is an amino acid sequence of SEQ ID NO: ][ 2, SEQ ID NO: ]
[ 1034 ] similarity = 1.0 [ 2, SEQ ID NO: ][ 2, SEQ ID NO: ]
[ 1035 ] similarity = 0.7787261 [ 2, SEQ ID NO: ][ 4, SEQ ID NO: ]
[ 1036 ] similarity = 1.0000002 [ 4, SEQ ID NO: ][ 4, SEQ ID NO: ]
[ 1037 ] similarity = 0.8158754 [ 4, SEQ ID NO: ][ 6, SEQ ID NO: ]
[ 1038 ] similarity = 0.8179097 [ 6, SEQ ID NO: ][ 7, SEQ ID NO: ]
[ 1039 ] similarity = 0.83411634 [ 7, SEQ ID NO: ][ 8, SEQ ID NO: ]
[ 1040 ] similarity = 1.0000001 [ 8, SEQ ID NO: ][ 8, SEQ ID NO: ]
[ 1041 ] similarity = 0.37975395 [ 8, SEQ ID NO: ][ 11, or a polypeptide having at least 95% amino acid identity to SEQ ID NO: ]
[ 1042 ] similarity = 0.34585476 [ 11, or a polypeptide having at least 95% amino acid identity to SEQ ID NO: ][ 2 or SEQ ID NO: ]
[ 1043 ] similarity = 0.29352474 [ 2 or SEQ ID NO: ][ 6, and ]
[ 1044 ] similarity = -0.017062245 [ 6, and ][ wherein said polypeptide is selected from the group consisting of a polypeptide having at least 95% amino acid identity to SEQ ID NO: ]
[ 1045 ] similarity = 0.08431062 [ wherein said polypeptide is selected from the group consisting of a polypeptide having at least 95% amino acid identity to SEQ ID NO: ][ 2 or SEQ ID NO: ]
[ 1046 ] similarity = 0.28418803 [ 2 or SEQ ID NO: ][ 6, a polypeptide having at least 95% amino acid identity to SEQ ID NO: ]
[ 1047 ] similarity = 0.9489667 [ 6, a polypeptide having at least 95% amino acid identity to SEQ ID NO: ][ 4, a polypeptide having at least 95% amino acid identity to SEQ ID NO: ]
[ 1048 ] similarity = -0.02251065 [ 4, a polypeptide having at least 95% amino acid identity to SEQ ID NO: ][ 6, and ]
[ 1049 ] similarity = -0.036533423 [ 6, and ][ a polypeptide having at least 95% amino acid identity to SEQ ID NO: ]
[ 1050 ] similarity = 0.037842825 [ a polypeptide having at least 95% amino acid identity to SEQ ID NO: ][ 11. ]
[ 1051 ] similarity = 0.30728802 [ A method of producing a polymeric composition comprising: ][ providing a first polymer, the first polymer comprising a first polymerizable moiety and a second polymerizable moiety; ]
[ 1052 ] similarity = 0.690441 [ providing a first polymer, the first polymer comprising a first polymerizable moiety and a second polymerizable moiety; ][ providing a second polymer, the second polymer comprising a second polymerizable moiety and a third polymerizable moiety; and ]
[ 1053 ] similarity = 0.491305 [ providing a second polymer, the second polymer comprising a second polymerizable moiety and a third polymerizable moiety; and ][ forming a polymer matrix from the first and second polymerizable moieties, the polymer matrix having a thickness and a cross-sectional dimension that are greater than a cross-sectional dimension of the first and second polymers. ]
[ 1054 ] similarity = 0.28989375 [ A method for producing an implant for use in a surgical procedure, the method comprising the steps of: ][ a) providing a surgical device having a proximal end and a distal end, the surgical device comprising a first end and a second end; ]
[ 1055 ] similarity = 0.53985095 [ a) providing a surgical device having a proximal end and a distal end, the surgical device comprising a first end and a second end; ][ b) providing a plurality of surgical instruments, each of the plurality of surgical instruments including a proximal end, a distal end, and ]
[ 1056 ] similarity = 0.45347568 [ b) providing a plurality of surgical instruments, each of the plurality of surgical instruments including a proximal end, a distal end, and ][ a first and second end, wherein each surgical instrument is configured to be implanted into a patient, wherein the first end and the second end of each surgical instrument are configured to be inserted into a patient's body and the distal end and the proximal end of each surgical instrument are configured to be inserted into a patient's body; and ]
[ 1057 ] similarity = 0.6875345 [ a first and second end, wherein each surgical instrument is configured to be implanted into a patient, wherein the first end and the second end of each surgical instrument are configured to be inserted into a patient's body and the distal end and the proximal end of each surgical instrument are configured to be inserted into a patient's body; and ][ c) positioning a first end and a second end of the surgical instrument in the proximal end, wherein the first and second ends of the surgical instrument are positioned in a first location and the distal end of the surgical instrument is positioned in a second location different than the first location. ]
[ 1058 ] similarity = 0.25418848 [ A method of providing an implantable medical device comprising: ][ (a) providing an implantable medical device having a plurality of electrodes and at least one conductive element, the implantable medical device having a first electrode and at least one second electrode, the first electrode and second electrode being connected to a first conductive element; ]
[ 1059 ] similarity = 0.7340524 [ (a) providing an implantable medical device having a plurality of electrodes and at least one conductive element, the implantable medical device having a first electrode and at least one second electrode, the first electrode and second electrode being connected to a first conductive element; ][ (b) providing a plurality of electrodes and at least one conductive element, the first and second electrodes being connected to a second conductive element; ]
[ 1060 ] similarity = 0.56169987 [ (b) providing a plurality of electrodes and at least one conductive element, the first and second electrodes being connected to a second conductive element; ][ (c) providing an electrode array, the electrode array including at least one electrode and at least one electrode layer; ]
[ 1061 ] similarity = 0.4773463 [ (c) providing an electrode array, the electrode array including at least one electrode and at least one electrode layer; ][ (d) providing a plurality of electrodes and an array of conductive elements; and ]
[ 1062 ] similarity = 0.5184139 [ (d) providing a plurality of electrodes and an array of conductive elements; and ][ (e) connecting the at least one conductive element to at least one of the electrodes in the array of conductive elements, ]
[ 1063 ] similarity = 0.5629118 [ (e) connecting the at least one conductive element to at least one of the electrodes in the array of conductive elements, ][ wherein at least one of the electrodes in the array of conductive elements includes a first electrode and a second electrode. ]
[ 1064 ] similarity = 0.05645329 [ A method for treating a patient with a disease or disorder, comprising administering to the patient a composition comprising a therapeutically effective amount of an anti-inflammatory agent and a therapeutically effective amount of a polypeptide, the anti-inflammatory agent being a polypeptide having the amino acid sequence as set forth in SEQ ID NO: ][ 1. ]
[ 1065 ] similarity = 0.1785962 [ An implantable medical device, comprising: ][ a body having an inner surface and an outer surface; ]
[ 1066 ] similarity = 0.33760142 [ a body having an inner surface and an outer surface; ][ an inner surface of the body defining a first region of a plurality of first electrodes, wherein the first region comprises a first electrode and a second region of the plurality of first electrodes that is adjacent the first region, wherein a first electrode is positioned on the outer surface of the first region and a second electrode is positioned on the outer surface of the first region; and ]
[ 1067 ] similarity = 0.77796817 [ an inner surface of the body defining a first region of a plurality of first electrodes, wherein the first region comprises a first electrode and a second region of the plurality of first electrodes that is adjacent the first region, wherein a first electrode is positioned on the outer surface of the first region and a second electrode is positioned on the outer surface of the first region; and ][ a second region of the plurality of first electrodes, wherein the second region comprises an electrode positioned on the inner surface of the second region and a first electrode and a second electrode, wherein: ]
[ 1068 ] similarity = 0.7472258 [ a second region of the plurality of first electrodes, wherein the second region comprises an electrode positioned on the inner surface of the second region and a first electrode and a second electrode, wherein: ][ a first electrode of the first region is positioned on the inner surface of the second region; and ]
[ 1069 ] similarity = 0.86345446 [ a first electrode of the first region is positioned on the inner surface of the second region; and ][ a second electrode of the second region is positioned on the outer surface of the first region; ]
[ 1070 ] similarity = 0.7336066 [ a second electrode of the second region is positioned on the outer surface of the first region; ][ a first electrode of the first region is positioned on the inner surface of the first region; and ]
[ 1071 ] similarity = 0.751606 [ a first electrode of the first region is positioned on the inner surface of the first region; and ][ a second electrode of the second region is positioned on the outer surface of the first region; and ]
[ 1072 ] similarity = 0.51929593 [ a second electrode of the second region is positioned on the outer surface of the first region; and ][ a first conductive element of the first electrode and a second conductive element of the second electrode, ]
[ 1073 ] similarity = 0.6986825 [ a first conductive element of the first electrode and a second conductive element of the second electrode, ][ wherein a first portion of the first electrode and a second portion of the second electrode are located on the inner surface of the body, and ]
[ 1074 ] similarity = 0.83701026 [ wherein a first portion of the first electrode and a second portion of the second electrode are located on the inner surface of the body, and ][ wherein the first portion of the first electrode is disposed in the first region and the second portion of the second electrode is disposed in the second region. ]
[ 1075 ] similarity = 0.29363286 [ An implantable medical device comprising: ][ a housing having an interior; ]
[ 1076 ] similarity = 0.04277821 [ a housing having an interior; ][ an electrical connection between an electrical device and the housing, the electrical connection including an electrically conductive portion, a first electrode and a second electrode; and ]
[ 1077 ] similarity = 0.3922938 [ an electrical connection between an electrical device and the housing, the electrical connection including an electrically conductive portion, a first electrode and a second electrode; and ][ an electrically conductive layer on the interior of the housing, the electrically conductive layer having a first thickness and a second thickness, wherein the first thickness is greater than the second thickness. ]
[ 1078 ] similarity = 0.12614843 [ A method for treating a patient with a disorder in the central nervous system, the method comprising: ][ providing at least one device that is capable of receiving and transmitting signals from at least one of a plurality of different sources; ]
[ 1079 ] similarity = 1.0000002 [ providing at least one device that is capable of receiving and transmitting signals from at least one of a plurality of different sources; ][ providing at least one device that is capable of receiving and transmitting signals from at least one of a plurality of different sources; ]
[ 1080 ] similarity = 0.79000974 [ providing at least one device that is capable of receiving and transmitting signals from at least one of a plurality of different sources; ][ receiving at least one signal from the at least one of the plurality of different sources; ]
[ 1081 ] similarity = 0.86289036 [ receiving at least one signal from the at least one of the plurality of different sources; ][ determining, by the at least one device, whether the received at least one signal is indicative of the at least one of the plurality of different sources; ]
[ 1082 ] similarity = 0.9680036 [ determining, by the at least one device, whether the received at least one signal is indicative of the at least one of the plurality of different sources; ][ determining, by the at least one device, that the received at least one signal is indicative of the at least one of the plurality of different sources; and ]
[ 1083 ] similarity = 0.8490767 [ determining, by the at least one device, that the received at least one signal is indicative of the at least one of the plurality of different sources; and ][ if the received at least one signal is not indicative of the at least one of the plurality of different sources: ]
[ 1084 ] similarity = 0.6703069 [ if the received at least one signal is not indicative of the at least one of the plurality of different sources: ][ transmitting the received at least one signal to a source that is capable of receiving and transmitting signals from at least one of a plurality of different sources; and ]
[ 1085 ] similarity = 0.98976296 [ transmitting the received at least one signal to a source that is capable of receiving and transmitting signals from at least one of a plurality of different sources; and ][ transmitting the received at least one signal to a source that is capable of receiving and transmitting signals from at least one of a plurality of different sources. ]
[ 1086 ] similarity = 0.3770532 [ A system for the monitoring of the movement of a patient's heart, said system comprising: ][ a sensor configured to sense a heart rate signal; ]
[ 1087 ] similarity = 0.76398426 [ a sensor configured to sense a heart rate signal; ][ a processor configured to determine a heart rate signal value for the heart rate signal; ]
[ 1088 ] similarity = 0.24673298 [ a processor configured to determine a heart rate signal value for the heart rate signal; ][ at least one processor coupled to the processor and to the sensor, the at least one processor configured to: ]
[ 1089 ] similarity = 0.05015119 [ at least one processor coupled to the processor and to the sensor, the at least one processor configured to: ][ receive a heart rate signal value for a first heart rate signal; ]
[ 1090 ] similarity = 0.877877 [ receive a heart rate signal value for a first heart rate signal; ][ determine a first heart rate signal value based upon a first heart rate signal value for the first heart rate signal; and ]
[ 1091 ] similarity = 0.834159 [ determine a first heart rate signal value based upon a first heart rate signal value for the first heart rate signal; and ][ determine a second heart rate signal value based upon a second heart rate signal value, the first heart rate signal value being different from the second heart rate signal value, the first heart rate signal value being a heart rate signal value that is indicative of the heart rate of the patient; ]
[ 1092 ] similarity = 0.028082598 [ determine a second heart rate signal value based upon a second heart rate signal value, the first heart rate signal value being different from the second heart rate signal value, the first heart rate signal value being a heart rate signal value that is indicative of the heart rate of the patient; ][ a processor configured to: ]
[ 1093 ] similarity = 0.059439074 [ a processor configured to: ][ determine an amount of time that a patient's heart rate is at its highest heart rate; and ]
[ 1094 ] similarity = 0.91371983 [ determine an amount of time that a patient's heart rate is at its highest heart rate; and ][ determine an amount of time that a user's heart rate has been at its highest heart rate. ]
[ 1095 ] similarity = 0.60356593 [ A method of providing a medical device to a patient, comprising: ][ providing a medical device to a patient, the medical device having an implantable device and a medical device housing; ]
[ 1096 ] similarity = 0.81014174 [ providing a medical device to a patient, the medical device having an implantable device and a medical device housing; ][ providing an implantable medical device to a patient in a medical device housing, the implantable medical device being adapted to be implanted in a patient, the implantable medical device housing being adapted to be received within a patient, the implantable medical device having a plurality of ports for connecting a plurality of medical devices, the implantable medical device housing having a first port configured for insertion into a first medical device; and ]
[ 1097 ] similarity = 0.7294734 [ providing an implantable medical device to a patient in a medical device housing, the implantable medical device being adapted to be implanted in a patient, the implantable medical device housing being adapted to be received within a patient, the implantable medical device having a plurality of ports for connecting a plurality of medical devices, the implantable medical device housing having a first port configured for insertion into a first medical device; and ][ connecting a first medical device to a first port of the implantable medical device housing, the first port configured for insertion into a first medical device. ]
[ 1098 ] similarity = 0.26626563 [ An implantable device comprising: ][ an elongated member having an outer surface, a first end, and ]
[ 1099 ] similarity = 0.42381465 [ an elongated member having an outer surface, a first end, and ][ an inner surface; and ]
[ 1100 ] similarity = 0.2746455 [ an inner surface; and ][ a plurality of electrodes arranged on an outer surface of said elongated member, ]
[ 1101 ] similarity = 0.23828284 [ a plurality of electrodes arranged on an outer surface of said elongated member, ][ wherein each of said plurality of electrodes is arranged in a first configuration and a second configuration, wherein said first and second configurations are different from each other, and ]
[ 1102 ] similarity = 0.5652534 [ wherein each of said plurality of electrodes is arranged in a first configuration and a second configuration, wherein said first and second configurations are different from each other, and ][ wherein the plurality of electrodes are arranged in a first configuration that has the outer surface of said elongated member and the inner surface of said elongated member is substantially parallel to the inner surface of said elongated member, wherein the first configuration is arranged on a first portion of said elongated member, the second configuration is arranged on a second portion of said elongated member, and ]
[ 1103 ] similarity = 0.2721458 [ wherein the plurality of electrodes are arranged in a first configuration that has the outer surface of said elongated member and the inner surface of said elongated member is substantially parallel to the inner surface of said elongated member, wherein the first configuration is arranged on a first portion of said elongated member, the second configuration is arranged on a second portion of said elongated member, and ][ the first portion and the second portion are substantially parallel, and ]
[ 1104 ] similarity = 0.31272417 [ the first portion and the second portion are substantially parallel, and ][ wherein the inner surface of said elongated member is substantially flat, and ]
[ 1105 ] similarity = 0.67347044 [ wherein the inner surface of said elongated member is substantially flat, and ][ wherein the plurality of electrodes are arranged on a first surface of said elongated member and a second surface of said elongated member, wherein the second surface of said elongated member has an outer surface that is substantially flat, and ]
[ 1106 ] similarity = 0.6058857 [ wherein the plurality of electrodes are arranged on a first surface of said elongated member and a second surface of said elongated member, wherein the second surface of said elongated member has an outer surface that is substantially flat, and ][ wherein the first and second surfaces of said elongated member are substantially parallel. ]
[ 1107 ] similarity = 0.35742468 [ An apparatus comprising: ][ a first housing; ]
[ 1108 ] similarity = 0.44567543 [ a first housing; ][ a first support member; ]
[ 1109 ] similarity = 0.5392578 [ a first support member; ][ a first support member member having a first end and a second end, wherein the first support member member member includes a first end and a second end; ]
[ 1110 ] similarity = 0.8697387 [ a first support member member having a first end and a second end, wherein the first support member member member includes a first end and a second end; ][ a first support member member having a first end and a second end, wherein the first support member member member includes a first end and a second end, wherein the first support member member member is configured for placement within the first housing and wherein the first support member member member is configured to be attached to a first end of the first housing; ]
[ 1111 ] similarity = 0.2524837 [ a first support member member having a first end and a second end, wherein the first support member member member includes a first end and a second end, wherein the first support member member member is configured for placement within the first housing and wherein the first support member member member is configured to be attached to a first end of the first housing; ][ a first support structure; ]
[ 1112 ] similarity = 0.57497513 [ a first support structure; ][ a first support member member; ]
[ 1113 ] similarity = 0.6098823 [ a first support member member; ][ a first support member member having a first end and a second end, wherein the first support member member member includes a first end and a second end, wherein the first support member member member is configured for placement within the first housing and wherein the first support member member is configured to be attached to a second end of the first housing; and ]
[ 1114 ] similarity = 0.74955356 [ a first support member member having a first end and a second end, wherein the first support member member member includes a first end and a second end, wherein the first support member member member is configured for placement within the first housing and wherein the first support member member is configured to be attached to a second end of the first housing; and ][ a second housing, the first support member member, the second housing, the first support member member, and ]
[ 1115 ] similarity = 0.7512513 [ a second housing, the first support member member, the second housing, the first support member member, and ][ the second support member member are disposed within the second housing. ]
[ 1116 ] similarity = 0.32442966 [ A system for the treatment of a patient, comprising: ][ a patient-specific device; ]
[ 1117 ] similarity = 0.41626596 [ a patient-specific device; ][ a patient-specific implant; and ]
[ 1118 ] similarity = 0.26005173 [ a patient-specific implant; and ][ a plurality of electrodes, ]
[ 1119 ] similarity = 0.63673675 [ a plurality of electrodes, ][ wherein the plurality of electrodes comprises: ]
[ 1120 ] similarity = 0.19932699 [ wherein the plurality of electrodes comprises: ][ a first electrode disposed on an outer surface of a first electrode-shaped portion of the patient-specific device and configured to be implanted into a patient's tissue; ]
[ 1121 ] similarity = 0.83989614 [ a first electrode disposed on an outer surface of a first electrode-shaped portion of the patient-specific device and configured to be implanted into a patient's tissue; ][ a second electrode disposed on an inner surface of the first electrode-shaped portion of the patient-specific device and configured to be implanted into the patient's tissue, the second electrode being disposed in a position different from the first electrode-shaped portion of the patient-specific device; and ]
[ 1122 ] similarity = 0.49912027 [ a second electrode disposed on an inner surface of the first electrode-shaped portion of the patient-specific device and configured to be implanted into the patient's tissue, the second electrode being disposed in a position different from the first electrode-shaped portion of the patient-specific device; and ][ a plurality of electrodes, each electrode-shaped portion having a plurality of electrodes, wherein the plurality of electrodes are disposed in a position different from the patient-specific device. ]
[ 1123 ] similarity = 0.4618672 [ An apparatus for treating an eye of a patient, the eye having a pupil, the apparatus comprising: ][ a light source for illuminating the pupil of the eye; ]
[ 1124 ] similarity = 0.50750995 [ a light source for illuminating the pupil of the eye; ][ a first lens for focusing the illuminating light; ]
[ 1125 ] similarity = 0.63333875 [ a first lens for focusing the illuminating light; ][ a second lens having a first end and a second end, the second lens having a first lens surface, the first lens surface configured for focusing the illuminating light; and ]
[ 1126 ] similarity = 0.69344115 [ a second lens having a first end and a second end, the second lens having a first lens surface, the first lens surface configured for focusing the illuminating light; and ][ a first filter for selectively filtering light from the second lens, the first filter comprising a first filter surface and an intermediate layer of the light source and the first lens surface, ]
[ 1127 ] similarity = 0.6227612 [ a first filter for selectively filtering light from the second lens, the first filter comprising a first filter surface and an intermediate layer of the light source and the first lens surface, ][ wherein the first filter surface is configured for focusing the illumination light to a first portion of the pupil of the eye, ]
[ 1128 ] similarity = 0.781286 [ wherein the first filter surface is configured for focusing the illumination light to a first portion of the pupil of the eye, ][ wherein the first filter surface is configured for focusing the light from the second lens to a second portion of the pupil of the eye, and ]
[ 1129 ] similarity = 0.67105806 [ wherein the first filter surface is configured for focusing the light from the second lens to a second portion of the pupil of the eye, and ][ wherein the second portion of the pupil is not illuminated by the illumination of the first portion of the pupil. ]
[ 1130 ] similarity = 0.48233432 [ A device for providing a patient with a treatment, comprising: ][ a patient support; ]
[ 1131 ] similarity = 0.1779564 [ a patient support; ][ a first electrode disposed in a first region of the patient support, the first electrode having an electrode surface; and ]
[ 1132 ] similarity = 0.80575144 [ a first electrode disposed in a first region of the patient support, the first electrode having an electrode surface; and ][ a plurality of electrodes disposed on the first electrode, each electrode having an electrode surface, ]
[ 1133 ] similarity = 0.18378186 [ a plurality of electrodes disposed on the first electrode, each electrode having an electrode surface, ][ wherein the first region includes a first region of the patient support, ]
[ 1134 ] similarity = 0.79078686 [ wherein the first region includes a first region of the patient support, ][ wherein a first electrode is disposed in the first region of the patient support, ]
[ 1135 ] similarity = 0.69813645 [ wherein a first electrode is disposed in the first region of the patient support, ][ wherein the first electrode has a first electrode surface, and ]
[ 1136 ] similarity = 0.5649414 [ wherein the first electrode has a first electrode surface, and ][ wherein the electrode surface is substantially flat. ]
[ 1137 ] similarity = 0.1692988 [ A system for treating an eye, comprising: ][ an implantable medical device having a proximal end and a distal end; and ]
[ 1138 ] similarity = 0.44971126 [ an implantable medical device having a proximal end and a distal end; and ][ an implantable medical device controller configured to: ]
[ 1139 ] similarity = 0.28065926 [ an implantable medical device controller configured to: ][ receive a signal from a first device; ]
[ 1140 ] similarity = 0.46145895 [ receive a signal from a first device; ][ determine a first treatment parameter from the signal; ]
[ 1141 ] similarity = 0.64044476 [ determine a first treatment parameter from the signal; ][ determine a second treatment parameter from the signal; and<|span|> determine an eye treatment parameter from a second device, ]
[ 1142 ] similarity = 0.3954547 [ determine a second treatment parameter from the signal; and<|span|> determine an eye treatment parameter from a second device, ][ wherein the first device is a first device configured to treat an eye and the second device is a second device configured to treat an eye, and ]
[ 1143 ] similarity = 0.49350405 [ wherein the first device is a first device configured to treat an eye and the second device is a second device configured to treat an eye, and ][ wherein the first and second treatment parameters are associated with the implantable medical device. ]
[ 1144 ] similarity = 0.4835118 [ A method for treating a patient, comprising: ][ providing a patient with a first implant; ]
[ 1145 ] similarity = 0.57461464 [ providing a patient with a first implant; ][ providing a first infusion device for administering a first infusion of a first fluid to the patient; ]
[ 1146 ] similarity = 0.84047705 [ providing a first infusion device for administering a first infusion of a first fluid to the patient; ][ providing a first infusion pump for delivering the first fluid to the patient; ]
[ 1147 ] similarity = 0.6987985 [ providing a first infusion pump for delivering the first fluid to the patient; ][ administering a first infusion to the first infusion device; and ]
[ 1148 ] similarity = 0.45755225 [ administering a first infusion to the first infusion device; and ][ providing a first fluid to the first fluid pump; ]
[ 1149 ] similarity = 0.13525954 [ providing a first fluid to the first fluid pump; ][ administering a second infusion to the patient; and ]
[ 1150 ] similarity = 0.8447174 [ administering a second infusion to the patient; and ][ delivering a second infusion to the patient; ]
[ 1151 ] similarity = 0.34856325 [ delivering a second infusion to the patient; ][ wherein the first infusion device and the first infusion pump are configured for use in a single infusion cycle, wherein each infusion cycle comprises a single dose of a first infusion of a first fluid and a single dose of a second infusion of the first fluid, wherein the second infusion is administered at a different time than the first infusion. ]
[ 1152 ] similarity = 0.46292764 [ A method of treating a patient having a tumor in an organ, comprising: ][ providing a tissue-selective antibody that specifically binds a tumor specific antigen, wherein the tumor specific antigen is a human T-cell antigen; ]
[ 1153 ] similarity = 0.3019641 [ providing a tissue-selective antibody that specifically binds a tumor specific antigen, wherein the tumor specific antigen is a human T-cell antigen; ][ administering the tissue-selective antibody to the patient; and ]
[ 1154 ] similarity = 0.49106094 [ administering the tissue-selective antibody to the patient; and ][ administering an effective amount of an anti-T-cell antibody to the patient, wherein the anti-T-cell antibody specifically binds the tumor specific antigen. ]
[ 1155 ] similarity = 0.069975704 [ A method for the treatment of a patient having a tumor, comprising administering to said patient a therapeutically effective amount of an effective amount of an anti-tumor agent comprising a polypeptide comprising a sequence of SEQ ID NO: ][ 1 or SEQ ID NO: ]
[ 1156 ] similarity = 0.23255429 [ 1 or SEQ ID NO: ][ 2 and wherein the anti-tumor agent is a polypeptide having the amino acid sequence of SEQ ID NO: 2, ]
[ 1157 ] similarity = 0.12546834 [ 2 and wherein the anti-tumor agent is a polypeptide having the amino acid sequence of SEQ ID NO: 2, ][ wherein the anti-tumor agent is administered in a dose effective to treat said patient. ]
[ 1158 ] similarity = 0.20814963 [ A method of providing a therapeutic agent to a subject in need thereof in a manner that does not require a pharmaceutically acceptable carrier, the method comprising: ][ a) providing a first delivery device having an outer surface and an inner surface, the inner surface of the delivery device being configured to be disposed within an internal space of the subject; and ]
[ 1159 ] similarity = 0.6791981 [ a) providing a first delivery device having an outer surface and an inner surface, the inner surface of the delivery device being configured to be disposed within an internal space of the subject; and ][ b) providing a second delivery device having an outer surface and a plurality of electrodes disposed on the inner surface of the delivery device, the plurality of electrodes being configured to be disposed within the internal space of the subject, wherein: ]
[ 1160 ] similarity = 0.6571498 [ b) providing a second delivery device having an outer surface and a plurality of electrodes disposed on the inner surface of the delivery device, the plurality of electrodes being configured to be disposed within the internal space of the subject, wherein: ][ i) a) the plurality of electrodes are disposed within an inner surface of the delivery device; and ]
[ 1161 ] similarity = 0.7429413 [ i) a) the plurality of electrodes are disposed within an inner surface of the delivery device; and ][ ii) the plurality of electrodes are configured to be disposed in the inner surface of the delivery device to be electrically coupled to the inner surface of the delivery device; ]
[ 1162 ] similarity = 0.24629997 [ ii) the plurality of electrodes are configured to be disposed in the inner surface of the delivery device to be electrically coupled to the inner surface of the delivery device; ][ c) the plurality of electrodes are configured to provide a therapeutic agent; and ]
[ 1163 ] similarity = 0.7423791 [ c) the plurality of electrodes are configured to provide a therapeutic agent; and ][ d) the plurality of electrodes are configured to deliver the therapeutic agent to the subject. ]
[ 1164 ] similarity = 0.12421341 [ A method for treating a patient having an inflammatory bowel disease, comprising administering to the patient a therapeutically effective amount of a compound selected from the group consisting of: ][ (i) a pharmaceutically acceptable salt thereof; and ]
[ 1165 ] similarity = 0.470281 [ (i) a pharmaceutically acceptable salt thereof; and ][ (ii) a pharmaceutically acceptable carrier. ]
[ 1166 ] similarity = 0.43652642 [ A method of treating a condition in a mammal comprising administering to the mammal a therapeutically effective amount of a composition comprising: ][ (a) a pharmaceutically effective amount of an antibody comprising a nucleic acid sequence selected from the group consisting of: ]
[ 1167 ] similarity = 0.03228225 [ (a) a pharmaceutically effective amount of an antibody comprising a nucleic acid sequence selected from the group consisting of: ][ (i) SEQ ID NO: 1, ]
[ 1168 ] similarity = 0.69176424 [ (i) SEQ ID NO: 1, ][ (ii) SEQ ID NO: 2, ]
[ 1169 ] similarity = 0.5436652 [ (ii) SEQ ID NO: 2, ][ (iii) SEQ ID NO: 4, and ]
[ 1170 ] similarity = 0.73929745 [ (iii) SEQ ID NO: 4, and ][ (iv) SEQ ID NO: 7; and ]
[ 1171 ] similarity = -0.00798826 [ (iv) SEQ ID NO: 7; and ][ (b) a pharmaceutically effective amount of a pharmaceutically acceptable carrier; ]
[ 1172 ] similarity = -0.033447295 [ (b) a pharmaceutically effective amount of a pharmaceutically acceptable carrier; ][ wherein the antibody is selected from the group consisting of: ]
[ 1173 ] similarity = 0.02153949 [ wherein the antibody is selected from the group consisting of: ][ (i) an antibody comprising a nucleic acid sequence having a sequence that encodes the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, or SEQ ID NO: 8; ]
[ 1174 ] similarity = 0.5986679 [ (i) an antibody comprising a nucleic acid sequence having a sequence that encodes the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, or SEQ ID NO: 8; ][ (ii) an antibody comprising a nucleic acid sequence having a sequence that encodes the amino acid sequence of SEQ ID NO: 1; and ]
[ 1175 ] similarity = 0.83988017 [ (ii) an antibody comprising a nucleic acid sequence having a sequence that encodes the amino acid sequence of SEQ ID NO: 1; and ][ (iii) an antibody comprising a nucleic acid sequence that encodes a sequence having a amino acid sequence having a sequence having a sequence that encodes SEQ ID NO: 1; ]
[ 1176 ] similarity = 0.15447575 [ (iii) an antibody comprising a nucleic acid sequence that encodes a sequence having a amino acid sequence having a sequence having a sequence that encodes SEQ ID NO: 1; ][ wherein said antibody is a humanized antibody, and ]
[ 1177 ] similarity = 0.39423874 [ wherein said antibody is a humanized antibody, and ][ wherein said antibody is selected from the group consisting of humanized antibody, humanized antibody with a humanized antibody sequence having a sequence having an amino acid sequence that encodes SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, or SEQ ID NO: 8. ]
[ 1178 ] similarity = 0.03650532 [ A method for treating a patient suffering from a chronic pain syndrome, the method comprising administering to the patient a therapeutically effective amount of a compound selected from the group consisting of: ][ (i) an isolated peptide comprising the amino acid sequence of SEQ ID NO: ]
[ 1179 ] similarity = 0.03130941 [ (i) an isolated peptide comprising the amino acid sequence of SEQ ID NO: ][ 1; and ]
[ 1180 ] similarity = 0.059122223 [ 1; and ][ (ii) a compound that inhibits the binding of an amino acid sequence of SEQ ID NO: ]
[ 1181 ] similarity = 0.45816112 [ (ii) a compound that inhibits the binding of an amino acid sequence of SEQ ID NO: ][ 1 to a peptide of SEQ ID NO: ]
[ 1182 ] similarity = 0.04255686 [ 1 to a peptide of SEQ ID NO: ][ 2. ]
[ 1183 ] similarity = 0.38584888 [ An apparatus comprising: ][ a housing; ]
[ 1184 ] similarity = 0.13842946 [ a housing; ][ a first and second electrode assembly disposed on the housing and configured to be disposed within a first and a second cavity; ]
[ 1185 ] similarity = 0.8831145 [ a first and second electrode assembly disposed on the housing and configured to be disposed within a first and a second cavity; ][ a first electrical connector disposed within the first cavity and configured to be disposed within a first and a second electrode assembly disposed within a second cavity; ]
[ 1186 ] similarity = 0.7262199 [ a first electrical connector disposed within the first cavity and configured to be disposed within a first and a second electrode assembly disposed within a second cavity; ][ a second electrical connector disposed within the second cavity and configured to be disposed within a second and a third cavity; ]
[ 1187 ] similarity = 0.70889425 [ a second electrical connector disposed within the second cavity and configured to be disposed within a second and a third cavity; ][ a plurality of conductive elements disposed within the first cavity and disposed within the second cavity and configured to be disposed within the first cavity and the second cavity; ]
[ 1188 ] similarity = 0.8316194 [ a plurality of conductive elements disposed within the first cavity and disposed within the second cavity and configured to be disposed within the first cavity and the second cavity; ][ a plurality of conductive elements disposed within the second cavity and disposed within the third cavity and configured to be disposed within the third cavity; ]
[ 1189 ] similarity = 0.9069879 [ a plurality of conductive elements disposed within the second cavity and disposed within the third cavity and configured to be disposed within the third cavity; ][ a plurality of conductive elements disposed within the third cavity and disposed within the fourth cavity; ]
[ 1190 ] similarity = 0.921631 [ a plurality of conductive elements disposed within the third cavity and disposed within the fourth cavity; ][ a plurality of conductive elements disposed within the fourth cavity and disposed within the fifth cavity; and ]
[ 1191 ] similarity = 0.92804754 [ a plurality of conductive elements disposed within the fourth cavity and disposed within the fifth cavity; and ][ a plurality of conductive elements disposed within the fifth cavity and configured to be disposed within the fifth cavity. ]
[ 1192 ] similarity = 0.50534177 [ An implantable medical device for delivering a drug to the body comprising: ][ a first electrode configured to deliver a drug to an implant; ]
[ 1193 ] similarity = 0.69633746 [ a first electrode configured to deliver a drug to an implant; ][ a first electrode support configured to support a first electrode; ]
[ 1194 ] similarity = 0.7698731 [ a first electrode support configured to support a first electrode; ][ an implantable electrode support configured to support a second electrode; and ]
[ 1195 ] similarity = 0.7493564 [ an implantable electrode support configured to support a second electrode; and ][ an implantable electrode support support comprising: ]
[ 1196 ] similarity = 0.5819297 [ an implantable electrode support support comprising: ][ a first electrode support member configured to support a first electrode; ]
[ 1197 ] similarity = 0.87019885 [ a first electrode support member configured to support a first electrode; ][ a first electrode support member support member configured to support a second electrode; and ]
[ 1198 ] similarity = 0.87518024 [ a first electrode support member support member configured to support a second electrode; and ][ a second electrode support member configured to support a second electrode; wherein the first electrode support member support member is configured to support a first portion of the first electrode and the second electrode support member support member is configured to support a second portion of the second electrode, ]
[ 1199 ] similarity = 0.8452302 [ a second electrode support member configured to support a second electrode; wherein the first electrode support member support member is configured to support a first portion of the first electrode and the second electrode support member support member is configured to support a second portion of the second electrode, ][ wherein the first electrode support member and the second electrode support member support member are configured to support a first portion of the drug, and ]
[ 1200 ] similarity = 0.75349164 [ wherein the first electrode support member and the second electrode support member support member are configured to support a first portion of the drug, and ][ wherein at least a portion of the first electrode and the second electrode support member are configured to support a first portion of the first electrode. ]
[ 1201 ] similarity = 0.3223551 [ A method of treating cancer comprising administering to a mammal in need thereof a compound selected from the group consisting of: (a) a pharmaceutically acceptable salt thereof; (b) a salt of a compound selected from the group consisting of: (i) an amino acid salt thereof, and ][ (ii) a salt thereof; and ]
[ 1202 ] similarity = 0.06392947 [ (ii) a salt thereof; and ][ (c) a pharmaceutically acceptable carrier; wherein the cancer is cancer in situ or metastasis of a cell. ]
[ 1203 ] similarity = 0.37047094 [ A method for treating a disease comprising: ][ providing at least one patient with a first therapeutic agent, the at least one patient having a first condition; ]
[ 1204 ] similarity = 0.72127825 [ providing at least one patient with a first therapeutic agent, the at least one patient having a first condition; ][ administering to the first patient at least one second therapeutic agent, the at least one second therapeutic agent having a second condition; ]
[ 1205 ] similarity = 0.6352469 [ administering to the first patient at least one second therapeutic agent, the at least one second therapeutic agent having a second condition; ][ administering to the first and second conditions at least one third therapeutic agent; and ]
[ 1206 ] similarity = 0.89627224 [ administering to the first and second conditions at least one third therapeutic agent; and ][ administering to the first and second conditions at least one third therapeutic agent having a fourth condition. ]
[ 1207 ] similarity = 0.5911501 [ A method of providing an implant for implantation in a body tissue, the method comprising: ][ providing a first implant for implantation in the body tissue, the first implant comprising a first implant body and a second implant body, the first implant body and the second implant body being different from one another, and ]
[ 1208 ] similarity = 0.75871843 [ providing a first implant for implantation in the body tissue, the first implant comprising a first implant body and a second implant body, the first implant body and the second implant body being different from one another, and ][ wherein the first implant body is adapted to be implanted in a first region of a body tissue and the second implant body is adapted to be implanted in a second region of the body tissue; and ]
[ 1209 ] similarity = 0.7859197 [ wherein the first implant body is adapted to be implanted in a first region of a body tissue and the second implant body is adapted to be implanted in a second region of the body tissue; and ][ providing a second implant for implantation in the body tissue, the second implant body comprising a second implant body and a third implant body, the third implant body and the second implant body being different from one another and wherein the third implant body is adapted to be implanted in a third region of the body tissue and the second implant body is adapted to be implanted in a fourth region of the body tissue, ]
[ 1210 ] similarity = 0.6278572 [ providing a second implant for implantation in the body tissue, the second implant body comprising a second implant body and a third implant body, the third implant body and the second implant body being different from one another and wherein the third implant body is adapted to be implanted in a third region of the body tissue and the second implant body is adapted to be implanted in a fourth region of the body tissue, ][ wherein the first implant body is adapted to be implanted in a first region of the first region of the body tissue and the second implant body comprises an elongate member having a first end and a second end. ]
[ 1211 ] similarity = 0.40064615 [ A method of treating an autoimmune condition comprising administering a therapeutically effective amount of a polypeptide having a sequence of SEQ ID NOS: ][ 4, 5 or 6 to a patient, wherein the therapeutically effective amount is effective to treat the autoimmune condition. ]
[ 1212 ] similarity = 0.49944857 [ A method for treating a subject having an inflammatory disease comprising administering to the subject a composition having an effective amount of a compound selected from the group consisting of: ][ a compound selected from the group consisting of: ]
[ 1213 ] similarity = 0.048027866 [ a compound selected from the group consisting of: ][ (i) a pharmaceutically acceptable salt thereof and (ii) one or more pharmaceutically acceptable esters thereof; and ]
[ 1214 ] similarity = 0.34344012 [ (i) a pharmaceutically acceptable salt thereof and (ii) one or more pharmaceutically acceptable esters thereof; and ][ a pharmaceutically acceptable carrier. ]
[ 1215 ] similarity = 0.28209594 [ A method of treating an autoimmune disorder comprising administering to a subject in need of such treatment a therapeutically effective amount of a pharmaceutical composition comprising: ][ a) at least one of a pharmaceutically acceptable salt, a pharmaceutically acceptable carrier, a pharmaceutically acceptable adjuvant, a pharmaceutically acceptable carrier-in-vitro, a pharmaceutically acceptable adjuvant-in-vitro, and ]
[ 1216 ] similarity = 0.48504758 [ a) at least one of a pharmaceutically acceptable salt, a pharmaceutically acceptable carrier, a pharmaceutically acceptable adjuvant, a pharmaceutically acceptable carrier-in-vitro, a pharmaceutically acceptable adjuvant-in-vitro, and ][ a therapeutically acceptable carrier-in-vitro; and ]
[ 1217 ] similarity = 0.4477741 [ a therapeutically acceptable carrier-in-vitro; and ][ b) at least one of a pharmaceutically acceptable salt, a pharmaceutically acceptable carrier, a pharmaceutically acceptable adjuvant, a pharmaceutically acceptable carrier-in-vitro, a pharmaceutically acceptable adjuvant-in-vitro, and ]
[ 1218 ] similarity = 0.91876936 [ b) at least one of a pharmaceutically acceptable salt, a pharmaceutically acceptable carrier, a pharmaceutically acceptable adjuvant, a pharmaceutically acceptable carrier-in-vitro, a pharmaceutically acceptable adjuvant-in-vitro, and ][ a pharmaceutically acceptable adjuvant-in-vitro, wherein the at least one of a pharmaceutically acceptable salt, a pharmaceutically acceptable carrier, a pharmaceutically acceptable adjuvant, a pharmaceutically acceptable carrier-in-vitro, a pharmaceutically acceptable adjuvant-in-vitro and a pharmaceutically acceptable adjuvant-in-vitro comprises a pharmaceutically acceptable carrier, a pharmaceutically acceptable adjuvant, a pharmaceutically acceptable carrier-in-vitro, a pharmaceutically acceptable adjuvant-in-vitro, and ]
[ 1219 ] similarity = 0.67124444 [ a pharmaceutically acceptable adjuvant-in-vitro, wherein the at least one of a pharmaceutically acceptable salt, a pharmaceutically acceptable carrier, a pharmaceutically acceptable adjuvant, a pharmaceutically acceptable carrier-in-vitro, a pharmaceutically acceptable adjuvant-in-vitro and a pharmaceutically acceptable adjuvant-in-vitro comprises a pharmaceutically acceptable carrier, a pharmaceutically acceptable adjuvant, a pharmaceutically acceptable carrier-in-vitro, a pharmaceutically acceptable adjuvant-in-vitro, and ][ a pharmaceutically acceptable adjuvant-in-vitro. ]
[ 1220 ] similarity = 0.545977 [ A system for providing an implantable device to a patient, comprising: ][ a first implantable device; and<|span|> a second implantable device, the second implantable device being adapted to provide a first electrical stimulation to a first nerve of the patient; ]
[ 1221 ] similarity = 0.5293471 [ a first implantable device; and<|span|> a second implantable device, the second implantable device being adapted to provide a first electrical stimulation to a first nerve of the patient; ][ wherein the first implantable device is adapted to be implanted in a patient's body; ]
[ 1222 ] similarity = 0.39683092 [ wherein the first implantable device is adapted to be implanted in a patient's body; ][ wherein the second implantable device is adapted to be implanted in the patient's body, wherein the second implantable device is adapted to provide a second electrical stimulation to a second nerve of the patient, wherein the first electrical stimulation is delivered to the first nerve and the second electrical stimulation is delivered to the second nerve, and ]
[ 1223 ] similarity = 0.73935306 [ wherein the second implantable device is adapted to be implanted in the patient's body, wherein the second implantable device is adapted to provide a second electrical stimulation to a second nerve of the patient, wherein the first electrical stimulation is delivered to the first nerve and the second electrical stimulation is delivered to the second nerve, and ][ wherein the first and second electrical stimulations provide a first stimulation to the patient and a second stimulation to the patient, wherein the second stimulation is provided at least partially by a second electrical stimulation. ]
[ 1224 ] similarity = 0.14639598 [ A method of providing a patient-side support for a surgical instrument comprising: ][ providing a first body having a first end and a second end; ]
[ 1225 ] similarity = 0.8605013 [ providing a first body having a first end and a second end; ][ providing a second body including a first end and a second end; ]
[ 1226 ] similarity = 0.36293662 [ providing a second body including a first end and a second end; ][ providing a first body support member including a first body support member body and a second body support member body, the first body support member body being disposed within the second body support member body, and ]
[ 1227 ] similarity = 0.86578214 [ providing a first body support member including a first body support member body and a second body support member body, the first body support member body being disposed within the second body support member body, and ][ the second body support member body being disposed within the first body support member body; ]
[ 1228 ] similarity = 0.50621235 [ the second body support member body being disposed within the first body support member body; ][ attaching the first body support member to a surgical instrument; ]
[ 1229 ] similarity = 0.55144036 [ attaching the first body support member to a surgical instrument; ][ attaching the second body support member to the second end of the surgical instrument; and ]
[ 1230 ] similarity = 0.42021382 [ attaching the second body support member to the second end of the surgical instrument; and ][ providing a support member having a first end portion and a second end portion, the first end portion of the support member having a first end and a second end, the second end portion of the support member having a third end, the first end portion of the support member including a first end support surface and a second end support surface; ]
[ 1231 ] similarity = 0.4202302 [ providing a support member having a first end portion and a second end portion, the first end portion of the support member having a first end and a second end, the second end portion of the support member having a third end, the first end portion of the support member including a first end support surface and a second end support surface; ][ attaching the support member to the second end of the surgical instrument; ]
[ 1232 ] similarity = 0.37589598 [ attaching the support member to the second end of the surgical instrument; ][ attaching the second body support member including a second body support member body and a first body support member body to the first body support member; ]
[ 1233 ] similarity = 0.5659371 [ attaching the second body support member including a second body support member body and a first body support member body to the first body support member; ][ attaching the first body support member to the second end of the surgical instrument; ]
[ 1234 ] similarity = 0.7183011 [ attaching the first body support member to the second end of the surgical instrument; ][ attaching the second body support member including a first body support member body and a second body support member body to the second end of the surgical instrument; and ]
[ 1235 ] similarity = 0.5776651 [ attaching the second body support member including a first body support member body and a second body support member body to the second end of the surgical instrument; and ][ attaching the support member to the second end of the surgical instrument. ]
[ 1236 ] similarity = 0.3246408 [ A method of providing a treatment to a subject, the method comprising: ][ providing an implantable medical device comprising: ]
[ 1237 ] similarity = 0.22808734 [ providing an implantable medical device comprising: ][ a first electrode configured to be electrically connected to a blood vessel; and ]
[ 1238 ] similarity = 0.7617846 [ a first electrode configured to be electrically connected to a blood vessel; and ][ a second electrode, wherein said first electrode is configured to be electrically connected to the blood vessel and said second electrode is configured to be electrically disconnected from the blood vessel; and ]
[ 1239 ] similarity = -0.01161654 [ a second electrode, wherein said first electrode is configured to be electrically connected to the blood vessel and said second electrode is configured to be electrically disconnected from the blood vessel; and ][ providing a treatment to the subject. ]
[ 1240 ] similarity = 0.22585508 [ A method for treating a subject having a tumor comprising administering to the patient an amount of an effective amount of an anti-cancer agent selected from the group consisting of: ][ (a) an antibody or antigen-binding fragment thereof that specifically binds to a human CD4+ T cell receptor, ]
[ 1241 ] similarity = 0.8154431 [ (a) an antibody or antigen-binding fragment thereof that specifically binds to a human CD4+ T cell receptor, ][ (b) an antibody or antigen-binding fragment thereof that specifically binds to an anti-cancer cell-cell receptor, ]
[ 1242 ] similarity = 0.87779355 [ (b) an antibody or antigen-binding fragment thereof that specifically binds to an anti-cancer cell-cell receptor, ][ (c) an antibody or antigen-binding fragment thereof that specifically binds to a tumor-cell receptor, ]
[ 1243 ] similarity = 0.8901026 [ (c) an antibody or antigen-binding fragment thereof that specifically binds to a tumor-cell receptor, ][ (d) an antibody or antigen-binding fragment thereof that specifically binds to an anti-tumor cell-cell receptor, and ]
[ 1244 ] similarity = 0.89101064 [ (d) an antibody or antigen-binding fragment thereof that specifically binds to an anti-tumor cell-cell receptor, and ][ (e) an antibody or antigen-binding fragment thereof that specifically binds to a tumor-cell receptor. ]
[ 1245 ] similarity = 0.27571836 [ A device, comprising: ][ an inner surface; ]
[ 1246 ] similarity = 0.74247956 [ an inner surface; ][ an outer surface; ]
[ 1247 ] similarity = 0.26138765 [ an outer surface; ][ an elongated member having a proximal portion, a distal portion, and ]
[ 1248 ] similarity = 0.62206423 [ an elongated member having a proximal portion, a distal portion, and ][ a longitudinal axis, the elongated member having a first portion and a second portion; and ]
[ 1249 ] similarity = 0.53656673 [ a longitudinal axis, the elongated member having a first portion and a second portion; and ][ a plurality of elongate members extending from the proximal portion to the distal portion of the elongated member and extending in a longitudinal direction, wherein the plurality of elongate members have a plurality of elongate members extending in parallel with each other, the plurality of elongate members having a first end and a second end and the first end being disposed between the first and second portions of the elongated member and the second end being disposed between the proximal portion and the distal portion of the elongated member, and ]
[ 1250 ] similarity = 0.583048 [ a plurality of elongate members extending from the proximal portion to the distal portion of the elongated member and extending in a longitudinal direction, wherein the plurality of elongate members have a plurality of elongate members extending in parallel with each other, the plurality of elongate members having a first end and a second end and the first end being disposed between the first and second portions of the elongated member and the second end being disposed between the proximal portion and the distal portion of the elongated member, and ][ the elongated member being disposed between the first portion and the second portion of the elongated member; ]
[ 1251 ] similarity = 0.58461815 [ the elongated member being disposed between the first portion and the second portion of the elongated member; ][ a first elongate member having a first end, a first portion and a second portion, the first portion of the elongate member having a length that is shorter than the first portion of the elongate member, the second portion having a length that is longer than the length of the first portion of the elongate member; and ]
[ 1252 ] similarity = 0.9255654 [ a first elongate member having a first end, a first portion and a second portion, the first portion of the elongate member having a length that is shorter than the first portion of the elongate member, the second portion having a length that is longer than the length of the first portion of the elongate member; and ][ a second elongate member having a first portion and a second portion, the first portion of the elongate member having a length that is shorter than the length of the second portion, the second portion of the elongate member having a length that is longer than the length of the first portion of the elongate member. ]
[ 1253 ] similarity = 0.28101593 [ A method of treating a disease, comprising administering to an individual having the disease a therapeutically effective amount of an effective amount of a polypeptide comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and ][ SEQ ID NO: 5. ]
[ 1254 ] similarity = 0.72252715 [ An isolated nucleic acid comprising a nucleotide sequence that is at least 90% identical to SEQ ID NO: 2 or a fragment thereof, ][ wherein the fragment is at least 90% identical to the nucleotide sequence of SEQ ID NO: ]
[ 1255 ] similarity = -0.115277424 [ wherein the fragment is at least 90% identical to the nucleotide sequence of SEQ ID NO: ][ 2. ]
[ 1256 ] similarity = -0.12698893 [ A method for producing a compound having an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein: ][ R1 is H, C1-C6 alkyl, C1-C4 alkoxy, C1-C4 alkylamino or C1-C6 alkylaminoalkyl, ]
[ 1257 ] similarity = 0.32872224 [ R1 is H, C1-C6 alkyl, C1-C4 alkoxy, C1-C4 alkylamino or C1-C6 alkylaminoalkyl, ][ R2 and R3 independently of each other are each independently a hydrogen, C1-C4 alkylene, a C1-C4 alkyloxy, a C1-C4 alkoxyalkyl, a C1-C4 alkenyl or a C1-C3 alkynyl, ]
[ 1258 ] similarity = 0.33131665 [ R2 and R3 independently of each other are each independently a hydrogen, C1-C4 alkylene, a C1-C4 alkyloxy, a C1-C4 alkoxyalkyl, a C1-C4 alkenyl or a C1-C3 alkynyl, ][ R4 is a C1-C4 alkyl, C1-C4 alkoxy or C1-C4 alkylaminoalkyl or a pharmaceutically acceptable salt thereof, ]
[ 1259 ] similarity = 0.6016058 [ R4 is a C1-C4 alkyl, C1-C4 alkoxy or C1-C4 alkylaminoalkyl or a pharmaceutically acceptable salt thereof, ][ R5 is a C1-C4 alkyl, C1-C4 alkoxy or C1-C4 alkylaminoalkyl, and ]
[ 1260 ] similarity = 0.47729725 [ R5 is a C1-C4 alkyl, C1-C4 alkoxy or C1-C4 alkylaminoalkyl, and ][ R6 is H, C3-C6 alkyl, C3-C6 alkylamino or C3-C6 alkylaminoalkyl. ]
[ 1261 ] similarity = 0.03821881 [ A method comprising: ][ providing an implantable medical device; ]
[ 1262 ] similarity = 0.7363025 [ providing an implantable medical device; ][ providing an implantable medical device interface configured to be coupled to the implantable medical device; ]
[ 1263 ] similarity = 0.16752686 [ providing an implantable medical device interface configured to be coupled to the implantable medical device; ][ providing a plurality of electrodes, each electrode comprising: ]
[ 1264 ] similarity = 0.38375938 [ providing a plurality of electrodes, each electrode comprising: ][ a first electrode configured to be coupled to a first portion of an implantable medical device, the first electrode configured to be coupled to a second portion of the implantable medical device; ]
[ 1265 ] similarity = 0.79982316 [ a first electrode configured to be coupled to a first portion of an implantable medical device, the first electrode configured to be coupled to a second portion of the implantable medical device; ][ a second electrode configured to be coupled to a second portion of the implantable medical device, the second electrode configured to be coupled to a third portion of the implantable medical device; and ]
[ 1266 ] similarity = 0.83762705 [ a second electrode configured to be coupled to a second portion of the implantable medical device, the second electrode configured to be coupled to a third portion of the implantable medical device; and ][ a third electrode configured to be coupled to a fourth portion of the implantable medical device; ]
[ 1267 ] similarity = 0.5902395 [ a third electrode configured to be coupled to a fourth portion of the implantable medical device; ][ providing a first electrode interface configured to receive a first portion of the implantable medical device; and ]
[ 1268 ] similarity = 0.7951795 [ providing a first electrode interface configured to receive a first portion of the implantable medical device; and ][ delivering a first electrical signal to the first electrode interface to cause the first portion of the implantable medical device to be electrically coupled to the first electrode; and ]
[ 1269 ] similarity = 0.48511112 [ delivering a first electrical signal to the first electrode interface to cause the first portion of the implantable medical device to be electrically coupled to the first electrode; and ][ providing a second electrode interface configured to receive a second portion of the implantable medical device; ]
[ 1270 ] similarity = 0.6023282 [ providing a second electrode interface configured to receive a second portion of the implantable medical device; ][ wherein the first electrode interface is configured to receive the first electrical signal and the second electrode interface is configured to receive the second electrical signal, wherein the third electrode is configured to be coupled to the second portion of the implantable medical device and the fourth electrode is configured to be coupled to the third portion of the implantable medical device. ]
[ 1271 ] similarity = 0.037604667 [ A method for treating a patient in need thereof comprising administering to the patient in need thereof an effective amount of a compound of Formula II: wherein: ][ R1 and R2 are independently selected from the group consisting of hydrogen, aryl, heteroaryl, heterocyclyl or heteroalkyl; ]
[ 1272 ] similarity = 0.41646397 [ R1 and R2 are independently selected from the group consisting of hydrogen, aryl, heteroaryl, heterocyclyl or heteroalkyl; ][ R1 and R2 each have an integer value from 0 to 3, ]
[ 1273 ] similarity = -0.012451439 [ R1 and R2 each have an integer value from 0 to 3, ][ &#x2014; ]
[ 1274 ] similarity = 0.25606805 [ &#x2014; ][ CH2; ]
[ 1275 ] similarity = 0.16993281 [ CH2; ][ R1 and R2 each have a hydrogen atom; ]
[ 1276 ] similarity = 0.13339376 [ R1 and R2 each have a hydrogen atom; ][ R1 is independently selected from the group consisting of a hydrogen atom, a heterocyclyl group, a heteroalkyl group, a heteroaryl group, a heterocyclyl group, a heteroalkyl group, a heteroalkyl group, a heteroaryl group or a heterocyclyl group; ]
[ 1277 ] similarity = 0.0816212 [ R1 is independently selected from the group consisting of a hydrogen atom, a heterocyclyl group, a heteroalkyl group, a heteroaryl group, a heterocyclyl group, a heteroalkyl group, a heteroalkyl group, a heteroaryl group or a heterocyclyl group; ][ R1 has an integer value from 0 to 3, ]
[ 1278 ] similarity = -0.00898115 [ R1 has an integer value from 0 to 3, ][ &#x2014; ]
[ 1279 ] similarity = 0.14227396 [ &#x2014; ][ CH2; and ]
[ 1280 ] similarity = 0.057155237 [ CH2; and ][ R2 has an integer value from 0 to 3, ]
[ 1281 ] similarity = -0.046257794 [ R2 has an integer value from 0 to 3, ][ &#x2014; ]
[ 1282 ] similarity = 0.25606805 [ &#x2014; ][ CH2. ]
[ 1283 ] similarity = 0.42630756 [ A method of treating a patient suffering from a condition comprising: ][ providing a first pharmaceutical composition comprising an effective amount of an anti-inflammatory agent; and ]
[ 1284 ] similarity = 0.55898875 [ providing a first pharmaceutical composition comprising an effective amount of an anti-inflammatory agent; and ][ delivering a second pharmaceutical composition to the patient, wherein the second pharmaceutical composition comprises a pharmaceutically acceptable carrier. ]
[ 1285 ] similarity = 0.6636015 [ A system for providing a patient-specific medical treatment to a patient, the system comprising: ][ a medical treatment system including a first medical treatment device, a second medical treatment device, and ]
[ 1286 ] similarity = 0.6919597 [ a medical treatment system including a first medical treatment device, a second medical treatment device, and ][ a patient-specific device for providing a first treatment to the patient, wherein the medical treatment system is configured to provide a first treatment to the patient and a second treatment, wherein the first and the second treatment are provided by the same medical treatment device and the first and second treatment devices are coupled together in a single device; ]
[ 1287 ] similarity = 0.39105704 [ a patient-specific device for providing a first treatment to the patient, wherein the medical treatment system is configured to provide a first treatment to the patient and a second treatment, wherein the first and the second treatment are provided by the same medical treatment device and the first and second treatment devices are coupled together in a single device; ][ a patient interface configured for receiving a user-specified medical treatment request from a patient; ]
[ 1288 ] similarity = 0.5806688 [ a patient interface configured for receiving a user-specified medical treatment request from a patient; ][ a patient device for providing the first treatment; ]
[ 1289 ] similarity = 0.5624492 [ a patient device for providing the first treatment; ][ a patient interface for receiving a user-specified medical treatment request from a patient; and ]
[ 1290 ] similarity = 0.6034059 [ a patient interface for receiving a user-specified medical treatment request from a patient; and ][ a first medical treatment device for delivering a first treatment to the patient; and ]
[ 1291 ] similarity = 0.69736385 [ a first medical treatment device for delivering a first treatment to the patient; and ][ a second medical treatment device for delivering a second treatment to the patient. ]
[ 1292 ] similarity = 0.10802864 [ A method for treating a disease or disorder in a mammal, comprising administering to said mammal a therapeutically effective amount of an effective amount of a compound selected from the group consisting of: ][ (a) an isolated nucleic acid molecule encoding a polypeptide having the amino acid sequence of SEQ ID NO: ]
[ 1293 ] similarity = -0.026209295 [ (a) an isolated nucleic acid molecule encoding a polypeptide having the amino acid sequence of SEQ ID NO: ][ 3; ]
[ 1294 ] similarity = -0.03918355 [ 3; ][ (b) a polypeptide having the amino acid sequence of SEQ ID NO: ]
[ 1295 ] similarity = 0.040456556 [ (b) a polypeptide having the amino acid sequence of SEQ ID NO: ][ 4; and ]
[ 1296 ] similarity = 0.05958865 [ 4; and ][ (c) a polypeptide having the amino acid sequence of SEQ ID NO: ]
[ 1297 ] similarity = 0.0060510617 [ (c) a polypeptide having the amino acid sequence of SEQ ID NO: ][ 5. ]
[ 1298 ] similarity = 0.07742696 [ A method for treating a patient with a disease or condition in the patient, the method comprising administering to the patient a composition comprising an effective amount of a compound having the structure: ][ (1) wherein: ]
[ 1299 ] similarity = -0.05934628 [ (1) wherein: ][ (A) a) and (B) are independently selected from the group consisting of: ]
[ 1300 ] similarity = 0.0049818233 [ (A) a) and (B) are independently selected from the group consisting of: ][ (i) a) an amino acid sequence having at least 95% identity to SEQ ID NO: 2, and ]
[ 1301 ] similarity = 0.45390606 [ (i) a) an amino acid sequence having at least 95% identity to SEQ ID NO: 2, and ][ (ii) a sequence selected from the group consisting of SEQ ID NO: 2, ]
[ 1302 ] similarity = 0.31677157 [ (ii) a sequence selected from the group consisting of SEQ ID NO: 2, ][ (iii) a nucleic acid sequence having at least 95% identity to SEQ ID NO: 3, and ]
[ 1303 ] similarity = 0.55731034 [ (iii) a nucleic acid sequence having at least 95% identity to SEQ ID NO: 3, and ][ (iv) a sequence selected from the group consisting of SEQ ID NO: 3, and ]
[ 1304 ] similarity = 0.53415453 [ (iv) a sequence selected from the group consisting of SEQ ID NO: 3, and ][ (v) a nucleic acid sequence having at least 95% identity to SEQ ID NO: 4; and ]
[ 1305 ] similarity = -0.045347854 [ (v) a nucleic acid sequence having at least 95% identity to SEQ ID NO: 4; and ][ (b) a pharmaceutically acceptable carrier; ]
[ 1306 ] similarity = 0.20104437 [ (b) a pharmaceutically acceptable carrier; ][ (2) wherein the composition is administered to the patient by means of a pharmaceutical delivery system. ]
[ 1307 ] similarity = 0.16073799 [ A method for treating a patient having a disease comprising administering to said patient a therapeutically effective amount of a pharmaceutically acceptable composition comprising an active agent and an anti-inflammatory agent, wherein the active agent and the anti-inflammatory agent comprise at least one compound selected from the following group consisting of a compound selected from the group consisting of: ][ (a) a pharmaceutically acceptable salt of a polypeptide having the structure of SEQ ID NO: ]
[ 1308 ] similarity = -0.031556793 [ (a) a pharmaceutically acceptable salt of a polypeptide having the structure of SEQ ID NO: ][ 3; ]
[ 1309 ] similarity = 0.004213769 [ 3; ][ (b) a polypeptide having the structure of SEQ ID NO: ]
[ 1310 ] similarity = 0.04456645 [ (b) a polypeptide having the structure of SEQ ID NO: ][ 4; and ]
[ 1311 ] similarity = 0.061433125 [ 4; and ][ (c) a polypeptide having the structure of SEQ ID NO: ]
[ 1312 ] similarity = -0.0021257224 [ (c) a polypeptide having the structure of SEQ ID NO: ][ 5. ]
[ 1313 ] similarity = 0.44798806 [ A method for the production of an effective amount of an anti-inflammatory agent comprising the steps of: ][ (i) contacting a composition comprising a composition of a polypeptide comprising an anti-inflammatory agent with a first anti-inflammatory agent, the anti-inflammatory agent having an affinity for a target tissue, and ]
[ 1314 ] similarity = 0.4981003 [ (i) contacting a composition comprising a composition of a polypeptide comprising an anti-inflammatory agent with a first anti-inflammatory agent, the anti-inflammatory agent having an affinity for a target tissue, and ][ the first anti-inflammatory agent being a polypeptide comprising a polypeptide of SEQ ID NO: ]
[ 1315 ] similarity = 0.23070696 [ the first anti-inflammatory agent being a polypeptide comprising a polypeptide of SEQ ID NO: ][ 2, SEQ ID NO: ]
[ 1316 ] similarity = 0.7720622 [ 2, SEQ ID NO: ][ 3, SEQ ID NO: ]
[ 1317 ] similarity = 0.79470795 [ 3, SEQ ID NO: ][ 4, SEQ ID NO: ]
[ 1318 ] similarity = 0.8005054 [ 4, SEQ ID NO: ][ 5, SEQ ID NO: ]
[ 1319 ] similarity = 0.71591413 [ 5, SEQ ID NO: ][ 6 and SEQ ID NO: ]
[ 1320 ] similarity = 0.2975747 [ 6 and SEQ ID NO: ][ 7; ]
[ 1321 ] similarity = 0.0025333222 [ 7; ][ (ii) contacting a composition comprising a composition of a polypeptide comprising an anti-inflammatory agent with a second anti-inflammatory agent; ]
[ 1322 ] similarity = 0.8298837 [ (ii) contacting a composition comprising a composition of a polypeptide comprising an anti-inflammatory agent with a second anti-inflammatory agent; ][ (iii) contacting a composition comprising a composition comprising a polypeptide comprising an anti-inflammatory agent with a third anti-inflammatory agent; and ]
[ 1323 ] similarity = 0.6947179 [ (iii) contacting a composition comprising a composition comprising a polypeptide comprising an anti-inflammatory agent with a third anti-inflammatory agent; and ][ (iv) contacting a composition comprising a composition comprising a polypeptide comprising a polypeptide of SEQ ID NO: ]
[ 1324 ] similarity = 0.152194 [ (iv) contacting a composition comprising a composition comprising a polypeptide comprising a polypeptide of SEQ ID NO: ][ 2, SEQ ID NO: ]
[ 1325 ] similarity = 0.7720622 [ 2, SEQ ID NO: ][ 3, SEQ ID NO: ]
[ 1326 ] similarity = 0.79470795 [ 3, SEQ ID NO: ][ 4, SEQ ID NO: ]
[ 1327 ] similarity = 0.7092637 [ 4, SEQ ID NO: ][ 5 and SEQ ID NO: ]
[ 1328 ] similarity = 0.3327471 [ 5 and SEQ ID NO: ][ 6. ]
[ 1329 ] similarity = 0.9130634 [ A method for the production of a compound having an effective amount of a pharmaceutically acceptable salt of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 1 or SEQ ID NO: 3, comprising: ][ (a) preparing a first compound comprising a pharmaceutically acceptable salt of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 1 or SEQ ID NO: 3; ]
[ 1330 ] similarity = 0.8416972 [ (a) preparing a first compound comprising a pharmaceutically acceptable salt of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 1 or SEQ ID NO: 3; ][ (b) contacting a first pharmaceutically acceptable salt with a first pharmaceutically acceptable salt of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 1 or SEQ ID NO: 3, wherein the first compound is a pharmaceutically acceptable salt of SEQ ID NO: 1 or SEQ ID NO: 1 or SEQ ID NO: 3; and ]
[ 1331 ] similarity = 0.8860247 [ (b) contacting a first pharmaceutically acceptable salt with a first pharmaceutically acceptable salt of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 1 or SEQ ID NO: 3, wherein the first compound is a pharmaceutically acceptable salt of SEQ ID NO: 1 or SEQ ID NO: 1 or SEQ ID NO: 3; and ][ (c) contacting a second compound comprising a pharmaceutically acceptable salt of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 1 or SEQ ID NO: 3 with the first compound, wherein the second compound has the same effective amount of the pharmaceutically acceptable salt of SEQ ID NO: 1 or SEQ ID NO: 1 or SEQ ID NO: 3 as the first compound. ]
[ 1332 ] similarity = 0.41369987 [ A method for producing an implant for a patient comprising: ][ (a) obtaining an implant having a proximal end and a distal end; ]
[ 1333 ] similarity = 0.3464049 [ (a) obtaining an implant having a proximal end and a distal end; ][ (b) forming a first portion of the implant into a first cavity; ]
[ 1334 ] similarity = 0.6140226 [ (b) forming a first portion of the implant into a first cavity; ][ (c) forming a second portion of the implant into a second cavity; ]
[ 1335 ] similarity = 0.53801227 [ (c) forming a second portion of the implant into a second cavity; ][ (d) forming a first seal between the first portion and the second portion of the implant to prevent the first and second portions from moving; ]
[ 1336 ] similarity = 0.6253897 [ (d) forming a first seal between the first portion and the second portion of the implant to prevent the first and second portions from moving; ][ (e) forming a first seal seal between the first portion and the second portion of the implant, wherein the first seal seal comprises a first seal member; ]
[ 1337 ] similarity = 0.8046167 [ (e) forming a first seal seal between the first portion and the second portion of the implant, wherein the first seal seal comprises a first seal member; ][ (f) forming a second seal seal between the first seal member and the second seal seal member to prevent the first and second portions from moving, the first seal seal member comprising a second seal member; and ]
[ 1338 ] similarity = 0.717078 [ (f) forming a second seal seal between the first seal member and the second seal seal member to prevent the first and second portions from moving, the first seal seal member comprising a second seal member; and ][ (g) applying a first pressure to a first portion of the first cavity and a second portion of the first cavity to form a first sealing member, the first seal member and the second seal member forming a seal, wherein the first seal member and the second seal member form a seal seal, wherein the first and second portions of the implant are positioned in a first and second cavities of the first and second cavities, respectively, and ]
[ 1339 ] similarity = 0.60318184 [ (g) applying a first pressure to a first portion of the first cavity and a second portion of the first cavity to form a first sealing member, the first seal member and the second seal member forming a seal, wherein the first seal member and the second seal member form a seal seal, wherein the first and second portions of the implant are positioned in a first and second cavities of the first and second cavities, respectively, and ][ wherein the first and second portions of the implant are positioned in the first and second cavities of the first and second cavities respectively. ]
[ 1340 ] similarity = 0.18919648 [ A method of treating a disease comprising: ][ (a) providing a therapeutically effective amount of a compound of formula (I): ]
[ 1341 ] similarity = 0.024940263 [ (a) providing a therapeutically effective amount of a compound of formula (I): ][ whereinR1, R2, R3, R4, R5, R6, R7, R8, R9 are each optionally substituted with one or more hydrogen atoms, and ]
[ 1342 ] similarity = 0.24511948 [ whereinR1, R2, R3, R4, R5, R6, R7, R8, R9 are each optionally substituted with one or more hydrogen atoms, and ][ each R1 is optionally substituted with a hydrogen atom selected from the group consisting of hydrogen, oxygen, nitrogen, sulfur, and ]
[ 1343 ] similarity = 7.950887e-05 [ each R1 is optionally substituted with a hydrogen atom selected from the group consisting of hydrogen, oxygen, nitrogen, sulfur, and ][ a C1 to C4 alkyl group, and ]
[ 1344 ] similarity = -0.12716565 [ a C1 to C4 alkyl group, and ][ each R2 is optionally substituted with one or more hydrogen atoms, ]
[ 1345 ] similarity = 0.5977538 [ each R2 is optionally substituted with one or more hydrogen atoms, ][ R9 and R10 are each optionally substituted with one or more hydrogen atoms, and ]
[ 1346 ] similarity = 0.57712567 [ R9 and R10 are each optionally substituted with one or more hydrogen atoms, and ][ wherein R9 is optionally substituted with one or more hydrogen atoms selected from the group consisting of hydrogen and oxygen, and ]
[ 1347 ] similarity = 0.82472813 [ wherein R9 is optionally substituted with one or more hydrogen atoms selected from the group consisting of hydrogen and oxygen, and ][ R10 is optionally substituted with one or more hydrogen atoms selected from the group consisting of hydrogen and sulfur, and ]
[ 1348 ] similarity = 0.80091065 [ R10 is optionally substituted with one or more hydrogen atoms selected from the group consisting of hydrogen and sulfur, and ][ wherein R9 and R10 are each optionally substituted with one or more hydrogen atoms selected from the group consisting of hydrogen and oxygen, and ]
[ 1349 ] similarity = 0.86852837 [ wherein R9 and R10 are each optionally substituted with one or more hydrogen atoms selected from the group consisting of hydrogen and oxygen, and ][ wherein R11 is optionally substituted with one or more hydrogen atoms selected from the group consisting of hydrogen and oxygen. ]
[ 1350 ] similarity = 0.31886697 [ A device for providing an implantation site for a surgical procedure to a patient, comprising: ][ a) a first body having a first proximal end; ]
[ 1351 ] similarity = 0.29576087 [ a) a first body having a first proximal end; ][ b) a second body having a second proximal end, wherein the first and second bodies are disposed in a first and second parallel longitudinal direction, wherein the second body is disposed in the first direction; ]
[ 1352 ] similarity = 0.13847692 [ b) a second body having a second proximal end, wherein the first and second bodies are disposed in a first and second parallel longitudinal direction, wherein the second body is disposed in the first direction; ][ c) a first support structure having a first support member and a first support member support structure; ]
[ 1353 ] similarity = 0.6533319 [ c) a first support structure having a first support member and a first support member support structure; ][ d) a second support structure having a second support member and a second support member support structure; ]
[ 1354 ] similarity = 0.3284393 [ d) a second support structure having a second support member and a second support member support structure; ][ e) a first shaft having a first shaft member and a first shaft member support structure; ]
[ 1355 ] similarity = 0.59997785 [ e) a first shaft having a first shaft member and a first shaft member support structure; ][ f) a second shaft having a second shaft member and a second shaft member support structure; ]
[ 1356 ] similarity = 0.7370966 [ f) a second shaft having a second shaft member and a second shaft member support structure; ][ g) a first shaft member having a first shaft member support structure and a second shaft member support structure; ]
[ 1357 ] similarity = 0.81057703 [ g) a first shaft member having a first shaft member support structure and a second shaft member support structure; ][ h) a second shaft member having a second shaft member support structure and a second shaft member support structure; and ]
[ 1358 ] similarity = 0.65912575 [ h) a second shaft member having a second shaft member support structure and a second shaft member support structure; and ][ i) a third shaft member having a third shaft member support structure; ]
[ 1359 ] similarity = 0.21080688 [ i) a third shaft member having a third shaft member support structure; ][ wherein the first support structure and the second support structure are disposed in a first and second parallel longitudinal direction, wherein the first support structure is disposed in the first direction and the second support structure is disposed in the second direction, and ]
[ 1360 ] similarity = 0.56296194 [ wherein the first support structure and the second support structure are disposed in a first and second parallel longitudinal direction, wherein the first support structure is disposed in the first direction and the second support structure is disposed in the second direction, and ][ wherein the first shaft and the second shaft are disposed in the same longitudinal direction. ]
[ 1361 ] similarity = 0.049764734 [ A method of treating a subject having a heart defect, the method comprising administering a compound of formula (I) to a subject having a heart defect, wherein: ][ X represents a hydrogen atom or a substituted or unsubstituted hydrogen atom, ]
[ 1362 ] similarity = 0.34911597 [ X represents a hydrogen atom or a substituted or unsubstituted hydrogen atom, ][ R1 is hydrogen or an alkyl group, ]
[ 1363 ] similarity = 0.6586085 [ R1 is hydrogen or an alkyl group, ][ R2 is hydrogen, or an alkyl group; or R3 is a hydrogen atom or an alkyl group; or R4 and R4&#x2032; ]
[ 1364 ] similarity = 0.5904836 [ R2 is hydrogen, or an alkyl group; or R3 is a hydrogen atom or an alkyl group; or R4 and R4&#x2032; ][ R5 represent a hydrogen atom or an alkyl group, ]
[ 1365 ] similarity = -0.0177188 [ R5 represent a hydrogen atom or an alkyl group, ][ wherein the compound is selected from the group consisting of an amino acid substitution, a substitution for a substituted or unsubstituted amino acid or a substitution for a substituted or unsubstituted alkyl group, and ]
[ 1366 ] similarity = 0.4257086 [ wherein the compound is selected from the group consisting of an amino acid substitution, a substitution for a substituted or unsubstituted amino acid or a substitution for a substituted or unsubstituted alkyl group, and ][ a substitution for an alkyl group. ]
[ 1367 ] similarity = 0.7017218 [ A method of providing an integrated circuit comprising an integrated circuit module, the method comprising: ][ (a) providing a first integrated circuit module; ]
[ 1368 ] similarity = 0.6477077 [ (a) providing a first integrated circuit module; ][ (b) providing a second integrated circuit module; ]
[ 1369 ] similarity = 0.45389265 [ (b) providing a second integrated circuit module; ][ (c) coupling the first and second integrated circuit modules together to form a single unit, wherein the single unit is configured to provide a first integrated circuit module to a first device; and ]
[ 1370 ] similarity = 0.71609145 [ (c) coupling the first and second integrated circuit modules together to form a single unit, wherein the single unit is configured to provide a first integrated circuit module to a first device; and ][ (d) coupling the second integrated circuit module and the first integrated circuit module to form an integrated circuit module; ]
[ 1371 ] similarity = 0.5933643 [ (d) coupling the second integrated circuit module and the first integrated circuit module to form an integrated circuit module; ][ wherein each integrated circuit module includes: ]
[ 1372 ] similarity = 0.5363873 [ wherein each integrated circuit module includes: ][ (1) a first integrated circuit module; and ]
[ 1373 ] similarity = 0.6696985 [ (1) a first integrated circuit module; and ][ (2) a first logic module; wherein the first logic module comprises a first integrated circuit module and a first integrated circuit module, the first integrated circuit module and the first integrated circuit module are coupled to each other, and ]
[ 1374 ] similarity = 0.74975646 [ (2) a first logic module; wherein the first logic module comprises a first integrated circuit module and a first integrated circuit module, the first integrated circuit module and the first integrated circuit module are coupled to each other, and ][ wherein each integrated circuit module is configured to be coupled to the first integrated circuit module to form a single integrated circuit module. ]
[ 1375 ] similarity = 0.2126859 [ An implantable medical device comprising: ][ a first electrode having an electrode surface; and ]
[ 1376 ] similarity = 0.6229217 [ a first electrode having an electrode surface; and ][ a second electrode, wherein said first electrode and said second electrode are disposed in a first configuration and wherein said first configuration has a first electrode surface and said second configuration has a second electrode surface, wherein said first electrode surface is configured to contact the medical device and wherein said second electrode surface is configured to contact a patient, and ]
[ 1377 ] similarity = 0.8285333 [ a second electrode, wherein said first electrode and said second electrode are disposed in a first configuration and wherein said first configuration has a first electrode surface and said second configuration has a second electrode surface, wherein said first electrode surface is configured to contact the medical device and wherein said second electrode surface is configured to contact a patient, and ][ wherein a first portion of said first electrode surface has a first electrode surface shape and a second portion of said first electrode surface is configured to contact a patient, and ]
[ 1378 ] similarity = 0.372374 [ wherein a first portion of said first electrode surface has a first electrode surface shape and a second portion of said first electrode surface is configured to contact a patient, and ][ wherein the second electrode is disposed in a third configuration that is different than said first configuration, wherein said third configuration is different than said first configuration, and ]
[ 1379 ] similarity = 0.3604645 [ wherein the second electrode is disposed in a third configuration that is different than said first configuration, wherein said third configuration is different than said first configuration, and ][ wherein said first portion of said first electrode surface has a first electrode surface shape and a second portion of said first electrode surface is configured to contact a patient, wherein said first electrode surface has a first surface shape that is substantially the same as the first surface shape of said second electrode surface, and ]
[ 1380 ] similarity = 0.6996048 [ wherein said first portion of said first electrode surface has a first electrode surface shape and a second portion of said first electrode surface is configured to contact a patient, wherein said first electrode surface has a first surface shape that is substantially the same as the first surface shape of said second electrode surface, and ][ wherein said second electrode surface has a second surface shape that is substantially the same as the second surface shape of said second electrode surface. ]
[ 1381 ] similarity = 0.1337553 [ A method of treating a patient suffering from an inflammatory disease, comprising administering to the patient a composition comprising: a) an effective amount of a polypeptide having the amino acid sequence as set forth in SEQ ID NO: 2; and ][ b) a pharmaceutically acceptable carrier. ]
[ 1382 ] similarity = 0.1129203 [ An isolated polypeptide consisting of a nucleic acid sequence selected from the group consisting of: ][ (a) SEQ ID NO: ]
[ 1383 ] similarity = 0.25084674 [ (a) SEQ ID NO: ][ 1; ]
[ 1384 ] similarity = 0.25311852 [ 1; ][ (b) SEQ ID NO: ]
[ 1385 ] similarity = 0.25311852 [ (b) SEQ ID NO: ][ 1, ]
[ 1386 ] similarity = 0.21297397 [ 1, ][ (c) SEQ ID NO: ]
[ 1387 ] similarity = 0.21297397 [ (c) SEQ ID NO: ][ 1, ]
[ 1388 ] similarity = 0.29281935 [ 1, ][ (d) SEQ ID NO: ]
[ 1389 ] similarity = 0.21983254 [ (d) SEQ ID NO: ][ 2; ]
[ 1390 ] similarity = 0.20633128 [ 2; ][ (e) SEQ ID NO: ]
[ 1391 ] similarity = 0.17870328 [ (e) SEQ ID NO: ][ 2, and ]
[ 1392 ] similarity = 0.13672134 [ 2, and ][ (f) SEQ ID NO: ]
[ 1393 ] similarity = 0.22501665 [ (f) SEQ ID NO: ][ 3. ]
[ 1394 ] similarity = 0.66769934 [ An isolated nucleic acid molecule encoding a protein comprising a nucleic acid sequence comprising SEQ ID NO: ][ 1 or a nucleic acid sequence comprising the amino acid sequence set forth in SEQ ID NO: ]
[ 1395 ] similarity = 0.42930067 [ 1 or a nucleic acid sequence comprising the amino acid sequence set forth in SEQ ID NO: ][ 1, wherein the nucleic acid molecule is selected from the group consisting of: ]
[ 1396 ] similarity = 0.45997828 [ 1, wherein the nucleic acid molecule is selected from the group consisting of: ][ a) a nucleic acid molecule comprising a first amino acid sequence having the sequence of SEQ ID NO: ]
[ 1397 ] similarity = 0.0040790644 [ a) a nucleic acid molecule comprising a first amino acid sequence having the sequence of SEQ ID NO: ][ 1; ]
[ 1398 ] similarity = -0.015600413 [ 1; ][ b) a nucleic acid molecule comprising a second amino acid sequence having the sequence of SEQ ID NO: ]
[ 1399 ] similarity = 0.058154225 [ b) a nucleic acid molecule comprising a second amino acid sequence having the sequence of SEQ ID NO: ][ 1; and ]
[ 1400 ] similarity = 0.036538616 [ 1; and ][ c) a nucleic acid molecule comprising a third amino acid sequence having the sequence of SEQ ID NO: ]
[ 1401 ] similarity = 0.64159524 [ c) a nucleic acid molecule comprising a third amino acid sequence having the sequence of SEQ ID NO: ][ 1, wherein the third amino acid sequence is not identical to the first amino acid sequence. ]
[ 1402 ] similarity = 0.67371225 [ A method for the treatment of an inflammatory condition comprising administering to a patient in need thereof a therapeutically effective amount of an antibody or antigen binding fragment thereof, wherein the antibody or antigen binding fragment comprises a sequence that is at least 90% identical to the sequence of the human immunodeficiency virus type 1 (HIV-1) antigen, wherein the antibody or antigen binding fragment is selected from the group consisting of: (1) the human immunodeficiency virus type 1 (HIV-1) antigen, (2) the human immunodeficiency virus type 1 (HIV-1) antigen, (3) an antibody or antigen binding fragment thereof, and ][ (4) a nucleic acid encoding a fragment of the human immunodeficiency virus, wherein the antibody or antigen binding fragment comprises a nucleic acid sequence that is at least 90% identical to the sequence of the human immunodeficiency virus, and ]
[ 1403 ] similarity = 0.59648335 [ (4) a nucleic acid encoding a fragment of the human immunodeficiency virus, wherein the antibody or antigen binding fragment comprises a nucleic acid sequence that is at least 90% identical to the sequence of the human immunodeficiency virus, and ][ the method further comprises administering to the patient in need thereof a therapeutically effective amount of at least one other antibody or antigen binding fragment of the human immunodeficiency virus type 1 (HIV-1) antigen. ]
[ 1404 ] similarity = 0.32498077 [ A system for providing an implantable medical device, comprising: ][ an interface device configured to be coupled with the implantable medical device and configured to receive a first set of instructions from a user, the first set of instructions comprising a plurality of instructions, the plurality of instructions including instructions for: ]
[ 1405 ] similarity = 0.20147945 [ an interface device configured to be coupled with the implantable medical device and configured to receive a first set of instructions from a user, the first set of instructions comprising a plurality of instructions, the plurality of instructions including instructions for: ][ providing an implantable medical device; and ]
[ 1406 ] similarity = 0.27787057 [ providing an implantable medical device; and ][ providing a first user interface device configured to be configured to be coupled with the implantable medical device and configured to receive a second set of instructions from the user, the second set of instructions comprising instructions for: ]
[ 1407 ] similarity = 0.4018801 [ providing a first user interface device configured to be configured to be coupled with the implantable medical device and configured to receive a second set of instructions from the user, the second set of instructions comprising instructions for: ][ providing a first user interface device; ]
[ 1408 ] similarity = 0.75239253 [ providing a first user interface device; ][ displaying a first image on the first user interface device; ]
[ 1409 ] similarity = 0.6607298 [ displaying a first image on the first user interface device; ][ receiving an instruction from the first user interface device; and ]
[ 1410 ] similarity = 0.5419308 [ receiving an instruction from the first user interface device; and ][ providing a second user interface device; ]
[ 1411 ] similarity = 0.43287098 [ providing a second user interface device; ][ wherein the first and second user interfaces are coupled together and configured to communicate with the implantable medical device. ]
[ 1412 ] similarity = 0.29816675 [ A method of providing an implant for use in an implantable medical device, the method comprising: ][ providing an implant having a first surface and a second surface, wherein the first surface is configured to receive a plurality of electrodes; ]
[ 1413 ] similarity = 0.636765 [ providing an implant having a first surface and a second surface, wherein the first surface is configured to receive a plurality of electrodes; ][ providing an electrode assembly comprising a first electrode and a second electrode, wherein the first electrode and the second electrode are configured to couple to the first surface of the implant, and ]
[ 1414 ] similarity = 0.650023 [ providing an electrode assembly comprising a first electrode and a second electrode, wherein the first electrode and the second electrode are configured to couple to the first surface of the implant, and ][ wherein the first surface is configured to be positioned on the first electrode; and ]
[ 1415 ] similarity = 0.59493864 [ wherein the first surface is configured to be positioned on the first electrode; and ][ providing an electrode assembly comprising a first electrode and a second electrode, wherein the first electrode and the second electrode are configured to couple to the second surface of the implant, and ]
[ 1416 ] similarity = 0.5476119 [ providing an electrode assembly comprising a first electrode and a second electrode, wherein the first electrode and the second electrode are configured to couple to the second surface of the implant, and ][ wherein the first surface is not configured to be positioned on the second electrode. ]
[ 1417 ] similarity = 0.22888073 [ A method of treating a disease in a subject comprising: ][ administering to the subject an effective amount of a composition comprising a therapeutically effective amount of a pharmaceutically effective amount of an anti-TNF antibody, wherein the anti-TNF antibody comprises a heavy chain variable region and a light chain variable region; and ]
[ 1418 ] similarity = 0.45778137 [ administering to the subject an effective amount of a composition comprising a therapeutically effective amount of a pharmaceutically effective amount of an anti-TNF antibody, wherein the anti-TNF antibody comprises a heavy chain variable region and a light chain variable region; and ][ administering to the subject a composition containing an effective amount of the composition. ]
[ 1419 ] similarity = -0.012331111 [ An isolated polypeptide comprising the amino acid sequence of SEQ ID NO: ][ 1. ]
[ 1420 ] similarity = 0.44464153 [ A method for determining a location for a surgical instrument, the method comprising: ][ providing a surgical instrument; ]
[ 1421 ] similarity = 0.22321366 [ providing a surgical instrument; ][ providing a plurality of sensors; and ]
[ 1422 ] similarity = 0.4930474 [ providing a plurality of sensors; and ][ receiving, by a processor, data from each of the plurality of sensors, ]
[ 1423 ] similarity = 0.36905676 [ receiving, by a processor, data from each of the plurality of sensors, ][ wherein a plurality of the plurality of sensors are located within an anatomical region of the surgical instrument, ]
[ 1424 ] similarity = 0.8067311 [ wherein a plurality of the plurality of sensors are located within an anatomical region of the surgical instrument, ][ wherein the anatomical region is defined by a plurality of surgical instruments, ]
[ 1425 ] similarity = 0.47693712 [ wherein the anatomical region is defined by a plurality of surgical instruments, ][ wherein the surgical instrument is configured to be inserted through a surgical opening in a body of a patient, and ]
[ 1426 ] similarity = 0.6455827 [ wherein the surgical instrument is configured to be inserted through a surgical opening in a body of a patient, and ][ wherein the surgical instrument is configured to be positioned at least partially within the anatomical region, ]
[ 1427 ] similarity = 0.34956506 [ wherein the surgical instrument is configured to be positioned at least partially within the anatomical region, ][ wherein the plurality of the plurality of sensors are located within the anatomical region, and ]
[ 1428 ] similarity = 0.56308854 [ wherein the plurality of the plurality of sensors are located within the anatomical region, and ][ wherein the plurality of sensors are configured to receive data from the surgical instrument. ]
[ 1429 ] similarity = 0.35742468 [ An apparatus comprising: ][ a first housing; ]
[ 1430 ] similarity = 0.40704715 [ a first housing; ][ an actuator configured to be mounted to the first housing, the actuator comprising: ]
[ 1431 ] similarity = 0.35119712 [ an actuator configured to be mounted to the first housing, the actuator comprising: ][ a housing body; ]
[ 1432 ] similarity = 0.46410137 [ a housing body; ][ an actuator body configured to engage with the housing body, the actuator body comprising: ]
[ 1433 ] similarity = 0.45121524 [ an actuator body configured to engage with the housing body, the actuator body comprising: ][ a first actuator body having a first end and a second end, wherein the first end is configured to engage with the housing body, and ]
[ 1434 ] similarity = 0.5338863 [ a first actuator body having a first end and a second end, wherein the first end is configured to engage with the housing body, and ][ the second end is configured to engage with the housing body; ]
[ 1435 ] similarity = 0.34783065 [ the second end is configured to engage with the housing body; ][ at least one actuator body coupled to the first end of the first actuator body; and ]
[ 1436 ] similarity = 0.7628294 [ at least one actuator body coupled to the first end of the first actuator body; and ][ a first coupling member configured to engage the first end of the actuator body; ]
[ 1437 ] similarity = 0.09660071 [ a first coupling member configured to engage the first end of the actuator body; ][ a second housing; ]
[ 1438 ] similarity = 0.21608262 [ a second housing; ][ a first actuator body having a first end and a second end, wherein the first end is configured to engage with the first housing, and ]
[ 1439 ] similarity = 0.67507136 [ a first actuator body having a first end and a second end, wherein the first end is configured to engage with the first housing, and ][ the second end is configured to engage with the first housing; and ]
[ 1440 ] similarity = 0.3754775 [ the second end is configured to engage with the first housing; and ][ at least one actuator body coupled to the first end of the first actuator body; ]
[ 1441 ] similarity = 0.12983012 [ at least one actuator body coupled to the first end of the first actuator body; ][ a second housing; ]
[ 1442 ] similarity = 0.37228194 [ a second housing; ][ a second actuator body having a first end and a second end, wherein the first end is configured to engage with the second housing, and ]
[ 1443 ] similarity = 0.73566985 [ a second actuator body having a first end and a second end, wherein the first end is configured to engage with the second housing, and ][ the second end is configured to engage with the second housing; and ]
[ 1444 ] similarity = 0.37609333 [ the second end is configured to engage with the second housing; and ][ at least one actuator body coupled to the first end of the second actuator body. ]
[ 1445 ] similarity = 0.14162624 [ A method of treating a patient suffering from a chronic pain syndrome comprising administering to the patient a composition comprising an effective amount of a compound selected from the group consisting of: ][ an agonist for the receptor for a peptide having the structure (SEQ ID NO: ]
[ 1446 ] similarity = 0.01171508 [ an agonist for the receptor for a peptide having the structure (SEQ ID NO: ][ 4) or a pharmaceutically acceptable salt thereof; ]
[ 1447 ] similarity = 0.038884647 [ 4) or a pharmaceutically acceptable salt thereof; ][ an antagonist for the receptor for a peptide having the structure (SEQ ID NO: ]
[ 1448 ] similarity = 0.038884647 [ an antagonist for the receptor for a peptide having the structure (SEQ ID NO: ][ 4) or a pharmaceutically acceptable salt thereof; ]
[ 1449 ] similarity = 0.34882194 [ 4) or a pharmaceutically acceptable salt thereof; ][ a pharmaceutically acceptable carrier; and ]
[ 1450 ] similarity = 0.62839735 [ a pharmaceutically acceptable carrier; and ][ a pharmaceutically acceptable composition. ]
[ 1451 ] similarity = -0.052715644 [ A method of producing an isolated polypeptide comprising the sequence of SEQ ID NO: ][ 4. ]
[ 1452 ] similarity = 0.15919307 [ A method of producing a polypeptide comprising a nucleic acid encoding a peptide comprising a first amino acid sequence and a second amino acid sequence different from the first amino acid sequence, the first and second amino acid sequences being complementary, wherein the first and second amino acid sequences are selected from the group consisting of SEQ ID NO: ][ 1 and SEQ ID NO: ]
[ 1453 ] similarity = 0.38193482 [ 1 and SEQ ID NO: ][ 2, and ]
[ 1454 ] similarity = -0.05886967 [ 2, and ][ wherein the polypeptide has an amino acid sequence having a length greater than about 100 nucleotides. ]
[ 1455 ] similarity = 0.26628366 [ A method of producing a compound having an effective amount of an amino acid sequence selected from the group consisting of: ][ a) a sequence having a sequence of amino acids having the sequence of SEQ ID NO: 1, 2, 4, 6, 7, 8 or 9; and ]
[ 1456 ] similarity = 0.7252953 [ a) a sequence having a sequence of amino acids having the sequence of SEQ ID NO: 1, 2, 4, 6, 7, 8 or 9; and ][ b) a sequence of amino acids that is at least 95% identical to SEQ ID NO: 1, 2, 4, 6, 7, 8, 9, or 10. ]
[ 1457 ] similarity = 0.08177601 [ A method for treating a disease in a mammal, the method comprising: ][ administering to the disease a therapeutically effective amount of an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or derivative thereof, wherein R1 is a first alkyl group, a substituted alkyl group, or a substituted substituted alkyl group; ]
[ 1458 ] similarity = 0.1009613 [ administering to the disease a therapeutically effective amount of an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or derivative thereof, wherein R1 is a first alkyl group, a substituted alkyl group, or a substituted substituted alkyl group; ][ R2 is a second alkyl group; and ]
[ 1459 ] similarity = 0.52794886 [ R2 is a second alkyl group; and ][ R3 is a third alkyl group. ]
[ 1460 ] similarity = -0.07118446 [ An isolated nucleic acid molecule encoding a protein comprising a nucleic acid sequence comprising the sequence set forth in SEQ ID NO: ][ 2. ]
[ 1461 ] similarity = 0.1603846 [ A method of treating an inflammatory bowel disease, comprising administering to a patient a composition comprising a pharmaceutically acceptable carrier, wherein said carrier is a polypeptide comprising the amino acid sequence of SEQ ID NO: ][ 1, or a pharmaceutically acceptable salt thereof, or a combination thereof, and ]
[ 1462 ] similarity = 0.042635325 [ 1, or a pharmaceutically acceptable salt thereof, or a combination thereof, and ][ wherein the composition is administered to a patient. ]
[ 1463 ] similarity = 0.13225232 [ A method of treating a patient with an inflammatory disease comprising administering to the patient a therapeutically effective amount of a compound of the formula: ][ or a pharmaceutically acceptable salt thereof, wherein: ]
[ 1464 ] similarity = -0.08442333 [ or a pharmaceutically acceptable salt thereof, wherein: ][ X represents an integer from 1 to 4; and ]
[ 1465 ] similarity = 0.0451503 [ X represents an integer from 1 to 4; and ][ R represents H, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable salt thereof; ]
[ 1466 ] similarity = 0.10795808 [ R represents H, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable salt thereof; ][ R2 and R3 are independently selected from the group consisting of hydrogen, alkyl, alkoxy, heteroaryl, alkyloxy, alkylamino, alkylaminoalkyl, alkylaminoaryl, heteroarylalkyl, alkylarylalkyl, heteroarylarylalkyl, alkylarylalkylalkyl or alkylsulfonyl. ]
[ 1467 ] similarity = 0.1598201 [ An apparatus for providing a patient with an infusion therapy device, comprising: ][ a housing having a first opening and a second opening; ]
[ 1468 ] similarity = 0.33685994 [ a housing having a first opening and a second opening; ][ a first infusion pump configured to provide a first infusion of an infusion fluid into the patient's body through the first opening; ]
[ 1469 ] similarity = 0.7102326 [ a first infusion pump configured to provide a first infusion of an infusion fluid into the patient's body through the first opening; ][ a second infusion pump configured to provide a second infusion of the infusion fluid into the patient's body through the second opening; ]
[ 1470 ] similarity = 0.47751594 [ a second infusion pump configured to provide a second infusion of the infusion fluid into the patient's body through the second opening; ][ a first valve configured to allow the first infusion to pass through the first opening and the second opening; ]
[ 1471 ] similarity = 0.6428531 [ a first valve configured to allow the first infusion to pass through the first opening and the second opening; ][ a second valve configured to allow the second infusion to pass through the second opening; ]
[ 1472 ] similarity = 0.33554086 [ a second valve configured to allow the second infusion to pass through the second opening; ][ a first pump configured to provide a first pump of the infusion fluid to the first infusion pump; ]
[ 1473 ] similarity = 0.71225464 [ a first pump configured to provide a first pump of the infusion fluid to the first infusion pump; ][ a second pump configured to provide a second pump of the infusion fluid to the second infusion pump; ]
[ 1474 ] similarity = 0.35901308 [ a second pump configured to provide a second pump of the infusion fluid to the second infusion pump; ][ a first valve configured to allow the first pump to pass through the first opening and the second opening; and ]
[ 1475 ] similarity = 0.61230874 [ a first valve configured to allow the first pump to pass through the first opening and the second opening; and ][ a second valve configured to allow the second pump to pass through the second opening. ]
[ 1476 ] similarity = 0.27211657 [ A method for producing an implantable device comprising: ][ providing a first material; ]
[ 1477 ] similarity = 0.5641608 [ providing a first material; ][ providing a second material; ]
[ 1478 ] similarity = 0.2969818 [ providing a second material; ][ providing a first electrode; ]
[ 1479 ] similarity = 0.64444166 [ providing a first electrode; ][ providing a second electrode; and ]
[ 1480 ] similarity = 0.21458286 [ providing a second electrode; and ][ providing a first material and a second material, wherein each material comprises a plurality of electrodes; ]
[ 1481 ] similarity = 0.20516552 [ providing a first material and a second material, wherein each material comprises a plurality of electrodes; ][ applying a pressure to each electrode to generate a pressure wave; ]
[ 1482 ] similarity = 0.53433967 [ applying a pressure to each electrode to generate a pressure wave; ][ applying a current to each electrode to produce an electrical current; and ]
[ 1483 ] similarity = 0.88700104 [ applying a current to each electrode to produce an electrical current; and ][ applying a voltage to each electrode to produce an electric current. ]
[ 1484 ] similarity = 0.4965536 [ An apparatus for treating a patient, the apparatus comprising: ][ an implantable device; and ]
[ 1485 ] similarity = 0.24268128 [ an implantable device; and ][ a plurality of sensors, wherein the plurality of sensors is configured to detect a condition of the patient, and ]
[ 1486 ] similarity = 0.82729876 [ a plurality of sensors, wherein the plurality of sensors is configured to detect a condition of the patient, and ][ wherein each of the plurality of sensors is configured to detect a different type of sensor, and ]
[ 1487 ] similarity = 0.8685471 [ wherein each of the plurality of sensors is configured to detect a different type of sensor, and ][ wherein each of the plurality of sensors is configured to detect a different type of condition. ]
[ 1488 ] similarity = 0.17139359 [ A method of producing a pharmaceutical composition for use in treating a condition in a mammal, the method comprising: ][ a) providing an isolated polypeptide having a sequence having at least 95% sequence identity with SEQ ID NO: ]
[ 1489 ] similarity = 0.19464707 [ a) providing an isolated polypeptide having a sequence having at least 95% sequence identity with SEQ ID NO: ][ 1, wherein said polypeptide is a human immunodeficiency virus (HIV) polypeptide; and ]
[ 1490 ] similarity = 0.12734023 [ 1, wherein said polypeptide is a human immunodeficiency virus (HIV) polypeptide; and ][ b) contacting said isolated polypeptide with a pharmaceutical composition comprising a pharmaceutically active agent to produce a pharmaceutical composition having a pharmaceutically active agent in the form of an effective amount of at least one of an active substance or a pharmaceutical composition, wherein the pharmaceutical composition is a pharmaceutically active agent comprising a pharmaceutically active agent selected from the group consisting of: an active substance, a pharmaceutical agent, and ]
[ 1491 ] similarity = 0.14839435 [ b) contacting said isolated polypeptide with a pharmaceutical composition comprising a pharmaceutically active agent to produce a pharmaceutical composition having a pharmaceutically active agent in the form of an effective amount of at least one of an active substance or a pharmaceutical composition, wherein the pharmaceutical composition is a pharmaceutically active agent comprising a pharmaceutically active agent selected from the group consisting of: an active substance, a pharmaceutical agent, and ][ a pharmaceutically acceptable salt thereof; ]
[ 1492 ] similarity = 0.3778527 [ a pharmaceutically acceptable salt thereof; ][ wherein the pharmaceutical composition comprises at least one active substance and at least one pharmaceutically acceptable salt. ]
[ 1493 ] similarity = 0.13904744 [ A method of treating a disease comprising administering to a subject in need thereof an effective amount of a composition comprising: ][ a pharmaceutically acceptable salt or ester of an amino acid selected from the group consisting of: ]
[ 1494 ] similarity = 0.14161909 [ a pharmaceutically acceptable salt or ester of an amino acid selected from the group consisting of: ][ (i) the amino acid sequence of SEQ ID NO: ]
[ 1495 ] similarity = -0.07129474 [ (i) the amino acid sequence of SEQ ID NO: ][ 2; and ]
[ 1496 ] similarity = 0.04657219 [ 2; and ][ (ii) an amino acid selected from the group consisting of: ]
[ 1497 ] similarity = 0.510553 [ (ii) an amino acid selected from the group consisting of: ][ (A) a sequence selected from the group consisting of amino acids 1 to 8 of SEQ ID NO: ]
[ 1498 ] similarity = -0.020220507 [ (A) a sequence selected from the group consisting of amino acids 1 to 8 of SEQ ID NO: ][ 2; and ]
[ 1499 ] similarity = 0.02478702 [ 2; and ][ (B) an amino acid sequence selected from the group consisting of amino acids 1 to 8 of SEQ ID NO: ]
[ 1500 ] similarity = -0.064355016 [ (B) an amino acid sequence selected from the group consisting of amino acids 1 to 8 of SEQ ID NO: ][ 2. ]
[ 1501 ] similarity = 0.38584888 [ An apparatus comprising: ][ a housing; ]
[ 1502 ] similarity = 0.26030076 [ a housing; ][ a support member; and ]
[ 1503 ] similarity = 0.37076694 [ a support member; and ][ an elongate member extending from the housing and configured to be disposed in a plane of the support member, wherein the elongate member comprises a first end, a second end, and ]
[ 1504 ] similarity = 0.6864776 [ an elongate member extending from the housing and configured to be disposed in a plane of the support member, wherein the elongate member comprises a first end, a second end, and ][ a third end, wherein the first end and the second end are connected to the elongate member by a first and a second connection member, the first connection member and the second connection member are configured to be disposed at a first and second location on the elongate member, the first location being in a plane perpendicular to the plane of the support member, and ]
[ 1505 ] similarity = 0.70990276 [ a third end, wherein the first end and the second end are connected to the elongate member by a first and a second connection member, the first connection member and the second connection member are configured to be disposed at a first and second location on the elongate member, the first location being in a plane perpendicular to the plane of the support member, and ][ the second location being in a plane parallel to the plane of the support member, wherein the first and second locations are configured to receive the first and second connections member, the elongate member being configured to be positioned between the first and second locations, the first and second locations being configured to be in a substantially parallel relationship to one another, the first and second connections member being configured to be disposed at a location in between the first and second locations, the first and second locations being configured to be in a substantially parallel relationship to one another, and ]
[ 1506 ] similarity = 0.39700907 [ the second location being in a plane parallel to the plane of the support member, wherein the first and second locations are configured to receive the first and second connections member, the elongate member being configured to be positioned between the first and second locations, the first and second locations being configured to be in a substantially parallel relationship to one another, the first and second connections member being configured to be disposed at a location in between the first and second locations, the first and second locations being configured to be in a substantially parallel relationship to one another, and ][ the elongate member being configured to be disposed in an elongate position relative to the support member; wherein the elongate member comprises a first end, a second end, and ]
[ 1507 ] similarity = 0.4094062 [ the elongate member being configured to be disposed in an elongate position relative to the support member; wherein the elongate member comprises a first end, a second end, and ][ a third end, wherein the first end and the second end are configured to be disposed in the plane perpendicular to the plane of the support member and the third end is disposed in the plane parallel to the plane of the support member. ]
[ 1508 ] similarity = 0.14677188 [ A method of providing a medical treatment to a patient, comprising: ][ providing a first device for providing a first treatment to a patient, the first device including a first electrode and a first conductive material, the first electrode being electrically connected to a first electrode of the first device, the first conductive material being electrically connected to a first conductive material of the first electrode; ]
[ 1509 ] similarity = 0.4368999 [ providing a first device for providing a first treatment to a patient, the first device including a first electrode and a first conductive material, the first electrode being electrically connected to a first electrode of the first device, the first conductive material being electrically connected to a first conductive material of the first electrode; ][ providing a second device for providing a second treatment to the patient, the second device including a second electrode and a second conductive material, the second electrode being electrically connected to a second electrode of the second device, the second conductive material being electrically connected to a second conductive material of the second electrode; and ]
[ 1510 ] similarity = 0.6090113 [ providing a second device for providing a second treatment to the patient, the second device including a second electrode and a second conductive material, the second electrode being electrically connected to a second electrode of the second device, the second conductive material being electrically connected to a second conductive material of the second electrode; and ][ electrically coupling the first electrode and the second electrode to each other to form a first connection between the first electrode and the second electrode. ]
[ 1511 ] similarity = -0.022076247 [ A method for treating a disease comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a compound selected from the group consisting of: ][ (a) an amino acid sequence of SEQ. ID NO: ]
[ 1512 ] similarity = -0.03356288 [ (a) an amino acid sequence of SEQ. ID NO: ][ 2; ]
[ 1513 ] similarity = -0.053193428 [ 2; ][ (b) a nucleic acid sequence of SEQ. ID NO: ]
[ 1514 ] similarity = 0.0462291 [ (b) a nucleic acid sequence of SEQ. ID NO: ][ 4; ]
[ 1515 ] similarity = 0.030009914 [ 4; ][ (c) an amino acid sequence of SEQ. ID NO: ]
[ 1516 ] similarity = -0.06270703 [ (c) an amino acid sequence of SEQ. ID NO: ][ 8; and ]
[ 1517 ] similarity = -0.06559063 [ 8; and ][ (d) a nucleic acid sequence of SEQ. ID NO: ]
[ 1518 ] similarity = 0.023161575 [ (d) a nucleic acid sequence of SEQ. ID NO: ][ 10. ]
[ 1519 ] similarity = 0.18584777 [ Apparatus for the treatment of a patient, comprising: ][ a) a first implantable medical device having a plurality of electrodes, wherein each electrode comprises a first portion having a first electrode surface and a second portion having a second electrode surface, wherein the first portion and second portion have a plurality of electrodes; and ]
[ 1520 ] similarity = 0.9517063 [ a) a first implantable medical device having a plurality of electrodes, wherein each electrode comprises a first portion having a first electrode surface and a second portion having a second electrode surface, wherein the first portion and second portion have a plurality of electrodes; and ][ b) at least one second implantable medical device having a plurality of electrodes and a plurality of electrodes, wherein each electrode comprises a first portion having a first electrode surface and a second portion having a second electrode surface, wherein the first portion and the second portion each have a plurality of electrodes, and ]
[ 1521 ] similarity = 0.83234936 [ b) at least one second implantable medical device having a plurality of electrodes and a plurality of electrodes, wherein each electrode comprises a first portion having a first electrode surface and a second portion having a second electrode surface, wherein the first portion and the second portion each have a plurality of electrodes, and ][ wherein each of the plurality of electrodes has at least one of a first electrode surface and a second electrode surface, wherein the second portion of each electrode is disposed within the first portion of a second implantable medical device and the second portion of each electrode is disposed within the first portion of a first implantable medical device. ]
[ 1522 ] similarity = 0.22554107 [ A method for treating a patient having an abnormal heart rate, comprising: ][ administering to said patient an effective amount of an effective dose of an antibody or antigen-binding fragment thereof that specifically binds to an amino acid sequence of SEQ ID NO: 1 or a fragment thereof that specifically binds to SEQ ID NO: 1; ]
[ 1523 ] similarity = 0.55206203 [ administering to said patient an effective amount of an effective dose of an antibody or antigen-binding fragment thereof that specifically binds to an amino acid sequence of SEQ ID NO: 1 or a fragment thereof that specifically binds to SEQ ID NO: 1; ][ wherein the antibody or antigen-binding fragment of the effective dose of the antibody or antigen-binding fragment thereof is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and ]
[ 1524 ] similarity = 0.85758054 [ wherein the antibody or antigen-binding fragment of the effective dose of the antibody or antigen-binding fragment thereof is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and ][ SEQ ID NO: 4, wherein the amino acid sequence of the antibody or antigen-binding fragment of the effective dose of said antibody or antigen-binding fragment thereof is SEQ ID NO: 1 or SEQ ID NO: 2, and ]
[ 1525 ] similarity = 0.7517756 [ SEQ ID NO: 4, wherein the amino acid sequence of the antibody or antigen-binding fragment of the effective dose of said antibody or antigen-binding fragment thereof is SEQ ID NO: 1 or SEQ ID NO: 2, and ][ wherein the amino acid sequence of said antibody or antigen-binding fragment thereof is SEQ ID NO: 3. ]
[ 1526 ] similarity = 0.1680238 [ A system for providing an implantable medical device to a patient, said system comprising: ][ a) a housing; ]
[ 1527 ] similarity = 0.1339356 [ a) a housing; ][ b) an implantable medical device having a first portion having an implantable medical device interface and a second portion having a medical device; ]
[ 1528 ] similarity = 0.35605156 [ b) an implantable medical device having a first portion having an implantable medical device interface and a second portion having a medical device; ][ c) at least one first sensor configured to detect a first signal indicative of a first position of the first portion of the medical device; ]
[ 1529 ] similarity = 0.51689297 [ c) at least one first sensor configured to detect a first signal indicative of a first position of the first portion of the medical device; ][ d) at least one second sensor configured to detect a second signal indicative of a second position of the second portion of the medical device; ]
[ 1530 ] similarity = 0.5502076 [ d) at least one second sensor configured to detect a second signal indicative of a second position of the second portion of the medical device; ][ e) at least one processor coupled with said at least one first sensor and said at least one second sensor; ]
[ 1531 ] similarity = 0.88992244 [ e) at least one processor coupled with said at least one first sensor and said at least one second sensor; ][ f) at least one memory coupled to said at least one first sensor and said at least one second sensor; and ]
[ 1532 ] similarity = 0.37699917 [ f) at least one memory coupled to said at least one first sensor and said at least one second sensor; and ][ g) a processor configured to receive said first signal and said second signal and to determine a first position and a second position of the implantable medical device interface based on said detected first signal and said detected second signal and said first position and said second position, wherein said processor further comprises a memory for storing said determined first position and said determined second position. ]
[ 1533 ] similarity = 0.44398215 [ A method of producing an isolated peptide comprising: ][ a) contacting the isolated peptide with an antibody that specifically binds to a protein of the human immunodeficiency virus type 1; and ]
[ 1534 ] similarity = 0.58253956 [ a) contacting the isolated peptide with an antibody that specifically binds to a protein of the human immunodeficiency virus type 1; and ][ b) detecting a binding of the isolated peptide to the antibody. ]
[ 1535 ] similarity = 0.4483396 [ A method of treating a patient having a condition that inhibits the production of an antibody, wherein said patient is a patient with an inflammatory bowel disease or a patient with an autoimmune disorder, comprising: ][ administering to the patient in need of said treatment a composition comprising: ]
[ 1536 ] similarity = 0.20571955 [ administering to the patient in need of said treatment a composition comprising: ][ (a) a therapeutically effective amount of a peptide selected from the group consisting of SEQ ID NO: ]
[ 1537 ] similarity = 0.19783159 [ (a) a therapeutically effective amount of a peptide selected from the group consisting of SEQ ID NO: ][ 2; SEQ ID NO: ]
[ 1538 ] similarity = 0.7720622 [ 2; SEQ ID NO: ][ 3; SEQ ID NO: ]
[ 1539 ] similarity = 0.774873 [ 3; SEQ ID NO: ][ 6; SEQ ID NO: ]
[ 1540 ] similarity = 0.83281016 [ 6; SEQ ID NO: ][ 8; SEQ ID NO: ]
[ 1541 ] similarity = 0.84770155 [ 8; SEQ ID NO: ][ 9; SEQ ID NO: ]
[ 1542 ] similarity = 0.82152116 [ 9; SEQ ID NO: ][ 10; SEQ ID NO: ]
[ 1543 ] similarity = 0.83725446 [ 10; SEQ ID NO: ][ 11; SEQ ID NO: ]
[ 1544 ] similarity = 0.8285377 [ 11; SEQ ID NO: ][ 12; SEQ ID NO: ]
[ 1545 ] similarity = 0.8230533 [ 12; SEQ ID NO: ][ 13; SEQ ID NO: ]
[ 1546 ] similarity = 0.79828423 [ 13; SEQ ID NO: ][ 14; SEQ ID NO: ]
[ 1547 ] similarity = 0.8184645 [ 14; SEQ ID NO: ][ 16; SEQ ID NO: ]
[ 1548 ] similarity = 0.68855596 [ 16; SEQ ID NO: ][ 17; SEQ ID NOS: ]
[ 1549 ] similarity = 0.24080093 [ 17; SEQ ID NOS: ][ 1, ]
[ 1550 ] similarity = 0.3568561 [ 1, ][ 2 and 3; ]
[ 1551 ] similarity = 0.02801006 [ 2 and 3; ][ (b) a pharmaceutically acceptable carrier; ]
[ 1552 ] similarity = 0.054176748 [ (b) a pharmaceutically acceptable carrier; ][ (c) at least one of the amino acids of said peptide selected from the group consisting of SEQ ID NO: ]
[ 1553 ] similarity = -0.063782364 [ (c) at least one of the amino acids of said peptide selected from the group consisting of SEQ ID NO: ][ 2; ]
[ 1554 ] similarity = -0.013143187 [ 2; ][ (d) a pharmaceutically acceptable salt thereof, and ]
[ 1555 ] similarity = 0.45194346 [ (d) a pharmaceutically acceptable salt thereof, and ][ (e) a pharmaceutically acceptable carrier. ]
[ 1556 ] similarity = 0.34713402 [ A method for treating a subject having an inflammatory disease comprising administering to said subject a therapeutically effective amount of an antibody that specifically binds to the human immunodeficiency virus-1 (HIV-1) protein, wherein the antibody is selected from the group consisting of: ][ a) a human antibody comprising a nucleic acid sequence encoding a nucleic acid sequence having a sequence sequence selected from the group consisting of SEQ ID NO: ]
[ 1557 ] similarity = 0.19755957 [ a) a human antibody comprising a nucleic acid sequence encoding a nucleic acid sequence having a sequence sequence selected from the group consisting of SEQ ID NO: ][ 2, SEQ ID NO: ]
[ 1558 ] similarity = 0.6738225 [ 2, SEQ ID NO: ][ 3 and SEQ ID NO: ]
[ 1559 ] similarity = 0.43537137 [ 3 and SEQ ID NO: ][ 4, and ]
[ 1560 ] similarity = 0.04523122 [ 4, and ][ b) a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: ]
[ 1561 ] similarity = -0.08053836 [ b) a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: ][ 2. ]
[ 1562 ] similarity = 0.21921295 [ A method for the production of a polypeptide comprising a first amino acid sequence and a second amino acid sequence, the second amino acid sequence being a sequence selected from the group consisting of: ][ (i) the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, and ]
[ 1563 ] similarity = 0.47137108 [ (i) the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, and ][ SEQ ID NO: 11; ]
[ 1564 ] similarity = 0.50077426 [ SEQ ID NO: 11; ][ (ii) the amino acid sequence of SEQ ID NO: 12; ]
[ 1565 ] similarity = 0.6490402 [ (ii) the amino acid sequence of SEQ ID NO: 12; ][ (iii) the amino acid sequence of SEQ ID NO: 13; and ]
[ 1566 ] similarity = 0.5032869 [ (iii) the amino acid sequence of SEQ ID NO: 13; and ][ (iv) a sequence having at least 95% sequence identity to the first amino acid sequence. ]
[ 1567 ] similarity = 0.0021768995 [ A method for producing a composition comprising a compound of formula (I) or an pharmaceutically acceptable salt thereof, wherein R1 is H, a C1H-C2H-alkyl, or a C1H-C1H-alkyl; and ][ R2 is H; ]
[ 1568 ] similarity = 0.2227836 [ R2 is H; ][ wherein R1 is H, a C1H-C2H-alkyl, or a C1H-C1H-alkyl; and ]
[ 1569 ] similarity = 0.33403945 [ wherein R1 is H, a C1H-C2H-alkyl, or a C1H-C1H-alkyl; and ][ R2 is H; and ]
[ 1570 ] similarity = -0.009593989 [ R2 is H; and ][ wherein the composition comprises at least one compound of formula (III) or an pharmaceutically acceptable salt thereof. ]
[ 1571 ] similarity = 0.64093864 [ A system for providing a patient with a therapeutic agent, the system comprising: ][ a first device configured to provide an initial therapeutic agent to a patient; ]
[ 1572 ] similarity = 0.58304256 [ a first device configured to provide an initial therapeutic agent to a patient; ][ a second device configured to deliver a second therapeutic agent to the patient; and ]
[ 1573 ] similarity = 0.2565515 [ a second device configured to deliver a second therapeutic agent to the patient; and ][ a processor configured to: ]
[ 1574 ] similarity = 0.26750696 [ a processor configured to: ][ receive an input from the first device; ]
[ 1575 ] similarity = 0.3218771 [ receive an input from the first device; ][ determine an amount of the first therapeutic agent to be delivered to the patient based on the input; ]
[ 1576 ] similarity = 0.905973 [ determine an amount of the first therapeutic agent to be delivered to the patient based on the input; ][ determine an amount of the second therapeutic agent to be delivered to the patient based on the input; ]
[ 1577 ] similarity = 0.6342991 [ determine an amount of the second therapeutic agent to be delivered to the patient based on the input; ][ determine a time interval for delivering the second therapeutic agent based on the time interval; ]
[ 1578 ] similarity = 0.6593293 [ determine a time interval for delivering the second therapeutic agent based on the time interval; ][ determine whether to deliver the first therapeutic agent at a first time interval and a second time interval; and ]
[ 1579 ] similarity = 0.7968106 [ determine whether to deliver the first therapeutic agent at a first time interval and a second time interval; and ][ determine whether to deliver the second therapeutic agent at a second time interval and a third time interval different than the first time interval. ]
[ 1580 ] similarity = 0.67446226 [ An isolated nucleic acid molecule comprising a nucleotide sequence encoding an amino acid sequence of SEQ ID NO: ][ 3, wherein said nucleotide sequence comprises the amino acid sequence of SEQ ID NO: ]
[ 1581 ] similarity = 0.6875617 [ 3, wherein said nucleotide sequence comprises the amino acid sequence of SEQ ID NO: ][ 3, wherein the amino acid sequence of SEQ ID NO: 3 is at least 95% identical to SEQ ID NO: ]
[ 1582 ] similarity = 0.7035576 [ 3, wherein the amino acid sequence of SEQ ID NO: 3 is at least 95% identical to SEQ ID NO: ][ 3, wherein the nucleotide sequence of SEQ ID NO: ]
[ 1583 ] similarity = 0.21818082 [ 3, wherein the nucleotide sequence of SEQ ID NO: ][ 3 is selected from the group consisting of: ]
[ 1584 ] similarity = 0.067166194 [ 3 is selected from the group consisting of: ][ SEQ ID NO: 3: ]
[ 1585 ] similarity = 0.8615458 [ SEQ ID NO: 3: ][ SEQ ID NO: 4: ]
[ 1586 ] similarity = 0.8088041 [ SEQ ID NO: 4: ][ SEQ ID NO: 6: ]
[ 1587 ] similarity = 0.8596324 [ SEQ ID NO: 6: ][ SEQ ID NO: 8, ]
[ 1588 ] similarity = 0.8610319 [ SEQ ID NO: 8, ][ SEQ ID NO: 9, ]
[ 1589 ] similarity = 0.77008766 [ SEQ ID NO: 9, ][ SEQ ID NO: 10, and ]
[ 1590 ] similarity = 0.8025479 [ SEQ ID NO: 10, and ][ SEQ ID NO: 11. ]
[ 1591 ] similarity = 0.059804767 [ A method of treating a cancer in a subject comprising administering an effective amount of a polypeptide comprising a nucleic acid sequence selected from the group consisting of: ][ (a) SEQ ID NO: 1; ]
[ 1592 ] similarity = 0.7100579 [ (a) SEQ ID NO: 1; ][ (b) SEQ ID NO: 2; ]
[ 1593 ] similarity = 0.6895937 [ (b) SEQ ID NO: 2; ][ (c) SEQ ID NO: 3; ]
[ 1594 ] similarity = 0.6745219 [ (c) SEQ ID NO: 3; ][ (d) SEQ ID NO: 4; and ]
[ 1595 ] similarity = 0.34616473 [ (d) SEQ ID NO: 4; and ][ (e) SEQ ID NO: 5, wherein the nucleic acid sequence of the polypeptide comprises the amino acid sequence of SEQ ID NO: 1. ]
[ 1596 ] similarity = 0.6285925 [ A system for treating a patient, comprising: ][ a first patient-specific delivery system comprising: ]
[ 1597 ] similarity = 0.5377215 [ a first patient-specific delivery system comprising: ][ a first delivery system delivery device configured to deliver a first dose of a therapeutically acceptable drug to a first patient, wherein the first delivery system delivery device is configured to deliver the first dose of the therapeutically acceptable drug to the first patient in a first dose delivery sequence; and ]
[ 1598 ] similarity = 0.32102096 [ a first delivery system delivery device configured to deliver a first dose of a therapeutically acceptable drug to a first patient, wherein the first delivery system delivery device is configured to deliver the first dose of the therapeutically acceptable drug to the first patient in a first dose delivery sequence; and ][ a second patient-specific delivery system comprising: ]
[ 1599 ] similarity = 0.43427446 [ a second patient-specific delivery system comprising: ][ a second delivery system delivery device configured to deliver a second dose of the therapeutically acceptable drug to the first patient in a second dose delivery sequence, the second dose delivery sequence being different than the first dose delivery sequence, and ]
[ 1600 ] similarity = 0.8179796 [ a second delivery system delivery device configured to deliver a second dose of the therapeutically acceptable drug to the first patient in a second dose delivery sequence, the second dose delivery sequence being different than the first dose delivery sequence, and ][ wherein the delivery device is configured to deliver a second dose of the therapeutically acceptable drug to a patient in the first dose delivery sequence, ]
[ 1601 ] similarity = 0.89998305 [ wherein the delivery device is configured to deliver a second dose of the therapeutically acceptable drug to a patient in the first dose delivery sequence, ][ wherein the delivery device is configured to deliver the first dose of the therapeutically acceptable drug to the patient in the first dose delivery sequence, and ]
[ 1602 ] similarity = 0.74374634 [ wherein the delivery device is configured to deliver the first dose of the therapeutically acceptable drug to the patient in the first dose delivery sequence, and ][ the delivery device is configured to deliver the second dose of the therapeutically acceptable drug to the patient in the second dose delivery sequence. ]
[ 1603 ] similarity = 0.2928575 [ A system for treating a patient with a condition in which a patient is suffering from an inflammatory disorder, the system comprising: ][ a) an isolated antibody or antigen binding fragment thereof; and ]
[ 1604 ] similarity = 0.21749015 [ a) an isolated antibody or antigen binding fragment thereof; and ][ b) a therapeutically effective amount of an effective amount of the antibody, wherein: ]
[ 1605 ] similarity = 0.33153456 [ b) a therapeutically effective amount of an effective amount of the antibody, wherein: ][ (i) said antibody is a monoclonal antibody, and ]
[ 1606 ] similarity = 0.5453883 [ (i) said antibody is a monoclonal antibody, and ][ wherein the monoclonal antibody is a human antibody, a human antibody, a human monoclonal antibody, a human antibody, a human monoclonal polypeptide, a human polypeptide, or a human polypeptide having the amino acid sequence of SEQ ID NO: ]
[ 1607 ] similarity = 0.069023445 [ wherein the monoclonal antibody is a human antibody, a human antibody, a human monoclonal antibody, a human antibody, a human monoclonal polypeptide, a human polypeptide, or a human polypeptide having the amino acid sequence of SEQ ID NO: ][ 1 or SEQ ID NO: ]
[ 1608 ] similarity = 0.0895263 [ 1 or SEQ ID NO: ][ 2; or (ii) said monoclonal antibody is a human antibody, a human antibody, a human antibody, a human monoclonal antibody, a human monoclonal polypeptide, a human polypeptide, or a human polypeptide having the amino acid sequence of SEQ ID NO: ]
[ 1609 ] similarity = 0.08952629 [ 2; or (ii) said monoclonal antibody is a human antibody, a human antibody, a human antibody, a human monoclonal antibody, a human monoclonal polypeptide, a human polypeptide, or a human polypeptide having the amino acid sequence of SEQ ID NO: ][ 1 or SEQ ID NO: ]
[ 1610 ] similarity = 0.20480038 [ 1 or SEQ ID NO: ][ 2. ]
[ 1611 ] similarity = 0.25014424 [ A method for treating a disease in a mammal comprising: ][ (i) providing a first pharmaceutical composition comprising an effective amount of a compound of formula (1): ]
[ 1612 ] similarity = 0.044238154 [ (i) providing a first pharmaceutical composition comprising an effective amount of a compound of formula (1): ][ or a pharmaceutically acceptable salt thereof; and ]
[ 1613 ] similarity = 0.47902805 [ or a pharmaceutically acceptable salt thereof; and ][ (ii) administering to said mammal a therapeutically effective amount of said compound or pharmaceutically acceptable salt thereof. ]
[ 1614 ] similarity = -0.036318295 [ A method for treating a disease or condition, comprising administering an effective amount of a composition comprising an effective amount of a polysaccharide, wherein the composition comprises a polysaccharide comprising the amino acid sequence of SEQ ID NO: ][ 2. ]
[ 1615 ] similarity = 0.20554452 [ A method for treating a disease or condition in a mammal, comprising administering a therapeutically effective amount of a compound of formula (I): ][ or a pharmaceutically acceptable salt thereof, wherein: ]
[ 1616 ] similarity = -0.069313325 [ or a pharmaceutically acceptable salt thereof, wherein: ][ X represents a C1-C30 alkyl group; ]
[ 1617 ] similarity = 0.37210494 [ X represents a C1-C30 alkyl group; ][ R1 represents an alkyl group having at least one hydrogen atom; ]
[ 1618 ] similarity = 0.26009595 [ R1 represents an alkyl group having at least one hydrogen atom; ][ R3 and R5 represent an alkyl group having an alkyl group group ring, a heterocyclic ring, or a cycloalkyl group, wherein the heterocyclic ring and the cycloalkyl group are each independently hydrogen atom-containing; and ]
[ 1619 ] similarity = 0.25296813 [ R3 and R5 represent an alkyl group having an alkyl group group ring, a heterocyclic ring, or a cycloalkyl group, wherein the heterocyclic ring and the cycloalkyl group are each independently hydrogen atom-containing; and ][ R6 represents a hydrogen or a C1-C30 alkoxy group; ]
[ 1620 ] similarity = 0.35868356 [ R6 represents a hydrogen or a C1-C30 alkoxy group; ][ R8 represents an alkoxy group having at least one carbon atom; ]
[ 1621 ] similarity = 0.23853475 [ R8 represents an alkoxy group having at least one carbon atom; ][ R9 represents a hydrogen atom, a C1-C30 alkyl group, or a heterocyclyl group, or a cycloalkyl group; or a pharmaceutically acceptable salt thereof. ]
[ 1622 ] similarity = 0.17998068 [ A method comprising: ][ receiving a plurality of data sets from an external device; ]
[ 1623 ] similarity = 0.3796054 [ receiving a plurality of data sets from an external device; ][ determining whether a first data set is present in a first data set; ]
[ 1624 ] similarity = 0.75551075 [ determining whether a first data set is present in a first data set; ][ determining a first value associated with the first data set based on the received plurality of data sets; and ]
[ 1625 ] similarity = 0.62013054 [ determining a first value associated with the first data set based on the received plurality of data sets; and ][ determining a second value associated with the second data set based on the first value. ]
[ 1626 ] similarity = 0.46085012 [ A device for the insertion into a patient's stomach or stomach wall of an elongate, flexible tube having a proximal end, a distal end, and ][ an opening at the proximal end, the device comprising: ]
[ 1627 ] similarity = 0.24414277 [ an opening at the proximal end, the device comprising: ][ a body portion; ]
[ 1628 ] similarity = 0.32640243 [ a body portion; ][ a first end portion, wherein a portion of the first end portion is adapted to be inserted into a stomach of a patient and a portion of the first end portion is adapted to be disposed within a stomach wall of the patient; and ]
[ 1629 ] similarity = 0.7158784 [ a first end portion, wherein a portion of the first end portion is adapted to be inserted into a stomach of a patient and a portion of the first end portion is adapted to be disposed within a stomach wall of the patient; and ][ a second end portion, wherein the second end portion is adapted to be disposed within a stomach wall of the patient; ]
[ 1630 ] similarity = 0.0001803711 [ a second end portion, wherein the second end portion is adapted to be disposed within a stomach wall of the patient; ][ the device further comprising: ]
[ 1631 ] similarity = -0.04158274 [ the device further comprising: ][ a first portion having a proximal end, wherein the first portion is disposed within a distal opening of the tube and is configured for insertion within a stomach wall of the patient; and ]
[ 1632 ] similarity = 0.8559265 [ a first portion having a proximal end, wherein the first portion is disposed within a distal opening of the tube and is configured for insertion within a stomach wall of the patient; and ][ a second portion having a proximal end, wherein the second portion is disposed within a distal opening of the tube and is configured and adapted for insertion into a stomach wall of the patient; ]
[ 1633 ] similarity = 0.7815108 [ a second portion having a proximal end, wherein the second portion is disposed within a distal opening of the tube and is configured and adapted for insertion into a stomach wall of the patient; ][ wherein the tube is adapted to be inserted through the stomach wall of the patient and the tube further comprises a first end portion and a second end portion, the first and second ends of the first portion being configured to engage the stomach wall of the patient and the second end portion of the tube being disposed in a distal opening of the tube and the second end portion of the tube being disposed within the opening of the stomach wall of the patient. ]
[ 1634 ] similarity = -0.03526715 [ An isolated antibody or antigen binding fragment thereof that binds to a polypeptide of SEQ ID NO: ][ 2. ]
[ 1635 ] similarity = 0.50020224 [ A method of providing medical treatment to a patient, comprising: ][ receiving, by a first medical device, a first patient-specific medical treatment request from the first medical device; ]
[ 1636 ] similarity = 0.6094459 [ receiving, by a first medical device, a first patient-specific medical treatment request from the first medical device; ][ receiving, by a second medical device, a second patient-specific medical treatment request from the second medical device; ]
[ 1637 ] similarity = 0.4199471 [ receiving, by a second medical device, a second patient-specific medical treatment request from the second medical device; ][ determining, by the first device, a first treatment plan for the patient based at least in part on the received first patient-specific medical treatment request; ]
[ 1638 ] similarity = 0.8397619 [ determining, by the first device, a first treatment plan for the patient based at least in part on the received first patient-specific medical treatment request; ][ determining, by the first device, a second treatment plan for the patient based at least in part on the received second patient-specific medical treatment request; ]
[ 1639 ] similarity = 0.6376902 [ determining, by the first device, a second treatment plan for the patient based at least in part on the received second patient-specific medical treatment request; ][ receiving, by the first medical device, a first medical treatment request from the second medical device; ]
[ 1640 ] similarity = 0.75166005 [ receiving, by the first medical device, a first medical treatment request from the second medical device; ][ receiving, by the second medical device, a second medical treatment request from the second device; ]
[ 1641 ] similarity = 0.28877634 [ receiving, by the second medical device, a second medical treatment request from the second device; ][ receiving, by the first device, a first treatment plan for the patient based at least in part on the received first treatment plan and the received first treatment request; ]
[ 1642 ] similarity = 0.96777 [ receiving, by the first device, a first treatment plan for the patient based at least in part on the received first treatment plan and the received first treatment request; ][ determining, by the first device, a first treatment plan for the patient based at least in part on the received first treatment plan and the received first treatment request; and ]
[ 1643 ] similarity = 0.56166023 [ determining, by the first device, a first treatment plan for the patient based at least in part on the received first treatment plan and the received first treatment request; and ][ receiving, by the second device, a second treatment plan for the patient based at least in part on the received second medical treatment request. ]
[ 1644 ] similarity = 0.2567873 [ A method of treating a patient having a cancer, comprising: ][ providing a biopsy sample comprising a tumor tissue, the tumor tissue having a tumor site and an extracellular matrix; ]
[ 1645 ] similarity = 0.5911948 [ providing a biopsy sample comprising a tumor tissue, the tumor tissue having a tumor site and an extracellular matrix; ][ exposing the tumor tissue to an agent that specifically inhibits the growth of the cancer; ]
[ 1646 ] similarity = 0.8940654 [ exposing the tumor tissue to an agent that specifically inhibits the growth of the cancer; ][ exposing the tumor site to an agent that specifically inhibits the proliferation of the cancer; ]
[ 1647 ] similarity = 0.78372633 [ exposing the tumor site to an agent that specifically inhibits the proliferation of the cancer; ][ exposing a second tumor site to the agent that specifically inhibits proliferation of the tumor; and ]
[ 1648 ] similarity = 0.023860337 [ exposing a second tumor site to the agent that specifically inhibits proliferation of the tumor; and ][ administering to said patient a therapeutically effective amount of a composition comprising a polypeptide selected from the group consisting of SEQ ID NO: ]
[ 1649 ] similarity = 0.13587496 [ administering to said patient a therapeutically effective amount of a composition comprising a polypeptide selected from the group consisting of SEQ ID NO: ][ 2, SEQ ID NO: ]
[ 1650 ] similarity = 0.7787261 [ 2, SEQ ID NO: ][ 4, SEQ ID NO: ]
[ 1651 ] similarity = 0.8158754 [ 4, SEQ ID NO: ][ 6, SEQ ID NO: ]
[ 1652 ] similarity = 0.83281016 [ 6, SEQ ID NO: ][ 8, SEQ ID NO: ]
[ 1653 ] similarity = 0.8040749 [ 8, SEQ ID NO: ][ 10, SEQ ID NO: ]
[ 1654 ] similarity = 0.73589647 [ 10, SEQ ID NO: ][ 14, SEQ ID NO: ]
[ 1655 ] similarity = 0.326712 [ 14, SEQ ID NO: ][ 16, and ]
[ 1656 ] similarity = 0.13589305 [ 16, and ][ SEQ ID NO: ]
[ 1657 ] similarity = 0.22325712 [ SEQ ID NO: ][ 18. ]
[ 1658 ] similarity = 0.2012668 [ A method for the preparation of a pharmaceutical composition comprising: ][ a. preparing an isolated polypeptide from a plant having the amino acid sequence of SEQ ID NO: ]
[ 1659 ] similarity = -0.014030267 [ a. preparing an isolated polypeptide from a plant having the amino acid sequence of SEQ ID NO: ][ 1; ]
[ 1660 ] similarity = 0.029021129 [ 1; ][ b. preparing a pharmaceutically acceptable carrier, the carrier having a molecular weight of from about 10 to about 500 daltons; and ]
[ 1661 ] similarity = 0.45501864 [ b. preparing a pharmaceutically acceptable carrier, the carrier having a molecular weight of from about 10 to about 500 daltons; and ][ c. introducing into the composition a pharmaceutical agent comprising a pharmaceutically acceptable carrier, wherein the carrier is an isolated polypeptide from a plant having the amino acid sequence of SEQ ID NO: ]
[ 1662 ] similarity = 0.0072089992 [ c. introducing into the composition a pharmaceutical agent comprising a pharmaceutically acceptable carrier, wherein the carrier is an isolated polypeptide from a plant having the amino acid sequence of SEQ ID NO: ][ 1. ]
[ 1663 ] similarity = 0.12738742 [ A method of treating or preventing the progression of a disease or condition comprising the steps of: ][ (a) providing a first therapeutic agent, the first therapeutic agent comprising a compound selected from the group consisting of: (i) a pharmaceutically acceptable salt thereof, (ii) an amino acid sequence of at least 95% sequence identity to SEQ ID NO: ]
[ 1664 ] similarity = 0.055635884 [ (a) providing a first therapeutic agent, the first therapeutic agent comprising a compound selected from the group consisting of: (i) a pharmaceutically acceptable salt thereof, (ii) an amino acid sequence of at least 95% sequence identity to SEQ ID NO: ][ 1, and ]
[ 1665 ] similarity = 0.016270991 [ 1, and ][ (iii) at least one of the amino acids selected from the group consisting of: (i) a pharmaceutically acceptable salt thereof, (ii) an amino acid sequence of at least 95% sequence identity to SEQ ID NO: ]
[ 1666 ] similarity = 0.016270977 [ (iii) at least one of the amino acids selected from the group consisting of: (i) a pharmaceutically acceptable salt thereof, (ii) an amino acid sequence of at least 95% sequence identity to SEQ ID NO: ][ 1; and ]
[ 1667 ] similarity = 0.04277853 [ 1; and ][ (b) administering the first therapeutic agent to a subject in need for treatment, the subject having an inflammatory disease or condition. ]
[ 1668 ] similarity = 0.4185627 [ A system for providing a medical treatment to a patient, the system comprising: ][ at least one medical treatment device; ]
[ 1669 ] similarity = 0.55463785 [ at least one medical treatment device; ][ at least one sensor; ]
[ 1670 ] similarity = 0.18058363 [ at least one sensor; ][ a processor configured to: ]
[ 1671 ] similarity = 0.1634281 [ a processor configured to: ][ receive at least one medical treatment device data; ]
[ 1672 ] similarity = 0.71215206 [ receive at least one medical treatment device data; ][ generate an indication for a treatment of the at least one medical treatment device; ]
[ 1673 ] similarity = 0.66549647 [ generate an indication for a treatment of the at least one medical treatment device; ][ determine a first treatment parameter of the medical treatment device; and ]
[ 1674 ] similarity = 0.8051169 [ determine a first treatment parameter of the medical treatment device; and ][ determine a second treatment parameter of the medical treatment device; ]
[ 1675 ] similarity = 0.16789083 [ determine a second treatment parameter of the medical treatment device; ][ the processor configured to: ]
[ 1676 ] similarity = 0.10820784 [ the processor configured to: ][ receive the at least one medical treatment device data; ]
[ 1677 ] similarity = 0.38235506 [ receive the at least one medical treatment device data; ][ generate a first indication of a first treatment parameter of the medical treatment device based on at least a first of the first treatment parameter of the medical treatment device and a first of the second treatment parameters; ]
[ 1678 ] similarity = 0.7480911 [ generate a first indication of a first treatment parameter of the medical treatment device based on at least a first of the first treatment parameter of the medical treatment device and a first of the second treatment parameters; ][ generate a second indication of a second treatment parameter of the medical treatment device based on at least a second of the first treatment parameter of the medical treatment device and at least one of the second treatment parameter of the medical treatment device; and ]
[ 1679 ] similarity = 0.68828773 [ generate a second indication of a second treatment parameter of the medical treatment device based on at least a second of the first treatment parameter of the medical treatment device and at least one of the second treatment parameter of the medical treatment device; and ][ generate a first treatment parameter for the medical treatment device based on at least a first of the first treatment parameter and at least a second of the second treatment parameter; wherein the first treatment parameter is a first of the first treatment parameter and a first of the second treatment parameter, and ]
[ 1680 ] similarity = 0.9067213 [ generate a first treatment parameter for the medical treatment device based on at least a first of the first treatment parameter and at least a second of the second treatment parameter; wherein the first treatment parameter is a first of the first treatment parameter and a first of the second treatment parameter, and ][ wherein the first treatment parameter is a first of at least one of the first treatment parameter and the second treatment parameter. ]
[ 1681 ] similarity = 0.31106892 [ An apparatus for treating a patient comprising: ][ a plurality of treatment electrodes, the electrodes being configured to be placed on a patient's body, the electrodes being configured to be placed on a patient's body in an arrangement that is substantially parallel to the patient's spine and to be positioned in the patient's spine; and ]
[ 1682 ] similarity = 0.7055161 [ a plurality of treatment electrodes, the electrodes being configured to be placed on a patient's body, the electrodes being configured to be placed on a patient's body in an arrangement that is substantially parallel to the patient's spine and to be positioned in the patient's spine; and ][ a plurality of treatment modules, each module being configured to be positioned on an electrode of the plurality of treatment electrodes, the treatment modules being configured to be positioned in the patient's spinal column and to provide treatment for a disease of the patient's body. ]
[ 1683 ] similarity = 0.23860931 [ An apparatus for treating a patient having a disease characterized by a reduced ability to regulate blood flow in the blood vessel, comprising: ][ at least one blood vessel; ]
[ 1684 ] similarity = 0.64981526 [ at least one blood vessel; ][ at least one blood vessel pump for delivering at least one of blood from said at least one blood vessel to a patient; and ]
[ 1685 ] similarity = 0.7623589 [ at least one blood vessel pump for delivering at least one of blood from said at least one blood vessel to a patient; and ][ at least one blood vessel controller for controlling said at least one blood vessel, wherein said at least one blood vessel controller comprises: ]
[ 1686 ] similarity = 0.79695046 [ at least one blood vessel controller for controlling said at least one blood vessel, wherein said at least one blood vessel controller comprises: ][ at least one blood vessel controller module configured to control at least one of the blood vessel pump and the at least one blood vessel controller module, wherein said at least one blood vessel controller module is configured to control the at least one blood vessel pump and the at least one blood vessel controller module, and ]
[ 1687 ] similarity = 0.65095866 [ at least one blood vessel controller module configured to control at least one of the blood vessel pump and the at least one blood vessel controller module, wherein said at least one blood vessel controller module is configured to control the at least one blood vessel pump and the at least one blood vessel controller module, and ][ wherein said at least one blood vessel controller module comprises: ]
[ 1688 ] similarity = 0.35575196 [ wherein said at least one blood vessel controller module comprises: ][ a blood vessel pump module; ]
[ 1689 ] similarity = 0.5712797 [ a blood vessel pump module; ][ a blood vessel controller module configured to control at least one of a blood vessel pump and a blood vessel controller module, wherein the blood vessel controller module and the blood vessel pump module are each configured to control a different one of the blood vessel pump and the blood vessel controller module, and ]
[ 1690 ] similarity = 0.44779283 [ a blood vessel controller module configured to control at least one of a blood vessel pump and a blood vessel controller module, wherein the blood vessel controller module and the blood vessel pump module are each configured to control a different one of the blood vessel pump and the blood vessel controller module, and ][ wherein the blood volume of the at least one blood vessel is configured to vary according to a patient's condition; and ]
[ 1691 ] similarity = 0.37133962 [ wherein the blood volume of the at least one blood vessel is configured to vary according to a patient's condition; and ][ a blood vessel control module configured to control the blood vessel pump module and the blood vessel controller module. ]
[ 1692 ] similarity = 0.14411515 [ A method comprising: ][ receiving a plurality of images of a patient; ]
[ 1693 ] similarity = 0.48782828 [ receiving a plurality of images of a patient; ][ identifying at least one image from the plurality of images; and ]
[ 1694 ] similarity = 0.49872363 [ identifying at least one image from the plurality of images; and ][ generating a first image of the patient based on the at least one image, wherein the first image comprises at least one image of the at least one patient. ]
[ 1695 ] similarity = 0.20537663 [ A method of treating an autoimmune disease in a mammal comprising administering to said mammal an amount of a compound that specifically inhibits the binding of the polypeptide of SEQ ID NO: ][ 2 to the human IL-6 receptor, wherein the IL-6 receptor is a member of the IL-6 receptor complex, and ]
[ 1696 ] similarity = 0.14234859 [ 2 to the human IL-6 receptor, wherein the IL-6 receptor is a member of the IL-6 receptor complex, and ][ wherein the compound is selected from a group consisting of a polypeptide of SEQ ID NO: ]
[ 1697 ] similarity = 0.17973518 [ wherein the compound is selected from a group consisting of a polypeptide of SEQ ID NO: ][ 1, SEQ ID NO: ]
[ 1698 ] similarity = 0.7964808 [ 1, SEQ ID NO: ][ 2, SEQ ID NO: ]
[ 1699 ] similarity = 0.7787261 [ 2, SEQ ID NO: ][ 4, SEQ ID No: ]
[ 1700 ] similarity = 0.8005054 [ 4, SEQ ID No: ][ 5, SEQ ID NO: ]
[ 1701 ] similarity = 0.83311415 [ 5, SEQ ID NO: ][ 6, SEQ ID NO: ]
[ 1702 ] similarity = 0.8179097 [ 6, SEQ ID NO: ][ 7, SEQ ID NO: ]
[ 1703 ] similarity = 0.22510418 [ 7, SEQ ID NO: ][ 8, and ]
[ 1704 ] similarity = 0.10373196 [ 8, and ][ SEQ ID NO: ]
[ 1705 ] similarity = 0.23349217 [ SEQ ID NO: ][ 9. ]
[ 1706 ] similarity = 0.095035695 [ A method for treating a disease in a patient comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of: a) a compound of formula (I): ][ or a pharmaceutically acceptable salt thereof; ]
[ 1707 ] similarity = 0.079578064 [ or a pharmaceutically acceptable salt thereof; ][ b) an amino acid sequence having the sequence of SEQ ID NO: ]
[ 1708 ] similarity = -0.078761816 [ b) an amino acid sequence having the sequence of SEQ ID NO: ][ 1 or 2; or a compound of formula (II): ]
[ 1709 ] similarity = 0.15088505 [ 1 or 2; or a compound of formula (II): ][ or a pharmaceutically acceptable salt thereof. ]
[ 1710 ] similarity = 0.07800987 [ A method of treating a patient, comprising administering to the patient in need thereof an effective amount of an anti-CD4-mediated antibody or an anti-CD4-mediated antigen-binding fragment thereof, wherein the anti-CD4-mediated antibody or anti-CD4-mediated antigen-binding fragment thereof comprises a CDR1 or CDR2 sequence selected from the group consisting of SEQ ID NO: ][ 4, SEQ ID NO: ]
[ 1711 ] similarity = 0.8158754 [ 4, SEQ ID NO: ][ 6, SEQ ID NO: ]
[ 1712 ] similarity = 0.83281016 [ 6, SEQ ID NO: ][ 8, SEQ ID NO: ]
[ 1713 ] similarity = 0.84770155 [ 8, SEQ ID NO: ][ 9, SEQ ID NO: ]
[ 1714 ] similarity = 0.8291399 [ 9, SEQ ID NO: ][ 11, SEQ ID NO: ]
[ 1715 ] similarity = 0.82356983 [ 11, SEQ ID NO: ][ 13, SEQ ID NO: ]
[ 1716 ] similarity = 0.30090815 [ 13, SEQ ID NO: ][ 16, and ]
[ 1717 ] similarity = 0.13589305 [ 16, and ][ SEQ ID NO: ]
[ 1718 ] similarity = 0.1955956 [ SEQ ID NO: ][ 17, and ]
[ 1719 ] similarity = -0.020846352 [ 17, and ][ wherein said anti-CD4-mediated antibody or anti-CD4-mediated antigen-binding fragment thereof is effective in treating the patient. ]
[ 1720 ] similarity = 0.0920966 [ Apparatus for the treatment of a patient with cancer or an immune-related disease, comprising: ][ a) an implantable device having a plurality of electrodes, wherein each of the electrodes is adapted to receive an electrical signal from a target tissue, wherein the electrical signal is generated by a plurality of electrodes; ]
[ 1721 ] similarity = 0.71484643 [ a) an implantable device having a plurality of electrodes, wherein each of the electrodes is adapted to receive an electrical signal from a target tissue, wherein the electrical signal is generated by a plurality of electrodes; ][ b) at least one electrode having a first electrode and a second electrode, wherein the first electrode is configured to receive the electrical signal generated by the plurality of electrodes; ]
[ 1722 ] similarity = 0.909271 [ b) at least one electrode having a first electrode and a second electrode, wherein the first electrode is configured to receive the electrical signal generated by the plurality of electrodes; ][ c) at least one electrode having a third electrode, wherein the second electrode is configured to receive the electrical signal generated by the plurality of electrodes, and ]
[ 1723 ] similarity = 0.7489249 [ c) at least one electrode having a third electrode, wherein the second electrode is configured to receive the electrical signal generated by the plurality of electrodes, and ][ the third electrode is configured to generate an electrical signal that is different from the electrical signal received by the first electrode; and ]
[ 1724 ] similarity = 0.61448884 [ the third electrode is configured to generate an electrical signal that is different from the electrical signal received by the first electrode; and ][ d) an implantable device having an electrode array, wherein at least one electrode in the electrode array is configured to be connected to the first electrode and the second electrode, and ]
[ 1725 ] similarity = 0.7425624 [ d) an implantable device having an electrode array, wherein at least one electrode in the electrode array is configured to be connected to the first electrode and the second electrode, and ][ the electrode array is configured to receive at least one electrical signal generated by the first electrode and to receive at least one electrical signal generated by the second electrode. ]
[ 1726 ] similarity = 0.32810056 [ A method for the production of an implantable medical device comprising: ][ providing a plurality of electrodes; ]
[ 1727 ] similarity = 0.49262753 [ providing a plurality of electrodes; ][ providing a plurality of electrodes having a first electrode surface and a second electrode surface; ]
[ 1728 ] similarity = 0.65867364 [ providing a plurality of electrodes having a first electrode surface and a second electrode surface; ][ providing a plurality of electrodes having a first electrode electrode surface and a second electrode surface, wherein the first electrode surface has an outer surface that is a surface of an implantable medical device, the first electrode surface has a first surface that has an outer surface that is a surface of an implantable medical device, the second electrode surface has a second surface that has an outer surface that is a surface of an implantable medical device, and ]
[ 1729 ] similarity = 0.6481733 [ providing a plurality of electrodes having a first electrode electrode surface and a second electrode surface, wherein the first electrode surface has an outer surface that is a surface of an implantable medical device, the first electrode surface has a first surface that has an outer surface that is a surface of an implantable medical device, the second electrode surface has a second surface that has an outer surface that is a surface of an implantable medical device, and ][ the outer surface of the first electrode surface has a first thickness that is less than the first thickness of the second electrode surface; and ]
[ 1730 ] similarity = 0.58856076 [ the outer surface of the first electrode surface has a first thickness that is less than the first thickness of the second electrode surface; and ][ providing a plurality of electrodes having a first electrode surface and a second electrode surface. ]
[ 1731 ] similarity = 0.24766862 [ A device for a medical instrument, comprising: ][ a first housing; ]
[ 1732 ] similarity = 0.47049987 [ a first housing; ][ a first body member disposed in said first housing and having a first end, a second end, and ]
[ 1733 ] similarity = 0.0034087533 [ a first body member disposed in said first housing and having a first end, a second end, and ][ a proximal portion; ]
[ 1734 ] similarity = 0.024288889 [ a proximal portion; ][ an outer surface disposed between said first body member and said first housing; ]
[ 1735 ] similarity = 0.6568122 [ an outer surface disposed between said first body member and said first housing; ][ a first connector disposed between the first body member and said first connector; ]
[ 1736 ] similarity = 0.72438234 [ a first connector disposed between the first body member and said first connector; ][ a first end of a second connector disposed in said outer surface of said first connector; ]
[ 1737 ] similarity = 0.9264599 [ a first end of a second connector disposed in said outer surface of said first connector; ][ a second end of a second connector disposed in said outer surface of said first connector; ]
[ 1738 ] similarity = 0.48852777 [ a second end of a second connector disposed in said outer surface of said first connector; ][ a third connector disposed in the first housing; and ]
[ 1739 ] similarity = 0.84528756 [ a third connector disposed in the first housing; and ][ a fourth connector disposed in the first housing; ]
[ 1740 ] similarity = 0.41800755 [ a fourth connector disposed in the first housing; ][ wherein the first housing and the first body member are configured to couple with each other to form a first coupling; ]
[ 1741 ] similarity = 0.8486091 [ wherein the first housing and the first body member are configured to couple with each other to form a first coupling; ][ wherein the first body member is configured to couple with the first housing; ]
[ 1742 ] similarity = 0.50175774 [ wherein the first body member is configured to couple with the first housing; ][ wherein the second connector is configured to couple with the second housing; and ]
[ 1743 ] similarity = 0.579391 [ wherein the second connector is configured to couple with the second housing; and ][ wherein the fourth connector is configured to couple with the third connector. ]
[ 1744 ] similarity = 0.57253146 [ A method of providing a medical device to a patient, comprising: ][ providing a first medical device; ]
[ 1745 ] similarity = 0.7042281 [ providing a first medical device; ][ providing a second medical device; ]
[ 1746 ] similarity = 0.5477246 [ providing a second medical device; ][ providing at least one first medical device interface; and ]
[ 1747 ] similarity = 0.8648331 [ providing at least one first medical device interface; and ][ providing at least one first medical device interface interface; ]
[ 1748 ] similarity = 0.66708755 [ providing at least one first medical device interface interface; ][ wherein the first and second medical device interfaces are coupled to one another by a first interface and a second interface, the first and second interfaces being configured to provide communication between at least one first medical device interface and at least one second medical device, the first interface being coupled to the first medical device and the second interface to the second medical device. ]
[ 1749 ] similarity = 0.28306067 [ A system for treating a patient with a cancer comprising: ][ a first implantable medical device having a first implantable medical device interface; ]
[ 1750 ] similarity = 0.41734326 [ a first implantable medical device having a first implantable medical device interface; ][ a plurality of second medical devices; ]
[ 1751 ] similarity = 0.32200605 [ a plurality of second medical devices; ][ at least one first medical device interface disposed within the system, each first medical device having a first medical device interface, the first medical devices having a first interface; ]
[ 1752 ] similarity = 0.5958228 [ at least one first medical device interface disposed within the system, each first medical device having a first medical device interface, the first medical devices having a first interface; ][ at least one second medical device interface disposed within the system, the at least one second medical device interface having a second interface; ]
[ 1753 ] similarity = 0.9121195 [ at least one second medical device interface disposed within the system, the at least one second medical device interface having a second interface; ][ at least one first medical device interface and at least one second medical device interface disposed within the system, the at least one first medical device interface and at least one second medical device interface each including a second interface; and ]
[ 1754 ] similarity = 0.87128067 [ at least one first medical device interface and at least one second medical device interface disposed within the system, the at least one first medical device interface and at least one second medical device interface each including a second interface; and ][ a first device interface disposed within the first implantable medical device, the first device interface including at least one first device interface and at least one second device interface, the second device interface including a second interface, wherein the first device interface includes an interface that is configured to receive data from at least one of the at least one medical device interface and the at least second medical device interface. ]
[ 1755 ] similarity = 0.339347 [ A system for treating a patient, comprising: ][ an implantable medical device; ]
[ 1756 ] similarity = 0.412155 [ an implantable medical device; ][ an electrical stimulation system for generating electrical signals to the implantable medical device, wherein the system includes an implantable electrical stimulation circuit configured to receive electrical signals from the implantable medical device, wherein the electrical stimulation system includes a first circuit configured to generate electrical stimulation signals to the implantable medical device, and ]
[ 1757 ] similarity = 0.7100462 [ an electrical stimulation system for generating electrical signals to the implantable medical device, wherein the system includes an implantable electrical stimulation circuit configured to receive electrical signals from the implantable medical device, wherein the electrical stimulation system includes a first circuit configured to generate electrical stimulation signals to the implantable medical device, and ][ a second circuit configured to generate a signal to the implantable medical device, wherein the first circuit and the second circuit are configured to receive the electrical stimulation signals and to generate a signal; ]
[ 1758 ] similarity = 0.39447767 [ a second circuit configured to generate a signal to the implantable medical device, wherein the first circuit and the second circuit are configured to receive the electrical stimulation signals and to generate a signal; ][ a processor configured to process the signal to determine whether the signal has been received; and ]
[ 1759 ] similarity = 0.44015718 [ a processor configured to process the signal to determine whether the signal has been received; and ][ a display configured to display a patient-specific information associated with the signal. ]
[ 1760 ] similarity = -0.038070668 [ A method of producing a compound of Formula II: ][ wherein: ]
[ 1761 ] similarity = -0.022768093 [ wherein: ][ R1 is hydrogen, a substituted or unsubstituted alkyl, a substituted alkenyl, a substituted alkynyl, an substituted aliphatic alkyl, or a substituted alkynylalkyl; and ]
[ 1762 ] similarity = 0.03639827 [ R1 is hydrogen, a substituted or unsubstituted alkyl, a substituted alkenyl, a substituted alkynyl, an substituted aliphatic alkyl, or a substituted alkynylalkyl; and ][ R2 is a hydrogen atom or a halogen atom; ]
[ 1763 ] similarity = 0.4785029 [ R2 is a hydrogen atom or a halogen atom; ][ R3 is a hydrogen atom or an alkyl group having a C1-4alkyl group; ]
[ 1764 ] similarity = 0.8363564 [ R3 is a hydrogen atom or an alkyl group having a C1-4alkyl group; ][ R4 is a hydrogen atom or an alkyl group having a C1-4alkyl group; ]
[ 1765 ] similarity = 0.45962098 [ R4 is a hydrogen atom or an alkyl group having a C1-4alkyl group; ][ R5 is a hydrogen atom or a halogen atom; and ]
[ 1766 ] similarity = 0.42970473 [ R5 is a hydrogen atom or a halogen atom; and ][ R6 is a hydrogen atom or an alkyl group having a C1-4alkyl group. ]
[ 1767 ] similarity = 0.3241673 [ A device for treating a wound, said device comprising: ][ a first portion of a flexible material; and ]
[ 1768 ] similarity = 0.52234244 [ a first portion of a flexible material; and ][ a second portion of the flexible material, said flexible material having a first surface and a second surface, said first portion of the flexible material being adapted to receive a first portion of a tissue, said first surface being adapted to be exposed to a first surface of a wound; ]
[ 1769 ] similarity = 0.556192 [ a second portion of the flexible material, said flexible material having a first surface and a second surface, said first portion of the flexible material being adapted to receive a first portion of a tissue, said first surface being adapted to be exposed to a first surface of a wound; ][ wherein said first surface of said first portion of the flexible material has a thickness of less than 10&#xb0; ]
[ 1770 ] similarity = 0.07715892 [ wherein said first surface of said first portion of the flexible material has a thickness of less than 10&#xb0; ][ m, and ]
[ 1771 ] similarity = 0.03158473 [ m, and ][ said second portion of the flexible material has a thickness greater than 10&#xb0; ]
[ 1772 ] similarity = 0.04799343 [ said second portion of the flexible material has a thickness greater than 10&#xb0; ][ m. ]
[ 1773 ] similarity = 0.2774432 [ A system, comprising: ][ an implantable medical device; ]
[ 1774 ] similarity = 0.73876566 [ an implantable medical device; ][ an implantable medical device controller coupled to the implantable medical device; and ]
[ 1775 ] similarity = 0.75437975 [ an implantable medical device controller coupled to the implantable medical device; and ][ a memory coupled to the implantable medical device controller and to the implantable medical device, the memory storing instructions for controlling the implantable medical device, the instructions including: ]
[ 1776 ] similarity = 0.5488943 [ a memory coupled to the implantable medical device controller and to the implantable medical device, the memory storing instructions for controlling the implantable medical device, the instructions including: ][ an instruction for controlling the implantable medical device based at least in part on a medical condition of a patient; and, ]
[ 1777 ] similarity = 0.7484702 [ an instruction for controlling the implantable medical device based at least in part on a medical condition of a patient; and, ][ an instruction for providing an implantable medical device to the patient based on the medical condition of the patient. ]
[ 1778 ] similarity = 0.5926447 [ A method of treating a patient having an inflammatory disease comprising administering to the patient an effective amount of a therapeutically effective amount of an isolated monoclonal antibody or fragment thereof that binds to an epitope of the human CD4+ T cell receptor, wherein said antibody or fragment thereof is selected from the group consisting of: ][ a) a monoclonal antibody or fragment thereof that binds to the human CD4+ T cell receptor; and ]
[ 1779 ] similarity = 0.8822957 [ a) a monoclonal antibody or fragment thereof that binds to the human CD4+ T cell receptor; and ][ b) an antibody or fragment thereof that binds to the human CD4+ T cell receptor. ]
[ 1780 ] similarity = 0.4488576 [ A method for treating a condition in a patient comprising: ][ providing a first device for administering to a patient a therapeutically effective amount of an antibody comprising a fragment of SEQ ID NO: 1 and an antigen binding fragment thereof; ]
[ 1781 ] similarity = 0.8165087 [ providing a first device for administering to a patient a therapeutically effective amount of an antibody comprising a fragment of SEQ ID NO: 1 and an antigen binding fragment thereof; ][ providing a second device for administering to a patient a therapeutically effective amount of an antigen binding fragment of SEQ ID NO: 2 and an antigen binding fragment thereof; ]
[ 1782 ] similarity = 0.5589826 [ providing a second device for administering to a patient a therapeutically effective amount of an antigen binding fragment of SEQ ID NO: 2 and an antigen binding fragment thereof; ][ providing an antigen-binding fragment of SEQ ID NO: 2 and an antigen-binding fragment of SEQ ID NO: 2, wherein the antigen binding fragment is a fragment of SEQ ID NO: 2 and the antigen binding fragment is a fragment of SEQ ID NO: 2 and the antigen binding fragment is a fragment of SEQ ID NO: 2 and the antigen binding fragment is a fragment of SEQ ID NO: 2 and the antigen binding fragment is a fragment of SEQ ID NO: 2 and the antigen binding fragment is an antigen-binding fragment of SEQ ID NO: 2 and the antigen binding fragment is a fragment of SEQ ID NO: 2 and the antigen binding fragment is a fragment of SEQ ID NO: 2; and ]
[ 1783 ] similarity = 0.01572922 [ providing an antigen-binding fragment of SEQ ID NO: 2 and an antigen-binding fragment of SEQ ID NO: 2, wherein the antigen binding fragment is a fragment of SEQ ID NO: 2 and the antigen binding fragment is a fragment of SEQ ID NO: 2 and the antigen binding fragment is a fragment of SEQ ID NO: 2 and the antigen binding fragment is a fragment of SEQ ID NO: 2 and the antigen binding fragment is a fragment of SEQ ID NO: 2 and the antigen binding fragment is an antigen-binding fragment of SEQ ID NO: 2 and the antigen binding fragment is a fragment of SEQ ID NO: 2 and the antigen binding fragment is a fragment of SEQ ID NO: 2; and ][ administering the first device and the second device to the patient. ]
[ 1784 ] similarity = 0.10471697 [ A method for the treatment of a subject having a condition that is associated with an increased risk of developing an autoimmune disease comprising administering to the subject a therapeutically effective amount of a polypeptide having a sequence of SEQ ID NO: ][ 4 or SEQ ID NO: ]
[ 1785 ] similarity = 0.29797566 [ 4 or SEQ ID NO: ][ 5, and ]
[ 1786 ] similarity = -0.021490337 [ 5, and ][ wherein the polypeptide is selected from the group consisting of SEQ ID NO: ]
[ 1787 ] similarity = 0.24759215 [ wherein the polypeptide is selected from the group consisting of SEQ ID NO: ][ 1, SEQ ID NO: ]
[ 1788 ] similarity = 0.7964808 [ 1, SEQ ID NO: ][ 2, SEQ ID NO: ]
[ 1789 ] similarity = 0.7720622 [ 2, SEQ ID NO: ][ 3, SEQ ID NO: ]
[ 1790 ] similarity = 0.25497612 [ 3, SEQ ID NO: ][ 4, and ]
[ 1791 ] similarity = 0.22023514 [ 4, and ][ SEQ ID NO: ]
[ 1792 ] similarity = 0.19577388 [ SEQ ID NO: ][ 5. ]
[ 1793 ] similarity = 0.47659102 [ A device for treating an organ of the body, the device comprisinga body portion having a first end and a second end and a proximal end and a distal end, the body portion comprising: ][ a proximal body portion; ]
[ 1794 ] similarity = 0.9264965 [ a proximal body portion; ][ a distal body portion; ]
[ 1795 ] similarity = 0.5995567 [ a distal body portion; ][ a first end portion extending proximally from the body portion; ]
[ 1796 ] similarity = 0.6800766 [ a first end portion extending proximally from the body portion; ][ a distal end portion extending distal of the first end portion; and ]
[ 1797 ] similarity = 0.75277156 [ a distal end portion extending distal of the first end portion; and ][ a distal body portion having a distal end portion and an inner surface, the inner surface having a distal end portion that is proximal of the first end portion and a proximal end portion that is proximal of the distal end portion, wherein the inner surface is configured to be in fluid communication with the first end portion, and ]
[ 1798 ] similarity = 0.59900147 [ a distal body portion having a distal end portion and an inner surface, the inner surface having a distal end portion that is proximal of the first end portion and a proximal end portion that is proximal of the distal end portion, wherein the inner surface is configured to be in fluid communication with the first end portion, and ][ the inner surface is configured to be in fluid communication with the distal end portion; ]
[ 1799 ] similarity = 0.7936282 [ the inner surface is configured to be in fluid communication with the distal end portion; ][ wherein the proximal body portion has an inner surface that is configured to be in fluid communication with the distal body portion and the inner surface is configured to be in fluid communication with the distal end portion. ]
[ 1800 ] similarity = 0.5482892 [ A system for treating a disease or condition, comprisinga) a plurality of electrodes for applying a treatment agent to a patient's skin, wherein the plurality of electrodes comprises at least two electrodes each having a plurality of electrodes, wherein each of the plurality of electrodes comprises a plurality of electrodes; and ][ b) at least one electrode for applying the treatment agent to the patient's skin, the at least one electrode having a plurality of conductive fibers, wherein the at least one electrode comprises a conductive fiber having a conductive material, wherein the at least one conductive fiber is configured to contact the patient's skin, wherein the conductive fiber has a plurality of conductive fibers, each of the plurality of conductive fibers having a conductive material, wherein the plurality of conductive fibers have a plurality of conductive fibers, each of the plurality of conductive fibers having a conductive material, wherein the plurality of conductive fibers have a length, and ]
[ 1801 ] similarity = 0.66012 [ b) at least one electrode for applying the treatment agent to the patient's skin, the at least one electrode having a plurality of conductive fibers, wherein the at least one electrode comprises a conductive fiber having a conductive material, wherein the at least one conductive fiber is configured to contact the patient's skin, wherein the conductive fiber has a plurality of conductive fibers, each of the plurality of conductive fibers having a conductive material, wherein the plurality of conductive fibers have a plurality of conductive fibers, each of the plurality of conductive fibers having a conductive material, wherein the plurality of conductive fibers have a length, and ][ wherein the conductive fiber has a conductive material, wherein the length of the conductive fibers is shorter than a length of the conductive material of the conductive fibers, and ]
[ 1802 ] similarity = 0.9314165 [ wherein the conductive fiber has a conductive material, wherein the length of the conductive fibers is shorter than a length of the conductive material of the conductive fibers, and ][ wherein the length of the conductive fibers is shorter than a length of the conductive material of the conductive fibers. ]
[ 1803 ] similarity = 0.4077894 [ A method of treating a disease comprising administering to a subject in need thereof an effective amount of an effective amount of a pharmaceutically acceptable carrier, wherein said effective amount of said carrier is selected from the group consisting of: ][ a) an oral composition comprising a pharmaceutically acceptable carrier; ]
[ 1804 ] similarity = 0.4631843 [ a) an oral composition comprising a pharmaceutically acceptable carrier; ][ b) a pharmaceutically acceptable carrier in a liquid form; ]
[ 1805 ] similarity = 0.6390666 [ b) a pharmaceutically acceptable carrier in a liquid form; ][ c) a liquid composition comprising a pharmaceutically acceptable carrier; ]
[ 1806 ] similarity = 0.41223246 [ c) a liquid composition comprising a pharmaceutically acceptable carrier; ][ d) a liquid composition in which said carrier is not present and wherein said carrier is present in an amount sufficient to treat said disease; ]
[ 1807 ] similarity = 0.35464114 [ d) a liquid composition in which said carrier is not present and wherein said carrier is present in an amount sufficient to treat said disease; ][ wherein said carrier is selected from the group consisting of: ]
[ 1808 ] similarity = 0.19117346 [ wherein said carrier is selected from the group consisting of: ][ a) a pharmaceutically acceptable carrier in a liquid form; ]
[ 1809 ] similarity = 0.62120295 [ a) a pharmaceutically acceptable carrier in a liquid form; ][ b) a liquid composition comprising a pharmaceutically acceptable carrier; ]
[ 1810 ] similarity = 0.5897026 [ b) a liquid composition comprising a pharmaceutically acceptable carrier; ][ c) a liquid composition in which said carrier is present; ]
[ 1811 ] similarity = 0.23584259 [ c) a liquid composition in which said carrier is present; ][ d) a pharmaceutically acceptable carrier; ]
[ 1812 ] similarity = 0.6137568 [ d) a pharmaceutically acceptable carrier; ][ e) a pharmaceutically acceptable carrier in a liquid form; and ]
[ 1813 ] similarity = 0.7289023 [ e) a pharmaceutically acceptable carrier in a liquid form; and ][ f) a pharmaceutically acceptable carrier in a solid form. ]
[ 1814 ] similarity = 0.15299828 [ A method for the treatment of a patient, comprising the steps of: ][ providing a plurality of patient-specific antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein; ]
[ 1815 ] similarity = 0.6433466 [ providing a plurality of patient-specific antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein; ][ contacting the patient with the plurality of patient-specific antibodies, wherein the plurality of antibodies are selected from the group consisting of a plurality of antibodies that are selected from the group consisting of: a) a plurality of antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein; and ]
[ 1816 ] similarity = 0.4704342 [ contacting the patient with the plurality of patient-specific antibodies, wherein the plurality of antibodies are selected from the group consisting of a plurality of antibodies that are selected from the group consisting of: a) a plurality of antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein; and ][ b) antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein that is not the same as the human papillomavirus (HPV) subtype 1 protein; and ]
[ 1817 ] similarity = 0.2538637 [ b) antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein that is not the same as the human papillomavirus (HPV) subtype 1 protein; and ][ administering the plurality of patient-specific antibodies to the patient; ]
[ 1818 ] similarity = 0.44702566 [ administering the plurality of patient-specific antibodies to the patient; ][ wherein the plurality of antibodies are selected from the group consisting of: a) a plurality of antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein; and ]
[ 1819 ] similarity = 0.61964273 [ wherein the plurality of antibodies are selected from the group consisting of: a) a plurality of antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein; and ][ b) antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein that is not the same as the human papillomavirus (HPV) subtype 1 protein; and ]
[ 1820 ] similarity = 0.609331 [ b) antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein that is not the same as the human papillomavirus (HPV) subtype 1 protein; and ][ wherein the plurality of antibodies are selected from the group consisting of a plurality of antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein; and ]
[ 1821 ] similarity = 0.44773054 [ wherein the plurality of antibodies are selected from the group consisting of a plurality of antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein; and ][ administering the plurality of patient-specific antibodies to the patient, ]
[ 1822 ] similarity = 0.44773057 [ administering the plurality of patient-specific antibodies to the patient, ][ wherein the plurality of antibodies are selected from the group consisting of a plurality of antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein; and ]
[ 1823 ] similarity = 0.8892753 [ wherein the plurality of antibodies are selected from the group consisting of a plurality of antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein; and ][ wherein the plurality of antibodies are selected from the group consisting of a plurality of antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein that is not the same as the human papillomavirus (HPV) subtype 1 protein. ]
[ 1824 ] similarity = 0.45157808 [ A method for treating an inflammatory disease in a subject, comprising: ][ administering to the subject a composition comprising: ]
[ 1825 ] similarity = 0.10804674 [ administering to the subject a composition comprising: ][ (a) a polymeric matrix comprising a polymeric polymer and a polymeric polyamide, wherein the polymeric polymer comprises a polymeric polymer having a polymeric polymerizable portion and a nonpolymerizable portion; ]
[ 1826 ] similarity = -0.02940098 [ (a) a polymeric matrix comprising a polymeric polymer and a polymeric polyamide, wherein the polymeric polymer comprises a polymeric polymer having a polymeric polymerizable portion and a nonpolymerizable portion; ][ (b) a pharmaceutically acceptable carrier; and ]
[ 1827 ] similarity = 0.15004686 [ (b) a pharmaceutically acceptable carrier; and ][ (c) a pharmaceutically acceptable agent, wherein the composition is effective to treat the inflammatory disease, wherein the polymeric matrix comprises a polymeric polyamide and the polymeric polymer comprises a polymeric polyamide. ]
[ 1828 ] similarity = 0.21308683 [ An implantable device, comprising: ][ an elongate body having a first end, a second end, and ]
[ 1829 ] similarity = 0.28861144 [ an elongate body having a first end, a second end, and ][ a proximal end; the elongate body having a first longitudinal axis and a second longitudinal axis; the first longitudinal axis and the second longitudinal axis intersect at an end of the elongate body; the first longitudinal axis is substantially parallel with the second longitudinal axis; and ]
[ 1830 ] similarity = 0.40285012 [ a proximal end; the elongate body having a first longitudinal axis and a second longitudinal axis; the first longitudinal axis and the second longitudinal axis intersect at an end of the elongate body; the first longitudinal axis is substantially parallel with the second longitudinal axis; and ][ a first electrode positioned at a proximal end of the elongate body, the first electrode having a first end and a second end; the second end of the second electrode is positioned at the proximal end of the elongate body; the second end of the first electrode and the second end of the second electrode are spaced from each other by a first distance, and ]
[ 1831 ] similarity = 0.62946355 [ a first electrode positioned at a proximal end of the elongate body, the first electrode having a first end and a second end; the second end of the second electrode is positioned at the proximal end of the elongate body; the second end of the first electrode and the second end of the second electrode are spaced from each other by a first distance, and ][ the first and second ends of the first and second electrodes are spaced from each other by a second distance, the first and second distances being substantially equal. ]
[ 1832 ] similarity = 0.440972 [ A method for the treatment of a patient with a disease or condition, comprising the steps of: ][ (a) obtaining a first set of data from a patient, wherein the first set of data comprises at least one set of medical information; ]
[ 1833 ] similarity = 0.5630585 [ (a) obtaining a first set of data from a patient, wherein the first set of data comprises at least one set of medical information; ][ (b) identifying a second set of data from the first set of data; ]
[ 1834 ] similarity = 0.56721187 [ (b) identifying a second set of data from the first set of data; ][ (c) obtaining a second set of data from at least one other source; ]
[ 1835 ] similarity = 0.43411627 [ (c) obtaining a second set of data from at least one other source; ][ (d) comparing at least one set of medical information from the second set of data to a predetermined medical information; wherein the second set of data comprises at least one set of information that is not from a first set of medical information and that is not from a second set of medical information; ]
[ 1836 ] similarity = 0.5418154 [ (d) comparing at least one set of medical information from the second set of data to a predetermined medical information; wherein the second set of data comprises at least one set of information that is not from a first set of medical information and that is not from a second set of medical information; ][ (e) determining whether a difference exists between the predetermined medical information and the second set of medical information based on the comparison; and ]
[ 1837 ] similarity = 0.32156694 [ (e) determining whether a difference exists between the predetermined medical information and the second set of medical information based on the comparison; and ][ (f) if the difference exists, treating the patient with a therapy. ]
[ 1838 ] similarity = 0.22459483 [ A device for the placement in a patient's body, comprising: ][ a first portion having an outer circumference and an inner circumference; ]
[ 1839 ] similarity = 0.91181266 [ a first portion having an outer circumference and an inner circumference; ][ a second portion having an inner circumference and an outer circumference; ]
[ 1840 ] similarity = 0.3175064 [ a second portion having an inner circumference and an outer circumference; ][ at least a first portion and at least a second portion having a plurality of first and second ends, wherein the first portion is adapted to be placed in the patient's body and the second portion is adapted to be inserted in the patient's body; ]
[ 1841 ] similarity = 0.60389507 [ at least a first portion and at least a second portion having a plurality of first and second ends, wherein the first portion is adapted to be placed in the patient's body and the second portion is adapted to be inserted in the patient's body; ][ a first portion having a first end and a second end, wherein the first portion is disposed in a first region of the second portion and the second portion is disposed in a second region of the second portion, wherein the first end of the first portion and the first end of the second portion define a first region of a first portion and a second region of a second portion, wherein the first region is a first region of the second portion and the second region is a second region of the first portion and the second portion; ]
[ 1842 ] similarity = 0.8760088 [ a first portion having a first end and a second end, wherein the first portion is disposed in a first region of the second portion and the second portion is disposed in a second region of the second portion, wherein the first end of the first portion and the first end of the second portion define a first region of a first portion and a second region of a second portion, wherein the first region is a first region of the second portion and the second region is a second region of the first portion and the second portion; ][ at least a first portion having a first end and a second end, wherein the first portion and the first end of the first portion define a first region of the first portion and a second region of a second portion, and ]
[ 1843 ] similarity = 0.73614633 [ at least a first portion having a first end and a second end, wherein the first portion and the first end of the first portion define a first region of the first portion and a second region of a second portion, and ][ wherein the first region of the first portion and the second region of the second portion are different than the first region of the second portion; ]
[ 1844 ] similarity = 0.8137179 [ wherein the first region of the first portion and the second region of the second portion are different than the first region of the second portion; ][ a first portion having a first end and a second end, wherein the first portion and the first end of the first portion define a first region of a first portion and a second region of a second portion, wherein the first region is a first region of the second portion and the second region is a second region of the first portion and the second portion; and ]
[ 1845 ] similarity = 0.82865304 [ a first portion having a first end and a second end, wherein the first portion and the first end of the first portion define a first region of a first portion and a second region of a second portion, wherein the first region is a first region of the second portion and the second region is a second region of the first portion and the second portion; and ][ a second portion having a first end and a second end, wherein the second portion and the second end of the first portion define an outer region of the second portion and the second region of the second portion. ]
[ 1846 ] similarity = 0.09367257 [ A method of treating a patient, comprising: ][ providing a first implantable medical device (IMD) having a first implantable device interface (IID) and a second interface (IIID), the first IMD having a first IMD interface and the second IMD having a second IMD interface; ]
[ 1847 ] similarity = 0.8068546 [ providing a first implantable medical device (IMD) having a first implantable device interface (IID) and a second interface (IIID), the first IMD having a first IMD interface and the second IMD having a second IMD interface; ][ receiving, by a processor, a first command from a user, the first IMD having a first IMD interface and the second IMD having a second IMD interface; and ]
[ 1848 ] similarity = 0.6875504 [ receiving, by a processor, a first command from a user, the first IMD having a first IMD interface and the second IMD having a second IMD interface; and ][ receiving a second command from a user, the second IMD having a second IMD interface, ]
[ 1849 ] similarity = 0.37190676 [ receiving a second command from a user, the second IMD having a second IMD interface, ][ wherein the first IMD interface comprises a first communication port and the second IMD interface comprises a first communication port and the first IMD is configured for use with a first implantable medical device (IMD) and a second IMD. ]
[ 1850 ] similarity = 0.6733206 [ A method for treating a subject with a condition in which the subject has a disorder of the immune system or a condition of the immune system that results from a mutation in a gene of a human immunoglobulin (HIV) gene, wherein said HIV gene comprises a mutation in a gene that is expressed by a portion of the human immunoglobulin (HIV) gene, comprising: ][ (a) introducing an antibody comprising a nucleic acid sequence encoding a human immunodeficiency virus (HIV) polypeptide into a subject with said disorder of immune system or said condition of immune system; and ]
[ 1851 ] similarity = 0.58495975 [ (a) introducing an antibody comprising a nucleic acid sequence encoding a human immunodeficiency virus (HIV) polypeptide into a subject with said disorder of immune system or said condition of immune system; and ][ (b) administering an effective amount of said antibody to said subject, wherein said subject has said disorder of immune system or said condition of immune system. ]
[ 1852 ] similarity = -0.031548824 [ A method for treating a disease or condition in a subject, the disease or condition including a cancer, the method comprising administering to the subject a compound of formula I, wherein: ][ R1 and R2 each independently hydrogen; and ]
[ 1853 ] similarity = 0.41362944 [ R1 and R2 each independently hydrogen; and ][ R4 and R5 are independently hydrogen or alkyl, wherein: ]
[ 1854 ] similarity = 0.6482008 [ R4 and R5 are independently hydrogen or alkyl, wherein: ][ R3 is independently hydrogen or alkyl, wherein: ]
[ 1855 ] similarity = 0.20089915 [ R3 is independently hydrogen or alkyl, wherein: ][ R4 is optionally substituted with one or more alkyl groups; and ]
[ 1856 ] similarity = 0.029691234 [ R4 is optionally substituted with one or more alkyl groups; and ][ the compound is a pharmaceutically acceptable salt or a pharmaceutically acceptable carrier. ]
[ 1857 ] similarity = 0.34553373 [ A device comprising: ][ a first housing; ]
[ 1858 ] similarity = 0.5071198 [ a first housing; ][ a first drive member; ]
[ 1859 ] similarity = 0.7054945 [ a first drive member; ][ a first drive shaft; ]
[ 1860 ] similarity = 0.645456 [ a first drive shaft; ][ a first drive gear; and ]
[ 1861 ] similarity = 0.5075642 [ a first drive gear; and ][ a first drive shaft shaft; ]
[ 1862 ] similarity = 0.021708863 [ a first drive shaft shaft; ][ wherein: ]
[ 1863 ] similarity = -0.044848382 [ wherein: ][ the first drive member is a first drive member having first and second drive members, wherein the first drive member has a first end and a second end; and ]
[ 1864 ] similarity = 0.78955305 [ the first drive member is a first drive member having first and second drive members, wherein the first drive member has a first end and a second end; and ][ the first drive member has a first drive member drive gear having first and second drive gears, wherein the first drive member is a first drive member drive gear having a first and second drive gears, and ]
[ 1865 ] similarity = 0.6362768 [ the first drive member has a first drive member drive gear having first and second drive gears, wherein the first drive member is a first drive member drive gear having a first and second drive gears, and ][ wherein the first drive member has a first and second drive shaft shaft shaft, and ]
[ 1866 ] similarity = 0.6792321 [ wherein the first drive member has a first and second drive shaft shaft shaft, and ][ wherein the first drive member is configured to drive a first drive member, and ]
[ 1867 ] similarity = 0.61982477 [ wherein the first drive member is configured to drive a first drive member, and ][ the first drive member has a first drive shaft drive gear having a first and second drive shaft shaft shaft, and ]
[ 1868 ] similarity = 0.7459519 [ the first drive member has a first drive shaft drive gear having a first and second drive shaft shaft shaft, and ][ wherein the first and second drive shaft shafts have different drive shafts. ]
[ 1869 ] similarity = 0.11671899 [ A method for treating a disease or condition in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound selected from the group consisting of a compound of formula I: ][ or a pharmaceutically acceptable salt thereof; ]
[ 1870 ] similarity = 0.014640683 [ or a pharmaceutically acceptable salt thereof; ][ wherein: ]
[ 1871 ] similarity = 0.02396462 [ wherein: ][ R1 is hydrogen or a salt thereof; ]
[ 1872 ] similarity = 0.84715855 [ R1 is hydrogen or a salt thereof; ][ R2 is hydrogen or a salt thereof; ]
[ 1873 ] similarity = 0.8347061 [ R2 is hydrogen or a salt thereof; ][ R3 is hydrogen or a salt thereof; ]
[ 1874 ] similarity = 0.80841726 [ R3 is hydrogen or a salt thereof; ][ R4 is hydrogen or a salt thereof; ]
[ 1875 ] similarity = 0.8333361 [ R4 is hydrogen or a salt thereof; ][ R5 is hydrogen or a salt thereof; ]
[ 1876 ] similarity = 0.8143576 [ R5 is hydrogen or a salt thereof; ][ R6 is hydrogen or a salt thereof; orR7 is hydrogen or a salt thereof; ]
[ 1877 ] similarity = 0.811061 [ R6 is hydrogen or a salt thereof; orR7 is hydrogen or a salt thereof; ][ R8 is hydrogen or a salt thereof; ]
[ 1878 ] similarity = 0.8428572 [ R8 is hydrogen or a salt thereof; ][ R9 is hydrogen, or a salt thereof; ]
[ 1879 ] similarity = 0.8983536 [ R9 is hydrogen, or a salt thereof; ][ R10 is hydrogen or a salt thereof; ]
[ 1880 ] similarity = 0.8619673 [ R10 is hydrogen or a salt thereof; ][ R11 is hydrogen, or a salt thereof; orwherein R1 is hydrogen or a salt thereof. ]
[ 1881 ] similarity = 0.01721223 [ A method of treating a patient in need of such treatment, comprising administering to said patient an effective amount of an effective amount of an effective amount of a compound having the formula: ][ wherein: ]
[ 1882 ] similarity = -0.018846676 [ wherein: ][ R1 and R2 are hydrogen; ]
[ 1883 ] similarity = 0.7910228 [ R1 and R2 are hydrogen; ][ R1 and R2 each independently is hydrogen; ]
[ 1884 ] similarity = 0.4695791 [ R1 and R2 each independently is hydrogen; ][ R1 and R2 are independently selected from the group consisting of H, C1-C4alkyl, C1-C4alkoxy, C1-C4alkenyl, C1-C4alkoxy-C1-C4alkoxy, and ]
[ 1885 ] similarity = -0.0071505755 [ R1 and R2 are independently selected from the group consisting of H, C1-C4alkyl, C1-C4alkoxy, C1-C4alkenyl, C1-C4alkoxy-C1-C4alkoxy, and ][ C1-C4alkenyl-C1-C4alkoxy; ]
[ 1886 ] similarity = -0.055925168 [ C1-C4alkenyl-C1-C4alkoxy; ][ R3 and R4 each independently is hydrogen; ]
[ 1887 ] similarity = 1.0 [ R3 and R4 each independently is hydrogen; ][ R3 and R4 each independently is hydrogen; ]
[ 1888 ] similarity = 0.5994636 [ R3 and R4 each independently is hydrogen; ][ R4 is hydrogen; and ]
[ 1889 ] similarity = 0.45354638 [ R4 is hydrogen; and ][ R5 is hydrogen or a C1-C4alkyl group; ]
[ 1890 ] similarity = 1.0000001 [ R5 is hydrogen or a C1-C4alkyl group; ][ R5 is hydrogen or a C1-C4alkyl group. ]
[ 1891 ] similarity = 0.1766494 [ A device for providing a therapeutic treatment to a patient, comprising: ][ a) a housing; ]
[ 1892 ] similarity = 0.14493778 [ a) a housing; ][ b) at least one electrode positioned within the housing and having a proximal end, a distal end and a longitudinal axis; and ]
[ 1893 ] similarity = 0.82243675 [ b) at least one electrode positioned within the housing and having a proximal end, a distal end and a longitudinal axis; and ][ c) a plurality of electrodes positioned in the housing and having a proximal end, a distal end and an axis of rotation; and ]
[ 1894 ] similarity = 0.42855775 [ c) a plurality of electrodes positioned in the housing and having a proximal end, a distal end and an axis of rotation; and ][ wherein the device includes at least one electrode for each of a plurality of electrodes, the at least one electrode for each of a plurality of electrodes having a proximal end and a distal end, the at least one electrode for each of the plurality of electrodes having a longitudinal axis, the at least one electrode for the plurality of electrodes having a longitudinal axis being substantially parallel with the longitudinal axis of the device and the device being adapted to be implanted within a body. ]
[ 1895 ] similarity = 0.7916411 [ A method for producing an implantable medical device comprising a first electrode having a first electrode surface and a plurality of electrodes, the first electrode surface having a first electrode surface area, the first electrode surface area being larger than the plurality of electrodes, the method comprising: ][ providing a plurality of electrodes having a first electrode surface area and a second electrode surface area; ]
[ 1896 ] similarity = 0.95740515 [ providing a plurality of electrodes having a first electrode surface area and a second electrode surface area; ][ providing a plurality of first and second electrodes having a first electrode surface area and a second electrode surface area; ]
[ 1897 ] similarity = 1.0 [ providing a plurality of first and second electrodes having a first electrode surface area and a second electrode surface area; ][ providing a plurality of first and second electrodes having a first electrode surface area and a second electrode surface area; ]
[ 1898 ] similarity = 1.0000001 [ providing a plurality of first and second electrodes having a first electrode surface area and a second electrode surface area; ][ providing a plurality of first and second electrodes having a first electrode surface area and a second electrode surface area; ]
[ 1899 ] similarity = 0.95918465 [ providing a plurality of first and second electrodes having a first electrode surface area and a second electrode surface area; ][ providing a first plurality of first electrodes having a first electrode surface area and a second electrode surface area; ]
[ 1900 ] similarity = 1.0000001 [ providing a first plurality of first electrodes having a first electrode surface area and a second electrode surface area; ][ providing a first plurality of first electrodes having a first electrode surface area and a second electrode surface area; ]
[ 1901 ] similarity = 0.9777536 [ providing a first plurality of first electrodes having a first electrode surface area and a second electrode surface area; ][ providing a first plurality of second electrodes having a first electrode surface area and a second electrode surface area; ]
[ 1902 ] similarity = 0.9703628 [ providing a first plurality of second electrodes having a first electrode surface area and a second electrode surface area; ][ providing a first plurality of first electrodes having a first electrode surface area and a second electrode surface area; and ]
[ 1903 ] similarity = 0.9703628 [ providing a first plurality of first electrodes having a first electrode surface area and a second electrode surface area; and ][ providing a first plurality of second electrodes having a first electrode surface area and a second electrode surface area. ]
[ 1904 ] similarity = 0.055465434 [ A method for treating a patient with a condition associated with an increase in the level of a protein in a cell, the method comprising administering to the patient a therapeutically effective amount of a protein in a cell that comprises a protein having the amino acid sequence of SEQ ID NO: ][ 1 or SEQ ID NO: ]
[ 1905 ] similarity = 0.20480038 [ 1 or SEQ ID NO: ][ 2. ]
[ 1906 ] similarity = 0.34954828 [ A method for the treatment of a patient having a heart failure comprising: ][ providing an implantable medical device having an implantable cardiac device and an electrical circuit, the electrical circuit including a first electrical conductor for supplying power to the implantable cardiac device; ]
[ 1907 ] similarity = 0.23297237 [ providing an implantable medical device having an implantable cardiac device and an electrical circuit, the electrical circuit including a first electrical conductor for supplying power to the implantable cardiac device; ][ providing a first electrode; ]
[ 1908 ] similarity = 0.92088276 [ providing a first electrode; ][ providing a first electrode electrode; ]
[ 1909 ] similarity = 0.72841966 [ providing a first electrode electrode; ][ providing a second electrode; ]
[ 1910 ] similarity = 0.9999999 [ providing a second electrode; ][ providing a second electrode; ]
[ 1911 ] similarity = 0.47282428 [ providing a second electrode; ][ providing an electrically insulative membrane between the first and second electrodes, the electrically insulative membrane comprising a first electrode layer and a second electrode layer; ]
[ 1912 ] similarity = 0.75375164 [ providing an electrically insulative membrane between the first and second electrodes, the electrically insulative membrane comprising a first electrode layer and a second electrode layer; ][ providing an insulative membrane between the first and second electrodes; ]
[ 1913 ] similarity = 0.5436568 [ providing an insulative membrane between the first and second electrodes; ][ providing a first electrode layer; ]
[ 1914 ] similarity = 0.7880956 [ providing a first electrode layer; ][ providing a second electrode layer; ]
[ 1915 ] similarity = 0.56398547 [ providing a second electrode layer; ][ providing a first insulator layer; ]
[ 1916 ] similarity = 0.7760234 [ providing a first insulator layer; ][ providing a second insulator layer; ]
[ 1917 ] similarity = 0.5204984 [ providing a second insulator layer; ][ providing an insulative membrane between the first and second insulators; and ]
[ 1918 ] similarity = 0.63537186 [ providing an insulative membrane between the first and second insulators; and ][ applying an electrical current through the insulative membrane, the insulative membrane being electrically insulative to the first and second electrodes. ]
[ 1919 ] similarity = 0.5158913 [ A method for determining a level of a protein in a sample, the protein having at least one protein domain comprising a first amino acid sequence and a first domain comprising a second amino acid sequence, wherein said first amino acid sequence is different from said first domain, said method comprising: ][ (1) determining a level of the first amino acid sequence in the sample; ]
[ 1920 ] similarity = 0.60851264 [ (1) determining a level of the first amino acid sequence in the sample; ][ (2) determining a level of the first domain in the sample; ]
[ 1921 ] similarity = 0.5339228 [ (2) determining a level of the first domain in the sample; ][ (3) determining a level of the second amino acid sequence in the sample; ]
[ 1922 ] similarity = 0.7967618 [ (3) determining a level of the second amino acid sequence in the sample; ][ (4) determining a level of the first amino acid sequence in the sample; ]
[ 1923 ] similarity = 0.44844475 [ (4) determining a level of the first amino acid sequence in the sample; ][ (5) determining a level of the second domain in the sample; and ]
[ 1924 ] similarity = 0.65290356 [ (5) determining a level of the second domain in the sample; and ][ (6) determining a level of the first protein domain in the sample. ]
[ 1925 ] similarity = 0.24693866 [ A method for producing a therapeutic composition comprising: ][ providing a pharmaceutical composition comprising a first pharmaceutical agent and a second pharmaceutical agent, the first pharmaceutical agent having an affinity for the first pharmaceutical agent, the second pharmaceutical agent having an affinity for the second pharmaceutical agent; and ]
[ 1926 ] similarity = 0.093125075 [ providing a pharmaceutical composition comprising a first pharmaceutical agent and a second pharmaceutical agent, the first pharmaceutical agent having an affinity for the first pharmaceutical agent, the second pharmaceutical agent having an affinity for the second pharmaceutical agent; and ][ providing a pharmaceutically acceptable carrier, ]
[ 1927 ] similarity = 0.6165112 [ providing a pharmaceutically acceptable carrier, ][ wherein the carrier is a composition of a pharmaceutically acceptable carrier and a pharmaceutically acceptable carrier-containing material, ]
[ 1928 ] similarity = 0.18328963 [ wherein the carrier is a composition of a pharmaceutically acceptable carrier and a pharmaceutically acceptable carrier-containing material, ][ wherein the first pharmaceutical agent and the second pharmaceutical agent are selected from the group consisting of: ]
[ 1929 ] similarity = 0.5932724 [ wherein the first pharmaceutical agent and the second pharmaceutical agent are selected from the group consisting of: ][ (i) an anionic pharmaceutical agent having an affinity for the first pharmaceutical agent; and ]
[ 1930 ] similarity = 0.54187155 [ (i) an anionic pharmaceutical agent having an affinity for the first pharmaceutical agent; and ][ (ii) a pharmaceutically acceptable salt of the anionic pharmaceutical agent, ]
[ 1931 ] similarity = 0.30448964 [ (ii) a pharmaceutically acceptable salt of the anionic pharmaceutical agent, ][ wherein the composition comprises a pharmaceutically acceptable carrier and a pharmaceutically acceptable carrier-containing material. ]
[ 1932 ] similarity = 0.2293904 [ A method of treating a patient with an inflammatory disorder comprising administering to said patient an effective amount of a composition comprising: ][ (a) a pharmaceutically acceptable excipient; and ]
[ 1933 ] similarity = 0.58909273 [ (a) a pharmaceutically acceptable excipient; and ][ (b) a pharmaceutically acceptable carrier; ]
[ 1934 ] similarity = 0.3533623 [ (b) a pharmaceutically acceptable carrier; ][ wherein said excipient is a pharmaceutically acceptable excipient, and ]
[ 1935 ] similarity = 0.62387997 [ wherein said excipient is a pharmaceutically acceptable excipient, and ][ wherein the composition comprises a pharmaceutically acceptable excipient. ]
[ 1936 ] similarity = 0.24903554 [ A method for treating a subject having a condition in which a patient's skin is exposed to ultraviolet radiation, comprising: ][ providing a skin-care product comprising a polymeric composition comprising a polypeptide having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: ]
[ 1937 ] similarity = 0.8529204 [ providing a skin-care product comprising a polymeric composition comprising a polypeptide having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: ][ 3, wherein the composition is a skin-care composition comprising a polymeric composition having a polypeptide having a amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: ]
[ 1938 ] similarity = -0.015277378 [ 3, wherein the composition is a skin-care composition comprising a polymeric composition having a polypeptide having a amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: ][ 3; ]
[ 1939 ] similarity = 0.05198027 [ 3; ][ exposing a patient to a UV radiation that is at least about 10 times higher than the UV radiation received from the skin-care product; and ]
[ 1940 ] similarity = 0.38092586 [ exposing a patient to a UV radiation that is at least about 10 times higher than the UV radiation received from the skin-care product; and ][ treating the skin-care product with the polymeric composition to treat the condition. ]
[ 1941 ] similarity = 0.002341479 [ An implant for use in an implantable cardiac device, said implant comprising: ][ a first end, a second end and a first end-side surface, said first end being disposed in a longitudinal direction and said second end being disposed in a longitudinal direction; ]
[ 1942 ] similarity = 0.51998395 [ a first end, a second end and a first end-side surface, said first end being disposed in a longitudinal direction and said second end being disposed in a longitudinal direction; ][ a first electrode disposed on a first side of the first end-side surface of said implant and having an electrode surface, said electrode surface being substantially perpendicular to the longitudinal direction and substantially perpendicular to the second side of the first end-side surface of said implant; ]
[ 1943 ] similarity = 0.8851032 [ a first electrode disposed on a first side of the first end-side surface of said implant and having an electrode surface, said electrode surface being substantially perpendicular to the longitudinal direction and substantially perpendicular to the second side of the first end-side surface of said implant; ][ a second electrode disposed on a second side of the second end-side surface of said implant and having an electrode surface, said electrode surface being substantially perpendicular to the longitudinal direction and substantially perpendicular to the first side of the second end-side surface of said implant, and ]
[ 1944 ] similarity = 0.66061026 [ a second electrode disposed on a second side of the second end-side surface of said implant and having an electrode surface, said electrode surface being substantially perpendicular to the longitudinal direction and substantially perpendicular to the first side of the second end-side surface of said implant, and ][ having a plurality of first and second electrodes disposed on said first and second side of said first end-side surface of said implant; ]
[ 1945 ] similarity = 0.5815164 [ having a plurality of first and second electrodes disposed on said first and second side of said first end-side surface of said implant; ][ an outer surface of said second end-side surface of said implant being substantially parallel to a first longitudinal axis; and ]
[ 1946 ] similarity = 0.5710428 [ an outer surface of said second end-side surface of said implant being substantially parallel to a first longitudinal axis; and ][ a plurality of first and second electrodes disposed at a location between the first and second electrodes, said plurality of first and second electrodes being disposed on the outer surface of said second end-side surface of said implant, and ]
[ 1947 ] similarity = 0.652947 [ a plurality of first and second electrodes disposed at a location between the first and second electrodes, said plurality of first and second electrodes being disposed on the outer surface of said second end-side surface of said implant, and ][ said first and second electrodes each having a first end and a second end, ]
[ 1948 ] similarity = 0.457047 [ said first and second electrodes each having a first end and a second end, ][ wherein said outer surface of said second end-side surface of said implant has a first surface and a second surface, said first and second surfaces being substantially perpendicular to the first and second longitudinal directions, and ]
[ 1949 ] similarity = 0.72135246 [ wherein said outer surface of said second end-side surface of said implant has a first surface and a second surface, said first and second surfaces being substantially perpendicular to the first and second longitudinal directions, and ][ wherein the plurality of first and second electrodes are disposed on the first and second sides of said first and second surfaces. ]
[ 1950 ] similarity = 0.33690903 [ A method for the detection of a substance in a sample of blood, comprising the steps of (1) providing a first sample having a first concentration of the substance, and ][ (2) providing a second sample, wherein the first and second samples are each provided at different times and at different locations, ]
[ 1951 ] similarity = 0.39474338 [ (2) providing a second sample, wherein the first and second samples are each provided at different times and at different locations, ][ (3a) obtaining a first set of data from the first sample; and ]
[ 1952 ] similarity = 0.47358856 [ (3a) obtaining a first set of data from the first sample; and ][ (3b) obtaining a second set of data from the second sample, wherein the first and second sets of data are each obtained at different times and at different locations. ]
[ 1953 ] similarity = 0.38125694 [ A method for treating an individual having a disorder characterized by at least one of: ][ a) an increased susceptibility to a disease or condition; ]
[ 1954 ] similarity = 0.6668807 [ a) an increased susceptibility to a disease or condition; ][ b) an increased risk of developing a disease or condition; and ]
[ 1955 ] similarity = 0.078640334 [ b) an increased risk of developing a disease or condition; and ][ c) a decreased ability to perform activities of daily living, the method comprising administering to the individual a therapeutically effective amount of a compound selected from the group consisting of: ]
[ 1956 ] similarity = 0.43852624 [ c) a decreased ability to perform activities of daily living, the method comprising administering to the individual a therapeutically effective amount of a compound selected from the group consisting of: ][ a compound selected from the group consisting of: ]
[ 1957 ] similarity = 0.119248 [ a compound selected from the group consisting of: ][ a pharmaceutically acceptable salt thereof, and ]
[ 1958 ] similarity = 0.62950575 [ a pharmaceutically acceptable salt thereof, and ][ a pharmaceutically acceptable carrier, and ]
[ 1959 ] similarity = 0.5005993 [ a pharmaceutically acceptable carrier, and ][ a pharmaceutically acceptable salt thereof, ]
[ 1960 ] similarity = 0.12173708 [ a pharmaceutically acceptable salt thereof, ][ wherein the disorder is a disease characterized by an increased susceptibility to the disease or condition. ]
[ 1961 ] similarity = 0.3787709 [ A method for treating a patient with a disease comprising: ][ (a) administering to the subject a therapeutically effective amount of an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a protein that is a target for the treatment of the disease; and ]
[ 1962 ] similarity = 0.7666396 [ (a) administering to the subject a therapeutically effective amount of an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a protein that is a target for the treatment of the disease; and ][ (b) administering to the subject a therapeutically effective amount of an isolated polypeptide comprising an amino acid sequence that encodes a polypeptide that binds to a protein that is a target for the treatment of the disease, ]
[ 1963 ] similarity = 0.5206765 [ (b) administering to the subject a therapeutically effective amount of an isolated polypeptide comprising an amino acid sequence that encodes a polypeptide that binds to a protein that is a target for the treatment of the disease, ][ wherein the polypeptide binds to the protein. ]
[ 1964 ] similarity = 0.5173254 [ An apparatus for the treatment of a patient, comprising: ][ an implantable medical device comprising a plurality of electrodes; and ]
[ 1965 ] similarity = 0.3867823 [ an implantable medical device comprising a plurality of electrodes; and ][ a first electrode positioned on the implantable medical device and configured to deliver electrical signals to a patient, the first electrode configured to generate a first electrical stimulation signal and a second electrical stimulation signal; ]
[ 1966 ] similarity = 0.8523488 [ a first electrode positioned on the implantable medical device and configured to deliver electrical signals to a patient, the first electrode configured to generate a first electrical stimulation signal and a second electrical stimulation signal; ][ wherein the first electrode is configured to deliver the first electrical stimulation signal and the second electrical stimulation signal to the patient; ]
[ 1967 ] similarity = 0.9366324 [ wherein the first electrode is configured to deliver the first electrical stimulation signal and the second electrical stimulation signal to the patient; ][ wherein the first electrode is configured to deliver the second electrical stimulation signal to the patient; and ]
[ 1968 ] similarity = 0.9282615 [ wherein the first electrode is configured to deliver the second electrical stimulation signal to the patient; and ][ wherein the second electrode is configured to deliver the first electrical stimulation signal to the patient, ]
[ 1969 ] similarity = 0.7233304 [ wherein the second electrode is configured to deliver the first electrical stimulation signal to the patient, ][ wherein the first and second electrical stimulation signals are delivered by the same first electrode. ]
[ 1970 ] similarity = 0.028742682 [ A method of treating a patient in need of such treatment, comprising administering to said patient a therapeutically effective amount of a composition comprising a polypeptide having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: ][ 1. ]
[ 1971 ] similarity = 0.2827698 [ An apparatus for providing a therapeutic dose of a drug comprising: ][ a first drug delivery tube having a first end; and ]
[ 1972 ] similarity = 0.60053194 [ a first drug delivery tube having a first end; and ][ an intermediate drug delivery tube having a second end, ]
[ 1973 ] similarity = 0.64637756 [ an intermediate drug delivery tube having a second end, ][ wherein the intermediate drug delivery tube includes a first end and an opposite second end, and ]
[ 1974 ] similarity = 0.63607895 [ wherein the intermediate drug delivery tube includes a first end and an opposite second end, and ][ wherein a first portion of the first end of the first drug delivery tube is disposed in communication with a first portion of the intermediate drug delivery tube, and ]
[ 1975 ] similarity = 0.90926886 [ wherein a first portion of the first end of the first drug delivery tube is disposed in communication with a first portion of the intermediate drug delivery tube, and ][ wherein a first portion of the intermediate drug delivery tube is disposed in communication with a second portion of the first drug delivery tube. ]
[ 1976 ] similarity = 0.29851964 [ A method for the treatment of a subject in need thereof comprising administering to said subject a composition comprising a pharmaceutically acceptable carrier, wherein the carrier is selected from the group consisting of a pharmaceutical composition, an oral composition, and ][ an ophthalmic composition. ]
[ 1977 ] similarity = 0.4238124 [ A method of treating a patient suffering from an acute myeloid leukemia comprising: ][ providing a first therapeutic agent; ]
[ 1978 ] similarity = 0.7004779 [ providing a first therapeutic agent; ][ administering a first dose of the first therapeutic agent to the patient, ]
[ 1979 ] similarity = 0.34741598 [ administering a first dose of the first therapeutic agent to the patient, ][ wherein the first dose of the first therapeutic agent comprises an active component and a non-active component, wherein the active component comprises an amino acid sequence that is different than the amino acid sequence of a non-active component of the first therapeutic agent, and ]
[ 1980 ] similarity = 0.78459895 [ wherein the first dose of the first therapeutic agent comprises an active component and a non-active component, wherein the active component comprises an amino acid sequence that is different than the amino acid sequence of a non-active component of the first therapeutic agent, and ][ wherein the non-active component comprises an amino acid sequence that is different than the amino acid sequence of the active component of the first therapeutic agent. ]
[ 1981 ] similarity = -0.035825443 [ A method for producing a compound of formula I, in a pharmaceutical composition comprising an isolated polypeptide, wherein said polypeptide comprises a nucleotide sequence encoding a nucleic acid sequence of SEQ ID NO: ][ 2. ]
[ 1982 ] similarity = 0.31411955 [ A method for determining the presence or absence of a tumor in a subject comprising: ][ (a) obtaining a plurality of tumor images of the subject from a plurality of imaging devices, each image having an intensity of light emitted from the subject; ]
[ 1983 ] similarity = 0.7018987 [ (a) obtaining a plurality of tumor images of the subject from a plurality of imaging devices, each image having an intensity of light emitted from the subject; ][ (b) determining the intensity of light emitted from the subject based on the plurality of tumor images; ]
[ 1984 ] similarity = 0.45853323 [ (b) determining the intensity of light emitted from the subject based on the plurality of tumor images; ][ (c) determining a location of the subject in each image based on the intensity of light emitted from the subject and the location of the subject, wherein determining the location of the subject in each image is performed using a computer; ]
[ 1985 ] similarity = 0.7738683 [ (c) determining a location of the subject in each image based on the intensity of light emitted from the subject and the location of the subject, wherein determining the location of the subject in each image is performed using a computer; ][ (d) determining the size of the tumor in each image based on the intensity of light emitted from the subject and the location of the subject, wherein determining the size of the tumor in each image is performed using a computer; ]
[ 1986 ] similarity = 0.52013445 [ (d) determining the size of the tumor in each image based on the intensity of light emitted from the subject and the location of the subject, wherein determining the size of the tumor in each image is performed using a computer; ][ (e) determining a tumor volume based on the tumor image; and ]
[ 1987 ] similarity = 0.49264735 [ (e) determining a tumor volume based on the tumor image; and ][ (f) comparing the size of the tumor in each image to a predetermined threshold. ]
[ 1988 ] similarity = 0.7483847 [ A method for determining whether an object is a member of a group of objects comprising: ][ (a) determining whether a first member of said group of objects is a member of the group of objects; ]
[ 1989 ] similarity = 0.78132 [ (a) determining whether a first member of said group of objects is a member of the group of objects; ][ (b) determining whether a second member of said group of objects is a member of the group of objects; and ]
[ 1990 ] similarity = 0.7825879 [ (b) determining whether a second member of said group of objects is a member of the group of objects; and ][ (c) if said first member is a member of the group of objects, determining whether the second member is a member of the object; ]
[ 1991 ] similarity = 0.9157671 [ (c) if said first member is a member of the group of objects, determining whether the second member is a member of the object; ][ (d) if said second member is a member of the group of objects, determining whether the second member is a member of the object; ]
[ 1992 ] similarity = 0.9170191 [ (d) if said second member is a member of the group of objects, determining whether the second member is a member of the object; ][ (e) if said second member is a member of the group of objects, determining whether the first member is a member of the group of objects; ]
[ 1993 ] similarity = 0.95688105 [ (e) if said second member is a member of the group of objects, determining whether the first member is a member of the group of objects; ][ (f) if said second member is a member of the group of objects, determining whether the first member is a member of the group of objects; and ]
[ 1994 ] similarity = 0.81775135 [ (f) if said second member is a member of the group of objects, determining whether the first member is a member of the group of objects; and ][ (g) if said first member is a member of the group of objects: ]
[ 1995 ] similarity = 0.81743133 [ (g) if said first member is a member of the group of objects: ][ (1) if said first member is a member of the group of objects, determining whether the first member is a member of the group of objects; and ]
[ 1996 ] similarity = 0.93146235 [ (1) if said first member is a member of the group of objects, determining whether the first member is a member of the group of objects; and ][ (2) if said first member is a member of the group of objects, determining whether the first member is a member of the object. ]
[ 1997 ] similarity = 0.20576599 [ A method for treating an inflammatory disorder, comprising administering to a patient in need thereof an effective amount of an isolated antibody, comprising: ][ a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: ]
[ 1998 ] similarity = -0.071603626 [ a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: ][ 2; ]
[ 1999 ] similarity = -0.054603603 [ 2; ][ b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: ]
[ 2000 ] similarity = -0.050119124 [ b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: ][ 3; ]
[ 2001 ] similarity = -0.047852986 [ 3; ][ c) an amino acid sequence that is at least 95% identical to SEQ ID NO: 2, and ]
[ 2002 ] similarity = 0.15519798 [ c) an amino acid sequence that is at least 95% identical to SEQ ID NO: 2, and ][ wherein the heavy chain variable region and light chain variable region are bound to the same heavy chain variable region and the same light chain variable region; and ]
[ 2003 ] similarity = 0.46324652 [ wherein the heavy chain variable region and light chain variable region are bound to the same heavy chain variable region and the same light chain variable region; and ][ d) a light chain variable region comprising the amino acid sequence of SEQ ID NO: ]
[ 2004 ] similarity = -0.02818365 [ d) a light chain variable region comprising the amino acid sequence of SEQ ID NO: ][ 4. ]
[ 2005 ] similarity = 0.17369206 [ A device for the treatment of a patient, the device comprising: ][ at least one first electrode; ]
[ 2006 ] similarity = 0.6513325 [ at least one first electrode; ][ a second electrode; and ]
[ 2007 ] similarity = 0.48555598 [ a second electrode; and ][ at least one control device for selectively controlling the at least one first electrode and the at least one second electrode, wherein the control device includes a first electrode, a second electrode, and ]
[ 2008 ] similarity = 0.3429266 [ at least one control device for selectively controlling the at least one first electrode and the at least one second electrode, wherein the control device includes a first electrode, a second electrode, and ][ a first control circuit; and ]
[ 2009 ] similarity = 0.24665463 [ a first control circuit; and ][ wherein the first electrode and the second electrode are positioned at different locations in a first portion of the device, the first electrode including a first portion of an electrode body and a second portion of the electrode body, the second portion of the electrode body including a first portion of an electrode wall, the first portion of the electrode wall including a first portion of a plurality of first electrodes, each of the first electrodes including a first portion of a plurality of second electrodes, and ]
[ 2010 ] similarity = 0.7274499 [ wherein the first electrode and the second electrode are positioned at different locations in a first portion of the device, the first electrode including a first portion of an electrode body and a second portion of the electrode body, the second portion of the electrode body including a first portion of an electrode wall, the first portion of the electrode wall including a first portion of a plurality of first electrodes, each of the first electrodes including a first portion of a plurality of second electrodes, and ][ each of the first electrodes including a first portion of a plurality of second electrodes. ]
[ 2011 ] similarity = -0.008225366 [ An apparatus for the placement of a medical instrument, comprising: ][ an elongate shaft having a proximal end and a distal end, said elongate shaft including a plurality of elongate shaft members, each elongate shaft member having a proximal end and a distal end, wherein said elongate shaft members are connected by a connecting member, said connecting member including a plurality of connecting members, each connecting member including a distal end and a proximal end; ]
[ 2012 ] similarity = 0.7230443 [ an elongate shaft having a proximal end and a distal end, said elongate shaft including a plurality of elongate shaft members, each elongate shaft member having a proximal end and a distal end, wherein said elongate shaft members are connected by a connecting member, said connecting member including a plurality of connecting members, each connecting member including a distal end and a proximal end; ][ a plurality of elongate members having a first end and a second end, each of said plurality of elongate members including at least one elongate member extending through the elongate shaft member, said at least one elongate member including a first elongate member extending through the elongate shaft member and a second elongate member extending through the elongate shaft member, wherein each of said elongate members includes an outer surface and an inner surface, wherein the inner surface of each of said plurality of elongate members is configured to be positioned on a portion of the elongate shaft member; and ]
[ 2013 ] similarity = 0.3801432 [ a plurality of elongate members having a first end and a second end, each of said plurality of elongate members including at least one elongate member extending through the elongate shaft member, said at least one elongate member including a first elongate member extending through the elongate shaft member and a second elongate member extending through the elongate shaft member, wherein each of said elongate members includes an outer surface and an inner surface, wherein the inner surface of each of said plurality of elongate members is configured to be positioned on a portion of the elongate shaft member; and ][ a plurality of flexible members having a proximal end, a distal end, and ]
[ 2014 ] similarity = 0.7946469 [ a plurality of flexible members having a proximal end, a distal end, and ][ a distal edge, each of said plurality of flexible members including a proximal end, an outer surface, and ]
[ 2015 ] similarity = 0.642722 [ a distal edge, each of said plurality of flexible members including a proximal end, an outer surface, and ][ a distal end, wherein the proximal end and the distal end of each of said plurality of flexible members are configured to be positioned on the proximal and distal ends of the elongate shaft members. ]
[ 2016 ] similarity = 0.4631439 [ A method of treating a disease in a patient, said method comprising: ][ providing a first therapeutic agent, wherein said first therapeutic agent comprises an active agent; ]
[ 2017 ] similarity = 0.6910171 [ providing a first therapeutic agent, wherein said first therapeutic agent comprises an active agent; ][ administering to said patient a second therapeutic agent, wherein said second therapeutic agent comprises a non-active agent; and ]
[ 2018 ] similarity = 0.79164994 [ administering to said patient a second therapeutic agent, wherein said second therapeutic agent comprises a non-active agent; and ][ administering to said patient a third therapeutic agent, wherein said third therapeutic agent comprises a non-active agent. ]
[ 2019 ] similarity = 0.25575697 [ A method for producing an implant comprising: ][ providing a first material; ]
[ 2020 ] similarity = 0.29770422 [ providing a first material; ][ providing a second material, the first material and the second material having different molecular structures; and ]
[ 2021 ] similarity = 0.13023159 [ providing a second material, the first material and the second material having different molecular structures; and ][ providing a first polymer comprising a first polymer component and a second polymer component, wherein the first polymer is a polymeric polymer and the second polymer is a polymer. ]
[ 2022 ] similarity = 0.33306435 [ A method of treating a patient with a cancer comprising administering an effective amount of an anti-TNF-alpha antibody or an anti-TNF-alpha antibody/antibody complex comprising the amino acid sequence of the following amino acid sequence: ][ (a) the amino acid sequence of SEQ ID NO: ]
[ 2023 ] similarity = -0.04657647 [ (a) the amino acid sequence of SEQ ID NO: ][ 2, ]
[ 2024 ] similarity = -0.042116135 [ 2, ][ (b) the amino acid sequence of SEQ ID NO: ]
[ 2025 ] similarity = -0.0047008125 [ (b) the amino acid sequence of SEQ ID NO: ][ 3, ]
[ 2026 ] similarity = -0.02737266 [ 3, ][ (c) the amino acid sequence of SEQ ID NO, ]
[ 2027 ] similarity = 0.9038218 [ (c) the amino acid sequence of SEQ ID NO, ][ (d) the amino acid sequence of SEQ ID NO: ]
[ 2028 ] similarity = 0.05893414 [ (d) the amino acid sequence of SEQ ID NO: ][ 4, and ]
[ 2029 ] similarity = 0.09338905 [ 4, and ][ (e) the amino acid sequence of SEQ ID NO: ]
[ 2030 ] similarity = 0.03191434 [ (e) the amino acid sequence of SEQ ID NO: ][ 5. ]
[ 2031 ] similarity = 0.5481663 [ A method for treating a patient having a heart disease, the method comprising administering to the patient an effective amount of an antibody comprising a heavy chain variable region (HVCR) that specifically binds to a heavy chain variable region (HCV) comprising a heavy chain variable region of SEQ ID NO: ][ 2, wherein the HCV comprises a heavy chain variable region comprising a C1-C4 alkyl group and a heavy chain variable region comprising a C2-C4 alkyl group, and ]
[ 2032 ] similarity = 0.43019164 [ 2, wherein the HCV comprises a heavy chain variable region comprising a C1-C4 alkyl group and a heavy chain variable region comprising a C2-C4 alkyl group, and ][ wherein the heavy chain variable region is located at a position of greater affinity than the HCV. ]
[ 2033 ] similarity = 0.08149975 [ A method for treating a patient suffering from an inflammatory disease, comprising administering to a patient in need thereof, an effective amount of an antibody or antibody fragment thereof, wherein the antibody or antibody fragment has a molecular weight of less than about 1 000 &#x3bc; ][ M. ]
[ 2034 ] similarity = 0.043370686 [ A method for treating a patient suffering from an inflammatory disease comprising administering to the patient an effective amount of an antibody that specifically binds to an antigen-binding domain of a protein comprising the sequence of SEQ ID NO: ][ 1. ]
[ 2035 ] similarity = 0.24314861 [ An isolated antibody that binds to a polypeptide comprising a sequence of the amino acid sequence of SEQ ID NO: ][ 2 or SEQ ID NO: ]
[ 2036 ] similarity = 0.23113191 [ 2 or SEQ ID NO: ][ 3 and that specifically binds to a polypeptide comprising a sequence of a polypeptide of SEQ ID NO: ]
[ 2037 ] similarity = 0.23113191 [ 3 and that specifically binds to a polypeptide comprising a sequence of a polypeptide of SEQ ID NO: ][ 2 or SEQ ID NO: ]
[ 2038 ] similarity = -0.013158001 [ 2 or SEQ ID NO: ][ 3, wherein said antibody is a monoclonal antibody. ]
[ 2039 ] similarity = 0.41941518 [ An apparatus for providing a patient with a medical treatment, the apparatus comprising: ][ at least one medical device; ]
[ 2040 ] similarity = 0.24577022 [ at least one medical device; ][ a processor; ]
[ 2041 ] similarity = 0.3833844 [ a processor; ][ a memory; and ]
[ 2042 ] similarity = 0.22505626 [ a memory; and ][ a controller configured to execute instructions stored in the memory to: ]
[ 2043 ] similarity = 0.17028733 [ a controller configured to execute instructions stored in the memory to: ][ receive a first request from a user for medical information; ]
[ 2044 ] similarity = 0.7947625 [ receive a first request from a user for medical information; ][ receive a second request for medical information from a user; ]
[ 2045 ] similarity = 0.51809156 [ receive a second request for medical information from a user; ][ identify a medical device associated with the user; ]
[ 2046 ] similarity = 0.6637307 [ identify a medical device associated with the user; ][ identify a first medical device that is associated with a medical condition of the user, wherein the first medical device is associated with the medical condition; and ]
[ 2047 ] similarity = 0.7990111 [ identify a first medical device that is associated with a medical condition of the user, wherein the first medical device is associated with the medical condition; and ][ identify a second medical device that is associated with a different medical condition than the first medical device. ]
[ 2048 ] similarity = 0.10436045 [ An implantable device for a medical device comprising: ][ a first portion having a first end and a second end; ]
[ 2049 ] similarity = 0.23859428 [ a first portion having a first end and a second end; ][ a plurality of conductive electrodes arranged in the first portion; ]
[ 2050 ] similarity = 0.43711355 [ a plurality of conductive electrodes arranged in the first portion; ][ a first electrode configured to be implanted in a patient's body; and ]
[ 2051 ] similarity = 0.4252153 [ a first electrode configured to be implanted in a patient's body; and ][ at least one second electrode, wherein the plurality of conductive electrodes are arranged on a first side of the first portion and on a second side of the first portion, and ]
[ 2052 ] similarity = 0.45772192 [ at least one second electrode, wherein the plurality of conductive electrodes are arranged on a first side of the first portion and on a second side of the first portion, and ][ the first and second electrodes are configured to be implanted on a same side of the patient's body, ]
[ 2053 ] similarity = 0.14322129 [ the first and second electrodes are configured to be implanted on a same side of the patient's body, ][ wherein the first portion is a hollow body having a diameter of less than about 0.01 mm, and ]
[ 2054 ] similarity = 0.7692627 [ wherein the first portion is a hollow body having a diameter of less than about 0.01 mm, and ][ the second portion is a hollow body having a diameter of less than about 0.01 mm. ]
[ 2055 ] similarity = 0.62986165 [ A system for providing a therapeutic treatment to a subject, the system comprising: ][ a) a first electrode configured to deliver a therapeutic treatment to a subject; and, ]
[ 2056 ] similarity = 0.7225833 [ a) a first electrode configured to deliver a therapeutic treatment to a subject; and, ][ b) a second electrode coupled to the first electrode and configured to deliver a therapeutic treatment; and, ]
[ 2057 ] similarity = 0.63336986 [ b) a second electrode coupled to the first electrode and configured to deliver a therapeutic treatment; and, ][ c) an implantable device configured to be implanted in the subject, the implantable device comprising a first electrode configured to deliver a therapeutic treatment to the subject; a second electrode coupled to the first electrode, the second electrode configured to be implanted in the subject; a control circuit coupled to the implantable device, the control circuit configured to control the implantable device to deliver the therapeutic treatment to the subject; and, ]
[ 2058 ] similarity = 0.5117686 [ c) an implantable device configured to be implanted in the subject, the implantable device comprising a first electrode configured to deliver a therapeutic treatment to the subject; a second electrode coupled to the first electrode, the second electrode configured to be implanted in the subject; a control circuit coupled to the implantable device, the control circuit configured to control the implantable device to deliver the therapeutic treatment to the subject; and, ][ a sensor coupled to the implantable device, the sensor configured to detect a change in a physiological state of the subject. ]
[ 2059 ] similarity = 0.14586249 [ A method comprising: ][ providing a first medical device comprising a first electrode and a second electrode, wherein the first electrode is configured to receive a first medical device implant; ]
[ 2060 ] similarity = 0.6782759 [ providing a first medical device comprising a first electrode and a second electrode, wherein the first electrode is configured to receive a first medical device implant; ][ providing a medical device comprising a second electrode, the medical device comprising a second electrode and a third electrode; ]
[ 2061 ] similarity = 0.68210137 [ providing a medical device comprising a second electrode, the medical device comprising a second electrode and a third electrode; ][ coupling the first and second electrodes of the first electrode and the second electrode of the second electrode to a first medical device; ]
[ 2062 ] similarity = 0.91168475 [ coupling the first and second electrodes of the first electrode and the second electrode of the second electrode to a first medical device; ][ coupling the second and third electrodes of the first electrode and the second electrode of the second electrode to a second medical device; and ]
[ 2063 ] similarity = 0.92850506 [ coupling the second and third electrodes of the first electrode and the second electrode of the second electrode to a second medical device; and ][ coupling the first and second electrodes of the second electrode and the third electrode of the first electrode to a third medical device. ]
[ 2064 ] similarity = 0.2936146 [ A method for treating a patient having a disease characterized by a reduced ability to regulate a gene expression level, the method comprising the steps of: ][ a) administering to the patient an effective amount of a polypeptide comprising a nucleic acid sequence encoding an amino acid sequence having a amino acid sequence that is at least 95% identical to the sequence of SEQ ID NO: ]
[ 2065 ] similarity = 0.7344371 [ a) administering to the patient an effective amount of a polypeptide comprising a nucleic acid sequence encoding an amino acid sequence having a amino acid sequence that is at least 95% identical to the sequence of SEQ ID NO: ][ 1, wherein the polypeptide is an isolated polypeptide comprising a nucleic acid sequence encoding the gene encoding a human polypeptide having the amino acid sequence of SEQ ID NO: ]
[ 2066 ] similarity = 0.021209711 [ 1, wherein the polypeptide is an isolated polypeptide comprising a nucleic acid sequence encoding the gene encoding a human polypeptide having the amino acid sequence of SEQ ID NO: ][ 1. ]
[ 2067 ] similarity = 0.58681154 [ A system for treating a patient with a cancer comprising a first and a second device, the system comprising: ][ a first device configured to treat the patient; and ]
[ 2068 ] similarity = 0.6900451 [ a first device configured to treat the patient; and ][ a second device configured to treat the patient, the first device comprising a first device-specific device and a second device-specific device, ]
[ 2069 ] similarity = 0.46472394 [ a second device configured to treat the patient, the first device comprising a first device-specific device and a second device-specific device, ][ the first and second device-specific devices comprising: ]
[ 2070 ] similarity = 0.28834054 [ the first and second device-specific devices comprising: ][ a first device-specific device configured to treat cancer; and ]
[ 2071 ] similarity = 0.72380054 [ a first device-specific device configured to treat cancer; and ][ a second device-specific device configured to treat a patient with cancer, ]
[ 2072 ] similarity = 0.015704298 [ a second device-specific device configured to treat a patient with cancer, ][ wherein: ]
[ 2073 ] similarity = 0.038715716 [ wherein: ][ the first device-specific device comprises an implantable device, ]
[ 2074 ] similarity = 0.3005558 [ the first device-specific device comprises an implantable device, ][ wherein the first device-specific device is configured to treat a patient with cancer, and ]
[ 2075 ] similarity = 0.86234367 [ wherein the first device-specific device is configured to treat a patient with cancer, and ][ wherein the second device-specific device comprises a first device-specific device configured to treat a patient with cancer, and ]
[ 2076 ] similarity = 0.12090507 [ wherein the second device-specific device comprises a first device-specific device configured to treat a patient with cancer, and ][ wherein: ]
[ 2077 ] similarity = 0.024370937 [ wherein: ][ the first device-specific device is configured to be implanted in a patient's body; and, ]
[ 2078 ] similarity = 0.8378167 [ the first device-specific device is configured to be implanted in a patient's body; and, ][ the second device-specific device is configured to be implanted in the patient's body; and, ]
[ 2079 ] similarity = 0.72632766 [ the second device-specific device is configured to be implanted in the patient's body; and, ][ the first device-specific device is configured to be implanted in the patient's body in the presence of a first agent and the second device-specific device is configured to be implanted in the patient's body in the presence of a second agent. ]
[ 2080 ] similarity = 0.3594101 [ A method of treating a cancer in a patient, comprising: ][ (a) administering to the patient a therapeutically effective amount of a compound selected from the group consisting of: ]
[ 2081 ] similarity = 0.06167248 [ (a) administering to the patient a therapeutically effective amount of a compound selected from the group consisting of: ][ (i) an antibody that specifically binds to an epitope of a human CD4+ T cell, and ]
[ 2082 ] similarity = 0.7964678 [ (i) an antibody that specifically binds to an epitope of a human CD4+ T cell, and ][ (ii) an antibody that specifically binds to a human antigen that is different from the human antigen that binds to the epitope of the human CD4+ T cell; and ]
[ 2083 ] similarity = 0.1771526 [ (ii) an antibody that specifically binds to a human antigen that is different from the human antigen that binds to the epitope of the human CD4+ T cell; and ][ (b) administering to the patient a therapeutic agent, wherein the therapeutic agent comprises a pharmaceutically acceptable carrier. ]
[ 2084 ] similarity = 0.70542586 [ A method of producing a pharmaceutical composition comprising: ][ providing a pharmaceutical composition comprising a pharmaceutically acceptable carrier; ]
[ 2085 ] similarity = 0.45860392 [ providing a pharmaceutical composition comprising a pharmaceutically acceptable carrier; ][ contacting the pharmaceutically acceptable carrier with an active substance, wherein the active substance is a pharmaceutically acceptable carrier; ]
[ 2086 ] similarity = 0.8086996 [ contacting the pharmaceutically acceptable carrier with an active substance, wherein the active substance is a pharmaceutically acceptable carrier; ][ contacting a pharmaceutically acceptable carrier with an active substance that is a non-active substance, and ]
[ 2087 ] similarity = 0.4348898 [ contacting a pharmaceutically acceptable carrier with an active substance that is a non-active substance, and ][ wherein the non-active substance is a non-active substance; and ]
[ 2088 ] similarity = 0.32778502 [ wherein the non-active substance is a non-active substance; and ][ contacting the pharmaceutically acceptable carrier with an active substance that is a pharmaceutically acceptable carrier, wherein the active substance is a non-active substance. ]
[ 2089 ] similarity = 0.40991962 [ A method for determining whether an individual has a heart condition, the method comprising: ][ a. obtaining a first set of heart condition information from an electronic medical device; ]
[ 2090 ] similarity = 0.5628604 [ a. obtaining a first set of heart condition information from an electronic medical device; ][ b. obtaining, from a first user, a second set of heart condition information, wherein each of the first set of heart condition information and the second set of heart condition information includes information about a first heart condition and information about a second heart condition; ]
[ 2091 ] similarity = 0.78515893 [ b. obtaining, from a first user, a second set of heart condition information, wherein each of the first set of heart condition information and the second set of heart condition information includes information about a first heart condition and information about a second heart condition; ][ c. comparing each of a first set of the first set of heart condition information and the second set of the first set of heart condition information to a predetermined threshold; ]
[ 2092 ] similarity = 0.87003136 [ c. comparing each of a first set of the first set of heart condition information and the second set of the first set of heart condition information to a predetermined threshold; ][ d. comparing a first heart condition of the first set of the first set of heart condition information to a first predetermined condition; and ]
[ 2093 ] similarity = 0.901644 [ d. comparing a first heart condition of the first set of the first set of heart condition information to a first predetermined condition; and ][ e. comparing the first predetermined condition of the first set of the first set of heart condition information to a second predetermined condition. ]
[ 2094 ] similarity = 0.33559743 [ A method for treating an inflammatory bowel disease comprising administering a therapeutically effective amount of an anti-CD3 antibody or antigen-binding fragment thereof, to a subject in need of said treatment, and ][ administering a therapeutically effective amount of a pharmaceutically acceptable salt thereof. ]
[ 2095 ] similarity = 0.27998707 [ A method for treating an autoimmune disorder, comprising administering to a patient suffering from an autoimmune disorder a composition comprising: ][ a) a therapeutically effective amount of an anti-inflammatory agent; ]
[ 2096 ] similarity = 0.24786384 [ a) a therapeutically effective amount of an anti-inflammatory agent; ][ b) an anti-inflammatory agent that inhibits or reduces the expression or activity of a protein that is associated with the autoimmune disorder, wherein the antibody binds to the anti-inflammatory agent; and ]
[ 2097 ] similarity = 0.22869721 [ b) an anti-inflammatory agent that inhibits or reduces the expression or activity of a protein that is associated with the autoimmune disorder, wherein the antibody binds to the anti-inflammatory agent; and ][ c) an antibody that specifically binds to an epitope selected from the group consisting of the amino acid sequence of SEQ ID NO: 1, a sequence of SEQ ID NO: 2, a sequence of SEQ ID NO: 3, or an epitope of SEQ ID NO: 4. ]
[ 2098 ] similarity = 0.4074005 [ A method of providing a medical device to a patient, said method comprising: ][ providing a medical device comprising an implantable device having a first electrode and a second electrode; ]
[ 2099 ] similarity = 0.6996297 [ providing a medical device comprising an implantable device having a first electrode and a second electrode; ][ providing a first electrode and a second electrode; ]
[ 2100 ] similarity = 0.7983223 [ providing a first electrode and a second electrode; ][ electrically coupling a first electrode and a second electrode to the implantable device; ]
[ 2101 ] similarity = 0.36608338 [ electrically coupling a first electrode and a second electrode to the implantable device; ][ providing a plurality of electrodes; ]
[ 2102 ] similarity = 0.2586856 [ providing a plurality of electrodes; ][ providing a first electrical current between the first electrode and the second electrode; and ]
[ 2103 ] similarity = 0.59507823 [ providing a first electrical current between the first electrode and the second electrode; and ][ electrically coupling a plurality of electrodes to each of the plurality of electrodes, the first electrical current and the second electrical current being electrically coupled to the implantable device. ]
[ 2104 ] similarity = 0.25337818 [ A method for treating a patient having a heart failure, comprising: ][ administering a therapeutically effective amount of a compound selected from the group consisting of: ]
[ 2105 ] similarity = 0.17699775 [ administering a therapeutically effective amount of a compound selected from the group consisting of: ][ (a) a compound of Formula I: ]
[ 2106 ] similarity = 0.45599425 [ (a) a compound of Formula I: ][ or (b) a combination of Formula I and Formula II: ]
[ 2107 ] similarity = 0.15392706 [ or (b) a combination of Formula I and Formula II: ][ or (c) a compound selected from the group consisting of: ]
[ 2108 ] similarity = 0.16903296 [ or (c) a compound selected from the group consisting of: ][ (i) a compound of Formula III: ]
[ 2109 ] similarity = 0.2349957 [ (i) a compound of Formula III: ][ or (ii) a compound selected from the group consisting of: ]
[ 2110 ] similarity = 0.34834552 [ or (ii) a compound selected from the group consisting of: ][ (i) a compound of Formula II: ]
[ 2111 ] similarity = 0.69251585 [ (i) a compound of Formula II: ][ and(iii) a compound of Formula III: ]
[ 2112 ] similarity = -0.036935437 [ and(iii) a compound of Formula III: ][ wherein: ]
[ 2113 ] similarity = 0.06689431 [ wherein: ][ (a) is a hydrogen atom; and ]
[ 2114 ] similarity = 0.3262144 [ (a) is a hydrogen atom; and ][ (b) is an amino-acid. ]
[ 2115 ] similarity = 0.22157562 [ A system, comprising: ][ a housing having a first side, a second side, and ]
[ 2116 ] similarity = 0.56053454 [ a housing having a first side, a second side, and ][ a third side, the first side having a top and a bottom; ]
[ 2117 ] similarity = 0.45964044 [ a third side, the first side having a top and a bottom; ][ a first support member having a first end and a second end; ]
[ 2118 ] similarity = 0.9486617 [ a first support member having a first end and a second end; ][ a first support member member having a first end and a second end; and ]
[ 2119 ] similarity = 0.67675614 [ a first support member member having a first end and a second end; and ][ a second support member member having a first end and a second end, wherein the second side of the housing is configured to receive the first support member member and the second side of the housing is configured to receive the second support member member, the first support member member and the second support member member being disposed within the first and second support member members. ]
[ 2120 ] similarity = 0.17886221 [ A method for treating an inflammatory condition in a subject in need thereof, comprising: ][ administering to the subject a therapeutically effective amount of a polypeptide selected from the group consisting of SEQ ID NO: ]
[ 2121 ] similarity = 0.17587405 [ administering to the subject a therapeutically effective amount of a polypeptide selected from the group consisting of SEQ ID NO: ][ 1, SEQ ID NO: ]
[ 2122 ] similarity = 0.7964808 [ 1, SEQ ID NO: ][ 2, SEQ ID NO: ]
[ 2123 ] similarity = 0.7720622 [ 2, SEQ ID NO: ][ 3, SEQ ID NO: ]
[ 2124 ] similarity = 0.7367879 [ 3, SEQ ID NO: ][ 5, SEQ ID NO: ]
[ 2125 ] similarity = 0.75330436 [ 5, SEQ ID NO: ][ 8, SEQ ID NO: ]
[ 2126 ] similarity = 0.8040749 [ 8, SEQ ID NO: ][ 10, SEQ ID NO: ]
[ 2127 ] similarity = 0.829663 [ 10, SEQ ID NO: ][ 12, SEQ ID NO: ]
[ 2128 ] similarity = 0.8157853 [ 12, SEQ ID NO: ][ 14, SEQ ID NO: ]
[ 2129 ] similarity = 0.7537919 [ 14, SEQ ID NO: ][ 16 and SEQ ID NO: ]
[ 2130 ] similarity = 0.21248122 [ 16 and SEQ ID NO: ][ 17, wherein the polypeptide is a polypeptide having the amino acid sequence of SEQ ID NO: ]
[ 2131 ] similarity = -0.04403928 [ 17, wherein the polypeptide is a polypeptide having the amino acid sequence of SEQ ID NO: ][ 1. ]
[ 2132 ] similarity = 0.7973496 [ A method of treating a patient having a condition characterized by a reduced level of a protein that comprises a heavy chain variable chain variable region comprising: ][ (a) providing an immunogenic agent to a patient having a condition characterized by a reduced level of a protein that comprises the heavy chain variable chain variable region, the immunogenic agent comprising a heavy chain variable chain variable region of the following structure (A): ]
[ 2133 ] similarity = 0.75091124 [ (a) providing an immunogenic agent to a patient having a condition characterized by a reduced level of a protein that comprises the heavy chain variable chain variable region, the immunogenic agent comprising a heavy chain variable chain variable region of the following structure (A): ][ (B) wherein A is the heavy chain variable region of the heavy chain variable chain variable region of the protein; ]
[ 2134 ] similarity = 0.3898952 [ (B) wherein A is the heavy chain variable region of the heavy chain variable chain variable region of the protein; ][ (C) wherein C is a variable region; ]
[ 2135 ] similarity = 0.7836424 [ (C) wherein C is a variable region; ][ (D) wherein D is a variable region; ]
[ 2136 ] similarity = 0.77720326 [ (D) wherein D is a variable region; ][ (E) wherein E is a variable region; ]
[ 2137 ] similarity = 0.69899094 [ (E) wherein E is a variable region; ][ (F) wherein F is a variable region; and ]
[ 2138 ] similarity = 0.5548581 [ (F) wherein F is a variable region; and ][ (G) wherein G and E together form a variable chain variable region of the protein. ]
[ 2139 ] similarity = 0.26610655 [ A system for treating an inflammatory disorder, the system comprising: ][ a first medical instrument; and ]
[ 2140 ] similarity = 0.6560929 [ a first medical instrument; and ][ a second medical instrument, ]
[ 2141 ] similarity = 0.42042142 [ a second medical instrument, ][ wherein the first and second medical instruments are configured to be inserted into an individual's body, ]
[ 2142 ] similarity = 0.68086314 [ wherein the first and second medical instruments are configured to be inserted into an individual's body, ][ wherein each of the first and second medical instruments comprises: ]
[ 2143 ] similarity = 0.27792966 [ wherein each of the first and second medical instruments comprises: ][ (a) an elongate body having a first side and a second side; ]
[ 2144 ] similarity = 0.3706331 [ (a) an elongate body having a first side and a second side; ][ (b) a first electrode disposed within the elongate body and configured to be electrically connected to the first side of the first medical instrument and configured to be electrically connected to a first electrode on the second side of the first medical instrument; ]
[ 2145 ] similarity = 0.8976542 [ (b) a first electrode disposed within the elongate body and configured to be electrically connected to the first side of the first medical instrument and configured to be electrically connected to a first electrode on the second side of the first medical instrument; ][ (c) a first connector disposed within the elongate body and configured to be electrically connected to the first side of the first medical instrument and configured to be electrically connected to the second side of the first medical instrument; ]
[ 2146 ] similarity = 0.6263348 [ (c) a first connector disposed within the elongate body and configured to be electrically connected to the first side of the first medical instrument and configured to be electrically connected to the second side of the first medical instrument; ][ (d) a second connector disposed within the elongate body and configured to be electrically connected to a second side of the second medical instrument; ]
[ 2147 ] similarity = 0.71817446 [ (d) a second connector disposed within the elongate body and configured to be electrically connected to a second side of the second medical instrument; ][ (e) an electrical connector disposed within the elongate body and configured to be electrically connected to the first side, the second side, and ]
[ 2148 ] similarity = 0.1452592 [ (e) an electrical connector disposed within the elongate body and configured to be electrically connected to the first side, the second side, and ][ the first electrode; ]
[ 2149 ] similarity = 0.15532997 [ the first electrode; ][ (f) a plurality of electrodes disposed within the elongate body and configured to be connected to the electrical connectors; ]
[ 2150 ] similarity = 0.59367913 [ (f) a plurality of electrodes disposed within the elongate body and configured to be connected to the electrical connectors; ][ (g) a plurality of electrodes disposed within the second medical instrument, wherein each of the plurality of electrodes is configured to be connected to a corresponding electrode on the second medical instrument; and ]
[ 2151 ] similarity = 0.6645996 [ (g) a plurality of electrodes disposed within the second medical instrument, wherein each of the plurality of electrodes is configured to be connected to a corresponding electrode on the second medical instrument; and ][ (h) a plurality of conductors disposed within the second medical instrument, wherein each of the plurality of conductors is configured to be connected to the electrical connectors. ]
[ 2152 ] similarity = 0.23557346 [ A method of treating an eye, comprising: ][ providing an eye lens comprising an optical system having an optical axis and a plurality of optical elements; ]
[ 2153 ] similarity = 0.5443046 [ providing an eye lens comprising an optical system having an optical axis and a plurality of optical elements; ][ positioning the optical system in a patient's eye; and ]
[ 2154 ] similarity = 0.31370574 [ positioning the optical system in a patient's eye; and ][ applying a therapeutic dose of an effective amount of an anti-inflammatory agent to the eye lens to treat an inflammatory disorder of the eye. ]
[ 2155 ] similarity = 0.00087573007 [ A method for treating an inflammatory disease in a patient comprising administering to the patient an effective amount of a compound having an effective amount of a polypeptide having the amino acid sequence of SEQ ID NO: ][ 2. ]
[ 2156 ] similarity = -0.04150638 [ An isolated antibody that specifically binds to an epitope comprising the amino acid sequence of SEQ ID NO: ][ 3. ]
[ 2157 ] similarity = 0.12407808 [ A system for providing a therapeutic dose of a pharmaceutical agent to a subject, comprising: ][ a first delivery device having a first delivery tube having a first end and a second end; ]
[ 2158 ] similarity = 0.72547644 [ a first delivery device having a first delivery tube having a first end and a second end; ][ an infusion device having a second delivery tube having a second end, said second end having a first end and a second end, said first delivery tube and infusion device having a first delivery tube end and a second delivery tube end; ]
[ 2159 ] similarity = 0.6718958 [ an infusion device having a second delivery tube having a second end, said second end having a first end and a second end, said first delivery tube and infusion device having a first delivery tube end and a second delivery tube end; ][ a first delivery tube assembly including a first delivery tube and a second delivery tube; ]
[ 2160 ] similarity = 0.606864 [ a first delivery tube assembly including a first delivery tube and a second delivery tube; ][ an infusion device assembly including a second delivery tube assembly and a first infusion device; ]
[ 2161 ] similarity = 0.5654464 [ an infusion device assembly including a second delivery tube assembly and a first infusion device; ][ a first delivery tube assembly assembly including a first delivery tube assembly end and a second delivery tube assembly end, wherein said first delivery tube assembly end includes a first delivery tube assembly end opening and a second delivery tube assembly end opening, wherein said second delivery tube assembly end includes a second delivery tube assembly end opening, wherein said first delivery tube assembly end includes a first delivery tube opening and a second deliver tube opening, wherein said infusion device assembly including a second delivery tube assembly end opening and an infusion device opening, wherein said infusion device assembly end includes a second delivery tube opening and a second infusion tube opening. ]
[ 2162 ] similarity = 0.599878 [ A method of treating a patient having a heart failure, the method comprising administering a therapeutically effective amount of a polypeptide comprising the amino acid sequence of SEQ ID NO: ][ 2 to said heart failure patient, wherein the polypeptide is an amino acid sequence selected from the group consisting of SEQ ID NO: ]
[ 2163 ] similarity = 0.18590492 [ 2 to said heart failure patient, wherein the polypeptide is an amino acid sequence selected from the group consisting of SEQ ID NO: ][ 1 and SEQ ID NO: ]
[ 2164 ] similarity = 0.16446131 [ 1 and SEQ ID NO: ][ 2. ]
[ 2165 ] similarity = 0.3176111 [ A method of producing a composition, the method comprising the steps of: ][ providing a composition comprising a first polymeric material and a second polymeric material, wherein the first and second polymeric materials are each composed of a first polymeric material and a second polymeric material; ]
[ 2166 ] similarity = 0.47148353 [ providing a composition comprising a first polymeric material and a second polymeric material, wherein the first and second polymeric materials are each composed of a first polymeric material and a second polymeric material; ][ contacting the first and second polymeric materials with a first solvent, wherein the first solvent is a water solvent; and, ]
[ 2167 ] similarity = 0.6479449 [ contacting the first and second polymeric materials with a first solvent, wherein the first solvent is a water solvent; and, ][ contacting the second polymer material with a second solvent, wherein the second solvent is a water solvent. ]
[ 2168 ] similarity = 0.31134778 [ An implantable device comprising: ][ an electrode assembly; and ]
[ 2169 ] similarity = 0.3286876 [ an electrode assembly; and ][ a first and second conductive element having a conductivity, ]
[ 2170 ] similarity = 0.442877 [ a first and second conductive element having a conductivity, ][ wherein the first and second conductive elements are disposed within the electrode assembly and are electrically interconnected, ]
[ 2171 ] similarity = 0.5602745 [ wherein the first and second conductive elements are disposed within the electrode assembly and are electrically interconnected, ][ wherein the first and second conductive elements are disposed in a first position and the second position is opposite to the first position, and ]
[ 2172 ] similarity = 0.8353369 [ wherein the first and second conductive elements are disposed in a first position and the second position is opposite to the first position, and ][ wherein the first position is in a first position with the first and second conductive elements in a first configuration, ]
[ 2173 ] similarity = 0.72675043 [ wherein the first position is in a first position with the first and second conductive elements in a first configuration, ][ wherein the first and second conductive elements are disposed in a second position and the second position is opposite to the first position, and ]
[ 2174 ] similarity = 0.9035792 [ wherein the first and second conductive elements are disposed in a second position and the second position is opposite to the first position, and ][ wherein the second position is in a second position with the first and second conductive elements in a second configuration, and ]
[ 2175 ] similarity = 0.3839844 [ wherein the second position is in a second position with the first and second conductive elements in a second configuration, and ][ wherein the first and second configurations have different conductivity characteristics. ]
[ 2176 ] similarity = 0.023967182 [ A method of treating a patient with an inflammatory disease or condition in a patient, comprising administering to said patient an isolated peptide having at least 95% sequence identity to the sequence of SEQ ID NO: ][ 1. ]
[ 2177 ] similarity = 0.5465176 [ A method of producing a compound having a molecular weight of about 1.2 to about 1.5 g/mol, wherein said compound is selected from the group consisting of a pharmaceutically acceptable salt, a pharmaceutically acceptable salt-containing salt, a pharmaceutically acceptable ester, a pharmaceutically acceptable ester-containing salts, an alkoxy ester, an alkoxy ester-containing salt, an alkoxy ester-containing ester, a pharmaceutically acceptable ester, a pharmaceutically acceptable ester-containing ester, a salt of an ester, a salt of an ester-containing salt, a salt of a salt of an ester-containing ester, a salt of a salt-containing salt, a salt of a salt-containing ester, and ][ a salt of an ester-containing ester; and ]
[ 2178 ] similarity = 0.065061584 [ a salt of an ester-containing ester; and ][ wherein the compound is selected from the group consisting of: ]
[ 2179 ] similarity = 0.22944379 [ wherein the compound is selected from the group consisting of: ][ an amino acid substitution; a substitution of a substituent selected from the group consisting of an amino acid and a hydrophobic group; and ]
[ 2180 ] similarity = 0.60551226 [ an amino acid substitution; a substitution of a substituent selected from the group consisting of an amino acid and a hydrophobic group; and ][ an amino acid substitution, ]
[ 2181 ] similarity = 0.044497453 [ an amino acid substitution, ][ wherein the compound has a molecular weight of about 1.5 to about 2.0 g/mol, and ]
[ 2182 ] similarity = 0.59424853 [ wherein the compound has a molecular weight of about 1.5 to about 2.0 g/mol, and ][ wherein a concentration of said compound is less than 0.1% by weight of the compound. ]
[ 2183 ] similarity = 0.2232889 [ A method for treating a patient having a heart failure comprising administering an effective amount of a composition comprising: ][ a) a pharmaceutical agent; ]
[ 2184 ] similarity = 0.11967401 [ a) a pharmaceutical agent; ][ b) at least one compound of the formula: ]
[ 2185 ] similarity = 0.0062016807 [ b) at least one compound of the formula: ][ wherein R1 is hydrogen, alkyl, aryl, alkenyl and alkenyl group; ]
[ 2186 ] similarity = 0.7989043 [ wherein R1 is hydrogen, alkyl, aryl, alkenyl and alkenyl group; ][ R2 is hydrogen, alkyl, aryl, alkenyl and alkenyl group; ]
[ 2187 ] similarity = 0.6274244 [ R2 is hydrogen, alkyl, aryl, alkenyl and alkenyl group; ][ R3 and R4 each independently are hydrogen, alkyl, aryl, alkenyl and alkenyl group; ]
[ 2188 ] similarity = 0.6442846 [ R3 and R4 each independently are hydrogen, alkyl, aryl, alkenyl and alkenyl group; ][ R5 is hydrogen, alkyl, aryl, alkenyl and alkenyl group; ]
[ 2189 ] similarity = 0.83826554 [ R5 is hydrogen, alkyl, aryl, alkenyl and alkenyl group; ][ R6 is hydrogen, alkyl, aryl, alkenyl and alkenyl group; ]
[ 2190 ] similarity = 0.80023754 [ R6 is hydrogen, alkyl, aryl, alkenyl and alkenyl group; ][ R7 is hydrogen, alkyl, aryl, alkenyl and alkenyl group; and ]
[ 2191 ] similarity = 0.2692864 [ R7 is hydrogen, alkyl, aryl, alkenyl and alkenyl group; and ][ R8 is hydrogen; ]
[ 2192 ] similarity = 0.0012070686 [ R8 is hydrogen; ][ wherein the composition is administered in a dose effective to treat the patient with the heart failure. ]
[ 2193 ] similarity = 0.0073124142 [ A method for treating a patient with a disease comprising administering to the patient an effective amount of a therapeutically effective amount of a polypeptide comprising a sequence having the amino acid position of the sequence in SEQ ID NO: ][ 2. ]
[ 2194 ] similarity = -0.0062583014 [ A method of treating an inflammatory disorder in a patient, comprising administering to said patient a therapeutically effective amount of an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof: ][ wherein: ]
[ 2195 ] similarity = -0.10514447 [ wherein: ][ R1, R2 and R3 each independently represent one of the amino acid substitutions of the amino acid substitutions of formula (I): ]
[ 2196 ] similarity = 0.30239522 [ R1, R2 and R3 each independently represent one of the amino acid substitutions of the amino acid substitutions of formula (I): ][ R4 and R5 are independently selected from hydrogen, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 alkoxycarbonyl, and ]
[ 2197 ] similarity = 0.6711768 [ R4 and R5 are independently selected from hydrogen, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 alkoxycarbonyl, and ][ R6 and R7 are independently selected from hydrogen, C1-C6 alkyl, C1-C6 alkylcarbonyl, and ]
[ 2198 ] similarity = 0.1624526 [ R6 and R7 are independently selected from hydrogen, C1-C6 alkyl, C1-C6 alkylcarbonyl, and ][ C1-C6 alkylcarbonyl. ]
[ 2199 ] similarity = 0.018731385 [ A method of treating a disease comprising administering to a patient suffering from a cancer, wherein said cancer is a cancer associated with an epithelial cell, an effective amount of a compound selected from a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable carrier, wherein the compound comprises an amino acid sequence at least 95% identical to SEQ ID NO: ][ 3. ]
[ 2200 ] similarity = 0.3264368 [ An apparatus for treating a patient with a condition of the skin of the patient, comprising: ][ a) a plurality of skin grafts having a plurality of grafts each having an outer surface, the outer surface being configured to receive a skin graft; ]
[ 2201 ] similarity = 0.42634505 [ a) a plurality of skin grafts having a plurality of grafts each having an outer surface, the outer surface being configured to receive a skin graft; ][ b) a plurality of electrodes, each electrode being configured for receiving a tissue graft; and ]
[ 2202 ] similarity = 0.82455075 [ b) a plurality of electrodes, each electrode being configured for receiving a tissue graft; and ][ c) a plurality of electrodes, each electrode being configured for receiving a skin graft. ]
[ 2203 ] similarity = 0.31037802 [ A system for providing a medical treatment for a subject in need thereof, comprising: ][ a medical device; ]
[ 2204 ] similarity = 0.28607142 [ a medical device; ][ a first sensor configured to sense a first signal from the medical device; ]
[ 2205 ] similarity = 0.5559027 [ a first sensor configured to sense a first signal from the medical device; ][ a second sensor configured to sense a second signal from the medical device, wherein the second sensor is configured to detect a difference in an electrical current between the first and second sensors; ]
[ 2206 ] similarity = 0.8374075 [ a second sensor configured to sense a second signal from the medical device, wherein the second sensor is configured to detect a difference in an electrical current between the first and second sensors; ][ a processor configured to determine a difference between the first and second signals from the first and second sensors, wherein the difference is a difference between a first signal from the medical device and a second signal from a second sensor, wherein the second sensor is a sensor that is configured to detect an electrical current from a body of a subject; and ]
[ 2207 ] similarity = 0.35996097 [ a processor configured to determine a difference between the first and second signals from the first and second sensors, wherein the difference is a difference between a first signal from the medical device and a second signal from a second sensor, wherein the second sensor is a sensor that is configured to detect an electrical current from a body of a subject; and ][ a display configured to display a first image of a first portion of the subject, wherein the first image comprises a first image of the first portion and a first portion of the subject is a second image of the first portion, wherein the first portion comprises a first portion of the subject and the second portion comprises a second portion of the subject, wherein the first portion and the second portion are configured to be overlapped, and ]
[ 2208 ] similarity = 0.6146264 [ a display configured to display a first image of a first portion of the subject, wherein the first image comprises a first image of the first portion and a first portion of the subject is a second image of the first portion, wherein the first portion comprises a first portion of the subject and the second portion comprises a second portion of the subject, wherein the first portion and the second portion are configured to be overlapped, and ][ wherein the second portion comprises a second portion of the subject, wherein the second image comprises a second image of the second portion and a second portion of the subject is a third image of the second portion. ]
[ 2209 ] similarity = 0.48060742 [ An isolated polypeptide having a nucleic acid sequence comprising: ][ (A) a first amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: ]
[ 2210 ] similarity = 0.04086163 [ (A) a first amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: ][ 1; and ]
[ 2211 ] similarity = 0.015910944 [ 1; and ][ (B) a second amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: ]
[ 2212 ] similarity = -0.062843874 [ (B) a second amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: ][ 1. ]
[ 2213 ] similarity = 0.19690904 [ A device for treating an inflammatory disease, comprising: ][ a body having at least one surface that is capable of receiving a fluid and having a first surface and an opposing second surface; ]
[ 2214 ] similarity = 0.29997125 [ a body having at least one surface that is capable of receiving a fluid and having a first surface and an opposing second surface; ][ a first fluid reservoir having a first fluid volume and a second fluid volume, the first fluid volume and the second fluid volume being different from each other; ]
[ 2215 ] similarity = 0.965618 [ a first fluid reservoir having a first fluid volume and a second fluid volume, the first fluid volume and the second fluid volume being different from each other; ][ a second fluid reservoir having a first fluid volume and a second fluid volume, the second fluid volume and the first fluid volume being different from each other; and ]
[ 2216 ] similarity = 0.7626667 [ a second fluid reservoir having a first fluid volume and a second fluid volume, the second fluid volume and the first fluid volume being different from each other; and ][ a fluid flow control device configured to control the first fluid volume and the second fluid volume, ]
[ 2217 ] similarity = 0.44039434 [ a fluid flow control device configured to control the first fluid volume and the second fluid volume, ][ wherein the device comprises a first fluid reservoir and a second fluid reservoir. ]
[ 2218 ] similarity = -0.052243717 [ A method for producing a compound of formula (I) wherein: ][ R1 is hydrogen, alkyl, alkenyl, alkenylalkyl, alkylalkyl, alkenylalkoxy, alkylalkoxyalkyl, alkylalkoxyalkyl, or a pharmaceutically acceptable salt thereof. ]
[ 2219 ] similarity = 0.065248765 [ An apparatus for treating a patient, comprising: ][ a) an elongate body having an outer surface, an inner surface, a first end portion and a second end portion, wherein said outer surface is configured to be positioned between said inner and outer surfaces; ]
[ 2220 ] similarity = 0.5493665 [ a) an elongate body having an outer surface, an inner surface, a first end portion and a second end portion, wherein said outer surface is configured to be positioned between said inner and outer surfaces; ][ b) a first electrode disposed within said elongate body and configured to be electrically coupled to said inner and outer surfaces; and ]
[ 2221 ] similarity = 0.84453374 [ b) a first electrode disposed within said elongate body and configured to be electrically coupled to said inner and outer surfaces; and ][ c) a second electrode disposed within said elongate body and configured to be electrically coupled to said outer surface; ]
[ 2222 ] similarity = 0.59738874 [ c) a second electrode disposed within said elongate body and configured to be electrically coupled to said outer surface; ][ d) wherein said first electrode comprises a first electrode portion and a second electrode portion, said first electrode portion being configured to be disposed within said elongate body; and ]
[ 2223 ] similarity = 0.7867662 [ d) wherein said first electrode comprises a first electrode portion and a second electrode portion, said first electrode portion being configured to be disposed within said elongate body; and ][ e) wherein said second electrode portion comprises a third electrode portion and a fourth electrode portion, wherein said first electrode portion and said second electrode portion are configured to be electrically coupled to said third electrode portion and said fourth electrode portion, respectively. ]
[ 2224 ] similarity = -0.0090040155 [ A device for providing a therapeutic dose of a pharmaceutical composition comprising an effective amount of at least one compound of the formula: ][ wherein: ]
[ 2225 ] similarity = -0.08574605 [ wherein: ][ X1, X2, Y1, Y2 and Y3 are independently selected from a group consisting of hydrogen, alkyl, alkenyl, alkenylalkyl and aryl; ]
[ 2226 ] similarity = 0.52415574 [ X1, X2, Y1, Y2 and Y3 are independently selected from a group consisting of hydrogen, alkyl, alkenyl, alkenylalkyl and aryl; ][ R1, R2, R3 and R4 are independently selected from the group consisting of H and C1-C4 alkyl; and ]
[ 2227 ] similarity = 0.708676 [ R1, R2, R3 and R4 are independently selected from the group consisting of H and C1-C4 alkyl; and ][ R5, R6 and R7 are independently selected from the group consisting of H and C1-C4 alkyl. ]
[ 2228 ] similarity = 0.78480726 [ A method for producing an isolated antibody or antigen binding fragment of said antibody or antigen binding fragment comprising: ][ (a) contacting said antibody or antigen binding fragment with an antibody or antigen binding fragment of a human or animal cell, wherein the antibody or antigen binding fragment is a monoclonal antibody, an antigen-binding fragment of said antibody or antigen binding fragment of said human or animal cell, or an antigen-binding fragment of a human or animal cell that binds to said monoclonal antibody; ]
[ 2229 ] similarity = 0.8527414 [ (a) contacting said antibody or antigen binding fragment with an antibody or antigen binding fragment of a human or animal cell, wherein the antibody or antigen binding fragment is a monoclonal antibody, an antigen-binding fragment of said antibody or antigen binding fragment of said human or animal cell, or an antigen-binding fragment of a human or animal cell that binds to said monoclonal antibody; ][ (b) contacting said antibody or antigen binding fragment with a human antibody that is a humanized antibody or antigen-binding fragment thereof that is a monoclonal antibody or an antigen-binding fragment of said human antibody; and ]
[ 2230 ] similarity = 0.7094715 [ (b) contacting said antibody or antigen binding fragment with a human antibody that is a humanized antibody or antigen-binding fragment thereof that is a monoclonal antibody or an antigen-binding fragment of said human antibody; and ][ (c) contacting said antibody or antigen binding fragment with said human or animal cell. ]
[ 2231 ] similarity = 0.06450395 [ A method for treating a patient suffering from an inflammatory bowel disease comprising administering an effective amount of a composition comprising an isolated peptide comprising an amino acid sequence selected from the group consisting of: ][ SEQ ID NO: ]
[ 2232 ] similarity = 0.23162848 [ SEQ ID NO: ][ 1; ]
[ 2233 ] similarity = 0.23162848 [ 1; ][ SEQ ID NO: ]
[ 2234 ] similarity = 0.15015887 [ SEQ ID NO: ][ 2; and ]
[ 2235 ] similarity = 0.15015887 [ 2; and ][ SEQ ID NO: ]
[ 2236 ] similarity = 0.21018715 [ SEQ ID NO: ][ 3. ]
[ 2237 ] similarity = 0.13071212 [ An isolated nucleic acid molecule encoding a protein comprising: ][ a nucleotide sequence having at least 90% sequence identity with SEQ ID NO: 2; and ]
[ 2238 ] similarity = 0.9292916 [ a nucleotide sequence having at least 90% sequence identity with SEQ ID NO: 2; and ][ a nucleotide sequence having at least 90% sequence identity with SEQ ID NO: 1. ]
[ 2239 ] similarity = 0.8852838 [ A method of providing an implantable medical system, comprising: ][ providing an implantable medical system comprising: ]
[ 2240 ] similarity = 0.34220254 [ providing an implantable medical system comprising: ][ a first electrode configured to be coupled to an implantable medical device and configured to generate a signal; ]
[ 2241 ] similarity = 0.7762634 [ a first electrode configured to be coupled to an implantable medical device and configured to generate a signal; ][ a second electrode configured to be coupled to the implantable medical device; and ]
[ 2242 ] similarity = 0.5681944 [ a second electrode configured to be coupled to the implantable medical device; and ][ an actuator configured to be coupled with the first electrode and the second electrode, the actuator being configured to provide a first force to the first electrode, and ]
[ 2243 ] similarity = 0.6462752 [ an actuator configured to be coupled with the first electrode and the second electrode, the actuator being configured to provide a first force to the first electrode, and ][ a second force to the second electrode, the first and second forces being coupled to the actuator, wherein: ]
[ 2244 ] similarity = 0.47020906 [ a second force to the second electrode, the first and second forces being coupled to the actuator, wherein: ][ the first force is a first force applied by the first electrode; and ]
[ 2245 ] similarity = 0.48133066 [ the first force is a first force applied by the first electrode; and ][ the second force is a second force applied by the second electrode. ]
[ 2246 ] similarity = 0.41052943 [ A method of treating a patient suffering from an autoimmune disorder, comprising administering to the patient in need thereof an effective amount of a pharmaceutically acceptable composition that comprises an effective amount of a polypeptide comprising an amino acid sequence that encodes a polypeptide that is at least 90% identical to the amino acid sequence of SEQ ID NO: ][ 1 or a polypeptide comprising the amino acid sequence of SEQ ID NO: ]
[ 2247 ] similarity = -0.040093064 [ 1 or a polypeptide comprising the amino acid sequence of SEQ ID NO: ][ 2. ]
[ 2248 ] similarity = 0.01363807 [ A method for treating a subject having a disease or condition, the method comprising administering to the subject a therapeutically effective amount of an isolated antibody or antigen-binding fragment thereof that binds to a polypeptide comprising the following sequence: ][ A&#x2032; ]
[ 2249 ] similarity = 0.09644165 [ A&#x2032; ][ (SEQ ID NO: ]
[ 2250 ] similarity = 0.280955 [ (SEQ ID NO: ][ 1) or a pharmaceutically acceptable salt thereof, wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: ]
[ 2251 ] similarity = -0.0034521539 [ 1) or a pharmaceutically acceptable salt thereof, wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: ][ 1. ]
[ 2252 ] similarity = 0.51541203 [ A method for the production of a polymeric material comprising the steps of: ][ (a) forming a polymeric material from a polymer; ]
[ 2253 ] similarity = 0.19766472 [ (a) forming a polymeric material from a polymer; ][ (b) forming a polymerizable layer on said polymerizable layer; ]
[ 2254 ] similarity = 0.6409204 [ (b) forming a polymerizable layer on said polymerizable layer; ][ (c) forming a polymerizable layer on said polymeric material; and ]
[ 2255 ] similarity = 0.3945859 [ (c) forming a polymerizable layer on said polymeric material; and ][ (d) forming a polymerizable layer on said polymeric material, said step (c) further including the steps of (a) and (b), wherein said polymerizable layer includes at least one polymerizable polymer having an average molecular weight of less than about 500, ]
[ 2256 ] similarity = 0.05669185 [ (d) forming a polymerizable layer on said polymeric material, said step (c) further including the steps of (a) and (b), wherein said polymerizable layer includes at least one polymerizable polymer having an average molecular weight of less than about 500, ][ 000, ]
[ 2257 ] similarity = 0.56721437 [ 000, ][ 000 daltons. ]
[ 2258 ] similarity = 0.35490632 [ A method for producing a therapeutic compound, the method comprising: ][ providing a compound comprising a pharmaceutically acceptable salt, wherein the compound is a pharmaceutically acceptable salt of the compound selected from the group consisting of: ]
[ 2259 ] similarity = 0.50602555 [ providing a compound comprising a pharmaceutically acceptable salt, wherein the compound is a pharmaceutically acceptable salt of the compound selected from the group consisting of: ][ a) a salt of a pharmaceutically acceptable salt of an amino acid of SEQ ID NO: ]
[ 2260 ] similarity = 0.033253156 [ a) a salt of a pharmaceutically acceptable salt of an amino acid of SEQ ID NO: ][ 1; and ]
[ 2261 ] similarity = 0.029161144 [ 1; and ][ b) a salt of a pharmaceutically acceptable salt of an amino acid of SEQ ID NO: ]
[ 2262 ] similarity = -0.022746548 [ b) a salt of a pharmaceutically acceptable salt of an amino acid of SEQ ID NO: ][ 2. ]
[ 2263 ] similarity = -0.075973816 [ A method of providing an effective dose of an effective amount of a compound of the formula (I): ][ wherein: ]
[ 2264 ] similarity = 0.03507515 [ wherein: ][ X is a first or a second C1-C6 alkyl group; ]
[ 2265 ] similarity = 0.9726112 [ X is a first or a second C1-C6 alkyl group; ][ X is a first or a second C3-C6 alkyl group; ]
[ 2266 ] similarity = 0.52427673 [ X is a first or a second C3-C6 alkyl group; ][ X is a C1-C6 alkyl ring; ]
[ 2267 ] similarity = 0.17229056 [ X is a C1-C6 alkyl ring; ][ R1 is a first or a second C1-C6 alkyl group; and ]
[ 2268 ] similarity = 0.2943082 [ R1 is a first or a second C1-C6 alkyl group; and ][ R2 and R3 are each independently a C1-C4 alkyl group; ]
[ 2269 ] similarity = 0.30214185 [ R2 and R3 are each independently a C1-C4 alkyl group; ][ R4 is a first or a second C1-C4 alkyl group; ]
[ 2270 ] similarity = 0.25038427 [ R4 is a first or a second C1-C4 alkyl group; ][ R5 and R6 are each independently a C1-C4 alkyl group; ]
[ 2271 ] similarity = 0.23191 [ R5 and R6 are each independently a C1-C4 alkyl group; ][ R7 is a first or a second C1-C4 alkyl group; and ]
[ 2272 ] similarity = 0.69176316 [ R7 is a first or a second C1-C4 alkyl group; and ][ R8 is a first or a second C3-C6 alkyl group. ]
[ 2273 ] similarity = -0.014292523 [ A method for the production of an implantable medical device comprising: ][ a) providing a substrate having a first surface and a second surface, the first surface and the second surface having a first thickness and a second thickness that is greater than the first surface; ]
[ 2274 ] similarity = 0.3205789 [ a) providing a substrate having a first surface and a second surface, the first surface and the second surface having a first thickness and a second thickness that is greater than the first surface; ][ b) forming a first layer of a polymer on the substrate; ]
[ 2275 ] similarity = 0.7448947 [ b) forming a first layer of a polymer on the substrate; ][ c) forming a second layer of the polymer on the first surface of the substrate; and ]
[ 2276 ] similarity = 0.70869076 [ c) forming a second layer of the polymer on the first surface of the substrate; and ][ d) forming a third layer of the polymer on the first surface, the second layer of the polymer, and ]
[ 2277 ] similarity = 0.7378204 [ d) forming a third layer of the polymer on the first surface, the second layer of the polymer, and ][ the third layer of the polymer on the second surface of the substrate. ]
[ 2278 ] similarity = 0.38584888 [ An apparatus, comprising: ][ a housing; ]
[ 2279 ] similarity = 0.1319688 [ a housing; ][ a plurality of sensors configured to sense a plurality of physiological parameters; ]
[ 2280 ] similarity = 0.44465077 [ a plurality of sensors configured to sense a plurality of physiological parameters; ][ a processor configured to determine a set of physiological parameters based on a first physiological parameter and a second physiological parameter, wherein determining a first physiological parameter comprises determining whether a first physiological parameter is present in a first set of physiological parameters; ]
[ 2281 ] similarity = 0.60050964 [ a processor configured to determine a set of physiological parameters based on a first physiological parameter and a second physiological parameter, wherein determining a first physiological parameter comprises determining whether a first physiological parameter is present in a first set of physiological parameters; ][ a memory storing a first set of first physiological parameters; and ]
[ 2282 ] similarity = 0.5307569 [ a memory storing a first set of first physiological parameters; and ][ a processor configured to determine a set of second physiological parameters based on a second physiological parameter. ]
[ 2283 ] similarity = 0.17239255 [ A device for providing a first treatment to a patient, comprising: ][ a housing; ]
[ 2284 ] similarity = 0.13977678 [ a housing; ][ a first treatment device having a first end and a second end; ]
[ 2285 ] similarity = 0.4717063 [ a first treatment device having a first end and a second end; ][ an actuator coupled to the first device; ]
[ 2286 ] similarity = 0.5138012 [ an actuator coupled to the first device; ][ a first electrode coupled to the first end of the first treatment device and configured to be positioned on a surface of a patient; ]
[ 2287 ] similarity = 0.7994214 [ a first electrode coupled to the first end of the first treatment device and configured to be positioned on a surface of a patient; ][ a second electrode coupled to the second end of the first treatment device and configured to be positioned on a surface of the patient; ]
[ 2288 ] similarity = 0.72847354 [ a second electrode coupled to the second end of the first treatment device and configured to be positioned on a surface of the patient; ][ a first electrode coupled to the first electrode and configured to be positioned on a surface of the patient; ]
[ 2289 ] similarity = 0.57511413 [ a first electrode coupled to the first electrode and configured to be positioned on a surface of the patient; ][ a second electrode coupled to the second end of the second treatment device and configured to be positioned on a surface of the patient; and ]
[ 2290 ] similarity = 0.5581378 [ a second electrode coupled to the second end of the second treatment device and configured to be positioned on a surface of the patient; and ][ at least one electrode coupled to the first electrode and configured to be disposed on the surface of the patient, ]
[ 2291 ] similarity = 0.726548 [ at least one electrode coupled to the first electrode and configured to be disposed on the surface of the patient, ][ wherein, when the first electrode is positioned on the surface, the actuator is coupled to the first device and the first electrode is coupled to the first electrode, and ]
[ 2292 ] similarity = 0.5074163 [ wherein, when the first electrode is positioned on the surface, the actuator is coupled to the first device and the first electrode is coupled to the first electrode, and ][ the second electrode is coupled to the second device and the second electrode, ]
[ 2293 ] similarity = 0.5750528 [ the second electrode is coupled to the second device and the second electrode, ][ wherein, when the first electrode is positioned on the surface, the actuator is coupled to the first device and the first electrode is coupled to the first electrode, the second electrode is coupled to the actuator, and ]
[ 2294 ] similarity = 0.51952827 [ wherein, when the first electrode is positioned on the surface, the actuator is coupled to the first device and the first electrode is coupled to the first electrode, the second electrode is coupled to the actuator, and ][ the second electrode is coupled to the actuator and the second device, ]
[ 2295 ] similarity = 0.514674 [ the second electrode is coupled to the actuator and the second device, ][ wherein, when the actuator is coupled to the actuator, a first portion of the first electrode is positioned on the surface of the patient, the second portion of the second electrode is positioned on the surface of the patient, and ]
[ 2296 ] similarity = 0.9289125 [ wherein, when the actuator is coupled to the actuator, a first portion of the first electrode is positioned on the surface of the patient, the second portion of the second electrode is positioned on the surface of the patient, and ][ when the actuator is coupled to the actuator, a second portion of the first electrode is positioned on the surface of the patient and when the actuator is coupled to the actuator the second portion of the first electrode is positioned on the surface of the patient. ]
[ 2297 ] similarity = -0.03363864 [ An isolated nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ. ID NO: ][ 2. ]
[ 2298 ] similarity = 0.6845596 [ A method of providing a therapeutic dose of a therapeutic agent, comprising: ][ providing a first therapeutic agent; ]
[ 2299 ] similarity = 0.6813369 [ providing a first therapeutic agent; ][ providing a second therapeutic agent; and ]
[ 2300 ] similarity = 0.333329 [ providing a second therapeutic agent; and ][ mixing the first and second therapeutic agents, wherein the first therapeutic agent is a first compound of Formula I, the second therapeutic agent is a second compound of Formula I, the first compound being a compound of Formula I or an ester thereof and the second compound is a compound of Formula II, wherein the first and second therapeutic agents are administered to a patient. ]
[ 2301 ] similarity = 0.5868907 [ A method of providing a patient with a medical device comprising: ][ providing a patient-specific medical device; ]
[ 2302 ] similarity = 0.5027747 [ providing a patient-specific medical device; ][ providing at least one medical device component, said medical device component including at least one of a first medical device, a second medical device and a third medical device; ]
[ 2303 ] similarity = 0.3246919 [ providing at least one medical device component, said medical device component including at least one of a first medical device, a second medical device and a third medical device; ][ providing a first patient-specific device component; ]
[ 2304 ] similarity = 0.61142415 [ providing a first patient-specific device component; ][ providing a second patient-specific device component; and ]
[ 2305 ] similarity = 0.46082097 [ providing a second patient-specific device component; and ][ providing a fourth medical device component; ]
[ 2306 ] similarity = 0.46533674 [ providing a fourth medical device component; ][ wherein the first medical device is a first medical device and the second medical device is a second medical device; ]
[ 2307 ] similarity = 0.8047324 [ wherein the first medical device is a first medical device and the second medical device is a second medical device; ][ wherein the first medical device component is a first medical device component and the second medical device component is a second medical device component; ]
[ 2308 ] similarity = 0.98929226 [ wherein the first medical device component is a first medical device component and the second medical device component is a second medical device component; ][ wherein the first medical device component is a first medical device component and the second medical device is a second medical device component; ]
[ 2309 ] similarity = 0.9892922 [ wherein the first medical device component is a first medical device component and the second medical device is a second medical device component; ][ wherein the first medical device component is a first medical device component and the second medical device component is a second medical device component; ]
[ 2310 ] similarity = 0.74098665 [ wherein the first medical device component is a first medical device component and the second medical device component is a second medical device component; ][ wherein the fourth medical device component is a fourth medical device component; and ]
[ 2311 ] similarity = 0.6778078 [ wherein the fourth medical device component is a fourth medical device component; and ][ wherein the first medical device component is a first medical device component. ]
[ 2312 ] similarity = 0.35780293 [ A method for treating a disease or disorder in a subject comprising: ][ providing a first therapeutic agent, the first therapeutic agent comprising a first therapeutic agent composition comprising a first compound selected from the group consisting of: ]
[ 2313 ] similarity = 0.07759027 [ providing a first therapeutic agent, the first therapeutic agent comprising a first therapeutic agent composition comprising a first compound selected from the group consisting of: ][ a) a compound of formula (I) wherein R1 is a hydrogen atom, a substituted or unsubstituted alkyl group, an alkyl group having a C1-C6 carbon atoms, or a substituted or unsubstituted cycloalkyl group, and ]
[ 2314 ] similarity = 0.26126605 [ a) a compound of formula (I) wherein R1 is a hydrogen atom, a substituted or unsubstituted alkyl group, an alkyl group having a C1-C6 carbon atoms, or a substituted or unsubstituted cycloalkyl group, and ][ R2 is an alkyl group having a C3-C8 carbon atom; ]
[ 2315 ] similarity = 0.41082186 [ R2 is an alkyl group having a C3-C8 carbon atom; ][ b) a compound of formula (II) wherein R1 is a hydrogen atom or a substituted or unsubstituted alkyl group and R2 is an alkyl group having a C1-C6 carbon atom; and ]
[ 2316 ] similarity = 0.73895055 [ b) a compound of formula (II) wherein R1 is a hydrogen atom or a substituted or unsubstituted alkyl group and R2 is an alkyl group having a C1-C6 carbon atom; and ][ wherein the first compound is selected from the group consisting of a first compound of formula (I) and a first compound of formula (II) wherein R1 is a hydrogen atom, a substituted or unsubstituted alkyl group, an alkyl group having a C1-C6 carbon atom, an alkyl group having a C3-C8 carbon atom or a substituted or unsubstituted cycloalkyl group, and ]
[ 2317 ] similarity = 0.5405586 [ wherein the first compound is selected from the group consisting of a first compound of formula (I) and a first compound of formula (II) wherein R1 is a hydrogen atom, a substituted or unsubstituted alkyl group, an alkyl group having a C1-C6 carbon atom, an alkyl group having a C3-C8 carbon atom or a substituted or unsubstituted cycloalkyl group, and ][ R2 is an alkyl group having a C3-C8 carbon atom or an substituted or unsubstituted cycloalkyl group; and ]
[ 2318 ] similarity = -0.06522407 [ R2 is an alkyl group having a C3-C8 carbon atom or an substituted or unsubstituted cycloalkyl group; and ][ wherein the first therapeutic agent is administered to a subject. ]
[ 2319 ] similarity = 0.26607662 [ A method of treating a patient, comprising administering to the patient a composition comprising: ][ a) a compound selected from the group consisting of: ]
[ 2320 ] similarity = 0.076043606 [ a) a compound selected from the group consisting of: ][ (a) the amino acid sequence of SEQ ID NO: ]
[ 2321 ] similarity = 0.00048572477 [ (a) the amino acid sequence of SEQ ID NO: ][ 3, and ]
[ 2322 ] similarity = 0.12940368 [ 3, and ][ (b) an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, and ]
[ 2323 ] similarity = 0.39683115 [ (b) an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, and ][ SEQ ID NO: 4. ]
[ 2324 ] similarity = 0.3685078 [ A system for treating a patient with cancer, comprising: ][ a first medical imaging device configured to acquire a first image; ]
[ 2325 ] similarity = 0.66497433 [ a first medical imaging device configured to acquire a first image; ][ a second medical imaging device configured to acquire a second image; and ]
[ 2326 ] similarity = 0.39854082 [ a second medical imaging device configured to acquire a second image; and ][ a processor configured to determine whether the first and second images match at a point of interest (POI) and to generate an indication of whether the patient is at risk for cancer based on the image acquisition. ]
[ 2327 ] similarity = 0.2775085 [ An isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, and ][ SEQ ID NO: 3. ]
[ 2328 ] similarity = 0.16584352 [ Apparatus for measuring the concentration of a substance in an object, said apparatus comprising: ][ an analyte sensor; and ]
[ 2329 ] similarity = 0.08983435 [ an analyte sensor; and ][ an output device for outputting a signal indicative of the concentration of said substance in said object, said output device comprising: ]
[ 2330 ] similarity = 0.08924027 [ an output device for outputting a signal indicative of the concentration of said substance in said object, said output device comprising: ][ a first sensor; and ]
[ 2331 ] similarity = 0.36263892 [ a first sensor; and ][ an output device coupled to said first sensor, said output device being configured to receive the signal from the analyte sensor, ]
[ 2332 ] similarity = 0.32750717 [ an output device coupled to said first sensor, said output device being configured to receive the signal from the analyte sensor, ][ wherein said first sensor comprises a first electrode and a first electrode layer, ]
[ 2333 ] similarity = 0.8812666 [ wherein said first sensor comprises a first electrode and a first electrode layer, ][ wherein said first electrode layer comprises a first electrode layer and a second electrode layer, and ]
[ 2334 ] similarity = 0.98905486 [ wherein said first electrode layer comprises a first electrode layer and a second electrode layer, and ][ wherein the first electrode layer comprises a first electrode layer and a second electrode layer, and ]
[ 2335 ] similarity = 0.88403094 [ wherein the first electrode layer comprises a first electrode layer and a second electrode layer, and ][ wherein said first electrode layer is configured to receive a first electrode layer, and ]
[ 2336 ] similarity = 0.58221036 [ wherein said first electrode layer is configured to receive a first electrode layer, and ][ the output device comprises a second electrode layer and a second electrode layer. ]
[ 2337 ] similarity = 0.3950133 [ A system for providing a medical treatment to a patient comprising: ][ a medical device having at least one medical device interface configured to interface with at least one medical device, the medical device having an internal volume; and ]
[ 2338 ] similarity = 0.5073541 [ a medical device having at least one medical device interface configured to interface with at least one medical device, the medical device having an internal volume; and ][ a medical device controller configured to: ]
[ 2339 ] similarity = 0.438321 [ a medical device controller configured to: ][ receive a first medical device request from a first medical device; ]
[ 2340 ] similarity = 0.64313805 [ receive a first medical device request from a first medical device; ][ determine a first medical device type from at least two different medical device types; ]
[ 2341 ] similarity = 0.96992314 [ determine a first medical device type from at least two different medical device types; ][ determine a first medical device type from at least two different types of medical devices; ]
[ 2342 ] similarity = 0.8390447 [ determine a first medical device type from at least two different types of medical devices; ][ receive at least one medical device request from a second medical device that is different from the first medical device type; ]
[ 2343 ] similarity = 0.8440244 [ receive at least one medical device request from a second medical device that is different from the first medical device type; ][ determine at least one medical device type from at least two medical devices that have a similar medical device type, the at least two medical devices including a first medical device type, a second medical device type, or both of the first and second medical device types; ]
[ 2344 ] similarity = 0.9780814 [ determine at least one medical device type from at least two medical devices that have a similar medical device type, the at least two medical devices including a first medical device type, a second medical device type, or both of the first and second medical device types; ][ determine at least one medical device type from at least two medical device types that have the same medical device type, the at least two medical devices including the first medical device type, the second medical device type, or both of the first and second medical device types; and ]
[ 2345 ] similarity = 0.7498815 [ determine at least one medical device type from at least two medical device types that have the same medical device type, the at least two medical devices including the first medical device type, the second medical device type, or both of the first and second medical device types; and ][ provide a first medical device to the patient based at least in part on a determination of a second medical device type from a first set of medical device types. ]
[ 2346 ] similarity = 0.13537249 [ A method for treating a subject having a cancer comprising administering to the subject an effective amount of a compound selected from the group consisting of: ][ a pharmaceutically acceptable carrier; and ]
[ 2347 ] similarity = 0.58262086 [ a pharmaceutically acceptable carrier; and ][ a therapeutically effective amount of a pharmaceutically acceptable agent, the therapeutically acceptable agent being a pharmaceutically acceptable carrier, ]
[ 2348 ] similarity = 0.416431 [ a therapeutically effective amount of a pharmaceutically acceptable agent, the therapeutically acceptable agent being a pharmaceutically acceptable carrier, ][ wherein the carrier is a pharmaceutically acceptable carrier having at least 95% homogeneity with respect to the composition, wherein the carrier has a molecular weight of less than about 10 000 &#x3bc; ]
[ 2349 ] similarity = 0.062494285 [ wherein the carrier is a pharmaceutically acceptable carrier having at least 95% homogeneity with respect to the composition, wherein the carrier has a molecular weight of less than about 10 000 &#x3bc; ][ m, ]
[ 2350 ] similarity = 0.044402257 [ m, ][ wherein the carrier is an isolated polypeptide comprising at least one of the amino acid sequences set forth as SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and ]
[ 2351 ] similarity = 0.37114984 [ wherein the carrier is an isolated polypeptide comprising at least one of the amino acid sequences set forth as SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and ][ SEQ ID NO: 7. ]
[ 2352 ] similarity = 0.5489623 [ A method of treating a patient having a condition in which the patient's brain is damaged by a substance that is present in the substance, the method comprising: ][ administering to the patient a substance that inhibits a substance that is present in the substance; ]
[ 2353 ] similarity = 1.0 [ administering to the patient a substance that inhibits a substance that is present in the substance; ][ administering to the patient a substance that inhibits a substance that is present in the substance; ]
[ 2354 ] similarity = 1.0000001 [ administering to the patient a substance that inhibits a substance that is present in the substance; ][ administering to the patient a substance that inhibits a substance that is present in the substance; ]
[ 2355 ] similarity = 1.0000001 [ administering to the patient a substance that inhibits a substance that is present in the substance; ][ administering to the patient a substance that inhibits a substance that is present in the substance; ]
[ 2356 ] similarity = 0.99999994 [ administering to the patient a substance that inhibits a substance that is present in the substance; ][ administering to the patient a substance that inhibits a substance that is present in the substance; ]
[ 2357 ] similarity = 0.949901 [ administering to the patient a substance that inhibits a substance that is present in the substance; ][ administering to the patient a substance that inhibits a substance that is present in the substance; and ]
[ 2358 ] similarity = 0.949901 [ administering to the patient a substance that inhibits a substance that is present in the substance; and ][ administering to the patient a substance that inhibits a substance that is present in the substance. ]
[ 2359 ] similarity = 0.016500304 [ A method for treating a patient having a tumor comprising: ][ administering to said patient a therapeutically effective amount of an isolated nucleotide, wherein said isolated nucleotide comprises a nucleotide sequence having a amino acid sequence having a nucleotide sequence sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: ]
[ 2360 ] similarity = -0.009014089 [ administering to said patient a therapeutically effective amount of an isolated nucleotide, wherein said isolated nucleotide comprises a nucleotide sequence having a amino acid sequence having a nucleotide sequence sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: ][ 3. ]
[ 2361 ] similarity = 0.21288195 [ A method of treating an autoimmune disease, comprising administering a composition comprising: ][ (a) a therapeutically effective amount of a polypeptide, antigen-binding fragment, a peptide and a pharmaceutically acceptable salt thereof, and ]
[ 2362 ] similarity = 0.31896138 [ (a) a therapeutically effective amount of a polypeptide, antigen-binding fragment, a peptide and a pharmaceutically acceptable salt thereof, and ][ (b) a pharmaceutically acceptable carrier, wherein the composition is administered in a dosage form that is effective to treat the autoimmune disease. ]
[ 2363 ] similarity = 0.74600923 [ An implantable medical system comprising a plurality of transducer elements, the system including a plurality of transducer elements, each of the plurality of transducer elements comprising a first transducer element, a second transducer element, and ][ a plurality of transducer elements, the first and second transducer elements configured to receive signals from the plurality of transducer elements, wherein each of the plurality of transducer elements is arranged to be disposed within a respective of a first and a second body cavity, the first and second bodies of the plurality of transducer elements being disposed within the first and second body cavity. ]
[ 2364 ] similarity = 0.227301 [ A method for treating a disease in a patient in need thereof, comprising: ][ providing a first therapeutic agent, said first therapeutic agent comprising a compound selected from the group consisting of a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 and SEQ ID NO: 2; and ]
[ 2365 ] similarity = 0.8892708 [ providing a first therapeutic agent, said first therapeutic agent comprising a compound selected from the group consisting of a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 and SEQ ID NO: 2; and ][ a second therapeutic agent, said second therapeutic agent comprising a compound selected from the group consisting of a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 and SEQ ID NO: 2. ]
[ 2366 ] similarity = 0.021405512 [ A method of treating a disease or condition in a patient, said method comprising administering to said patient a composition comprising a compound having the formula: ][ wherein: ]
[ 2367 ] similarity = -0.033521205 [ wherein: ][ R1 and R2 are independently H, C1-C4 alkyl, C1-C4 alkenyl, C1-C4 alkoxy, C1-C4 alkylene, C3-C6 alkyl, C3-C6 alkoxyalkyl, or C3-C6 alkoxycarbonyl, wherein R1 and R2 are selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkylene, C3-C6 alkylcarbonyl, C1-C4 alkylene, C3-C6 alkylenealkyl, C1-C6 alkylcarbonyl, and ]
[ 2368 ] similarity = 0.105969146 [ R1 and R2 are independently H, C1-C4 alkyl, C1-C4 alkenyl, C1-C4 alkoxy, C1-C4 alkylene, C3-C6 alkyl, C3-C6 alkoxyalkyl, or C3-C6 alkoxycarbonyl, wherein R1 and R2 are selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkylene, C3-C6 alkylcarbonyl, C1-C4 alkylene, C3-C6 alkylenealkyl, C1-C6 alkylcarbonyl, and ][ C1-C4 alkoxyalkyl; and ]
[ 2369 ] similarity = 0.15021509 [ C1-C4 alkoxyalkyl; and ][ R3 and R4 are independently selected from the group consisting of H, C1-C4 alkyl, C1-C4 alkenyl, C1-C4 alkoxy, C3-C6 alkyl, C3-C6 alkoxyalkyl, C1-C6 alkylcarbonyl, and ]
[ 2370 ] similarity = 0.10797225 [ R3 and R4 are independently selected from the group consisting of H, C1-C4 alkyl, C1-C4 alkenyl, C1-C4 alkoxy, C3-C6 alkyl, C3-C6 alkoxyalkyl, C1-C6 alkylcarbonyl, and ][ C1-C4 alkoxycarbonyl. ]
[ 2371 ] similarity = 0.17186792 [ An apparatus for providing a therapeutic dose, comprising: ][ a first chamber; ]
[ 2372 ] similarity = 0.6677261 [ a first chamber; ][ a second chamber; ]
[ 2373 ] similarity = 0.20521413 [ a second chamber; ][ a first pump configured for providing a first dose of a therapeutic substance into the first chamber; ]
[ 2374 ] similarity = 0.77540183 [ a first pump configured for providing a first dose of a therapeutic substance into the first chamber; ][ at least one first pump controller configured for controlling the first pump to deliver the first dose of the therapeutic substance into the first chamber; and ]
[ 2375 ] similarity = 0.64550424 [ at least one first pump controller configured for controlling the first pump to deliver the first dose of the therapeutic substance into the first chamber; and ][ an actuator operatively coupled to the first pump, the actuator configured to provide a second dose of the therapeutic substance into the second chamber, ]
[ 2376 ] similarity = 0.3466461 [ an actuator operatively coupled to the first pump, the actuator configured to provide a second dose of the therapeutic substance into the second chamber, ][ wherein the first chamber is positioned in a first position, the first chamber is positioned in a second position, and ]
[ 2377 ] similarity = 0.7658856 [ wherein the first chamber is positioned in a first position, the first chamber is positioned in a second position, and ][ the first chamber is positioned between the second position and the first position. ]
[ 2378 ] similarity = 0.57253146 [ A method of providing a medical device to a patient, comprising: ][ providing a first medical device; ]
[ 2379 ] similarity = 0.6311244 [ providing a first medical device; ][ providing a second medical device; and ]
[ 2380 ] similarity = 0.29955414 [ providing a second medical device; and ][ providing a first medical device to the patient, wherein the first medical device is configured for use by a first patient; ]
[ 2381 ] similarity = 0.49980015 [ providing a first medical device to the patient, wherein the first medical device is configured for use by a first patient; ][ providing a second medical device to the patient; ]
[ 2382 ] similarity = 0.7894907 [ providing a second medical device to the patient; ][ providing a medical device to be used by the patient, the medical device being configured for use by a second patient; ]
[ 2383 ] similarity = 0.6805874 [ providing a medical device to be used by the patient, the medical device being configured for use by a second patient; ][ providing a first medical device to the first patient, wherein the first medical device is configured for use by the second patient; and ]
[ 2384 ] similarity = 0.65269876 [ providing a first medical device to the first patient, wherein the first medical device is configured for use by the second patient; and ][ providing an electronic device, the electronic device being configured for use by the first patient and the second patient. ]
[ 2385 ] similarity = 0.21549076 [ A method for treating an inflammatory disease in a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising: ][ (a) a pharmaceutically acceptable salt of the polypeptide of SEQ ID NO: ]
[ 2386 ] similarity = 0.012504739 [ (a) a pharmaceutically acceptable salt of the polypeptide of SEQ ID NO: ][ 2; ]
[ 2387 ] similarity = 0.036051765 [ 2; ][ (b) a pharmaceutically acceptable carrier; and ]
[ 2388 ] similarity = 0.65785563 [ (b) a pharmaceutically acceptable carrier; and ][ (c) a pharmaceutically acceptable excipient; ]
[ 2389 ] similarity = 0.106319554 [ (c) a pharmaceutically acceptable excipient; ][ wherein said excipient is a polypeptide of SEQ ID NO. 2. ]
[ 2390 ] similarity = 0.3084845 [ A method of treating a patient suffering from chronic obstructive pulmonary disease (COPD), wherein said method is adapted to treat the COPD, wherein said method comprises: ][ a) administering to said patient a first pharmaceutical composition comprising a pharmaceutically acceptable carrier, wherein said first pharmaceutical composition is a pharmaceutically acceptable carrier; and ]
[ 2391 ] similarity = 0.7306146 [ a) administering to said patient a first pharmaceutical composition comprising a pharmaceutically acceptable carrier, wherein said first pharmaceutical composition is a pharmaceutically acceptable carrier; and ][ b) administering to said patient a second pharmaceutical composition comprising a pharmaceutically acceptable carrier, wherein said second pharmaceutical composition is a pharmaceutically acceptable carrier, wherein said first and second pharmaceutical compositions are administered to said patient in a combination, wherein said second pharmaceutical composition comprises at least two different pharmaceutical components. ]
[ 2392 ] similarity = 0.4646592 [ A method for treating a cancer comprising: ][ administering a compound to a subject in need thereof to treat the cancer; and ]
[ 2393 ] similarity = 0.30009097 [ administering a compound to a subject in need thereof to treat the cancer; and ][ administering a therapeutically effective amount of the compound to the subject in need thereof, wherein the compound is selected from the group consisting of a pharmaceutically acceptable salt, a pharmaceutically acceptable carrier, a pharmaceutically acceptable carrier salt, a pharmaceutically acceptable salt, and ]
[ 2394 ] similarity = 0.5719094 [ administering a therapeutically effective amount of the compound to the subject in need thereof, wherein the compound is selected from the group consisting of a pharmaceutically acceptable salt, a pharmaceutically acceptable carrier, a pharmaceutically acceptable carrier salt, a pharmaceutically acceptable salt, and ][ a pharmaceutically acceptable carrier salt. ]
[ 2395 ] similarity = 0.21476927 [ An apparatus for treating an eye, the apparatus comprising: ][ an optical system having a first optical element and a second optical element; ]
[ 2396 ] similarity = 0.7883649 [ an optical system having a first optical element and a second optical element; ][ a first optical element disposed in the first optical system; ]
[ 2397 ] similarity = 0.6883235 [ a first optical element disposed in the first optical system; ][ a second optical element disposed in the optical system and having a substantially perpendicular surface, the second optical element being substantially parallel to the first optical element; ]
[ 2398 ] similarity = 0.66083086 [ a second optical element disposed in the optical system and having a substantially perpendicular surface, the second optical element being substantially parallel to the first optical element; ][ a first optical system member disposed in the optical system, the first optical system member being configured to be disposed in the eye; and ]
[ 2399 ] similarity = 0.5552138 [ a first optical system member disposed in the optical system, the first optical system member being configured to be disposed in the eye; and ][ a second optical system member disposed in the optical system, the second optical system member being configured to be disposed in a position adjacent to the first optical system member, the second optical system member being disposed substantially parallel to the first optical system member, the second optical system member having an outer surface, the second optical system member having a substantially perpendicular surface, the outer surface defining a plurality of optical elements and a plurality of optical paths, each of the optical paths being configured to be disposed in a substantially perpendicular direction, the plurality of optical paths including a plurality of paths extending in parallel from a center of a plurality of optical elements in a substantially perpendicular direction, each of the optical elements including a plurality of optical elements, the plurality of optical elements including a plurality of optical elements, each of the optical elements including a plurality of optical elements, the plurality of optical elements including a plurality of optical elements, and ]
[ 2400 ] similarity = 0.78241044 [ a second optical system member disposed in the optical system, the second optical system member being configured to be disposed in a position adjacent to the first optical system member, the second optical system member being disposed substantially parallel to the first optical system member, the second optical system member having an outer surface, the second optical system member having a substantially perpendicular surface, the outer surface defining a plurality of optical elements and a plurality of optical paths, each of the optical paths being configured to be disposed in a substantially perpendicular direction, the plurality of optical paths including a plurality of paths extending in parallel from a center of a plurality of optical elements in a substantially perpendicular direction, each of the optical elements including a plurality of optical elements, the plurality of optical elements including a plurality of optical elements, each of the optical elements including a plurality of optical elements, the plurality of optical elements including a plurality of optical elements, and ][ a first plurality of optical path segments, each of the plurality of optical paths including a plurality of optical paths extending in parallel from a center of a plurality of optical elements in a substantially perpendicular direction, each of the optical paths including a plurality of optical paths extending in parallel from a center of a plurality of optical elements in the substantially perpendicular direction. ]
[ 2401 ] similarity = 0.24171934 [ An isolated nucleic acid comprising an amino acid sequence selected from the group consisting of SEQ ID NO: ][ 1, SEQ ID NO: ]
[ 2402 ] similarity = 0.7964808 [ 1, SEQ ID NO: ][ 2, SEQ ID NO: ]
[ 2403 ] similarity = 0.7720622 [ 2, SEQ ID NO: ][ 3, SEQ ID NO: ]
[ 2404 ] similarity = 0.79470795 [ 3, SEQ ID NO: ][ 4, SEQ ID NO: ]
[ 2405 ] similarity = 0.8005054 [ 4, SEQ ID NO: ][ 5, SEQ ID NO: ]
[ 2406 ] similarity = 0.83311415 [ 5, SEQ ID NO: ][ 6, SEQ ID NO: ]
[ 2407 ] similarity = 0.8179097 [ 6, SEQ ID NO: ][ 7, SEQ ID NO: ]
[ 2408 ] similarity = 0.83411634 [ 7, SEQ ID NO: ][ 8, SEQ ID NO: ]
[ 2409 ] similarity = 0.29801184 [ 8, SEQ ID NO: ][ 9, and ]
[ 2410 ] similarity = 0.1655696 [ 9, and ][ SEQ ID NO: ]
[ 2411 ] similarity = 0.21041146 [ SEQ ID NO: ][ 10. ]
[ 2412 ] similarity = 0.20474651 [ A method for treating a disease or condition, comprising administering to a subject a therapeutically effective amount of a compound of formula (I): ][ or a pharmaceutically acceptable salt thereof. ]
[ 2413 ] similarity = 0.37074387 [ A system for treating a disease in a subject comprising: ][ a) a first medical device; and ]
[ 2414 ] similarity = 0.4616502 [ a) a first medical device; and ][ b) a second medical device, wherein the first medical device and the second medical device are configured to provide treatment to a subject, the system further comprising: ]
[ 2415 ] similarity = 0.5915395 [ b) a second medical device, wherein the first medical device and the second medical device are configured to provide treatment to a subject, the system further comprising: ][ i. a medical device comprising a first medical device, a first implantable medical device, and ]
[ 2416 ] similarity = 0.5509262 [ i. a medical device comprising a first medical device, a first implantable medical device, and ][ a second implantable medical device, ]
[ 2417 ] similarity = 0.5041696 [ a second implantable medical device, ][ ii. the first medical device and the second medical device are configured to be implanted in a first patient, ]
[ 2418 ] similarity = 0.83385575 [ ii. the first medical device and the second medical device are configured to be implanted in a first patient, ][ iii. the first medical device and the second medical device are configured to be implantable in a second patient, ]
[ 2419 ] similarity = 0.69434845 [ iii. the first medical device and the second medical device are configured to be implantable in a second patient, ][ iv. the medical device is configured such that the first and second medical devices are configured such that a first portion of the first medical device is configured to be implanted into a portion of a patient's body and a second portion of the first medical device is configured to be inserted into an interior of the second patient, and ]
[ 2420 ] similarity = 0.0025344137 [ iv. the medical device is configured such that the first and second medical devices are configured such that a first portion of the first medical device is configured to be implanted into a portion of a patient's body and a second portion of the first medical device is configured to be inserted into an interior of the second patient, and ][ v. wherein at least one of: ]
[ 2421 ] similarity = 0.27522653 [ v. wherein at least one of: ][ i) at least a portion of at least a portion of the medical device is configured to be implanted within a portion of the second patient, and ]
[ 2422 ] similarity = 0.90992236 [ i) at least a portion of at least a portion of the medical device is configured to be implanted within a portion of the second patient, and ][ ii) at least a portion of a portion of the medical device is configured to be implanted within a portion of an interior of the second patient, ]
[ 2423 ] similarity = 0.814108 [ ii) at least a portion of a portion of the medical device is configured to be implanted within a portion of an interior of the second patient, ][ iv) at least a portion of the first medical device is configured to be implanted within a portion of an exterior of a patient's body, and ]
[ 2424 ] similarity = 0.8573855 [ iv) at least a portion of the first medical device is configured to be implanted within a portion of an exterior of a patient's body, and ][ v) at least a portion of the second medical device is configured to be implanted into a portion of an interior of the patient's body. ]
[ 2425 ] similarity = 0.6546029 [ A method for producing an implantable medical device comprising: ][ a) providing an implantable medical device; and ]
[ 2426 ] similarity = 0.17620686 [ a) providing an implantable medical device; and ][ b) providing a plurality of electrodes; ]
[ 2427 ] similarity = 0.8816187 [ b) providing a plurality of electrodes; ][ c) providing a plurality of electrodes; ]
[ 2428 ] similarity = 0.45548898 [ c) providing a plurality of electrodes; ][ wherein the plurality of electrodes comprises a first electrode, a second electrode, and ]
[ 2429 ] similarity = 0.032554578 [ wherein the plurality of electrodes comprises a first electrode, a second electrode, and ][ an outer layer; ]
[ 2430 ] similarity = 0.12311675 [ an outer layer; ][ wherein the first electrode comprises an electrode core, and ]
[ 2431 ] similarity = 0.7756249 [ wherein the first electrode comprises an electrode core, and ][ wherein the second electrode comprises a first layer of conductive material; and ]
[ 2432 ] similarity = 0.65865266 [ wherein the second electrode comprises a first layer of conductive material; and ][ wherein the outer layer comprises a second layer of conductive material; ]
[ 2433 ] similarity = 0.43790057 [ wherein the outer layer comprises a second layer of conductive material; ][ and wherein the outer layer comprises a conductive layer having a conductivity of at least 50% and having an average conductivity of less than about 10% and a conductivity at least equal to the average conductivity of the first layer of conductive material. ]
[ 2434 ] similarity = 0.12562491 [ A method for treating a disease in a subject, comprising administering to the subject an effective amount of a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier, wherein the carrier is selected from the group consisting of a polypeptide, a peptide, a polypeptide fragment, a polypeptide, a polypeptide fragment, a polypeptide, a peptide, a peptide fragment, a peptide, a polypeptide fragment, a peptide fragment, a polypeptide fragment, a polypeptide fragment, a polypeptide fragment, a polypeptide, a polypeptide fragment, a polypeptide fragment, a polypeptide fragment, a polypeptide fragment, a polypeptide fragment, a polypeptide fragment, a polypeptide fragments, a polypeptides, and ][ a pharmaceutically acceptable salt thereof. ]
[ 2435 ] similarity = 0.588744 [ A device for providing an implantable medical device to a user of the medical device, the device comprising: a housing having a first opening, a second opening, a third opening, and ][ an aperture therethrough; an implantable medical device disposed in the housing, the implantable medical device having a proximal end, a distal end, a first end, a second end, a third end, and ]
[ 2436 ] similarity = 0.08143635 [ an aperture therethrough; an implantable medical device disposed in the housing, the implantable medical device having a proximal end, a distal end, a first end, a second end, a third end, and ][ a plurality of first, second, and ]
[ 2437 ] similarity = 0.15184197 [ a plurality of first, second, and ][ third openings; a first electrode disposed within the first opening of the housing; an actuator configured to be disposed within the first opening of the housing and configured to move the actuator within the first opening of said housing; and ]
[ 2438 ] similarity = 0.6327683 [ third openings; a first electrode disposed within the first opening of the housing; an actuator configured to be disposed within the first opening of the housing and configured to move the actuator within the first opening of said housing; and ][ a first sensor configured to be disposed within an aperture of the second opening of said housing, the first sensor configured to detect an electrical signal from the first electrode, the first sensor configured to detect a signal from the second electrode, the second electrode and the third electrode, and ]
[ 2439 ] similarity = 0.5023702 [ a first sensor configured to be disposed within an aperture of the second opening of said housing, the first sensor configured to detect an electrical signal from the first electrode, the first sensor configured to detect a signal from the second electrode, the second electrode and the third electrode, and ][ to determine a position of the second electrode and the third electrode. ]
[ 2440 ] similarity = 0.2696858 [ A method of producing an isolated polypeptide comprising the amino acids of SEQ ID NO: ][ 1, SEQ ID NO: ]
[ 2441 ] similarity = 0.21046716 [ 1, SEQ ID NO: ][ 2, and ]
[ 2442 ] similarity = 0.15015887 [ 2, and ][ SEQ ID NO: ]
[ 2443 ] similarity = 0.41246796 [ SEQ ID NO: ][ 3, wherein said isolated polypeptide has the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: ]
[ 2444 ] similarity = 0.31657034 [ 3, wherein said isolated polypeptide has the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: ][ 2, or SEQ ID NO: ]
[ 2445 ] similarity = 0.24734178 [ 2, or SEQ ID NO: ][ 3. ]
[ 2446 ] similarity = 0.15590607 [ A method for treating a patient having at least one of: ][ a) a heart disease, ]
[ 2447 ] similarity = 0.56060416 [ a) a heart disease, ][ b) a heart defect, or ]
[ 2448 ] similarity = 0.116245076 [ b) a heart defect, or ][ c) an inflammatory condition, comprising administering to the patient an effective amount of an isolated polypeptide comprising the amino acid sequence as shown in SEQ ID NO: ]
[ 2449 ] similarity = 0.459952 [ c) an inflammatory condition, comprising administering to the patient an effective amount of an isolated polypeptide comprising the amino acid sequence as shown in SEQ ID NO: ][ 2, wherein said isolated polypeptide has the ability to inhibit the activity of the polypeptide of SEQ ID NO: ]
[ 2450 ] similarity = 0.99027705 [ 2, wherein said isolated polypeptide has the ability to inhibit the activity of the polypeptide of SEQ ID NO: ][ 2, wherein said isolated polypeptide has the ability to inhibit the activity of a polypeptide of SEQ ID NO: ]
[ 2451 ] similarity = 1.0 [ 2, wherein said isolated polypeptide has the ability to inhibit the activity of a polypeptide of SEQ ID NO: ][ 2, wherein said isolated polypeptide has the ability to inhibit the activity of a polypeptide of SEQ ID NO: ]
[ 2452 ] similarity = 1.0 [ 2, wherein said isolated polypeptide has the ability to inhibit the activity of a polypeptide of SEQ ID NO: ][ 2, wherein said isolated polypeptide has the ability to inhibit the activity of a polypeptide of SEQ ID NO: ]
[ 2453 ] similarity = 0.5887091 [ 2, wherein said isolated polypeptide has the ability to inhibit the activity of a polypeptide of SEQ ID NO: ][ 2, wherein said isolated polypeptide is effective to treat the heart disease. ]
[ 2454 ] similarity = 0.3316362 [ A method for treating an inflammatory condition in a patient comprising administering to said patient an effective amount of a compound selected from the group consisting of a polypeptide having a sequence of amino acids from SEQ ID NO: ][ 3 and a polypeptide having a sequence of amino acids from SEQ ID NO: ]
[ 2455 ] similarity = -0.020215912 [ 3 and a polypeptide having a sequence of amino acids from SEQ ID NO: ][ 4. ]
[ 2456 ] similarity = 0.3764933 [ A method for treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising: ][ a) a therapeutically effective amount of a pharmaceutically acceptable salt; and ]
[ 2457 ] similarity = 0.26873022 [ a) a therapeutically effective amount of a pharmaceutically acceptable salt; and ][ b) a pharmaceutically acceptable carrier, salt, or carrier combination thereof, wherein the composition is a pharmaceutically acceptable carrier, salt, or combination thereof, wherein the composition comprises: ]
[ 2458 ] similarity = 0.3188793 [ b) a pharmaceutically acceptable carrier, salt, or carrier combination thereof, wherein the composition is a pharmaceutically acceptable carrier, salt, or combination thereof, wherein the composition comprises: ][ (a) a pharmaceutically acceptable salt, and ]
[ 2459 ] similarity = 0.44949138 [ (a) a pharmaceutically acceptable salt, and ][ (b) a pharmaceutically acceptable carrier, salt, or carrier combination thereof. ]
[ 2460 ] similarity = 0.21683411 [ A method for treating a subject in need thereof, the method comprising: ][ (a) administering a therapeutically effective amount of an effective amount of a polypeptide comprising the amino acid sequence of SEQ ID NO: ]
[ 2461 ] similarity = -0.0070364205 [ (a) administering a therapeutically effective amount of an effective amount of a polypeptide comprising the amino acid sequence of SEQ ID NO: ][ 1 to said subject in need thereof; ]
[ 2462 ] similarity = -0.012120959 [ 1 to said subject in need thereof; ][ (b) determining a level of a polypeptide comprising the amino acid sequence of SEQ ID NO: ]
[ 2463 ] similarity = 0.076207094 [ (b) determining a level of a polypeptide comprising the amino acid sequence of SEQ ID NO: ][ 1 in the subject in need thereof, wherein the level is greater than or equal to a threshold level; and ]
[ 2464 ] similarity = 0.104960606 [ 1 in the subject in need thereof, wherein the level is greater than or equal to a threshold level; and ][ (c) administering an effective amount of a pharmaceutically acceptable salt of the effective amount to the subject in need thereof. ]
[ 2465 ] similarity = 0.5779358 [ A method for the treatment of a patient having an inflammatory bowel disease in which the patient has a disorder of intestinal permeability, the method comprising: ][ administering to the patient an effective amount of an anti-inflammatory agent to reduce the inflammatory bowel disease; and ]
[ 2466 ] similarity = 0.54752403 [ administering to the patient an effective amount of an anti-inflammatory agent to reduce the inflammatory bowel disease; and ][ administering to the patient an effective amount of an effective amount of a therapeutically acceptable composition, ]
[ 2467 ] similarity = 0.3132047 [ administering to the patient an effective amount of an effective amount of a therapeutically acceptable composition, ][ wherein the therapeutically acceptable composition comprises: ]
[ 2468 ] similarity = -0.037949268 [ wherein the therapeutically acceptable composition comprises: ][ a) at least one of a polypeptide or a peptide having a amino acid sequence that is at least 80% identical to SEQ ID NO: ]
[ 2469 ] similarity = -0.04599523 [ a) at least one of a polypeptide or a peptide having a amino acid sequence that is at least 80% identical to SEQ ID NO: ][ 4, ]
[ 2470 ] similarity = -0.077852406 [ 4, ][ wherein the at least one of the polypeptide or the peptide comprises a peptide having a sequence that is at least 80% identical to SEQ ID NO: ]
[ 2471 ] similarity = -0.009705067 [ wherein the at least one of the polypeptide or the peptide comprises a peptide having a sequence that is at least 80% identical to SEQ ID NO: ][ 5, ]
[ 2472 ] similarity = 0.021064188 [ 5, ][ wherein the peptide comprises a peptide having a amino acid sequence that comprises a sequence that is at least 95% identical to SEQ ID NO: ]
[ 2473 ] similarity = -0.04401155 [ wherein the peptide comprises a peptide having a amino acid sequence that comprises a sequence that is at least 95% identical to SEQ ID NO: ][ 6, ]
[ 2474 ] similarity = -0.059583068 [ 6, ][ wherein the peptide has a sequence that is at least 95% identical to SEQ ID NO: ]
[ 2475 ] similarity = -0.06902923 [ wherein the peptide has a sequence that is at least 95% identical to SEQ ID NO: ][ 7, or a combination thereof. ]
[ 2476 ] similarity = 0.18727958 [ A method of treating a disease comprising: ][ (a) administering to a subject in need thereof a therapeutically effective amount of a pharmaceutically acceptable salt of a polypeptide having the amino acid sequence of SEQ ID NO: ]
[ 2477 ] similarity = 0.09295581 [ (a) administering to a subject in need thereof a therapeutically effective amount of a pharmaceutically acceptable salt of a polypeptide having the amino acid sequence of SEQ ID NO: ][ 2 or an isolated fragment thereof; and ]
[ 2478 ] similarity = 0.09252651 [ 2 or an isolated fragment thereof; and ][ (b) administering to the subject an effective amount of a therapeutically effective amount of a pharmaceutically acceptable carrier, wherein the carrier is a pharmaceutically acceptable salt of a polypeptide having the amino acid sequence of SEQ ID NO: ]
[ 2479 ] similarity = 0.11370953 [ (b) administering to the subject an effective amount of a therapeutically effective amount of a pharmaceutically acceptable carrier, wherein the carrier is a pharmaceutically acceptable salt of a polypeptide having the amino acid sequence of SEQ ID NO: ][ 2 or an isolated fragment thereof. ]
[ 2480 ] similarity = 0.5777438 [ An isolated nucleic acid comprising the amino acid sequence of SEQ ID NO: 2, wherein: ][ the nucleic acid is a nucleotide sequence selected from SEQ ID NO: ]
[ 2481 ] similarity = 0.19732201 [ the nucleic acid is a nucleotide sequence selected from SEQ ID NO: ][ 2 and SEQ ID NO: 2; and ]
[ 2482 ] similarity = 0.15914857 [ 2 and SEQ ID NO: 2; and ][ the nucleic acid is selected from the group consisting of SEQ ID NO: ]
[ 2483 ] similarity = 0.22140473 [ the nucleic acid is selected from the group consisting of SEQ ID NO: ][ 2, SEQ ID NO: ]
[ 2484 ] similarity = 0.7720622 [ 2, SEQ ID NO: ][ 3, SEQ ID NO: ]
[ 2485 ] similarity = 0.79470795 [ 3, SEQ ID NO: ][ 4, SEQ ID NO: ]
[ 2486 ] similarity = 0.8005054 [ 4, SEQ ID NO: ][ 5, SEQ ID NO: ]
[ 2487 ] similarity = 0.83311415 [ 5, SEQ ID NO: ][ 6, SEQ ID NO: ]
[ 2488 ] similarity = 0.8179097 [ 6, SEQ ID NO: ][ 7, SEQ ID NO: ]
[ 2489 ] similarity = 0.83411634 [ 7, SEQ ID NO: ][ 8, SEQ ID NO: ]
[ 2490 ] similarity = 0.29801184 [ 8, SEQ ID NO: ][ 9, and ]
[ 2491 ] similarity = 0.1655696 [ 9, and ][ SEQ ID NO: ]
[ 2492 ] similarity = 0.21041146 [ SEQ ID NO: ][ 10. ]
[ 2493 ] similarity = 0.29363656 [ A method for treating a subject in need thereof, comprising administering to the subject a composition comprising: ][ a) a compound selected from the group consisting of a compound of formula (I) or a salt thereof, and ]
[ 2494 ] similarity = 0.08388935 [ a) a compound selected from the group consisting of a compound of formula (I) or a salt thereof, and ][ b) at least one other substance; ]
[ 2495 ] similarity = 0.2891953 [ b) at least one other substance; ][ wherein the at least one other substance is selected from the group consisting of a polysaccharide and a polysaccharide-containing polysaccharide; ]
[ 2496 ] similarity = 0.7928955 [ wherein the at least one other substance is selected from the group consisting of a polysaccharide and a polysaccharide-containing polysaccharide; ][ wherein the polysaccharide is selected from the group consisting of a polysaccharide, a polysaccharide-containing polysaccharide, a polysaccharide-containing polysaccharide, and ]
[ 2497 ] similarity = 0.4728775 [ wherein the polysaccharide is selected from the group consisting of a polysaccharide, a polysaccharide-containing polysaccharide, a polysaccharide-containing polysaccharide, and ][ a polysaccharidose-containing polysaccharide; and ]
[ 2498 ] similarity = 0.44459075 [ a polysaccharidose-containing polysaccharide; and ][ wherein the polysaccharide-containing polysaccharide is selected from the group consisting of a polysaccharide, a polysaccharide-containing polysaccharide, and ]
[ 2499 ] similarity = 0.40809524 [ wherein the polysaccharide-containing polysaccharide is selected from the group consisting of a polysaccharide, a polysaccharide-containing polysaccharide, and ][ a monosaccharide; and ]
[ 2500 ] similarity = 0.40809524 [ a monosaccharide; and ][ wherein the polysaccharide-containing polysaccharide is selected from the group consisting of a polysaccharide, a polysaccharide-containing polysaccharide, and ]
[ 2501 ] similarity = 0.39695483 [ wherein the polysaccharide-containing polysaccharide is selected from the group consisting of a polysaccharide, a polysaccharide-containing polysaccharide, and ][ a monosaccharide. ]
[ 2502 ] similarity = 0.3182681 [ A method of providing an implantable medical device comprising: ][ a) providing an implantable medical device having at least one electrode and at least one conductive material, the at least one conductive material comprising at least one conductive material having a conductive material properties that are different from a conductive material properties of the at least one conductive material of the implantable medical device; and ]
[ 2503 ] similarity = 0.82217693 [ a) providing an implantable medical device having at least one electrode and at least one conductive material, the at least one conductive material comprising at least one conductive material having a conductive material properties that are different from a conductive material properties of the at least one conductive material of the implantable medical device; and ][ b) providing a plurality of conductive material electrodes, each electrode having an outer surface that is electrically conductive, wherein at least a portion of the at least one conductive material is electrically conductive, wherein each electrode comprises a conductive material that is electrically conductive and that has a conductive material properties that are different from conductive material properties of the at least one conductive material of the implantable medical device, and ]
[ 2504 ] similarity = 0.7239434 [ b) providing a plurality of conductive material electrodes, each electrode having an outer surface that is electrically conductive, wherein at least a portion of the at least one conductive material is electrically conductive, wherein each electrode comprises a conductive material that is electrically conductive and that has a conductive material properties that are different from conductive material properties of the at least one conductive material of the implantable medical device, and ][ wherein the conductive material properties are different from the conductive material properties of the at least one conductive material of the implantable medical device, ]
[ 2505 ] similarity = 0.84280187 [ wherein the conductive material properties are different from the conductive material properties of the at least one conductive material of the implantable medical device, ][ wherein the conductive material properties include a conductive material property of the conductive material having the conductive material properties of at least a portion of the conductive material, and ]
[ 2506 ] similarity = 0.86388683 [ wherein the conductive material properties include a conductive material property of the conductive material having the conductive material properties of at least a portion of the conductive material, and ][ a conductive material property of the conductive material having a conductive material properties that are different from conductive material properties of the at least one conductive material of the implantable medical device. ]
[ 2507 ] similarity = 0.05967993 [ A method of producing a polypeptide comprising a first amino acid sequence, wherein the first amino acid sequence is a nucleotide sequence of SEQ ID No: ][ 1, and ]
[ 2508 ] similarity = 0.013206901 [ 1, and ][ wherein the polypeptide comprises a polypeptide-binding domain comprising a nucleic acid sequence of SEQ ID NO: ]
[ 2509 ] similarity = -0.08024722 [ wherein the polypeptide comprises a polypeptide-binding domain comprising a nucleic acid sequence of SEQ ID NO: ][ 2, ]
[ 2510 ] similarity = 0.103693776 [ 2, ][ the method comprising: ]
[ 2511 ] similarity = 0.16022645 [ the method comprising: ][ a) contacting the first amino acid sequence of the polypeptide with a first polypeptide binding domain of an antibody that binds the first amino acid sequence of the polypeptide; ]
[ 2512 ] similarity = 0.7302581 [ a) contacting the first amino acid sequence of the polypeptide with a first polypeptide binding domain of an antibody that binds the first amino acid sequence of the polypeptide; ][ b) contacting the first polypeptide binding domain of the antibody with a second polypeptide binding domain of the antibody, wherein the second polypeptide binding domain comprises a nucleic acid sequence of SEQ ID NO: ]
[ 2513 ] similarity = 0.07736997 [ b) contacting the first polypeptide binding domain of the antibody with a second polypeptide binding domain of the antibody, wherein the second polypeptide binding domain comprises a nucleic acid sequence of SEQ ID NO: ][ 3; and ]
[ 2514 ] similarity = 0.06149132 [ 3; and ][ c) contacting the first polypeptide binding domain with a second polypeptide binding domain of the antibody. ]
[ 2515 ] similarity = 0.13495311 [ A system for the treatment of an inflammatory disorder comprising an antibody or antigen-binding fragment thereof which specifically binds to an inflammatory protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO: ][ 2 or SEQ ID NO: ]
[ 2516 ] similarity = 0.11048302 [ 2 or SEQ ID NO: ][ 3, wherein the system comprises an antibody or antigen-binding fragment thereof, and ]
[ 2517 ] similarity = 0.47707224 [ 3, wherein the system comprises an antibody or antigen-binding fragment thereof, and ][ an antigen binding agent which specifically binds to said antibody or antigen-binding fragment thereof. ]
[ 2518 ] similarity = 0.40226763 [ A method for treating a patient suffering from a disease comprising: ][ providing a patient-specific therapeutic agent; and ]
[ 2519 ] similarity = 0.4572587 [ providing a patient-specific therapeutic agent; and ][ administering to the patient a therapeutically effective amount of the patient-specific therapeutic agent to treat the disease. ]
[ 2520 ] similarity = 0.46487758 [ A system for the treatment of cancer, comprising: ][ an in vitro cell-based method comprising: ]
[ 2521 ] similarity = 0.71757936 [ an in vitro cell-based method comprising: ][ a) providing an in vitro cell-based method for the treatment of cancer, wherein the in vitro cell-based method comprises: ]
[ 2522 ] similarity = 0.17451714 [ a) providing an in vitro cell-based method for the treatment of cancer, wherein the in vitro cell-based method comprises: ][ i) providing a cell-based cell culture; and ]
[ 2523 ] similarity = 0.31750074 [ i) providing a cell-based cell culture; and ][ ii) introducing the in vitro cell-based cell culture to a cell-based tumor in the cell-based tumor, wherein the cell-based tumor is a cancer cell, wherein the tumor has a cell-based surface; and ]
[ 2524 ] similarity = 0.54676175 [ ii) introducing the in vitro cell-based cell culture to a cell-based tumor in the cell-based tumor, wherein the cell-based tumor is a cancer cell, wherein the tumor has a cell-based surface; and ][ b) measuring the expression of a tumor-specific antigen in the cell-based cell culture, wherein measuring the expression of the tumor-specific antigen in the cell-based cell culture is a method for detecting whether or not a tumor is in a metastasis state. ]
[ 2525 ] similarity = 0.83203554 [ A method for treating a subject suffering from a disease or disorder, comprising administering to the subject an effective amount of a composition comprising a compound selected from the group consisting of a polypeptide, a peptide, a peptide fragment, a fragment of a peptide, a polypeptide having a first amino acid sequence and an amino acid sequence having at least 90% identity to the amino acid sequence of the first amino acid sequence of the composition, a polypeptide having a second amino acid sequence and a second amino acid sequence having at least 90% identity to the amino acid sequence of the second amino acid sequence, a polypeptide having a third amino acid sequence and a third amino acid sequence having at least 90% identity to the amino acid sequence of the third amino acid sequence, and ][ a polypeptide having a fourth amino acid sequence and a fourth amino acid sequence having at least 90% identity to the amino acid sequence of the fourth amino acid sequence. ]
[ 2526 ] similarity = 0.21712506 [ A system for the treatment of a patient having a condition of a heart, comprising: ][ an implantable medical device having a first and a second chamber, the first chamber being in fluid communication with a blood vessel and the second chamber being in fluid communication with a blood vessel; ]
[ 2527 ] similarity = 0.4264843 [ an implantable medical device having a first and a second chamber, the first chamber being in fluid communication with a blood vessel and the second chamber being in fluid communication with a blood vessel; ][ a first blood pressure sensor configured to sense blood pressure within said first chamber; ]
[ 2528 ] similarity = 0.75897115 [ a first blood pressure sensor configured to sense blood pressure within said first chamber; ][ a blood pressure monitoring device configured to monitor a blood pressure within said first chamber; and ]
[ 2529 ] similarity = 0.6574352 [ a blood pressure monitoring device configured to monitor a blood pressure within said first chamber; and ][ a blood flow control device configured to control a flow of blood through said first chamber, wherein said flow control device is configured to control said first chamber to maintain a first blood pressure within a predetermined range, and, wherein said blood flow control device is configured to control a blood pressure within said second chamber to maintain a second blood pressure within a predetermined range. ]
[ 2530 ] similarity = 0.30287373 [ A system for providing an indication of a patient's status, comprising: ][ a first sensor that detects a presence of a first substance in a fluid; ]
[ 2531 ] similarity = 0.47966447 [ a first sensor that detects a presence of a first substance in a fluid; ][ a processor that receives a first signal from the first sensor, wherein the first signal comprises a plurality of data points, and ]
[ 2532 ] similarity = 0.7109084 [ a processor that receives a first signal from the first sensor, wherein the first signal comprises a plurality of data points, and ][ wherein the first signal is received from a plurality of sensors, wherein the processor is adapted to process each of the plurality of sensor data points in a manner that determines whether the first signal is a first signal indicative of an indication of a patient's status; ]
[ 2533 ] similarity = 0.21729615 [ wherein the first signal is received from a plurality of sensors, wherein the processor is adapted to process each of the plurality of sensor data points in a manner that determines whether the first signal is a first signal indicative of an indication of a patient's status; ][ a second sensor that detects a presence of a second substance in the fluid, wherein the second substance is different from the first substance; ]
[ 2534 ] similarity = 0.41289747 [ a second sensor that detects a presence of a second substance in the fluid, wherein the second substance is different from the first substance; ][ a processor that receives a second signal that is different from the first signal; ]
[ 2535 ] similarity = 0.24629259 [ a processor that receives a second signal that is different from the first signal; ][ a third sensor that senses the presence of an object in the fluid, wherein the third substance is different from the first substance; and ]
[ 2536 ] similarity = 0.8723944 [ a third sensor that senses the presence of an object in the fluid, wherein the third substance is different from the first substance; and ][ a second sensor that detects the presence of a third substance in the fluid, wherein the second substance is different from the first substance. ]
[ 2537 ] similarity = 0.36549446 [ A method of treating an inflammatory condition comprising administering an effective amount of an anti-tumor agent to a subject, wherein the anti-tumor agent has an anti-tumor agent binding affinity, wherein the anti-tumor agent is an anti-TGF-beta-2 (ATG-2) antagonist, and ][ wherein the anti-tumor agent is a compound of formula I: ]
[ 2538 ] similarity = 0.023603922 [ wherein the anti-tumor agent is a compound of formula I: ][ or a pharmaceutically acceptable salt thereof. ]
[ 2539 ] similarity = 0.24927008 [ An implantable medical instrument, comprising: ][ a housing; ]
[ 2540 ] similarity = 0.15300256 [ a housing; ][ a first portion having an opening for receiving a first implantable device, wherein the first portion is configured to be implanted within a body cavity of a patient; and ]
[ 2541 ] similarity = 0.48694366 [ a first portion having an opening for receiving a first implantable device, wherein the first portion is configured to be implanted within a body cavity of a patient; and ][ a second portion having an opening for receiving a second implantable device; ]
[ 2542 ] similarity = 0.28826153 [ a second portion having an opening for receiving a second implantable device; ][ wherein the first and second portions are configured to be inserted within a first cavity of the body cavity of the patient and configured to be positioned in the first and second openings of the housing to be in contact with the patient's body cavity. ]
[ 2543 ] similarity = 0.33927995 [ A method of providing a medical treatment for a patient in need of such treatment comprising: ][ providing a first medical device; ]
[ 2544 ] similarity = 0.7042281 [ providing a first medical device; ][ providing a second medical device; ]
[ 2545 ] similarity = 0.593907 [ providing a second medical device; ][ providing a first medical treatment device; ]
[ 2546 ] similarity = 0.71451604 [ providing a first medical treatment device; ][ providing a second medical treatment device; ]
[ 2547 ] similarity = 0.4378779 [ providing a second medical treatment device; ][ receiving a patient's request for a first medical treatment; ]
[ 2548 ] similarity = 0.8345685 [ receiving a patient's request for a first medical treatment; ][ receiving a patient's request for a second medical treatment; ]
[ 2549 ] similarity = 0.3498697 [ receiving a patient's request for a second medical treatment; ][ providing a first medical device; ]
[ 2550 ] similarity = 0.7042281 [ providing a first medical device; ][ providing a second medical device; ]
[ 2551 ] similarity = 0.593907 [ providing a second medical device; ][ providing a first medical treatment device; ]
[ 2552 ] similarity = 0.71451604 [ providing a first medical treatment device; ][ providing a second medical treatment device; ]
[ 2553 ] similarity = 0.6506499 [ providing a second medical treatment device; ][ providing a first medical treatment device; and ]
[ 2554 ] similarity = 0.6073086 [ providing a first medical treatment device; and ][ receiving a patient's request for a first medical treatment. ]
[ 2555 ] similarity = 0.5186315 [ A system for monitoring and controlling a plurality of sensors, comprising: ][ a sensor array comprising: ]
[ 2556 ] similarity = 0.7157599 [ a sensor array comprising: ][ a first sensor array; and ]
[ 2557 ] similarity = 0.63276625 [ a first sensor array; and ][ a second sensor array, each of the first sensor array and the second sensor array being configured for sensing a different one of a number of sensor inputs; and ]
[ 2558 ] similarity = 0.7092769 [ a second sensor array, each of the first sensor array and the second sensor array being configured for sensing a different one of a number of sensor inputs; and ][ a processor coupled to said first and second sensors, wherein the processor is configured to receive a plurality of sensor inputs from said first and second sensors, wherein the processor is configured to determine whether a first input from said first sensor array is a first input to a first sensor input and whether a second input from said second sensor array is a second input to a second sensor input, and ]
[ 2559 ] similarity = 0.8789815 [ a processor coupled to said first and second sensors, wherein the processor is configured to receive a plurality of sensor inputs from said first and second sensors, wherein the processor is configured to determine whether a first input from said first sensor array is a first input to a first sensor input and whether a second input from said second sensor array is a second input to a second sensor input, and ][ to determine whether a second input from said second sensor array is a second input to a first sensor input, wherein the processor determines if a first sensor input is a first sensor input and if a second sensor input is a second sensor input, and ]
[ 2560 ] similarity = 0.4933827 [ to determine whether a second input from said second sensor array is a second input to a first sensor input, wherein the processor determines if a first sensor input is a first sensor input and if a second sensor input is a second sensor input, and ][ to determine if the processor is configured to control said first and second sensors. ]
[ 2561 ] similarity = 0.4877997 [ A method of treating a patient with a condition that is caused by a mutation in a gene comprising: ][ identifying a mutation that causes the mutation, wherein said mutation is selected from the group consisting of mutations of a polypeptide, a polypeptide comprising a sequence that comprises the amino acid sequence of SEQ ID NO: ]
[ 2562 ] similarity = 0.008334814 [ identifying a mutation that causes the mutation, wherein said mutation is selected from the group consisting of mutations of a polypeptide, a polypeptide comprising a sequence that comprises the amino acid sequence of SEQ ID NO: ][ 1, and ]
[ 2563 ] similarity = 0.011709221 [ 1, and ][ a polypeptide comprising an amino acid sequence that comprises the sequence of SEQ ID NO: ]
[ 2564 ] similarity = -0.05894766 [ a polypeptide comprising an amino acid sequence that comprises the sequence of SEQ ID NO: ][ 1; ]
[ 2565 ] similarity = -0.0068776654 [ 1; ][ administering to the patient a therapeutically effective amount of the mutation, wherein the mutation is a mutation that causes the mutation; ]
[ 2566 ] similarity = 0.48089364 [ administering to the patient a therapeutically effective amount of the mutation, wherein the mutation is a mutation that causes the mutation; ][ detecting the mutation in a biological sample; ]
[ 2567 ] similarity = 0.75374794 [ detecting the mutation in a biological sample; ][ determining the mutation to cause the mutation in a biological sample by comparing the mutation detected in said biological sample with a mutation detected in a sample from a patient; and ]
[ 2568 ] similarity = 0.37356457 [ determining the mutation to cause the mutation in a biological sample by comparing the mutation detected in said biological sample with a mutation detected in a sample from a patient; and ][ administering to the patient a therapeutically effective amount of the mutation, ]
[ 2569 ] similarity = 0.20453453 [ administering to the patient a therapeutically effective amount of the mutation, ][ wherein the mutation is selected from the group consisting of mutations of a polypeptide, a polypeptide comprising a sequence that comprises the amino acid sequence of SEQ ID NO: ]
[ 2570 ] similarity = 0.0020634243 [ wherein the mutation is selected from the group consisting of mutations of a polypeptide, a polypeptide comprising a sequence that comprises the amino acid sequence of SEQ ID NO: ][ 1, and ]
[ 2571 ] similarity = 0.011709228 [ 1, and ][ a polypeptide comprising an amino acid sequence that comprises the sequence of SEQ ID NO: ]
[ 2572 ] similarity = -0.058947667 [ a polypeptide comprising an amino acid sequence that comprises the sequence of SEQ ID NO: ][ 1. ]
[ 2573 ] similarity = 0.17688681 [ An isolated nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: ][ 2, SEQ ID NO: ]
[ 2574 ] similarity = 0.7720622 [ 2, SEQ ID NO: ][ 3, SEQ ID NO: ]
[ 2575 ] similarity = 0.79470795 [ 3, SEQ ID NO: ][ 4, SEQ ID NO: ]
[ 2576 ] similarity = 0.8005054 [ 4, SEQ ID NO: ][ 5, SEQ ID NO: ]
[ 2577 ] similarity = 0.83311415 [ 5, SEQ ID NO: ][ 6, SEQ ID NO: ]
[ 2578 ] similarity = 0.8179097 [ 6, SEQ ID NO: ][ 7, SEQ ID NO: ]
[ 2579 ] similarity = 0.7166808 [ 7, SEQ ID NO: ][ 8 and SEQ ID NO: ]
[ 2580 ] similarity = 0.37590292 [ 8 and SEQ ID NO: ][ 9. ]
[ 2581 ] similarity = 0.34927487 [ A method for determining a position of a first object, the method comprising the steps of: ][ (a) receiving an image of a first object from a camera, the image comprising a plurality of points, wherein each of the plurality of points is located on a surface of the first object and the plurality of points are located in a first plane of the image; ]
[ 2582 ] similarity = 0.5922011 [ (a) receiving an image of a first object from a camera, the image comprising a plurality of points, wherein each of the plurality of points is located on a surface of the first object and the plurality of points are located in a first plane of the image; ][ (b) receiving an image of a second object from said camera, said second object being located on a surface of the second object and the plurality of points are located in a second plane of the image that is substantially parallel with the first plane, wherein the first plane is substantially perpendicular to said second plane and said first object is positioned in a first position in said first plane; and ]
[ 2583 ] similarity = 0.5979792 [ (b) receiving an image of a second object from said camera, said second object being located on a surface of the second object and the plurality of points are located in a second plane of the image that is substantially parallel with the first plane, wherein the first plane is substantially perpendicular to said second plane and said first object is positioned in a first position in said first plane; and ][ (c) determining, based on said image, the position of said first object in said first plane by: ]
[ 2584 ] similarity = 0.5623071 [ (c) determining, based on said image, the position of said first object in said first plane by: ][ (i) determining the first object's position in said second plane; and ]
[ 2585 ] similarity = 0.6071417 [ (i) determining the first object's position in said second plane; and ][ (ii) calculating a first position in the first plane based on a distance between the first object and said first object. ]
[ 2586 ] similarity = 0.03497997 [ A method of treating an autoimmune disease in a subject comprising administering to the subject a composition comprising: ][ (a) an isolated peptide having the amino acid sequence of SEQ ID NO: 1, ]
[ 2587 ] similarity = 0.72265434 [ (a) an isolated peptide having the amino acid sequence of SEQ ID NO: 1, ][ (b) at least a portion of the isolated peptide having the amino acid sequence of SEQ ID NO: 2, and ]
[ 2588 ] similarity = 0.45119223 [ (b) at least a portion of the isolated peptide having the amino acid sequence of SEQ ID NO: 2, and ][ (c) a pharmaceutically acceptable carrier, wherein the at least a portion of said isolated peptide is selected from the group consisting of: ]
[ 2589 ] similarity = 0.17782535 [ (c) a pharmaceutically acceptable carrier, wherein the at least a portion of said isolated peptide is selected from the group consisting of: ][ (i) an isolated peptide having SEQ ID NO: 2, and ]
[ 2590 ] similarity = 0.6248547 [ (i) an isolated peptide having SEQ ID NO: 2, and ][ (ii) an isolated peptide having a amino acid sequence of SEQ ID NO: 3, ]
[ 2591 ] similarity = 0.7551704 [ (ii) an isolated peptide having a amino acid sequence of SEQ ID NO: 3, ][ wherein the peptide has the amino acid sequence of SEQ ID NO: 3. ]
[ 2592 ] similarity = 0.5510049 [ A system for treating an animal having a heart defect, the system comprising: ][ a heart defect detection unit that detects a cardiac defect in the animal; ]
[ 2593 ] similarity = 0.44546217 [ a heart defect detection unit that detects a cardiac defect in the animal; ][ an animal control unit that controls an operation of an animal; ]
[ 2594 ] similarity = 0.37595886 [ an animal control unit that controls an operation of an animal; ][ a heart defect detection unit that detects a heart defect in an animal having the heart defect; ]
[ 2595 ] similarity = 0.60502446 [ a heart defect detection unit that detects a heart defect in an animal having the heart defect; ][ an animal therapy unit that provides a treatment of the cardiac defect in the animal; ]
[ 2596 ] similarity = 0.58982503 [ an animal therapy unit that provides a treatment of the cardiac defect in the animal; ][ a heart defect detection unit configured to detect a cardiac defect in an animal having the heart defect; ]
[ 2597 ] similarity = 0.57225 [ a heart defect detection unit configured to detect a cardiac defect in an animal having the heart defect; ][ an animal therapy unit configured to deliver a treatment of the cardiac defect in the animal; and ]
[ 2598 ] similarity = 0.21321823 [ an animal therapy unit configured to deliver a treatment of the cardiac defect in the animal; and ][ a control unit configured to: ]
[ 2599 ] similarity = 0.14568329 [ a control unit configured to: ][ receive a cardiac signal from the heart defect detection unit; ]
[ 2600 ] similarity = 0.69994533 [ receive a cardiac signal from the heart defect detection unit; ][ determine a heart defect in the animal having the cardiac defect based on the cardiac signal; and ]
[ 2601 ] similarity = 0.7952421 [ determine a heart defect in the animal having the cardiac defect based on the cardiac signal; and ][ determine whether the animal is at risk of developing the cardiac defect based on the determined heart defect, ]
[ 2602 ] similarity = 0.67458475 [ determine whether the animal is at risk of developing the cardiac defect based on the determined heart defect, ][ wherein a cardiac signal from the heart defect detection unit is used to determine whether the cardiac defect is in the heart defect detection unit. ]
[ 2603 ] similarity = 0.15804738 [ An implantable medical device, comprising: ][ a housing having an interior and a peripheral surface, wherein the peripheral surface of the housing is configured to be implanted within a patient's body and wherein a first end of the first end of the housing is configured for insertion into a patient; and ]
[ 2604 ] similarity = 0.65860045 [ a housing having an interior and a peripheral surface, wherein the peripheral surface of the housing is configured to be implanted within a patient's body and wherein a first end of the first end of the housing is configured for insertion into a patient; and ][ a first electrode configured for implantation into the patient's body, the first electrode having a first end configured for implantation into the body and an opposite second end configured to be inserted into the peripheral surface of the first end, the first end of the first end being configured to be inserted into a region of the body adjacent to an area of the first end configured to be inserted into the patient's body. ]
[ 2605 ] similarity = 0.22587457 [ A method for treating a disease in a subject comprising administering a therapeutically effective amount of at least one of: a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 each independently represent one or more amino acids of formula (I) or a pharmaceutically acceptable salt thereof; and ][ a pharmaceutically acceptable carrier, wherein: ]
[ 2606 ] similarity = 0.08853379 [ a pharmaceutically acceptable carrier, wherein: ][ R1 and R2 each independently represent one or more amino acids of formula (I) or a pharmaceutically acceptable salt thereof; and ]
[ 2607 ] similarity = 0.12880243 [ R1 and R2 each independently represent one or more amino acids of formula (I) or a pharmaceutically acceptable salt thereof; and ][ R3 represents a hydrogen atom, a C1-C4 alkyl or a C1-C4 alkenyl; ]
[ 2608 ] similarity = -0.041077066 [ R3 represents a hydrogen atom, a C1-C4 alkyl or a C1-C4 alkenyl; ][ wherein the compound of formula (I) or the pharmaceutically acceptable salt thereof is a compound selected from the group consisting of an antibody, an antigen-binding fragment of a antibody, an antibody-like fragment of an antibody, an antigen-binding fragment of an antibody, an antigen-binding fragment of an antigen-binding fragment, and ]
[ 2609 ] similarity = 0.66065216 [ wherein the compound of formula (I) or the pharmaceutically acceptable salt thereof is a compound selected from the group consisting of an antibody, an antigen-binding fragment of a antibody, an antibody-like fragment of an antibody, an antigen-binding fragment of an antibody, an antigen-binding fragment of an antigen-binding fragment, and ][ a fragment of a fragment of an antibody. ]
[ 2610 ] similarity = 0.15523578 [ A method comprising: ][ a) providing a first device having a first end and a second end, the first device including a first body and a second body; ]
[ 2611 ] similarity = 0.73133695 [ a) providing a first device having a first end and a second end, the first device including a first body and a second body; ][ b) providing a second device including a first end and a second end, the second end of the first device having a first end portion and a second end portion; ]
[ 2612 ] similarity = 0.59993887 [ b) providing a second device including a first end and a second end, the second end of the first device having a first end portion and a second end portion; ][ c) providing a plurality of first and second electrodes connected to the first and second ends of the first device; ]
[ 2613 ] similarity = 0.8248552 [ c) providing a plurality of first and second electrodes connected to the first and second ends of the first device; ][ d) providing a plurality of second electrodes connected to the first and second ends of the second device; ]
[ 2614 ] similarity = 0.80347705 [ d) providing a plurality of second electrodes connected to the first and second ends of the second device; ][ e) connecting the plurality of first and second electrodes to the first and second ends of the first and second devices; ]
[ 2615 ] similarity = 0.5628475 [ e) connecting the plurality of first and second electrodes to the first and second ends of the first and second devices; ][ f) providing a plurality of first and second conductive members; ]
[ 2616 ] similarity = 0.7978246 [ f) providing a plurality of first and second conductive members; ][ g) providing a plurality of second conductive members; and ]
[ 2617 ] similarity = 0.42897552 [ g) providing a plurality of second conductive members; and ][ h) connecting the second end of each of the first and second devices to the first end of the plurality of second conductive members. ]
[ 2618 ] similarity = 0.16069332 [ A method comprising: ][ detecting, by a processor, a first signal indicative of an activity of an animal; ]
[ 2619 ] similarity = 0.73409784 [ detecting, by a processor, a first signal indicative of an activity of an animal; ][ detecting, by the processor, a second signal indicative of an activity of the animal; and ]
[ 2620 ] similarity = 0.5971141 [ detecting, by the processor, a second signal indicative of an activity of the animal; and ][ determining, by the processor, whether the first or the second signal is indicative of a first activity or a second activity, ]
[ 2621 ] similarity = 0.6537783 [ determining, by the processor, whether the first or the second signal is indicative of a first activity or a second activity, ][ wherein the second activity is determined based on a difference between the first signal and the second signal. ]
[ 2622 ] similarity = 0.0012608487 [ A method of treating a patient having an abnormal heart rhythm comprising administering to said patient a therapeutically effective amount of a therapeutically effective amount of an isolated polypeptide, said polypeptide comprising an amino acid sequence having at least 80% identity to SEQ ID NO: ][ 2. ]
[ 2623 ] similarity = 0.31820077 [ A method of treating an individual suffering from a disease comprising administering to said individual in need thereof a therapeutically effective amount of a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: 2, wherein said salt is selected from the group consisting of: ][ an amino acid salt of SEQ ID NO: 2; ]
[ 2624 ] similarity = 0.8990303 [ an amino acid salt of SEQ ID NO: 2; ][ an amino acid salt of SEQ ID NO: 3; ]
[ 2625 ] similarity = 0.5990263 [ an amino acid salt of SEQ ID NO: 3; ][ a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: 2; and ]
[ 2626 ] similarity = 0.62324345 [ a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: 2; and ][ a pharmaceutically acceptable salt of SEQ ID NO: 3. ]
[ 2627 ] similarity = 0.0411703 [ A method for treating a disease in a subject, comprising administering to the subject an effective amount of a therapeutically effective amount of an antibody, wherein the antibody comprises an antigenic fragment thereof, wherein the antibody binds to a polypeptide selected from the group consisting of SEQ ID NO: ][ 2 and SEQ ID NO: ]
[ 2628 ] similarity = 0.20581083 [ 2 and SEQ ID NO: ][ 3. ]
[ 2629 ] similarity = 0.27122593 [ A method of treating a patient suffering from a disease or disorder comprising: ][ providing to the patient a composition comprising a therapeutically effective amount of a compound of formula I: ]
[ 2630 ] similarity = -0.049594775 [ providing to the patient a composition comprising a therapeutically effective amount of a compound of formula I: ][ wherein: ]
[ 2631 ] similarity = -0.026900116 [ wherein: ][ R1 is a hydrogen, alkyl, alkenyl, alkynyl, heterocyclic, or heteroaryl group having at least one of a hydrogen atom or a halogen atom; ]
[ 2632 ] similarity = 0.9422579 [ R1 is a hydrogen, alkyl, alkenyl, alkynyl, heterocyclic, or heteroaryl group having at least one of a hydrogen atom or a halogen atom; ][ R2 is a hydrogen, alkyl, alkenyl, alkynyl, heterocyclic, or heteroaryl group having at least one of a halogen atom or a hydrogen atom; and ]
[ 2633 ] similarity = 0.1456136 [ R2 is a hydrogen, alkyl, alkenyl, alkynyl, heterocyclic, or heteroaryl group having at least one of a halogen atom or a hydrogen atom; and ][ R1, R2, and ]
[ 2634 ] similarity = 0.07760926 [ R1, R2, and ][ R3 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heterocyclic, and ]
[ 2635 ] similarity = 0.14308545 [ R3 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heterocyclic, and ][ heteroaryl groups; and ]
[ 2636 ] similarity = 0.131796 [ heteroaryl groups; and ][ R1 is a hydrogen, alkyl, alkenyl, alkynyl, heterocyclic or heteroaryl group having at least one of a halogen atom, a hydrogen atom, a hydrogen atom, an alkyl, a alkenyl, a alkynyl, a cycloalkyl group, an alkynyl, or heterocyclic group; and ]
[ 2637 ] similarity = 0.0629477 [ R1 is a hydrogen, alkyl, alkenyl, alkynyl, heterocyclic or heteroaryl group having at least one of a halogen atom, a hydrogen atom, a hydrogen atom, an alkyl, a alkenyl, a alkynyl, a cycloalkyl group, an alkynyl, or heterocyclic group; and ][ a pharmaceutically acceptable carrier; and ]
[ 2638 ] similarity = 0.1689299 [ a pharmaceutically acceptable carrier; and ][ administering to the patient in an amount effective to treat the disease or disorder. ]
[ 2639 ] similarity = 0.11115482 [ A method for the treatment of a patient, comprising administering a therapeutically effective amount of a composition comprising a therapeutically effective amount of a polypeptide comprising an amino acid sequence of SEQ ID NO: ][ 2 to a patient in need thereof. ]
[ 2640 ] similarity = 0.20995839 [ A device for providing a therapeutic effect to a patient, comprising: ][ a) a first device having a first end and a second end, the first end being adapted for insertion into the patient and the second end being adapted for attachment to a first portion of an external body; ]
[ 2641 ] similarity = 0.7512474 [ a) a first device having a first end and a second end, the first end being adapted for insertion into the patient and the second end being adapted for attachment to a first portion of an external body; ][ b) a second device having a second end and adapted for insertion into an external body, the second end being adapted for attachment to a second portion of the external body, the first and second devices having a first and second end; ]
[ 2642 ] similarity = 0.42111716 [ b) a second device having a second end and adapted for insertion into an external body, the second end being adapted for attachment to a second portion of the external body, the first and second devices having a first and second end; ][ c) an adhesive disposed between the first device and the second device, the adhesive being configured to adhere to the first device and the second device to create an adhesion relationship; ]
[ 2643 ] similarity = 0.35032827 [ c) an adhesive disposed between the first device and the second device, the adhesive being configured to adhere to the first device and the second device to create an adhesion relationship; ][ d) a first portion of the first end of the first device being adapted for insertion into a portion of a patient's body that is not adapted for insertion into a portion of the patient's body that is adapted for insertion into the second device; and ]
[ 2644 ] similarity = 0.2884956 [ d) a first portion of the first end of the first device being adapted for insertion into a portion of a patient's body that is not adapted for insertion into a portion of the patient's body that is adapted for insertion into the second device; and ][ e) an adhesive disposed between the second device and the first device. ]
[ 2645 ] similarity = 0.012635618 [ A method of treating a cancer in a subject, the method comprising administering to the subject an effective amount of a compound having the structure: ][ wherein: ]
[ 2646 ] similarity = -0.05515175 [ wherein: ][ R1 is a hydrogen atom, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heteroaryl heteroatom or an alkyl group; ]
[ 2647 ] similarity = 0.8938242 [ R1 is a hydrogen atom, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heteroaryl heteroatom or an alkyl group; ][ R2 is a hydrogen atom, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heteroaryl heteroatom or an alkyl group; and ]
[ 2648 ] similarity = 0.31116846 [ R2 is a hydrogen atom, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heteroaryl heteroatom or an alkyl group; and ][ R1 and R2 together form a C-terminal or a C-terminal-substituted heteroaryl or heteroaryl heteroatom, and ]
[ 2649 ] similarity = 0.029839654 [ R1 and R2 together form a C-terminal or a C-terminal-substituted heteroaryl or heteroaryl heteroatom, and ][ wherein: ]
[ 2650 ] similarity = -0.01156158 [ wherein: ][ R1 is a substituted or unsaturated C-terminal, and ]
[ 2651 ] similarity = 0.567436 [ R1 is a substituted or unsaturated C-terminal, and ][ the C-terminal is substituted or unsubstituted, and ]
[ 2652 ] similarity = 0.58126235 [ the C-terminal is substituted or unsubstituted, and ][ the unsaturated C-terminal is a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heteroaryl heteroatom or an alkyl group; and ]
[ 2653 ] similarity = 0.24518993 [ the unsaturated C-terminal is a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heteroaryl heteroatom or an alkyl group; and ][ R1 and R2 together form a C-terminal or a C-terminal-substituted heteroaryl or heteroaryl heteroatom. ]
[ 2654 ] similarity = 0.32241923 [ A device for treating a patient, comprising: ][ a first portion; ]
[ 2655 ] similarity = 0.27601177 [ a first portion; ][ a second portion, wherein the first and second portions are configured to be placed in contact with one another, and ]
[ 2656 ] similarity = 0.6409787 [ a second portion, wherein the first and second portions are configured to be placed in contact with one another, and ][ wherein the first portion and the second portion are configured to be disposed in a substantially parallel relationship, wherein the first portion and the second portion are configured to be disposed in a substantially parallel relationship, and ]
[ 2657 ] similarity = 0.3110172 [ wherein the first portion and the second portion are configured to be disposed in a substantially parallel relationship, wherein the first portion and the second portion are configured to be disposed in a substantially parallel relationship, and ][ wherein the first, second, and ]
[ 2658 ] similarity = 0.10869121 [ wherein the first, second, and ][ third portions are disposed in a substantially parallel relationship; wherein the first portion is disposed in a substantially flat configuration; ]
[ 2659 ] similarity = 0.10869119 [ third portions are disposed in a substantially parallel relationship; wherein the first portion is disposed in a substantially flat configuration; ][ wherein the first, second, and ]
[ 2660 ] similarity = 0.39145333 [ wherein the first, second, and ][ fourth portions are disposed in a substantially flat configuration; wherein the first, second, and ]
[ 2661 ] similarity = 0.8089075 [ fourth portions are disposed in a substantially flat configuration; wherein the first, second, and ][ third portions are disposed in a substantially flat configuration; and ]
[ 2662 ] similarity = 0.18326311 [ third portions are disposed in a substantially flat configuration; and ][ wherein the first, second, and ]
[ 2663 ] similarity = 0.026427958 [ wherein the first, second, and ][ fourth portions are configured to be disposed in a substantially parallel relationship. ]
[ 2664 ] similarity = 0.29662928 [ A method for treating a subject, comprising: ][ providing an implantable therapeutic device; ]
[ 2665 ] similarity = 0.50110686 [ providing an implantable therapeutic device; ][ inserting an implantable therapeutic device into the subject, wherein the implantable therapeutic device is adapted to be placed within a patient's tissue; ]
[ 2666 ] similarity = 0.073058516 [ inserting an implantable therapeutic device into the subject, wherein the implantable therapeutic device is adapted to be placed within a patient's tissue; ][ providing a first electrode and a second electrode; ]
[ 2667 ] similarity = 0.7547361 [ providing a first electrode and a second electrode; ][ providing a first electrode electrode having a plurality of electrodes arranged in a first configuration, the first electrode electrode electrode having a first electrode electrode surface and a second electrode electrode surface, the first electrode electrode surface and the second electrode surface being disposed in a second configuration, the second configuration being a configuration different from the first configuration; ]
[ 2668 ] similarity = 0.79582906 [ providing a first electrode electrode having a plurality of electrodes arranged in a first configuration, the first electrode electrode electrode having a first electrode electrode surface and a second electrode electrode surface, the first electrode electrode surface and the second electrode surface being disposed in a second configuration, the second configuration being a configuration different from the first configuration; ][ inserting a second electrode electrode into a region of the subject's tissue adjacent to the first electrode electrode; and ]
[ 2669 ] similarity = 0.4887643 [ inserting a second electrode electrode into a region of the subject's tissue adjacent to the first electrode electrode; and ][ providing a third electrode electrode having a plurality of electrodes arranged in a third configuration, the third configurations having a plurality of electrodes arranged in the second configuration, the second configuration, and ]
[ 2670 ] similarity = 0.520473 [ providing a third electrode electrode having a plurality of electrodes arranged in a third configuration, the third configurations having a plurality of electrodes arranged in the second configuration, the second configuration, and ][ the third configuration being different from the first configuration, the second configuration, and ]
[ 2671 ] similarity = 0.5855579 [ the third configuration being different from the first configuration, the second configuration, and ][ the third configuration. ]
[ 2672 ] similarity = 0.42370367 [ A device for providing a first therapeutic effect to a patient, the first device comprising: ][ a first electrode having a first electrode surface; ]
[ 2673 ] similarity = 0.7171204 [ a first electrode having a first electrode surface; ][ a second electrode having a second electrode surface, the second electrode surface being adjacent to the first electrode surface; ]
[ 2674 ] similarity = 0.79224724 [ a second electrode having a second electrode surface, the second electrode surface being adjacent to the first electrode surface; ][ an insulating layer between the first electrode and the second electrode surface; ]
[ 2675 ] similarity = 0.5025569 [ an insulating layer between the first electrode and the second electrode surface; ][ an outer surface of the insulating layer; and ]
[ 2676 ] similarity = 0.77915555 [ an outer surface of the insulating layer; and ][ an inner surface of the insulating layer, ]
[ 2677 ] similarity = 0.50073874 [ an inner surface of the insulating layer, ][ wherein the outer surface of the insulating layer is configured to be disposed within a cavity of the patient, and ]
[ 2678 ] similarity = 0.887799 [ wherein the outer surface of the insulating layer is configured to be disposed within a cavity of the patient, and ][ wherein the inner surface of the insulating layer is configured to be disposed within a cavity of the patient. ]
[ 2679 ] similarity = -0.10516414 [ A method for producing a composition comprising a compound of formula I: ][ wherein R1 is a C1-C6 alkyl or C1-C6 cycloalkyl; ]
[ 2680 ] similarity = 0.6950666 [ wherein R1 is a C1-C6 alkyl or C1-C6 cycloalkyl; ][ R2 is a C1-C6 alkyl or C1-C6 cycloalkyl; ]
[ 2681 ] similarity = 0.659368 [ R2 is a C1-C6 alkyl or C1-C6 cycloalkyl; ][ R3 is a C1-C6 alkyl or C1-C6 cycloalkyl; or R6 is a cycloalkyl or a C1-C6 alkoxy; and ]
[ 2682 ] similarity = 0.70764315 [ R3 is a C1-C6 alkyl or C1-C6 cycloalkyl; or R6 is a cycloalkyl or a C1-C6 alkoxy; and ][ R7 is a C1-C6 alkyl or a C1-C6 cycloalkyl; ]
[ 2683 ] similarity = 0.6783054 [ R7 is a C1-C6 alkyl or a C1-C6 cycloalkyl; ][ wherein R8 is a C1-C6 alkyl or C1-C6 cycloalkyl; ]
[ 2684 ] similarity = 0.816769 [ wherein R8 is a C1-C6 alkyl or C1-C6 cycloalkyl; ][ wherein R9 is a C1-C6 alkyl or a C1-C6 cycloalkyl; ]
[ 2685 ] similarity = 0.5759288 [ wherein R9 is a C1-C6 alkyl or a C1-C6 cycloalkyl; ][ wherein R10 is a C1-C6 alkyl or a C1-C6 cycloalkyl; or R11 is a C1-C6 alkyl or a C1-C6 cycloalkyl, wherein the alkyls are selected from the group consisting of alkyl, C1-6alkyl, C3-C8alkyl, C4-C10alkyl, C6-C8alkyl, C6-C8alkenyl, C6-C8alkynyl and C6-C8alkoxyalkyl; ]
[ 2686 ] similarity = 0.6231706 [ wherein R10 is a C1-C6 alkyl or a C1-C6 cycloalkyl; or R11 is a C1-C6 alkyl or a C1-C6 cycloalkyl, wherein the alkyls are selected from the group consisting of alkyl, C1-6alkyl, C3-C8alkyl, C4-C10alkyl, C6-C8alkyl, C6-C8alkenyl, C6-C8alkynyl and C6-C8alkoxyalkyl; ][ wherein R13 is a C1-C6 alkyl or a C1-C6 cycloalkyl. ]
[ 2687 ] similarity = 0.29712123 [ A device for the insertion and removal of a catheter into a body cavity of an animal, the device comprising: ][ an elongate body having a proximal end and a distal end, the elongate body having a proximal end and a distal end; ]
[ 2688 ] similarity = 0.77130735 [ an elongate body having a proximal end and a distal end, the elongate body having a proximal end and a distal end; ][ a first portion of the elongate body having a proximal end and a distal end, the first portion of the elongate body being adapted to be inserted into a catheter and a second portion of the elongate body having a proximal end and a distal end, the second portion of the elongate body being adapted to be removed from the catheter; ]
[ 2689 ] similarity = 0.991849 [ a first portion of the elongate body having a proximal end and a distal end, the first portion of the elongate body being adapted to be inserted into a catheter and a second portion of the elongate body having a proximal end and a distal end, the second portion of the elongate body being adapted to be removed from the catheter; ][ a first portion of the elongate body having a proximal end and a distal end, the first portion of the elongate body being adapted for being inserted into a catheter and a second portion of the elongate body having a proximal end and a distal end, the second portion of the elongate body being adapted for being removed from the catheter; and ]
[ 2690 ] similarity = 0.8080895 [ a first portion of the elongate body having a proximal end and a distal end, the first portion of the elongate body being adapted for being inserted into a catheter and a second portion of the elongate body having a proximal end and a distal end, the second portion of the elongate body being adapted for being removed from the catheter; and ][ a second portion of the elongate body having a proximal end and a distal end, the second portion of the elongate body being adaptably adapted to be removed from the catheter and adapted to be inserted into a catheter and a distal end, the first portion of the elongate body being adapted to be inserted into the body cavity of the animal, the second portion of the elongate body being adapted to be removed from the catheter and adapted to be inserted into a catheter, wherein the second portion of the elongate body is adapted to be inserted into the body cavity of the animal, the first portion of the elongate body is adapted to be removed from the catheter and the second portion of the elongate body is adapted to be inserted into the catheter. ]
[ 2691 ] similarity = 0.019326877 [ An isolated nucleic acid encoding a protein of the type comprising a polypeptide having a nucleic acid sequence having at least 95% identity to SEQ ID NO: ][ 1. ]
[ 2692 ] similarity = 0.10125326 [ A method for the treatment of an animal, said method comprising the steps of: ][ providing a first implantable medical device (IMD); ]
[ 2693 ] similarity = 0.55912906 [ providing a first implantable medical device (IMD); ][ providing at least one second implantable medical device (SIMD); ]
[ 2694 ] similarity = 0.37797278 [ providing at least one second implantable medical device (SIMD); ][ providing a first medical device interface (MIDI); and ]
[ 2695 ] similarity = 0.63842076 [ providing a first medical device interface (MIDI); and ][ providing a second medical device interface (MIDDI); ]
[ 2696 ] similarity = 0.041271187 [ providing a second medical device interface (MIDDI); ][ wherein said first and second IMD are connected to said MIDI and said MIDDI, and ]
[ 2697 ] similarity = 0.75728416 [ wherein said first and second IMD are connected to said MIDI and said MIDDI, and ][ wherein the first IMD and the second IMD are connected to said MIDDI, and ]
[ 2698 ] similarity = 0.57761383 [ wherein the first IMD and the second IMD are connected to said MIDDI, and ][ wherein said IMD and the second IMD have a common interface, wherein the common interface includes a plurality of channels, wherein said plurality of channels are arranged in a first direction and wherein the first IMD is connected to the first MIDDI and the second IMD is connected to the second MIDDI, and ]
[ 2699 ] similarity = 0.78710246 [ wherein said IMD and the second IMD have a common interface, wherein the common interface includes a plurality of channels, wherein said plurality of channels are arranged in a first direction and wherein the first IMD is connected to the first MIDDI and the second IMD is connected to the second MIDDI, and ][ wherein said first and second IMD each have an interface, wherein the first IMD and the second IMD each have a plurality of ports, wherein said plurality of ports are arranged in a second direction, and ]
[ 2700 ] similarity = 0.5324805 [ wherein said first and second IMD each have an interface, wherein the first IMD and the second IMD each have a plurality of ports, wherein said plurality of ports are arranged in a second direction, and ][ wherein said first IMD and the second IMD are connected to each other. ]
[ 2701 ] similarity = 0.38584888 [ An apparatus comprising: ][ a housing; ]
[ 2702 ] similarity = 0.09075934 [ a housing; ][ an input device coupled to the housing, the input device including: a plurality of input elements, each input element including a plurality of input elements; ]
[ 2703 ] similarity = 0.7441906 [ an input device coupled to the housing, the input device including: a plurality of input elements, each input element including a plurality of input elements; ][ a plurality of control elements disposed in communication with the input elements, the plurality of control elements configured to control operation of the plurality of input elements; ]
[ 2704 ] similarity = 0.03181091 [ a plurality of control elements disposed in communication with the input elements, the plurality of control elements configured to control operation of the plurality of input elements; ][ a processor configured to: ]
[ 2705 ] similarity = 0.11249107 [ a processor configured to: ][ receive input from the input devices; ]
[ 2706 ] similarity = 0.15872945 [ receive input from the input devices; ][ generate, by the processor, a plurality of signals, the signals comprising at least one of a first signal and a second signal, wherein each of the first signal and the second signal is associated with a different input element; and ]
[ 2707 ] similarity = 0.62672925 [ generate, by the processor, a plurality of signals, the signals comprising at least one of a first signal and a second signal, wherein each of the first signal and the second signal is associated with a different input element; and ][ determine, by the processor, whether to operate the plurality of input elements based on the first signal and the second signal, ]
[ 2708 ] similarity = 0.21686421 [ determine, by the processor, whether to operate the plurality of input elements based on the first signal and the second signal, ][ wherein the processor is further configured to: ]
[ 2709 ] similarity = 0.009809054 [ wherein the processor is further configured to: ][ determine whether to operate the input elements based on the first signal and the second signal; ]
[ 2710 ] similarity = 0.9725027 [ determine whether to operate the input elements based on the first signal and the second signal; ][ determine whether to operate the input elements based on the first signal and the second signal; and ]
[ 2711 ] similarity = 0.9001901 [ determine whether to operate the input elements based on the first signal and the second signal; and ][ determine whether to operate the plurality of input elements based on the first signal and the second signal. ]
[ 2712 ] similarity = 0.5134147 [ A system for providing an implantable medical device (IMD) to a patient, said system comprising: ][ a first implantable medical device (IMD) having a first body and a first implantation device; ]
[ 2713 ] similarity = 0.56268543 [ a first implantable medical device (IMD) having a first body and a first implantation device; ][ a second implantable medical device (IMD) having a second body and a second implantation device; ]
[ 2714 ] similarity = 0.16764401 [ a second implantable medical device (IMD) having a second body and a second implantation device; ][ a first sensor configured to sense an external environment; ]
[ 2715 ] similarity = 0.7882283 [ a first sensor configured to sense an external environment; ][ a second sensor configured to sense an internal environment; ]
[ 2716 ] similarity = 0.29947624 [ a second sensor configured to sense an internal environment; ][ a first controller configured for controlling a first IMD to perform a first operation; and ]
[ 2717 ] similarity = 0.69985473 [ a first controller configured for controlling a first IMD to perform a first operation; and ][ a second controller configured for controlling a second IMD to perform the first operation, ]
[ 2718 ] similarity = 0.34449816 [ a second controller configured for controlling a second IMD to perform the first operation, ][ wherein the first and second IMDs are configured to be implanted in a patient, and ]
[ 2719 ] similarity = 0.8523158 [ wherein the first and second IMDs are configured to be implanted in a patient, and ][ wherein the first IMDD and the second IMDD are configured to be implanted in a patient's body. ]
[ 2720 ] similarity = -0.040739577 [ An isolated nucleic acid molecule comprising the nucleic acid sequence of SEQ ID NO: ][ 2. ]
[ 2721 ] similarity = 0.0986131 [ A method for the treatment of an animal, comprising the steps of: ][ a) providing a catheter having a distal end and a proximal end; ]
[ 2722 ] similarity = 0.46737653 [ a) providing a catheter having a distal end and a proximal end; ][ b) providing a catheter-invasive implant having an implant tip at the distal end of the catheter; ]
[ 2723 ] similarity = 0.43722773 [ b) providing a catheter-invasive implant having an implant tip at the distal end of the catheter; ][ c) providing a catheter-invasive implant-invasive implant assembly having an inlet and an outlet; ]
[ 2724 ] similarity = 0.40296787 [ c) providing a catheter-invasive implant-invasive implant assembly having an inlet and an outlet; ][ d) inserting the catheter-invasive implant assembly into a body part of a patient; ]
[ 2725 ] similarity = 0.7215302 [ d) inserting the catheter-invasive implant assembly into a body part of a patient; ][ e) inserting a catheter-invasive implant-invasive implant assembly into a body part of the animal, wherein the catheter-invasive implant assembly is adapted to be implanted within the body part; and ]
[ 2726 ] similarity = 0.49214754 [ e) inserting a catheter-invasive implant-invasive implant assembly into a body part of the animal, wherein the catheter-invasive implant assembly is adapted to be implanted within the body part; and ][ f) applying an ultrasonic therapy to the catheter-invasive implant assembly. ]
[ 2727 ] similarity = 0.47942114 [ A method of treating an individual with a disease comprising administering to the individual a therapeutically effective amount of an isolated nucleic acid molecule that encodes the human CD4+ T cell receptor (CD4T) protein, wherein the CD4T protein comprises a CD4T-like region, and ][ wherein the CD4T protein is encoded by an isolated nucleotide sequence that encodes a nucleotide sequence that comprises at least 95% sequence identity with the nucleotide sequence encoding the CD4T protein, wherein the CD4T protein is expressed by a T cells, and ]
[ 2728 ] similarity = 0.1667931 [ wherein the CD4T protein is encoded by an isolated nucleotide sequence that encodes a nucleotide sequence that comprises at least 95% sequence identity with the nucleotide sequence encoding the CD4T protein, wherein the CD4T protein is expressed by a T cells, and ][ wherein the T cells are a T lymphoma cell or a T lymphoma cell expressing CD4T. ]
[ 2729 ] similarity = -0.01614515 [ A method of treating a patient having a heart disease comprising administering to the patient a therapeutically effective amount of a compound of formula I: ][ wherein: ]
[ 2730 ] similarity = -0.03058181 [ wherein: ][ R1, R2 and R3 each independently comprise the amino acid sequence of SEQ ID NO: ]
[ 2731 ] similarity = 0.06147998 [ R1, R2 and R3 each independently comprise the amino acid sequence of SEQ ID NO: ][ 1, and ]
[ 2732 ] similarity = -0.058057792 [ 1, and ][ R5 is selected from the group consisting of: ]
[ 2733 ] similarity = -0.04281163 [ R5 is selected from the group consisting of: ][ (1) an amino acid sequence of SEQ ID NO: ]
[ 2734 ] similarity = 0.46763855 [ (1) an amino acid sequence of SEQ ID NO: ][ 1, or (2) a sequence having a sequence of at least 90% sequence identity to SEQ ID NO: ]
[ 2735 ] similarity = -0.056876473 [ 1, or (2) a sequence having a sequence of at least 90% sequence identity to SEQ ID NO: ][ 1, ]
[ 2736 ] similarity = 0.13434389 [ 1, ][ wherein: ]
[ 2737 ] similarity = 0.059508916 [ wherein: ][ R5 is a C1-5 alkyl or a C1-4alkyl; and ]
[ 2738 ] similarity = 0.35077858 [ R5 is a C1-5 alkyl or a C1-4alkyl; and ][ R6 is a C1-5 alkoxy, ]
[ 2739 ] similarity = 0.016750352 [ R6 is a C1-5 alkoxy, ][ wherein the compound of formula I is a pharmaceutically acceptable salt or ester, ]
[ 2740 ] similarity = 0.07327521 [ wherein the compound of formula I is a pharmaceutically acceptable salt or ester, ][ wherein the heart disease is a coronary heart disease, and ]
[ 2741 ] similarity = 0.8183102 [ wherein the heart disease is a coronary heart disease, and ][ the heart disease is a coronary heart disease associated with a coronary artery disease. ]
[ 2742 ] similarity = -0.013477854 [ A method for treating an inflammatory disorder comprising administering to an individual a compound of formula I or a pharmaceutically acceptable salt thereof: ][ wherein R1 is a C1-6 alkyl, C1-6 alkoxy, C1-6 alkyl-C1-6 alkoxyalkyl, C1-6 alkoxyalkyl, C1-6 alkyl-C1-6 alkyl-C1-6 alkoxyalkyl, or C3-6 alkylamino; ]
[ 2743 ] similarity = 0.6675118 [ wherein R1 is a C1-6 alkyl, C1-6 alkoxy, C1-6 alkyl-C1-6 alkoxyalkyl, C1-6 alkoxyalkyl, C1-6 alkyl-C1-6 alkyl-C1-6 alkoxyalkyl, or C3-6 alkylamino; ][ X is a C1-6 alkyl, C1-6 alkoxy, C1-6 alkyl-C1-6 alkyl-C1-6 alkyl-C1-6 alkoxyalkyl or C3-6 alkylamino; and ]
[ 2744 ] similarity = 0.6945153 [ X is a C1-6 alkyl, C1-6 alkoxy, C1-6 alkyl-C1-6 alkyl-C1-6 alkyl-C1-6 alkoxyalkyl or C3-6 alkylamino; and ][ R2 is a C1-6 alkoxy, C1-6 alkyl or C1-6 alkyl-C1-6 alkyl-C1-6 alkyl-C1-6 alkoxyalkyl. ]
[ 2745 ] similarity = 0.27915907 [ A system for providing a plurality of different treatment options for a patient in need of treatment, said system comprising: ][ a first patient care device; ]
[ 2746 ] similarity = 0.7311082 [ a first patient care device; ][ a second patient care device; ]
[ 2747 ] similarity = 0.7005383 [ a second patient care device; ][ a third patient care device; and ]
[ 2748 ] similarity = 0.82713693 [ a third patient care device; and ][ a fourth patient care device. ]
[ 2749 ] similarity = 0.10438202 [ A method for treating a subject suffering from an inflammatory disorder comprising administering to the subject a composition comprising an isolated polypeptide comprising the amino acid sequence of SEQ ID NO: ][ 2 or a pharmaceutically acceptable salt thereof. ]
[ 2750 ] similarity = 0.17115939 [ An implantable device for delivering a drug to an organ of a patient, comprising: ][ a body having a first surface and an opposite second surface; ]
[ 2751 ] similarity = 0.27489576 [ a body having a first surface and an opposite second surface; ][ an implantable device having a first portion having a plurality of first electrodes and a plurality of second electrodes; and ]
[ 2752 ] similarity = 0.40061218 [ an implantable device having a first portion having a plurality of first electrodes and a plurality of second electrodes; and ][ a first fluid delivery system configured to deliver the first fluid from the implantable device into a first fluid channel in the body; ]
[ 2753 ] similarity = 0.7629403 [ a first fluid delivery system configured to deliver the first fluid from the implantable device into a first fluid channel in the body; ][ a first fluid delivery channel having a first fluid outlet; ]
[ 2754 ] similarity = 0.8197619 [ a first fluid delivery channel having a first fluid outlet; ][ a first fluid conduit having a first fluid conduit outlet; and ]
[ 2755 ] similarity = 0.743807 [ a first fluid conduit having a first fluid conduit outlet; and ][ a first fluid delivery system having a first fluid delivery channel outlet, ]
[ 2756 ] similarity = 0.5786165 [ a first fluid delivery system having a first fluid delivery channel outlet, ][ wherein the first portion is configured to be inserted into a first fluid channel in the body and the first fluid channel outlet is configured to be inserted into a second fluid channel in the body, ]
[ 2757 ] similarity = 0.9209069 [ wherein the first portion is configured to be inserted into a first fluid channel in the body and the first fluid channel outlet is configured to be inserted into a second fluid channel in the body, ][ wherein the first fluid channel is configured to be inserted into the second fluid channel and the second fluid channel outlet is configured to be inserted into the first fluid channel outlet in the body. ]
[ 2758 ] similarity = 0.33806965 [ An apparatus for the treatment of an eye, comprising: ][ an optical system for producing an optical beam; ]
[ 2759 ] similarity = 0.28857073 [ an optical system for producing an optical beam; ][ at least one light source; ]
[ 2760 ] similarity = 0.6109713 [ at least one light source; ][ at least one light detector for detecting a first light beam emitted from the at least one light source; ]
[ 2761 ] similarity = 0.614179 [ at least one light detector for detecting a first light beam emitted from the at least one light source; ][ a first light source control circuit configured to control a first light beam source for producing an optical beam; ]
[ 2762 ] similarity = 0.71506596 [ a first light source control circuit configured to control a first light beam source for producing an optical beam; ][ a first light detector control circuit configured to control a first light detector for detecting the first light beam; ]
[ 2763 ] similarity = 0.48430872 [ a first light detector control circuit configured to control a first light detector for detecting the first light beam; ][ a second light source control circuit, configured to control a second light source for producing an optical beam; ]
[ 2764 ] similarity = 0.6743348 [ a second light source control circuit, configured to control a second light source for producing an optical beam; ][ a second light detector control circuit, configured to control a second light detector for detecting the second light beam; ]
[ 2765 ] similarity = 0.33519357 [ a second light detector control circuit, configured to control a second light detector for detecting the second light beam; ][ an optical path connecting the first and the second light sources; and ]
[ 2766 ] similarity = 0.28285307 [ an optical path connecting the first and the second light sources; and ][ an output device configured to output an output of the optical path to a display device; ]
[ 2767 ] similarity = 0.4664191 [ an output device configured to output an output of the optical path to a display device; ][ wherein the optical path is configured to be configured to be coupled to an external light source, the external light source having a first wavelength, the optical path being configured to be coupled to the external light source, wherein the optical path is configured to have an optical path length that is shorter than the optical path length of the external light source. ]
[ 2768 ] similarity = 0.16865227 [ A method for the treatment of a patient having cancer, the method comprising: ][ administering to the patient a therapeutically effective amount of an isolated polypeptide, wherein said isolated polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: ]
[ 2769 ] similarity = -0.0049074832 [ administering to the patient a therapeutically effective amount of an isolated polypeptide, wherein said isolated polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: ][ 1, 2, and ]
[ 2770 ] similarity = 0.1907455 [ 1, 2, and ][ 4; ]
[ 2771 ] similarity = -0.041783724 [ 4; ][ wherein said isolated polypeptide is selected from the group consisting of: ]
[ 2772 ] similarity = 0.0577233 [ wherein said isolated polypeptide is selected from the group consisting of: ][ (a) the amino acid sequence of SEQ ID NO: ]
[ 2773 ] similarity = -0.04657647 [ (a) the amino acid sequence of SEQ ID NO: ][ 2; ]
[ 2774 ] similarity = -0.042116143 [ 2; ][ (b) the amino acid sequence of SEQ ID NO: ]
[ 2775 ] similarity = -0.004700813 [ (b) the amino acid sequence of SEQ ID NO: ][ 3; ]
[ 2776 ] similarity = -0.047749363 [ 3; ][ (c) the sequence of the amino acid sequence of SEQ ID NO: ]
[ 2777 ] similarity = -0.052543804 [ (c) the sequence of the amino acid sequence of SEQ ID NO: ][ 2; and ]
[ 2778 ] similarity = -0.041078847 [ 2; and ][ (d) the sequence of the amino acid sequence of SEQ ID NO: ]
[ 2779 ] similarity = 0.056556508 [ (d) the sequence of the amino acid sequence of SEQ ID NO: ][ 4; and ]
[ 2780 ] similarity = -0.004221622 [ 4; and ][ wherein said isolated polypeptide comprises an antigenic component. ]
[ 2781 ] similarity = 0.20815693 [ An isolated antibody that specifically binds to the human immunodeficiency virus type 1 antigen (HIV-1) comprising: ][ (a) an antibody fragment comprising a first fragment and a second fragment; and ]
[ 2782 ] similarity = 0.44663662 [ (a) an antibody fragment comprising a first fragment and a second fragment; and ][ (b) a nucleic acid molecule that specifically binds the first fragment of the antibody. ]
[ 2783 ] similarity = 0.7141545 [ A method of producing a biodegradable, biodegradable, and ][ bioabsorbable, biodegradable, and ]
[ 2784 ] similarity = 1.0 [ bioabsorbable, biodegradable, and ][ bioabsorbable, biodegradable, and ]
[ 2785 ] similarity = 0.7424917 [ bioabsorbable, biodegradable, and ][ biodegradable, biodegradable and bioabsorbable, biodegradable and bioabsorbable, bioabsorbable, biodegradable, and ]
[ 2786 ] similarity = 0.74569523 [ biodegradable, biodegradable and bioabsorbable, biodegradable and bioabsorbable, bioabsorbable, biodegradable, and ][ bioabsorbable, bioabsorbable, biodegradable, and ]
[ 2787 ] similarity = 0.9418288 [ bioabsorbable, bioabsorbable, biodegradable, and ][ bioabsorbable, biodegradable, and ]
[ 2788 ] similarity = 0.20173427 [ bioabsorbable, biodegradable, and ][ bioabsorbable polymer, wherein the biodegradable and bioabsorbable polymer comprises a polymeric composition comprising a polymer having a molecular weight of at least 100, ]
[ 2789 ] similarity = 0.053313933 [ bioabsorbable polymer, wherein the biodegradable and bioabsorbable polymer comprises a polymeric composition comprising a polymer having a molecular weight of at least 100, ][ 000, and ]
[ 2790 ] similarity = 0.031889077 [ 000, and ][ wherein the biodegradable polymer comprises a polymer having a molecular weight of at least 100, ]
[ 2791 ] similarity = 0.84357 [ wherein the biodegradable polymer comprises a polymer having a molecular weight of at least 100, ][ 000 and the biodegradable polymer comprises a polymer having a molecular weight of less than 100, ]
[ 2792 ] similarity = 0.1356239 [ 000 and the biodegradable polymer comprises a polymer having a molecular weight of less than 100, ][ 000, ]
[ 2793 ] similarity = -0.0047140103 [ 000, ][ and wherein the biodegradable and bioabsorbable polymer is a biodegradable, biodegradable, and ]
[ 2794 ] similarity = 0.24267288 [ and wherein the biodegradable and bioabsorbable polymer is a biodegradable, biodegradable, and ][ bioabsorbable polymer comprising a polymer having a molecular weight of at least 100, ]
[ 2795 ] similarity = 0.89839834 [ bioabsorbable polymer comprising a polymer having a molecular weight of at least 100, ][ 000 and a biodegradable polymer comprising a polymer having a molecular weight of at least 100, ]
[ 2796 ] similarity = 0.9206542 [ 000 and a biodegradable polymer comprising a polymer having a molecular weight of at least 100, ][ 000 and a bioabsorbable polymer comprising a polymer having a molecular weight of less than 100, ]
[ 2797 ] similarity = 0.16195253 [ 000 and a bioabsorbable polymer comprising a polymer having a molecular weight of less than 100, ][ 000. ]
(relevant) count = 1240, ratio = 0.44333214158026457
(irrelevant) count = 1557, ratio = 0.5566678584197354
average similarity = 0.4383064795087749 (count=2798)
